Results

Max Cor PVal:

Min Odds:

Min PFR:

Top Hits:

Showing top of filtered results (total : )

Graph
Sankey Plot

Concepts: (types)

Overlapping Semantic MEDLINE Objects	ERG	PC	Shared	Score	Mean CP	Mean Odds	Min PFR

SemMedDB	Observed	Expected	Odds Ratio	P-value	Corrected P-value
PTEN gene\|PTEN\|\|PART_OF\|\|Malignant neoplasm of prostate:8414679	3/867	18/26,262,527	5066.07	4.77e-11	1.82e-09
TRANSCRIPTION FACTOR\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:6700909	6/867	36/26,262,527	5083.72	6.67e-21	6.56e-19
SOX9\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:13910081	2/867	5/26,262,527	12144.52	2.29e-08	4.06e-07
Androgens\|\|INTERACTS_WITH\|\|TMPRSS2 gene\|TMPRSS2:14808598	4/867	5/26,262,527	24345.33	1.49e-16	1.15e-14
Oncogene Proteins\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:14687839	2/867	3/26,262,527	20240.87	1.09e-08	2.09e-07
ERG gene\|ERG\|\|PART_OF\|\|Malignant neoplasm of prostate:7698415	9/867	13/26,262,527	21190.84	2.22e-35	3.79e-33
ERG gene\|ERG\|\|ISA\|\|Transcription factor genes:14808597	3/867	3/26,262,527	30396.44	7.17e-13	3.67e-11
PCA3\|\|PART_OF\|\|Malignant neoplasm of prostate:14154365	2/867	10/26,262,527	6072.26	7.18e-08	1.15e-06
Urine\|\|LOCATION_OF\|\|KLK3 gene\|KLK3:6733771	2/867	15/26,262,527	4048.17	1.48e-07	2.24e-06
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|cohort:1949503	8/867	306/26,262,527	799.29	2.90e-21	2.97e-19
FLVCR1\|\|PART_OF\|\|High-Grade Prostatic Intraepithelial Neoplasia:14953892	2/867	3/26,262,527	20240.87	1.09e-08	2.09e-07
ETS1 gene\|ETS1\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8886049	12/867	31/26,262,527	11890.21	2.38e-44	6.76e-42
Urine\|\|PART_OF\|\|Sediment:2135075	2/867	8/26,262,527	7590.32	4.90e-08	8.08e-07
leukemia\|\|COEXISTS_WITH\|\|Carcinoma:11623203	2/867	4/26,262,527	15180.65	1.63e-08	2.98e-07
TMPRSS2 gene\|TMPRSS2\|\|COEXISTS_WITH\|\|TMPRSS2 gene\|TMPRSS2:11961488	3/867	3/26,262,527	30396.44	7.17e-13	3.67e-11
Immunohistochemistry\|\|METHOD_OF\|\|Fluorescent in Situ Hybridization:6033168	6/867	159/26,262,527	1151.03	3.24e-17	2.76e-15
TMPRSS2 gene\|TMPRSS2\|\|PART_OF\|\|[M]Unspecified tumor cell NOS:12877216	2/867	2/26,262,527	30361.30	6.53e-09	1.40e-07
TMPRSS2 gene\|TMPRSS2\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:12782763	6/867	4/26,262,527	45753.52	2.67e-25	3.25e-23
cohort\|\|LOCATION_OF\|\|ERG gene\|ERG:12750061	5/867	7/26,262,527	21762.11	3.07e-20	2.80e-18
Proto-Oncogene Proteins c-ets\|\|ASSOCIATED_WITH\|\|Chromosomal Rearrangement:15879932	2/867	2/26,262,527	30361.30	6.53e-09	1.40e-07
ETV6 gene\|ETV6\|\|ASSOCIATED_WITH\|\|leukemia:6793236	4/867	22/26,262,527	5533.03	1.76e-14	1.19e-12
ERG gene\|ERG\|\|ASSOCIATED_WITH\|\|Carcinogenesis:8765110	2/867	2/26,262,527	30361.30	6.53e-09	1.40e-07
Heregulin\|\|STIMULATES\|\|Utrophin\|UTRN:8192901	2/867	3/26,262,527	20240.87	1.09e-08	2.09e-07
Malignant neoplasm of prostate\|\|COEXISTS_WITH\|\|Neoplasms, Epithelial:13211798	2/867	2/26,262,527	30361.30	6.53e-09	1.40e-07
ERG gene\|ERG\|\|ASSOCIATED_WITH\|\|Leukemia, Myelocytic, Acute:6174069	2/867	15/26,262,527	4048.17	1.48e-07	2.24e-06
Heregulin\|\|INTERACTS_WITH\|\|Utrophin\|UTRN:8192908	2/867	2/26,262,527	30361.30	6.53e-09	1.40e-07
Prostate-Specific Antigen\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:3137096	4/867	313/26,262,527	388.90	4.83e-10	1.65e-08
Chromosomal translocation\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:12317844	3/867	5/26,262,527	18237.86	2.01e-12	8.70e-11
TMPRSS2 gene\|TMPRSS2\|\|ASSOCIATED_WITH\|\|Prostate cancer metastatic:16392592	2/867	2/26,262,527	30361.30	6.53e-09	1.40e-07
Proto-Oncogene Proteins c-ets\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:11474231	5/867	8/26,262,527	19041.85	4.99e-20	4.40e-18
ETS1 gene\|ETS1\|\|ISA\|\|Transcription factor genes:7505708	4/867	17/26,262,527	7160.39	7.06e-15	4.88e-13
Candidate Disease Gene\|\|ASSOCIATED_WITH\|\|Neoplasm progression:8827548	2/867	15/26,262,527	4048.17	1.48e-07	2.24e-06
ETV1 gene\|ETV1\|\|ASSOCIATED_WITH\|\|Chromosomal Rearrangement:15879933	2/867	2/26,262,527	30361.30	6.53e-09	1.40e-07
ERG gene\|ERG\|\|ASSOCIATED_WITH\|\|Tumorigenesis:13345089	3/867	3/26,262,527	30396.44	7.17e-13	3.67e-11
Proto-Oncogene Proteins c-ets\|\|PART_OF\|\|Malignant neoplasm of prostate:12145028	2/867	3/26,262,527	20240.87	1.09e-08	2.09e-07
Carcinogens\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:6690955	2/867	34/26,262,527	1785.96	6.85e-07	9.57e-06
Prostate\|\|LOCATION_OF\|\|Cancer Model:1791745	3/867	425/26,262,527	214.56	4.60e-07	6.65e-06
Fluorescent in Situ Hybridization\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:5926668	3/867	12/26,262,527	7599.11	1.63e-11	6.62e-10
[M]Unspecified tumor cell NOS\|\|LOCATION_OF\|\|TMPRSS2 gene\|TMPRSS2:12877215	2/867	4/26,262,527	15180.65	1.63e-08	2.98e-07
ERG gene\|ERG\|\|ASSOCIATED_WITH\|\|Specimen from prostate:12969426	2/867	2/26,262,527	30361.30	6.53e-09	1.40e-07
Endopeptidases\|\|PART_OF\|\|integral to membrane:7867459	23/867	96/26,262,527	7455.02	1.37e-79	1.17e-76
ERG gene\|ERG\|\|ASSOCIATED_WITH\|\|Neoplasm progression:13453036	2/867	3/26,262,527	20240.87	1.09e-08	2.09e-07
ERG gene\|ERG\|\|PART_OF\|\|Family member:11727702	8/867	10/26,262,527	24458.69	5.97e-32	8.98e-30
Polymerase Chain Reaction\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:5717664	3/867	21/26,262,527	4342.35	7.25e-11	2.61e-09
Tissue specimen\|\|PART_OF\|\|Prostate:910138	3/867	96/26,262,527	949.89	5.61e-09	1.40e-07
epitheliasin\|ERG\|\|ISA\|\|Analyte:13573093	2/867	2/26,262,527	30361.30	6.53e-09	1.40e-07
acetyltransferase activity\|\|CAUSES\|\|acetyltransferase activity:819681	2/867	5/26,262,527	12144.52	2.29e-08	4.06e-07
Stimulation procedure\|\|USES\|\|Androgens:85392	5/867	553/26,262,527	275.46	1.69e-11	6.75e-10
Malignant neoplasm of prostate\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:2006383	4/867	219/26,262,527	555.82	1.18e-10	4.18e-09
Lymphoma\|\|COEXISTS_WITH\|\|Carcinoma:1474755	2/867	7/26,262,527	8674.66	3.92e-08	6.59e-07
Tumor stage\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:1972993	2/867	12/26,262,527	5060.21	9.90e-08	1.57e-06
PTEN gene\|PTEN\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:11792285	2/867	3/26,262,527	20240.87	1.09e-08	2.09e-07
ELK1 gene\|ELK1\|\|INTERACTS_WITH\|\|Proto-Oncogene Proteins c-fos\|FOS:5927653	2/867	6/26,262,527	10120.43	3.05e-08	5.19e-07
Chromosomal translocation\|\|COEXISTS_WITH\|\|Malignant Childhood Neoplasm:8782723	3/867	6/26,262,527	15198.22	3.01e-12	1.26e-10
sarcoma\|\|COEXISTS_WITH\|\|Carcinoma:2414	2/867	21/26,262,527	2891.55	2.75e-07	4.07e-06
Fluorescent in Situ Hybridization\|\|DIAGNOSES\|\|Small cell carcinoma of lung:9819146	2/867	3/26,262,527	20240.87	1.09e-08	2.09e-07
[M]Unspecified tumor cell NOS\|\|LOCATION_OF\|\|ERG gene\|ERG:13415226	2/867	3/26,262,527	20240.87	1.09e-08	2.09e-07
Chromosome abnormality\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:5100057	2/867	25/26,262,527	2428.90	3.82e-07	5.55e-06
Chromosomal Rearrangement\|\|COEXISTS_WITH\|\|Common Carcinoma:11474228	3/867	3/26,262,527	30396.44	7.17e-13	3.67e-11
Breast Cancer Cell\|\|LOCATION_OF\|\|ETV4:7134192	2/867	3/26,262,527	20240.87	1.09e-08	2.09e-07
Prostate\|\|LOCATION_OF\|\|Biopsy:116711	29/867	7,852/26,262,527	115.71	5.79e-49	2.47e-46
Fluorescent in Situ Hybridization\|\|METHOD_OF\|\|Gene Fusion:8289985	4/867	23/26,262,527	5292.46	2.07e-14	1.36e-12
ERG gene\|ERG\|\|INTERACTS_WITH\|\|TMPRSS2 gene\|TMPRSS2:15879938	4/867	4/26,262,527	30431.66	8.25e-17	6.60e-15
Transcription, Genetic\|\|PROCESS_OF\|\|network:4565077	5/867	1,968/26,262,527	77.40	9.10e-09	1.94e-07
ETV1 gene\|ETV1\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:11474229	10/867	23/26,262,527	13323.78	1.35e-37	2.65e-35
TMPRSS2 gene\|TMPRSS2\|\|ASSOCIATED_WITH\|\|Adenocarcinoma of prostate:15965997	2/867	2/26,262,527	30361.30	6.53e-09	1.40e-07
[M]Unspecified tumor cell NOS\|\|PART_OF\|\|Malignant neoplasm of prostate:5821122	2/867	29/26,262,527	2093.88	5.06e-07	7.27e-06
ERG gene\|ERG\|\|INTERACTS_WITH\|\|Carcinogens:15048507	2/867	2/26,262,527	30361.30	6.53e-09	1.40e-07
fluorouracil/methotrexate protocol\|\|AFFECTS\|\|Trans-Activation (Genetics):8082428	2/867	2/26,262,527	30361.30	6.53e-09	1.40e-07
Fusion Gene\|\|ASSOCIATED_WITH\|\|Carcinogenesis:12018234	2/867	5/26,262,527	12144.52	2.29e-08	4.06e-07
DNA Sequence\|\|COEXISTS_WITH\|\|ERG gene\|ERG:6072657	2/867	2/26,262,527	30361.30	6.53e-09	1.40e-07
Ets Variant Protein 1\|ETV1\|\|STIMULATES\|\|FAVOR:15879939	2/867	2/26,262,527	30361.30	6.53e-09	1.40e-07
Oncogenes\|\|PART_OF\|\|Erythroblastosis Virus, Avian:1626525	2/867	15/26,262,527	4048.17	1.48e-07	2.24e-06
TMPRSS2 gene\|TMPRSS2\|\|INTERACTS_WITH\|\|TMPRSS2 gene\|TMPRSS2:16539210	2/867	2/26,262,527	30361.30	6.53e-09	1.40e-07
Genomic Instability\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:6317187	4/867	11/26,262,527	11066.06	1.61e-15	1.14e-13
cohort\|\|LOCATION_OF\|\|PCA3:12782762	5/867	5/26,262,527	30466.96	9.76e-21	9.25e-19
[M]Unspecified tumor cell NOS\|\|PART_OF\|\|Prostate:578777	13/867	685/26,262,527	583.61	6.63e-32	9.42e-30
TMPRSS2 gene\|TMPRSS2\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:11474227	38/867	48/26,262,527	25079.77	8.38e-147	1.07e-143
PTEN gene\|PTEN\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:7432503	13/867	103/26,262,527	3881.35	2.77e-42	7.09e-40
DNA Sequence\|\|PART_OF\|\|Chicken Cells:2285234	2/867	8/26,262,527	7590.32	4.90e-08	8.08e-07
Prostate-Specific Antigen\|\|CAUSES\|\|Malignant neoplasm of prostate:3920605	2/867	16/26,262,527	3795.16	1.66e-07	2.50e-06
Prostatic secretions\|\|LOCATION_OF\|\|Specimen:1284808	3/867	28/26,262,527	3256.76	1.61e-10	5.64e-09
T-Lymphocyte\|\|LOCATION_OF\|\|Proto-Oncogene Proteins c-ets:5252801	2/867	4/26,262,527	15180.65	1.63e-08	2.98e-07
Urine\|\|LOCATION_OF\|\|PCA3 gene\|PCA3:13472762	2/867	9/26,262,527	6746.95	5.99e-08	9.69e-07
Urine\|\|LOCATION_OF\|\|PCA3:12782760	12/867	27/26,262,527	13651.72	6.06e-45	1.94e-42
Erythroblastosis\|\|PROCESS_OF\|\|Chickens:25226	2/867	30/26,262,527	2024.08	5.40e-07	7.66e-06
ERG gene\|ERG\|\|INTERACTS_WITH\|\|ETS1 gene\|ETS1:13612754	2/867	2/26,262,527	30361.30	6.53e-09	1.40e-07
Small cell carcinoma of lung\|\|PART_OF\|\|Prostate:2590419	4/867	324/26,262,527	375.69	5.54e-10	1.86e-08
ETV4 gene\|ETV4\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:12037000	8/867	12/26,262,527	20382.24	1.72e-31	2.31e-29
Cell Line, Tumor\|\|PART_OF\|\|Prostate:2418434	3/867	203/26,262,527	449.21	5.12e-08	8.40e-07
ETV6 gene\|ETV6\|\|INTERACTS_WITH\|\|ETV6 gene\|ETV6:8008680	2/867	6/26,262,527	10120.43	3.05e-08	5.19e-07
cohort\|\|LOCATION_OF\|\|TMPRSS2 gene\|TMPRSS2:14001363	2/867	2/26,262,527	30361.30	6.53e-09	1.40e-07
TMPRSS2 gene\|TMPRSS2\|\|PART_OF\|\|Malignant neoplasm of prostate:13719473	4/867	7/26,262,527	17389.52	3.89e-16	2.84e-14
Urine\|\|LOCATION_OF\|\|epitheliasin\|ERG:13573095	2/867	2/26,262,527	30361.30	6.53e-09	1.40e-07
Androgens\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:1581301	4/867	188/26,262,527	647.48	6.44e-11	2.42e-09
Androgen Receptor\|AR\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:5961629	3/867	155/26,262,527	588.31	2.30e-08	4.06e-07
Urine\|\|LOCATION_OF\|\|Plasma Kallikrein:17020333	2/867	2/26,262,527	30361.30	6.53e-09	1.40e-07
ETS Family Gene\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:12505777	2/867	4/26,262,527	15180.65	1.63e-08	2.98e-07
SCTR gene\|SCTR\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:15825310	2/867	2/26,262,527	30361.30	6.53e-09	1.40e-07
Transcription factor genes\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:11474226	3/867	4/26,262,527	22797.33	1.25e-12	5.63e-11
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Gene Rearrangement:13578905	2/867	2/26,262,527	30361.30	6.53e-09	1.40e-07
Gene Family\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:14002367	2/867	3/26,262,527	20240.87	1.09e-08	2.09e-07
ERG gene\|ERG\|\|COEXISTS_WITH\|\|TMPRSS2 gene\|TMPRSS2:11961489	2/867	2/26,262,527	30361.30	6.53e-09	1.40e-07
epitheliasin\|TMPRSS2\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:12284618	6/867	7/26,262,527	26144.87	2.18e-24	2.54e-22
Fusion Gene\|\|AFFECTS\|\|Tumorigenesis:13211797	2/867	3/26,262,527	20240.87	1.09e-08	2.09e-07
TMPRSS2 gene\|TMPRSS2\|\|AUGMENTS\|\|Malignant neoplasm of prostate:12050967	3/867	3/26,262,527	30396.44	7.17e-13	3.67e-11
Muramidase\|LYZ\|\|STIMULATES\|\|Muramidase\|LYZ:3093084	2/867	17/26,262,527	3571.92	1.86e-07	2.78e-06
ERG gene\|ERG\|\|ASSOCIATED_WITH\|\|Chromosomal Rearrangement:15879934	2/867	2/26,262,527	30361.30	6.53e-09	1.40e-07
ERG gene\|ERG\|\|ASSOCIATED_WITH\|\|Prostatic Neoplasms:13407288	3/867	2/26,262,527	45594.66	3.58e-13	2.13e-11
Aggressive cancer\|\|PART_OF\|\|Prostate:7211314	4/867	152/26,262,527	800.83	2.79e-11	1.10e-09
TMPRSS2 gene\|TMPRSS2\|\|PART_OF\|\|Chromosomes, Human, Pair 21:7385317	2/867	3/26,262,527	20240.87	1.09e-08	2.09e-07
Chromosomal Rearrangement\|\|COEXISTS_WITH\|\|Leukemia, Myelocytic, Acute:3945806	2/867	13/26,262,527	4670.97	1.14e-07	1.80e-06
ELF3 gene\|ELF3\|\|STIMULATES\|\|Binding Sites:7298616	2/867	2/26,262,527	30361.30	6.53e-09	1.40e-07
Tumorigenesis\|\|PART_OF\|\|Prostate:4164712	16/867	586/26,262,527	842.60	1.98e-41	4.60e-39
Diagnostic Neoplasm Staging\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:4328979	2/867	7/26,262,527	8674.66	3.92e-08	6.59e-07
Adenocarcinoma\|\|PART_OF\|\|Prostate:129573	15/867	4,414/26,262,527	104.73	1.72e-25	2.20e-23
ERG gene\|ERG\|\|AFFECTS\|\|Malignant neoplasm of prostate:15322686	2/867	2/26,262,527	30361.30	6.53e-09	1.40e-07
epitheliasin\|ERG\|\|INHIBITS\|\|ERG gene\|ERG:14834615	2/867	2/26,262,527	30361.30	6.53e-09	1.40e-07
TMPRSS2 gene\|TMPRSS2\|\|ASSOCIATED_WITH\|\|DELETION:14133792	2/867	2/26,262,527	30361.30	6.53e-09	1.40e-07
ERG gene\|ERG\|\|AUGMENTS\|\|Malignant neoplasm of prostate:12050966	2/867	4/26,262,527	15180.65	1.63e-08	2.98e-07
Epithelial Cells\|\|PART_OF\|\|Prostate:297645	12/867	2,326/26,262,527	158.45	7.83e-23	8.71e-21
ERG gene\|ERG\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:11474230	42/867	80/26,262,527	16712.47	2.17e-156	5.55e-153
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Ethnic group:8010174	2/867	34/26,262,527	1785.96	6.85e-07	9.57e-06
5' Untranslated Regions\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:12036999	2/867	2/26,262,527	30361.30	6.53e-09	1.40e-07
High-Risk Cancer\|\|PART_OF\|\|Prostate:6283097	4/867	1,926/26,262,527	63.20	6.46e-07	9.13e-06
PCA3\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:11964668	3/867	21/26,262,527	4342.35	7.25e-11	2.61e-09
Prostate\|\|LOCATION_OF\|\|Needle biopsy procedure:106970	10/867	1,070/26,262,527	286.39	8.06e-22	8.59e-20
Malignant neoplasm of prostate\|\|AFFECTS\|\|Neoplasm progression:8961557	2/867	22/26,262,527	2760.12	3.00e-07	4.41e-06
Androgens\|\|INTERACTS_WITH\|\|ETS1 gene\|ETS1:11785714	3/867	3/26,262,527	30396.44	7.17e-13	3.67e-11
Stem cells\|\|PART_OF\|\|Malignant neoplasm of prostate:11495865	3/867	318/26,262,527	286.76	1.94e-07	2.89e-06
ERG gene\|ERG\|\|STIMULATES\|\|Testosterone:15879940	2/867	2/26,262,527	30361.30	6.53e-09	1.40e-07
Radical prostatectomy\|\|TREATS\|\|Malignant neoplasm of prostate:505086	17/867	3,197/26,262,527	164.27	5.71e-32	8.98e-30
ETV6 gene\|ETV6\|\|ASSOCIATED_WITH\|\|Infantile fibrosarcoma:8008679	3/867	5/26,262,527	18237.86	2.01e-12	8.70e-11
Malignant neoplasm of prostate\|\|PRODUCES\|\|Fusion Gene:11961490	3/867	4/26,262,527	22797.33	1.25e-12	5.63e-11
Biopsy\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:207312	5/867	735/26,262,527	207.25	6.93e-11	2.57e-09
Urine\|\|LOCATION_OF\|\|TMPRSS2 gene\|TMPRSS2:12036998	14/867	18/26,262,527	23946.54	7.74e-55	3.96e-52
Malignant neoplasm of prostate\|\|AFFECTS\|\|Malignant neoplasm of prostate:244461	4/867	49/26,262,527	2484.21	3.45e-13	2.10e-11
ERG gene\|ERG\|\|compared_with\|\|PTEN gene\|PTEN:17559895	4/867	4/26,262,527	30431.66	8.25e-17	6.60e-15
Chromosomes, Human, Pair 21\|\|LOCATION_OF\|\|ERG gene\|ERG:3460155	3/867	11/26,262,527	8289.94	1.30e-11	5.38e-10
Androgen Receptor\|AR\|\|COEXISTS_WITH\|\|ERG gene\|ERG:16142279	2/867	2/26,262,527	30361.30	6.53e-09	1.40e-07
ERG gene\|ERG\|\|COEXISTS_WITH\|\|ERG gene\|ERG:14008549	2/867	6/26,262,527	10120.43	3.05e-08	5.19e-07
FLVCR1\|\|compared_with\|\|FLVCR1:2455929	2/867	25/26,262,527	2428.90	3.82e-07	5.55e-06
Epithelial Cells\|\|LOCATION_OF\|\|Muramidase\|LYZ:4271725	2/867	14/26,262,527	4337.33	1.31e-07	2.05e-06
Gene Rearrangement\|\|PROCESS_OF\|\|cohort:9821419	3/867	6/26,262,527	15198.22	3.01e-12	1.26e-10
CXCR4 gene\|CXCR4\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:14150483	2/867	9/26,262,527	6746.95	5.99e-08	9.69e-07
Prostate\|\|LOCATION_OF\|\|Cancer Diagnosis:3826937	16/867	1,180/26,262,527	418.43	1.26e-36	2.31e-34
TMPRSS2 gene\|TMPRSS2\|\|CAUSES\|\|DNA Damage:14692592	2/867	2/26,262,527	30361.30	6.53e-09	1.40e-07
Carcinogenesis\|\|PART_OF\|\|Prostate:1101843	21/867	1,403/26,262,527	464.63	1.65e-48	6.04e-46
Gel Shift Analysis\|\|USES\|\|Probes:3918986	2/867	15/26,262,527	4048.17	1.48e-07	2.24e-06
Homologous Gene\|\|PART_OF\|\|Chicken Cells:713556	2/867	6/26,262,527	10120.43	3.05e-08	5.19e-07
ETV1 gene\|ETV1\|\|INTERACTS_WITH\|\|TMPRSS2 gene\|TMPRSS2:15879937	2/867	2/26,262,527	30361.30	6.53e-09	1.40e-07
ERG gene\|ERG\|\|ASSOCIATED_WITH\|\|DELETION:14459383	3/867	3/26,262,527	30396.44	7.17e-13	3.67e-11
ETV1 gene\|ETV1\|\|AFFECTS\|\|Malignant neoplasm of prostate:15879941	2/867	2/26,262,527	30361.30	6.53e-09	1.40e-07
SPOP\|\|AUGMENTS\|\|Ubiquitination:16253593	2/867	4/26,262,527	15180.65	1.63e-08	2.98e-07
Tissue specimen\|\|PART_OF\|\|Malignant neoplasm of prostate:3931624	4/867	43/26,262,527	2830.85	2.10e-13	1.31e-11
Urine\|\|LOCATION_OF\|\|Analyte:13573096	2/867	6/26,262,527	10120.43	3.05e-08	5.19e-07
AR gene\|AR\|\|ASSOCIATED_WITH\|\|Tumorigenesis:9134451	2/867	10/26,262,527	6072.26	7.18e-08	1.15e-06
Noninfiltrating Intraductal Carcinoma\|\|PART_OF\|\|Prostate:750486	3/867	62/26,262,527	1470.79	1.56e-09	5.13e-08
PTEN gene\|PTEN\|\|PREDISPOSES\|\|Neoplasm progression:11264759	2/867	8/26,262,527	7590.32	4.90e-08	8.08e-07
TMPRSS2 gene\|TMPRSS2\|\|INTERACTS_WITH\|\|ETS1 gene\|ETS1:11474232	2/867	2/26,262,527	30361.30	6.53e-09	1.40e-07
PCA3\|\|PART_OF\|\|cohort:16213604	2/867	2/26,262,527	30361.30	6.53e-09	1.40e-07
ALK gene\|ALK\|\|ASSOCIATED_WITH\|\|Carcinoma, Non-Small-Cell Lung:13015030	2/867	30/26,262,527	2024.08	5.40e-07	7.66e-06
ERG gene\|ERG\|\|ASSOCIATED_WITH\|\|Prostate carcinoma:15737177	2/867	4/26,262,527	15180.65	1.63e-08	2.98e-07
Endopeptidases\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:14814548	3/867	4/26,262,527	22797.33	1.25e-12	5.63e-11
BRCA2 gene\|BRCA2\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:7823332	2/867	15/26,262,527	4048.17	1.48e-07	2.24e-06
SLC45A3\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:12744625	3/867	4/26,262,527	22797.33	1.25e-12	5.63e-11
Fusion Gene\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:11778261	10/867	14/26,262,527	21889.08	2.86e-39	6.09e-37
Human tissue\|\|PART_OF\|\|Malignant neoplasm of prostate:1532498	6/867	228/26,262,527	802.69	2.70e-16	2.03e-14
Androgens\|\|STIMULATES\|\|ERG gene\|ERG:14240305	3/867	4/26,262,527	22797.33	1.25e-12	5.63e-11
PCA3\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:12782761	3/867	15/26,262,527	6079.29	2.92e-11	1.13e-09
epitheliasin\|TMPRSS2\|\|ISA\|\|Serine Protease:8414625	3/867	31/26,262,527	2941.59	2.14e-10	7.41e-09
Neoplasm progression\|\|PART_OF\|\|Prostate:2822544	31/867	2,836/26,262,527	343.35	9.99e-67	6.39e-64
Digital Rectal Examination\|\|METHOD_OF\|\|Biopsy:2758026	3/867	53/26,262,527	1720.55	9.92e-10	3.30e-08
Chromosomal Rearrangement\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:12485775	3/867	4/26,262,527	22797.33	1.25e-12	5.63e-11
ERG gene\|ERG\|\|PREDISPOSES\|\|Neoplasm progression:9149609	2/867	2/26,262,527	30361.30	6.53e-09	1.40e-07
TMPRSS2 gene\|TMPRSS2\|\|AFFECTS\|\|Malignant neoplasm of prostate:13958268	3/867	4/26,262,527	22797.33	1.25e-12	5.63e-11
Leukemic Cell\|\|LOCATION_OF\|\|ERG gene\|ERG:5614500	2/867	2/26,262,527	30361.30	6.53e-09	1.40e-07
ERG gene\|ERG\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:13453037	2/867	2/26,262,527	30361.30	6.53e-09	1.40e-07
Tumor Suppressor Genes\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:6067966	5/867	202/26,262,527	754.13	1.16e-13	7.43e-12
Analyte\|\|ISA\|\|epitheliasin\|ERG:13573094	2/867	2/26,262,527	30361.30	6.53e-09	1.40e-07
Transcription Repressor/Corepressor\|\|ASSOCIATED_WITH\|\|Chromosomal Rearrangement:8008678	2/867	2/26,262,527	30361.30	6.53e-09	1.40e-07
Enhancer\|\|INTERACTS_WITH\|\|ETS Family Protein:5075158	2/867	3/26,262,527	20240.87	1.09e-08	2.09e-07
Malignant neoplasm of endocrine gland\|\|PART_OF\|\|Prostate:4609475	2/867	5/26,262,527	12144.52	2.29e-08	4.06e-07

SemMedDB	Observed	Expected	Odds Ratio	P-value	Corrected P-value
Alleles\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:10093238	28/138,393	29/26,262,527	183.26	1.81e-48	7.76e-46
Buserelin\|\|TREATS\|\|Prostate cancer metastatic:2494964	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
abiraterone\|\|compared_with\|\|Ketoconazole:10136690	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Carcinoma in Situ\|\|ASSOCIATED_WITH\|\|Bladder:1067190	8/138,393	42/26,262,527	36.15	2.52e-10	1.50e-08
Acetate\|\|TREATS\|\|Malignant neoplasm of prostate:9487092	61/138,393	67/26,262,527	172.85	1.13e-102	1.18e-99
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|high-risk group:6020335	18/138,393	20/26,262,527	170.81	2.71e-31	6.53e-29
Androgen Receptor\|AR\|\|AFFECTS\|\|Signal Transduction:9889600	6/138,393	10/26,262,527	113.87	1.59e-10	9.61e-09
Radical prostatectomy\|\|AFFECTS\|\|Malignant neoplasm of prostate:6047411	11/138,393	11/26,262,527	189.78	5.49e-20	7.78e-18
KLK3 gene\|KLK3\|\|INTERACTS_WITH\|\|KLK3 gene\|KLK3:2475785	21/138,393	50/26,262,527	79.71	5.47e-31	1.30e-28
abarelix\|\|ISA\|\|Gonadotropin releasing hormone antagonist:9433348	10/138,393	14/26,262,527	135.56	2.87e-17	3.37e-15
Extraction\|\|TREATS\|\|Malignant neoplasm of prostate:12747484	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Malignant neoplasm of prostate\|\|PART_OF\|\|Tissue, Paraffin:5926670	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Cystadenoma\|\|PART_OF\|\|Prostate:6012481	13/138,393	18/26,262,527	137.07	4.26e-22	6.89e-20
Refractory Carcinoma\|\|PART_OF\|\|Prostate:1349766	136/138,393	164/26,262,527	157.52	7.20e-223	1.70e-219
Androgens\|\|AFFECTS\|\|CAP - NOS:7154518	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Ductal Mouse MIN\|\|PART_OF\|\|Prostate:910167	8/138,393	10/26,262,527	151.82	2.38e-14	2.15e-12
Radical prostatectomy\|\|TREATS\|\|Neoplasm progression:6661265	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Prostate-Specific Antigen\|\|INTERACTS_WITH\|\|Prostate-Specific Antigen:3375195	61/138,393	68/26,262,527	170.31	2.13e-102	2.21e-99
G-Protein-Coupled Receptors\|\|PART_OF\|\|Malignant neoplasm of prostate:8883879	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Prostate\|\|LOCATION_OF\|\|SUBCUTANEOUS TUMOR:8216728	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Leuprolide\|\|INHIBITS\|\|Testosterone:2810108	12/138,393	21/26,262,527	108.45	1.38e-19	1.88e-17
SRD5A2 gene\|SRD5A2\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:10119650	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Salvage procedure\|\|TREATS\|\|Prostate cancer recurrent:7923186	16/138,393	17/26,262,527	178.63	3.48e-28	7.27e-26
Carcinoid Tumor\|\|PART_OF\|\|Prostate:1594013	10/138,393	11/26,262,527	172.53	5.24e-18	6.40e-16
Combined Modality Therapy\|\|USES\|\|Androgen Antagonists:2273607	20/138,393	29/26,262,527	130.89	5.99e-33	1.54e-30
Phytochemical\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:7272623	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Prostatic Intraepithelial Neoplasia of the Mouse Prostate Gland\|\|PART_OF\|\|Prostate:6470251	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Androgen Receptor\|AR\|\|AUGMENTS\|\|Drug Interactions:9006557	7/138,393	10/26,262,527	132.84	2.02e-12	1.52e-10
Taxol\|\|ISA\|\|Paclitaxel:5510313	43/138,393	1,602/26,262,527	5.09	4.42e-17	5.14e-15
Monoclonal Antibodies\|\|INTERACTS_WITH\|\|TRANCE protein:11544442	5/138,393	13/26,262,527	72.99	3.20e-08	1.43e-06
Monoclonal Antibodies\|\|PART_OF\|\|Prostatic Tissue:4232696	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Human Cell Line\|\|LOCATION_OF\|\|Prostate-Specific Antigen:5067799	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
Androgens\|\|AUGMENTS\|\|Cell Proliferation:2109852	10/138,393	24/26,262,527	79.08	1.83e-15	1.84e-13
Notch\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:12956079	11/138,393	16/26,262,527	130.48	9.91e-19	1.30e-16
Periodicals\|\|ISA\|\|Measurement:67798	81/138,393	4,389/26,262,527	3.50	9.86e-21	1.47e-18
Phosphoric Monoester Hydrolases\|\|ASSOCIATED_WITH\|\|Prostate carcinoma:71311	4/138,393	3/26,262,527	253.03	2.61e-08	1.17e-06
Radiotherapy, Intensity-Modulated\|\|TREATS\|\|Adenocarcinoma:9425764	8/138,393	14/26,262,527	108.44	1.71e-13	1.48e-11
zoledronic acid\|\|PREVENTS\|\|Secondary malignant neoplasm of bone:9102118	7/138,393	15/26,262,527	88.56	1.73e-11	1.23e-09
Malignant neoplasm of prostate\|\|PART_OF\|\|Epithelium:7622349	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Polymerase Chain Reaction\|\|DIAGNOSES\|\|Prostate carcinoma:8075696	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Androgen Receptor\|AR\|\|PART_OF\|\|Human Cell Line:7876832	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Malignant neoplasm of prostate\|\|COEXISTS_WITH\|\|Local disease:2055211	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Epithelial Cells\|\|LOCATION_OF\|\|Androgen Receptor\|AR:3672463	14/138,393	50/26,262,527	53.14	4.43e-19	5.89e-17
Anchorage-Independent Growth\|\|PROCESS_OF\|\|Mice, Nude:1583763	9/138,393	97/26,262,527	17.61	6.21e-09	2.99e-07
PROTEIN KINASE\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:13436586	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Localized Carcinoma\|\|PART_OF\|\|Prostate:843215	183/138,393	224/26,262,527	155.24	2.13e-298	7.73e-295
Dutasteride\|\|INHIBITS\|\|Stanolone:9784373	7/138,393	15/26,262,527	88.56	1.73e-11	1.23e-09
Supportive care\|\|TREATS\|\|Malignant neoplasm of prostate:5785684	12/138,393	13/26,262,527	175.19	2.10e-21	3.22e-19
Benign prostatic hypertrophy\|\|ISA\|\|Hypertrophy:2120089	6/138,393	15/26,262,527	75.91	1.05e-09	5.56e-08
Transforming Growth Factor beta\|\|ASSOCIATED_WITH\|\|Tumorigenesis:4883104	8/138,393	72/26,262,527	21.09	1.18e-08	5.50e-07
KLK3 gene\|KLK3\|\|PART_OF\|\|Prostate:6120999	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Somatomedins\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:5272999	18/138,393	18/26,262,527	189.79	7.40e-32	1.83e-29
Free prostate-specific antigen\|\|USES\|\|Protease Inhibitor:5880511	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Gastrin releasing peptide\|\|ISA\|\|Peptides:2026429	15/138,393	53/26,262,527	53.71	2.12e-20	3.13e-18
Androgen therapy\|\|METHOD_OF\|\|Cancer Treatment:13935348	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Testosterone\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:5423948	28/138,393	31/26,262,527	171.44	6.60e-48	2.77e-45
Malignant neoplasm of prostate\|\|ASSOCIATED_WITH\|\|Organ:1386540	11/138,393	11/26,262,527	189.78	5.49e-20	7.78e-18
Calcium\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:7558466	13/138,393	13/26,262,527	189.79	2.20e-23	3.82e-21
Biopsy\|\|DIAGNOSES\|\|Neoplasm Metastasis:387652	10/138,393	141/26,262,527	13.46	1.00e-08	4.72e-07
Monoclonal Antibodies\|\|PART_OF\|\|Prostate:2564446	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Radiotherapy Systems, Linear Accelerator\|\|TREATS\|\|Malignant neoplasm of prostate:10156792	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Gonadotropin-Releasing Hormone Analog\|\|ASSOCIATED_WITH\|\|Prostate cancer metastatic:3364182	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Implants\|\|TREATS\|\|Edema:9585059	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Recurrent tumor\|\|PART_OF\|\|Prostate:7634898	17/138,393	17/26,262,527	189.79	3.65e-30	8.38e-28
Androgens\|\|INHIBITS\|\|Steroid 17-alpha-monooxygenase\|CYP17A1:8182996	5/138,393	9/26,262,527	105.43	7.62e-09	3.62e-07
pars compacta\|\|PART_OF\|\|Entire substantia nigra:868800	1/138,393	4,449/26,262,527	0.04	4.17e-09	2.04e-07
Proto-Oncogene Proteins c-akt\|AKT1\|\|AFFECTS\|\|Phosphorylation:7573662	15/138,393	204/26,262,527	13.95	1.36e-12	1.04e-10
bicalutamide\|\|higher_than\|\|Flutamide:6651293	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Epithelium\|\|PART_OF\|\|Prostate:96399	124/138,393	293/26,262,527	80.38	2.41e-175	4.30e-172
Inverse\|\|ISA\|\|Relationships:20209	202/138,393	15,393/26,262,527	2.49	2.54e-29	5.60e-27
Cyproterone Acetate\|\|USES\|\|Cyproterone Acetate:731020	20/138,393	175/26,262,527	21.69	9.68e-20	1.37e-17
Secondary malignant neoplasm of bone\|\|PROCESS_OF\|\|Cancer Patient:749638	53/138,393	235/26,262,527	42.81	1.27e-63	7.34e-61
Prostate-Specific Antigen\|\|ASSOCIATED_WITH\|\|Neoplasm Metastasis:2892233	12/138,393	13/26,262,527	175.19	2.10e-21	3.22e-19
Clusterin\|CLU\|\|ASSOCIATED_WITH\|\|Prostate:4413932	7/138,393	19/26,262,527	69.92	6.56e-11	4.09e-09
SOX9\|\|ASSOCIATED_WITH\|\|Prostate:12189695	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
PTEN gene\|PTEN\|\|AFFECTS\|\|Tumor Suppression:8350315	5/138,393	15/26,262,527	63.26	5.75e-08	2.23e-06
Androgen Antagonists\|\|INHIBITS\|\|Stanolone:2007577	5/138,393	8/26,262,527	118.61	4.92e-09	2.37e-07
Dopamine\|\|PART_OF\|\|Neostriatum:423472	2/138,393	4,309/26,262,527	0.09	7.26e-08	2.81e-06
RECK\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:12283303	6/138,393	8/26,262,527	142.33	6.01e-11	3.76e-09
Prostate carcinoma\|\|PROCESS_OF\|\|Recipient, Transplant:12823694	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Primary Carcinoma\|\|PART_OF\|\|Bladder:48970	10/138,393	137/26,262,527	13.85	7.74e-09	3.67e-07
Seminal Vesicles\|\|PART_OF\|\|Prostate:977929	14/138,393	29/26,262,527	91.62	8.04e-22	1.29e-19
Prostate\|\|LOCATION_OF\|\|RNA:579444	13/138,393	44/26,262,527	56.07	4.46e-18	5.56e-16
Prostate\|\|PART_OF\|\|Participant:9016432	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Gonadotropin-Releasing Hormone Receptor\|\|PART_OF\|\|Prostate:8243339	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Prostate\|\|LOCATION_OF\|\|Atypical adenomatous hyperplasia:5640459	17/138,393	24/26,262,527	134.44	2.29e-28	4.84e-26
Insurance Coverage\|\|ISA\|\|Health:175351	51/138,393	3,340/26,262,527	2.90	8.67e-11	5.39e-09
Percutaneous insertion of nephrostomy tube\|\|TREATS\|\|Ureteral obstruction:2655132	6/138,393	37/26,262,527	30.77	1.07e-07	3.92e-06
Specimen from prostate\|\|PART_OF\|\|Intraepithelial Neoplasia:5391604	10/138,393	14/26,262,527	135.56	2.87e-17	3.37e-15
Combined Modality Therapy\|\|USES\|\|bicalutamide:8485319	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Prostate\|\|LOCATION_OF\|\|Scanning:772034	30/138,393	42/26,262,527	135.58	5.09e-49	2.22e-46
Epithelial Cells\|\|LOCATION_OF\|\|NKX3-1 gene\|NKX3-1:13956628	4/138,393	3/26,262,527	253.03	2.61e-08	1.17e-06
Growth Factor\|\|PART_OF\|\|Prostate:3017133	5/138,393	10/26,262,527	94.89	1.14e-08	5.31e-07
Androgen Suppression\|\|USES\|\|Gonadotropin-Releasing Hormone Analog:6836946	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Calcium intake\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:7558468	8/138,393	10/26,262,527	151.82	2.38e-14	2.15e-12
Stanolone\|\|ISA\|\|Androgens:860088	116/138,393	698/26,262,527	31.56	1.68e-123	2.17e-120
Interstitial brachytherapy\|\|TREATS\|\|Malignant neoplasm of prostate:2029036	82/138,393	104/26,262,527	149.71	8.89e-134	1.28e-130
Rhabdomyosarcoma\|\|PART_OF\|\|Bladder:37172	26/138,393	157/26,262,527	31.43	5.88e-29	1.28e-26
Division (procedure)\|\|TREATS\|\|Malignant neoplasm of prostate:4318743	45/138,393	50/26,262,527	170.85	5.20e-76	3.80e-73
fluorodeoxyglucose positron emission tomography\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:7832488	13/138,393	14/26,262,527	176.23	4.22e-23	7.15e-21
Prostatic Tissue\|\|LOCATION_OF\|\|archive:10935566	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
alpha 1-Antichymotrypsin\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:5699533	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
[M]Unspecified tumor cell NOS\|\|LOCATION_OF\|\|Adhesions:425243	13/138,393	379/26,262,527	6.51	2.43e-07	8.41e-06
Zoladex\|\|ISA\|\|Goserelin:3448226	19/138,393	78/26,262,527	46.23	2.21e-24	4.01e-22
AKR1C3\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:15568960	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
hydroxyflutamide\|\|ISA\|\|Androgen Antagonists:3443655	25/138,393	91/26,262,527	52.14	9.90e-33	2.55e-30
Antibiotic Prophylaxis\|\|USES\|\|Ciprofloxacin:4525053	7/138,393	21/26,262,527	63.26	1.17e-10	7.17e-09
Secondary malignant neoplasm of lymph node\|\|COEXISTS_WITH\|\|Locally Advanced Malignant Neoplasm:7692261	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Neoplasm Metastasis\|\|PART_OF\|\|Breast:35775	14/138,393	348/26,262,527	7.64	1.27e-08	5.93e-07
Cancer Treatment\|\|USES\|\|docetaxel:10126693	6/138,393	20/26,262,527	56.93	4.37e-09	2.14e-07
Primary Neoplasm\|\|COEXISTS_WITH\|\|Neoplasm Metastasis:74453	10/138,393	149/26,262,527	12.74	1.64e-08	7.59e-07
PCSK6\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:14716728	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Androgen therapy\|\|higher_than\|\|Androgen therapy:9767646	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Chemotherapy-Oncologic Procedure\|\|TREATS\|\|Malignant neoplasm of prostate:2212205	25/138,393	25/26,262,527	189.80	1.08e-43	4.10e-41
Breast\|\|LOCATION_OF\|\|Tissue Microarray:10332643	6/138,393	38/26,262,527	29.96	1.23e-07	4.49e-06
Dehydroepiandrosterone Sulfate\|\|ISA\|\|dehydroepiandrosterone:902483	9/138,393	139/26,262,527	12.29	1.14e-07	4.15e-06
Estramustine\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:4829998	13/138,393	13/26,262,527	189.79	2.20e-23	3.82e-21
R-1881\|\|STIMULATES\|\|Androgens:4229703	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Androgen therapy\|\|TREATS\|\|Adverse effects:12698303	12/138,393	14/26,262,527	162.67	3.88e-21	5.87e-19
Needle biopsy procedure\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:169320	74/138,393	77/26,262,527	182.47	2.07e-125	2.75e-122
Prostatic Diseases\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:7293088	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
MSMB protein, human\|MSMB\|\|DISRUPTS\|\|tumor growth:11493034	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Radiotherapy planning\|\|TREATS\|\|Malignant neoplasm of prostate:2070893	9/138,393	11/26,262,527	155.27	4.76e-16	4.94e-14
Cystectomy\|\|TREATS\|\|Carcinoma:46794	8/138,393	105/26,262,527	14.46	1.79e-07	6.32e-06
preference\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:6791123	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Oestrogen therapy\|\|TREATS\|\|Adenocarcinoma of prostate:4270300	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Bone Marrow\|\|LOCATION_OF\|\|Prostate-Specific Antigen:4164660	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
PTEN gene\|PTEN\|\|ASSOCIATED_WITH\|\|Tumorigenesis:7565612	20/138,393	86/26,262,527	44.14	3.10e-25	5.86e-23
Insulin-Like-Growth Factor I Receptor\|\|ASSOCIATED_WITH\|\|Neoplasm progression:11263549	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
epigallocatechin gallate\|\|TREATS\|\|Malignant neoplasm of prostate:9723720	14/138,393	15/26,262,527	177.13	8.52e-25	1.56e-22
Malignant neoplasm of prostate\|\|AFFECTS\|\|Epigenetic Process:10203203	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Reagents, Immunoassay, Tumor Marker, Enzyme, Prostate Specific Antigen\|\|INTERACTS_WITH\|\|Prostate-Specific Antigen:5542063	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Prostate-Specific Antigen\|\|ASSOCIATED_WITH\|\|Bone Marrow:3375744	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
Neuroendocrine tissue\|\|PART_OF\|\|Breast:16484375	6/138,393	10/26,262,527	113.87	1.59e-10	9.61e-09
agonists\|\|INHIBITS\|\|Androgens:1908587	24/138,393	34/26,262,527	133.98	2.00e-39	6.60e-37
Prostatectomy\|\|compared_with\|\|Open approach:11008356	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Benign prostatic hypertrophy\|\|ASSOCIATED_WITH\|\|Stroma:3586546	6/138,393	9/26,262,527	126.52	9.97e-11	6.13e-09
Chromosomal Instability\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:5961526	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Prostate\|\|LOCATION_OF\|\|Human Cell Line:1670844	11/138,393	13/26,262,527	160.59	1.92e-19	2.59e-17
Androgen Receptor\|AR\|\|INTERACTS_WITH\|\|Enhancer:8396811	10/138,393	11/26,262,527	172.53	5.24e-18	6.40e-16
Lipoma\|\|PART_OF\|\|Entire rib:159682	9/138,393	22/26,262,527	77.64	5.43e-14	4.83e-12
ethinyl estradiol sulfonate\|\|ISA\|\|Estrogens:986707	5/138,393	8/26,262,527	118.61	4.92e-09	2.37e-07
NF-kappa B\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9346579	21/138,393	22/26,262,527	181.17	1.21e-36	3.64e-34
Lymph Node Dissection\|\|TREATS\|\|stage, prostate cancer:5917602	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Dexamethasone\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:10743036	5/138,393	8/26,262,527	118.61	4.92e-09	2.37e-07
Screening procedure\|\|TREATS\|\|General Population:1071449	11/138,393	225/26,262,527	9.28	6.98e-08	2.70e-06
Analgesics\|\|TREATS\|\|Bone pain:1565729	7/138,393	19/26,262,527	69.92	6.56e-11	4.09e-09
Goserelin Acetate\|\|ISA\|\|Gonadotropin-Releasing Hormone Analog:4909815	11/138,393	12/26,262,527	173.97	1.05e-19	1.44e-17
prostate cancer prevention\|\|USES\|\|Vitamin E:8120359	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Vitamin D\|\|ASSOCIATED_WITH\|\|Neoplasm progression:10153077	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Endocrine therapy\|\|USES\|\|Androgen Antagonists:2465827	8/138,393	14/26,262,527	108.44	1.71e-13	1.48e-11
San Francisco\|\|ISA\|\|California:6066	26/138,393	1,099/26,262,527	4.49	7.93e-10	4.59e-08
Medical Castration\|\|USES\|\|agonists:9644783	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
Ketoconazole\|\|INHIBITS\|\|Steroid 17-alpha-monooxygenase\|CYP17A1:8135745	6/138,393	8/26,262,527	142.33	6.01e-11	3.76e-09
Anogenital region\|\|LOCATION_OF\|\|Biopsy:177784	15/138,393	23/26,262,527	123.77	8.56e-25	1.56e-22
Malignant neoplasm of prostate\|\|ASSOCIATED_WITH\|\|Prostate:357261	82/138,393	90/26,262,527	173.00	1.84e-137	2.74e-134
Prostatic Tissue\|\|PART_OF\|\|Intraepithelial Neoplasia:5717665	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Phosphoric Monoester Hydrolases\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:16233914	5/138,393	3/26,262,527	316.29	2.19e-10	1.31e-08
Malignant neoplasm of prostate\|\|PART_OF\|\|Uterus:4225110	6/138,393	5/26,262,527	227.73	9.37e-12	6.74e-10
Cancer Promoting Genes\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:12244141	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Cancer Patient\|\|USES\|\|Gleason grading system for prostatic cancer:11870965	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Zoladex\|\|ISA\|\|Goserelin Acetate:4011398	14/138,393	28/26,262,527	94.89	5.45e-22	8.79e-20
estramustine-binding protein\|\|INTERACTS_WITH\|\|Estramustine:5957925	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
cyclooxygenase 2\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:9433323	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Advanced cancer\|\|PART_OF\|\|Bladder:8578	7/138,393	69/26,262,527	19.25	1.73e-07	6.12e-06
Prostatic epithelium\|\|PRODUCES\|\|Prostate-Specific Antigen:6337347	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Suramin\|\|ISA\|\|Antineoplastic Agents:1838828	6/138,393	25/26,262,527	45.55	1.36e-08	6.33e-07
Biopsy\|\|USES\|\|Punch:62814	42/138,393	2,308/26,262,527	3.45	2.34e-11	1.56e-09
Sarcoma, Spindle Cell\|\|PART_OF\|\|Prostate:24649	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Prostate\|\|LOCATION_OF\|\|Observation parameter:2411952	23/138,393	66/26,262,527	66.14	2.97e-32	7.52e-30
Rectum\|\|PART_OF\|\|Prostate:8405672	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
VEGF protein, human\|VEGFA\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:7147526	56/138,393	78/26,262,527	136.30	3.20e-90	2.87e-87
Tumor Antigens\|\|PART_OF\|\|Prostate:2064158	38/138,393	43/26,262,527	167.75	3.21e-64	1.88e-61
Prostate carcinoma\|\|COEXISTS_WITH\|\|Adenocarcinoma:6962402	4/138,393	3/26,262,527	253.03	2.61e-08	1.17e-06
Prostate carcinoma\|\|COEXISTS_WITH\|\|Prostate carcinoma:4537588	12/138,393	12/26,262,527	189.78	1.10e-21	1.72e-19
Bone Marrow\|\|LOCATION_OF\|\|Micrometastasis:165353	16/138,393	519/26,262,527	5.85	4.34e-08	1.92e-06
Milk Thistle\|\|LOCATION_OF\|\|silybin:549984	9/138,393	59/26,262,527	28.95	1.11e-10	6.84e-09
Human Cell Line\|\|PART_OF\|\|Prostate carcinoma:1397652	226/138,393	269/26,262,527	159.69	0.00e+00	0.00e+00
Tumor stage\|\|ASSOCIATED_WITH\|\|KLK3 gene\|KLK3:10827794	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Radical prostatectomy\|\|ADMINISTERED_TO\|\|Urologist:8440950	17/138,393	23/26,262,527	140.28	1.35e-28	2.91e-26
Tomography, Emission-Computed\|\|ISA\|\|Scanning:2331594	14/138,393	404/26,262,527	6.58	7.53e-08	2.91e-06
Embolism\|\|PROCESS_OF\|\|Seeds:682582	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Endopeptidases\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:14814548	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Tumorigenicity\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:8278900	10/138,393	10/26,262,527	189.78	2.76e-18	3.46e-16
VAV3 gene\|VAV3\|\|AUGMENTS\|\|androgen receptor activity:11771779	5/138,393	10/26,262,527	94.89	1.14e-08	5.31e-07
Prostate\|\|ASSOCIATED_WITH\|\|Adenocarcinoma of prostate:1177912	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Pelvis\|\|LOCATION_OF\|\|Scanning:1426850	39/138,393	461/26,262,527	16.06	2.10e-32	5.35e-30
Basal Cell\|\|PART_OF\|\|Gland structure:3184208	17/138,393	21/26,262,527	153.64	4.41e-29	9.64e-27
Prostate\|\|LOCATION_OF\|\|Morphologically altered structure:423597	15/138,393	37/26,262,527	76.94	2.31e-22	3.80e-20
Prostate-Specific Antigen\|\|PART_OF\|\|Prostate:3161940	34/138,393	39/26,262,527	165.48	1.76e-57	9.02e-55
Androgen Receptor\|AR\|\|INTERACTS_WITH\|\|cofactor:12287382	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Alar\|\|compared_with\|\|valylvaline:10286608	5/138,393	8/26,262,527	118.61	4.92e-09	2.37e-07
Androgen therapy\|\|TREATS\|\|Toxic effect:16274196	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
RNA, Messenger\|\|ASSOCIATED_WITH\|\|Prostate:844713	22/138,393	77/26,262,527	54.23	2.62e-29	5.76e-27
Rectum\|\|LOCATION_OF\|\|Medical Imaging:2952635	6/138,393	22/26,262,527	51.76	7.08e-09	3.39e-07
Vasectomy\|\|AFFECTS\|\|Malignant neoplasm of prostate:3688549	10/138,393	14/26,262,527	135.56	2.87e-17	3.37e-15
Head and neck structure\|\|LOCATION_OF\|\|Malignant neoplasm of lung:1935579	13/138,393	29/26,262,527	85.08	5.00e-20	7.23e-18
Stem cells\|\|PART_OF\|\|Prostatic Neoplasms:12171213	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
MicroRNAs\|\|AFFECTS\|\|Malignant neoplasm of prostate:13798584	14/138,393	10/26,262,527	265.70	2.21e-26	4.32e-24
Radical prostatectomy\|\|TREATS\|\|Prostate cancer stage C:3156143	13/138,393	15/26,262,527	164.48	7.85e-23	1.31e-20
Transrectal Ultrasound\|\|METHOD_OF\|\|Medical Imaging:5134903	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Prostatic Tissue\|\|LOCATION_OF\|\|Magnetic Resonance Spectroscopy:7242880	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Breast\|\|PART_OF\|\|Malignant neoplasm of prostate:6046919	6/138,393	5/26,262,527	227.73	9.37e-12	6.74e-10
Orchiectomy\|\|TREATS\|\|Prostate cancer metastatic:2687559	36/138,393	41/26,262,527	166.67	7.51e-61	4.02e-58
TP53 gene\|TP53\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:11303964	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Testosterone\|\|INTERACTS_WITH\|\|Androgen Receptor\|AR:1665572	8/138,393	73/26,262,527	20.80	1.30e-08	6.06e-07
Malignant neoplasm of prostate\|\|PRECEDES\|\|Neoplasms, Second Primary:8691247	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Estramustine phosphate\|\|TREATS\|\|Prostate carcinoma:769247	19/138,393	24/26,262,527	150.25	3.32e-32	8.35e-30
Radiofrequency ablation\|\|TREATS\|\|Malignant neoplasm of prostate:7700308	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Core needle biopsy\|\|METHOD_OF\|\|Biopsy:3700846	17/138,393	56/26,262,527	57.62	2.28e-23	3.95e-21
CK2\|\|METHOD_OF\|\|Cancer Treatment:10989169	6/138,393	15/26,262,527	75.91	1.05e-09	5.56e-08
AR gene\|AR\|\|ASSOCIATED_WITH\|\|Prostate cancer metastatic:1691754	10/138,393	10/26,262,527	189.78	2.76e-18	3.46e-16
TRANSCRIPTION FACTOR\|\|INTERACTS_WITH\|\|Androgens:8954949	5/138,393	8/26,262,527	118.61	4.92e-09	2.37e-07
Prostatic Tissue\|\|LOCATION_OF\|\|GSTP1 gene\|GSTP1:7093504	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
CRISP-3 protein\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:11706394	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
physiological aspects\|\|PROCESS_OF\|\|Prostate:1896103	25/138,393	40/26,262,527	118.63	5.16e-40	1.74e-37
Prostatectomy\|\|PRECEDES\|\|Prostatectomy:2808427	7/138,393	11/26,262,527	120.77	3.29e-12	2.43e-10
Sexually Transmitted Diseases\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:5775308	6/138,393	8/26,262,527	142.33	6.01e-11	3.76e-09
docetaxel\|\|TREATS\|\|Refractory Carcinoma:6081875	7/138,393	16/26,262,527	83.03	2.48e-11	1.64e-09
Finasteride\|\|ISA\|\|5-Alpha reductase inhibitor:4154179	23/138,393	131/26,262,527	33.32	2.57e-26	5.04e-24
Prostatic Urethra\|\|LOCATION_OF\|\|Carcinoma in Situ:4525198	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Stanolone\|\|STIMULATES\|\|KLK3 gene\|KLK3:7678154	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Androgen Receptor\|AR\|\|DISRUPTS\|\|Transcription, Genetic:6700906	7/138,393	16/26,262,527	83.03	2.48e-11	1.64e-09
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Polish population:12732633	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
SRD5A2 gene\|SRD5A2\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:6425852	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Vitamin E\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:8160344	20/138,393	24/26,262,527	158.16	3.83e-34	1.04e-31
src-Family Kinases\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:12723756	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Estramustine\|\|USES\|\|Estramustine:1262601	12/138,393	19/26,262,527	119.86	5.54e-20	7.83e-18
Flutamide\|\|TREATS\|\|Malignant neoplasm of prostate:5114420	13/138,393	14/26,262,527	176.23	4.22e-23	7.15e-21
Anogenital region\|\|LOCATION_OF\|\|Incisional biopsy - action:128331	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Testosterone\|\|INHIBITS\|\|Stanolone:867744	6/138,393	43/26,262,527	26.48	2.39e-07	8.38e-06
tumor growth\|\|ASSOCIATED_WITH\|\|Prostate:7828186	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Prostate\|\|LOCATION_OF\|\|Tomography, Optical Coherence:8601225	5/138,393	10/26,262,527	94.89	1.14e-08	5.31e-07
8q24\|\|LOCATION_OF\|\|Carcinoma of the Large Intestine:12475542	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Malignant neoplasm of prostate\|\|MANIFESTATION_OF\|\|Tumorigenesis:7416481	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Brachytherapy\|\|PRECEDES\|\|Androgen therapy:9767648	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Prostatic Tissue\|\|LOCATION_OF\|\|Nodule:2790804	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostate\|\|LOCATION_OF\|\|Preservation, Biological:2281908	14/138,393	28/26,262,527	94.89	5.45e-22	8.79e-20
Prostate\|\|LOCATION_OF\|\|ABNORMAL GROWTH:2055215	29/138,393	42/26,262,527	131.06	4.04e-47	1.67e-44
Prostate\|\|PART_OF\|\|High-Grade Prostatic Intraepithelial Neoplasia:6594487	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
satraplatin\|\|TREATS\|\|Solid tumor:13510022	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Prostatic Intraepithelial Neoplasias\|\|COEXISTS_WITH\|\|Prostatic Intraepithelial Neoplasias:6314137	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
FAVOR\|\|INHIBITS\|\|Androgens:7027941	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Cholesterol\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:11026100	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Cryosurgery\|\|TREATS\|\|High-Risk Cancer:10058844	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Taxotere\|\|ISA\|\|docetaxel:5455637	81/138,393	677/26,262,527	22.72	2.03e-76	1.50e-73
Lymphoma, Non-Hodgkin's\|\|PART_OF\|\|Prostate:1880568	31/138,393	41/26,262,527	143.51	3.63e-51	1.63e-48
Prostate-Specific Antigen\|\|ASSOCIATED_WITH\|\|Pancreas:6769751	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
AR gene\|AR\|\|AFFECTS\|\|Malignant neoplasm of prostate:7188633	16/138,393	17/26,262,527	178.63	3.48e-28	7.27e-26
Epithelial Cells\|\|LOCATION_OF\|\|Malignant transformation:953946	34/138,393	235/26,262,527	27.46	1.37e-35	3.93e-33
Malignant neoplasm of prostate\|\|COEXISTS_WITH\|\|Benign prostatic hypertrophy:5551685	35/138,393	40/26,262,527	166.09	3.63e-59	1.91e-56
Prostate\|\|PART_OF\|\|Prostate:336517	46/138,393	103/26,262,527	84.78	5.11e-67	3.12e-64
gamma-Tocopherol\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:8907917	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Radical retropubic prostatectomy\|\|TREATS\|\|Adenocarcinoma:1806570	41/138,393	43/26,262,527	180.99	4.13e-70	2.68e-67
Asthenia\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:4661288	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Prostate cancer metastatic\|\|CAUSES\|\|Disseminated Intravascular Coagulation:1101088	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
peripheral blood\|\|LOCATION_OF\|\|KLK3 gene\|KLK3:8118959	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Prostate-Specific Antigen\|\|ASSOCIATED_WITH\|\|lymph nodes:5383027	11/138,393	15/26,262,527	139.17	5.90e-19	7.80e-17
tumor growth\|\|PART_OF\|\|Bladder:1117752	7/138,393	69/26,262,527	19.25	1.73e-07	6.12e-06
Tumor Suppressor Genes\|\|AFFECTS\|\|Prostate:12318823	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Flutamide\|\|INHIBITS\|\|Androgens:3314720	53/138,393	90/26,262,527	111.79	5.13e-82	4.00e-79
Androgen Receptor\|AR\|\|AUGMENTS\|\|Receptor Signaling:13593502	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Replacement therapy\|\|TREATS\|\|Hypogonadism:8588140	20/138,393	81/26,262,527	46.86	1.09e-25	2.08e-23
TGFB1 protein, human\|TGFB1\|\|ASSOCIATED_WITH\|\|Benign prostatic hypertrophy:5391607	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Prostatic Tissue\|\|LOCATION_OF\|\|TP53 gene\|TP53:7884925	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Matrix Metalloproteinases\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8346703	10/138,393	10/26,262,527	189.78	2.76e-18	3.46e-16
Supplementation\|\|METHOD_OF\|\|cancer prevention:4599802	5/138,393	8/26,262,527	118.61	4.92e-09	2.37e-07
Anti-Inflammatory Agents, Non-Steroidal\|\|TREATS\|\|Malignant neoplasm of prostate:9060938	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Prostatic Tissue\|\|LOCATION_OF\|\|Glutamate Carboxypeptidase II:7348998	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Epithelium\|\|PART_OF\|\|High-Grade Prostatic Intraepithelial Neoplasia:7967484	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Prostate\|\|LOCATION_OF\|\|Cyst:17191	6/138,393	42/26,262,527	27.11	2.11e-07	7.41e-06
Estrogens\|\|AFFECTS\|\|Prostate:317919	12/138,393	52/26,262,527	43.80	1.10e-15	1.12e-13
glutathione S-transferase pi\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9456029	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Apigenin\|\|ISA\|\|Flavonoids:2579910	13/138,393	302/26,262,527	8.17	1.95e-08	8.96e-07
Prostate\|\|LOCATION_OF\|\|Aggressive behavior:11611223	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Insulin-Like Growth Factor I\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:7236677	28/138,393	30/26,262,527	177.15	3.48e-48	1.48e-45
Phosphotransferases\|\|ASSOCIATED_WITH\|\|Neoplasm progression:7846238	6/138,393	29/26,262,527	39.26	2.96e-08	1.33e-06
Surgical Procedures, Laparoscopic\|\|TREATS\|\|Malignant neoplasm of prostate:5523922	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
Radical prostatectomy\|\|TREATS\|\|Prostate cancer metastatic:9731758	21/138,393	25/26,262,527	159.43	7.87e-36	2.27e-33
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Relative (related person):6107160	18/138,393	21/26,262,527	162.68	5.01e-31	1.19e-28
degarelix\|\|compared_with\|\|agonists:14027275	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Secondary malignant neoplasm of bone\|\|ASSOCIATED_WITH\|\|Prostate:6604963	11/138,393	12/26,262,527	173.97	1.05e-19	1.44e-17
Steroid hormone\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:5300346	10/138,393	9/26,262,527	210.87	1.39e-18	1.80e-16
Radical prostatectomy\|\|higher_than\|\|Patient observation:12632926	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Fluorouracil\|\|TREATS\|\|Prostate carcinoma:842910	5/138,393	4/26,262,527	237.22	4.90e-10	2.87e-08
Dietary Fats\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:7451798	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Young adult:2454187	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
Virus\|\|LOCATION_OF\|\|Propiolactone:305010	5/138,393	1/26,262,527	948.87	2.36e-11	1.58e-09
Prostatectomy\|\|METHOD_OF\|\|Radical prostatectomy:9253708	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
inhibitors\|\|ISA\|\|Chemicals:214254	39/138,393	1,952/26,262,527	3.79	8.37e-12	6.08e-10
Surface Antigens\|\|PART_OF\|\|Prostate:9007803	11/138,393	28/26,262,527	74.56	1.20e-16	1.37e-14
Androgen Receptor\|AR\|\|STIMULATES\|\|R-1881:9795314	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
ACAT1\|SLC25A5\|\|compared_with\|\|ACAT1\|SLC25A5:96630	7/138,393	20/26,262,527	66.42	8.81e-11	5.47e-09
docetaxel\|\|TREATS\|\|cohort:7917171	7/138,393	35/26,262,527	37.96	2.50e-09	1.26e-07
Etoposide\|\|TREATS\|\|Malignant neoplasm of prostate:4551094	11/138,393	14/26,262,527	149.11	3.42e-19	4.56e-17
zoledronic acid\|\|TREATS\|\|High-Risk Cancer:9997329	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Smooth muscle (tissue)\|\|PART_OF\|\|Prostate:2350776	13/138,393	127/26,262,527	19.43	8.72e-13	6.78e-11
Transurethral Resection of Prostate\|\|PRECEDES\|\|Transurethral Resection of Prostate:3138673	8/138,393	34/26,262,527	44.65	5.74e-11	3.64e-09
Smooth muscle (tissue)\|\|PART_OF\|\|Stroma:1018115	6/138,393	41/26,262,527	27.77	1.85e-07	6.54e-06
Androgen Antagonists\|\|TREATS\|\|Carcinoma:2077808	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Orchiectomy\|\|TREATS\|\|Metastatic Carcinoma:3103225	6/138,393	8/26,262,527	142.33	6.01e-11	3.76e-09
Prostate\|\|LOCATION_OF\|\|Ultrasonography, Doppler:4572538	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Breast\|\|LOCATION_OF\|\|Malignant neoplasm of prostate:7213888	16/138,393	18/26,262,527	168.70	6.55e-28	1.35e-25
Selenium\|\|INTERACTS_WITH\|\|Selenium:685963	13/138,393	191/26,262,527	12.92	1.03e-10	6.30e-09
Replacement blood transfusion\|\|TREATS\|\|Uremia:104666	9/138,393	1/26,262,527	1708.02	2.97e-20	4.33e-18
SLC25A4 protein, human\|SLC25A4\|\|PART_OF\|\|Malignant neoplasm of prostate:7465996	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Performance\|\|PROCESS_OF\|\|cohort:2738653	24/138,393	620/26,262,527	7.35	2.21e-13	1.89e-11
Androgen Receptor\|AR\|\|ISA\|\|Receptors, Nuclear:4705243	12/138,393	22/26,262,527	103.52	2.12e-19	2.85e-17
gene therapy\|\|TREATS\|\|Malignant neoplasm of prostate:5830456	121/138,393	152/26,262,527	151.20	6.22e-197	1.29e-193
Prostatic Intraepithelial Neoplasias\|\|PART_OF\|\|Prostate:5478298	22/138,393	23/26,262,527	181.55	2.47e-38	7.86e-36
Prostate-Specific Antigen\|\|PART_OF\|\|Surgical margins:6651329	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Human Age Group:5056216	11/138,393	12/26,262,527	173.97	1.05e-19	1.44e-17
Carcinogens\|\|CAUSES\|\|Prostatic Neoplasms:8609344	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostate\|\|LOCATION_OF\|\|Neoplasm Metastasis:949329	25/138,393	31/26,262,527	153.07	4.62e-42	1.68e-39
Neoplasm Metastasis\|\|ASSOCIATED_WITH\|\|Pelvic lymph node group:869051	19/138,393	56/26,262,527	64.39	1.01e-26	2.01e-24
Androgens\|\|STIMULATES\|\|Stanolone:2541766	5/138,393	13/26,262,527	72.99	3.20e-08	1.43e-06
Urokinase Plasminogen Activator Receptor\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:7846230	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Cell phenotype determination procedure\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:14958339	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Veterans:6239453	25/138,393	33/26,262,527	143.79	1.43e-41	5.10e-39
Malignant neoplasm of prostate\|\|AFFECTS\|\|cohort:12174732	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Entire neck\|\|LOCATION_OF\|\|APEX1 protein, human\|APEX1:7595171	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Cyproterone Acetate\|\|TREATS\|\|Malignant neoplasm of prostate:649297	36/138,393	39/26,262,527	175.22	2.13e-61	1.16e-58
Prostate carcinoma\|\|PART_OF\|\|Entire duct:1298822	7/138,393	11/26,262,527	120.77	3.29e-12	2.43e-10
Androgen therapy\|\|AFFECTS\|\|loss; bone:12148499	6/138,393	9/26,262,527	126.52	9.97e-11	6.13e-09
sulforafan\|\|DISRUPTS\|\|histone deacetylase activity:11623013	7/138,393	14/26,262,527	94.89	1.19e-11	8.48e-10
Malignant neoplasm of prostate\|\|LOCATION_OF\|\|Neoplastic Cell:8199899	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Benign prostatic hypertrophy\|\|PROCESS_OF\|\|Participant:4799839	6/138,393	15/26,262,527	75.91	1.05e-09	5.56e-08
Prostate carcinoma\|\|PART_OF\|\|Breast:1076072	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Bladder\|\|LOCATION_OF\|\|polyps:9336	5/138,393	15/26,262,527	63.26	5.75e-08	2.23e-06
Prostate size\|\|PROCESS_OF\|\|cohort:11051299	6/138,393	11/26,262,527	103.51	2.44e-10	1.46e-08
Malignant neoplasm of prostate\|\|LOCATION_OF\|\|macrophage:8729647	6/138,393	8/26,262,527	142.33	6.01e-11	3.76e-09
Cyproterone Acetate\|\|CAUSES\|\|Hepatitis:4414472	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Malignant neoplasm of prostate\|\|ASSOCIATED_WITH\|\|Intestines:7543351	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
hepsin\|HPN\|\|PART_OF\|\|Malignant neoplasm of prostate:9212011	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Prolactin\|PRL\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:1682600	12/138,393	11/26,262,527	207.04	5.52e-22	8.86e-20
Acupuncture procedure\|\|TREATS\|\|Malignant neoplasm of prostate:8268892	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
nilutamide\|\|ISA\|\|Androgen Antagonists:4108646	24/138,393	39/26,262,527	116.80	2.38e-38	7.61e-36
Urine\|\|LOCATION_OF\|\|TMPRSS2 gene\|TMPRSS2:12036998	15/138,393	18/26,262,527	158.16	5.88e-26	1.13e-23
Tumor Antigens\|\|PART_OF\|\|Dendritic Cells:5846352	14/138,393	223/26,262,527	11.91	5.43e-11	3.45e-09
TMPRSS2 gene\|TMPRSS2\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:11474227	42/138,393	48/26,262,527	166.10	1.10e-70	7.19e-68
Urethra\|\|PART_OF\|\|Prostate:1199450	5/138,393	8/26,262,527	118.61	4.92e-09	2.37e-07
Diphosphonates\|\|AFFECTS\|\|Malignant neoplasm of prostate:9922047	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Magnetic Resonance Imaging\|\|DIAGNOSES\|\|Carcinoma:2970759	7/138,393	51/26,262,527	26.05	2.59e-08	1.17e-06
Hydroxymethylglutaryl-CoA Reductase Inhibitors\|\|AFFECTS\|\|Neoplasm progression:14089322	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
cohort\|\|LOCATION_OF\|\|Prostate-Specific Antigen:6040470	36/138,393	40/26,262,527	170.84	4.02e-61	2.18e-58
Neck\|\|LOCATION_OF\|\|Breast:2488811	5/138,393	19/26,262,527	49.94	1.55e-07	5.48e-06
Doxorubicin\|\|USES\|\|Doxorubicin:1101191	40/138,393	2,099/26,262,527	3.62	1.82e-11	1.25e-09
Androgens\|\|AFFECTS\|\|Cell Proliferation:537325	16/138,393	37/26,262,527	82.07	4.01e-24	7.20e-22
Urothelium\|\|PART_OF\|\|Prostate:11051297	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Somatostatin Receptor\|\|ASSOCIATED_WITH\|\|Prostate:6436588	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Carcinoma, Transitional Cell\|\|PART_OF\|\|Prostatic Urethra:1295370	18/138,393	23/26,262,527	148.53	1.61e-30	3.77e-28
Leukocytes\|\|LOCATION_OF\|\|Adhesions:238195	3/138,393	4,747/26,262,527	0.12	9.49e-08	3.49e-06
2,3-bis(3'-hydroxybenzyl)butyrolactone\|\|PREVENTS\|\|Malignant neoplasm of prostate:11009557	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Metallothionein\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:5102657	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
ERBB2 gene\|ERBB2\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:5721794	20/138,393	24/26,262,527	158.16	3.83e-34	1.04e-31
Malignant neoplasm of prostate\|\|OCCURS_IN\|\|Black race:747578	10/138,393	9/26,262,527	210.87	1.39e-18	1.80e-16
Malignant neoplasm of prostate\|\|COEXISTS_WITH\|\|Secondary malignant neoplasm of bone:4898745	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Phosphoric Monoester Hydrolases\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:2006380	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Puboprostatic ligament\|\|LOCATION_OF\|\|Preservation, Biological:8796145	11/138,393	17/26,262,527	122.80	1.62e-18	2.10e-16
Hyperbaric Oxygenation\|\|TREATS\|\|Irradiation cystitis:5383029	8/138,393	37/26,262,527	41.03	1.03e-10	6.35e-09
Estrogens\|\|AFFECTS\|\|Malignant neoplasm of prostate:1980565	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Radical prostatectomy\|\|TREATS\|\|CAP - NOS:5795171	27/138,393	29/26,262,527	176.71	1.70e-46	6.90e-44
Primary Care Physicians\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:3658196	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Breast\|\|LOCATION_OF\|\|Single Nucleotide Polymorphism:14355572	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Prostate-Specific Antigen\|\|COEXISTS_WITH\|\|Single Nucleotide Polymorphism:13110533	8/138,393	11/26,262,527	138.02	4.09e-14	3.65e-12
TRANSCRIPTION FACTOR\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:6700909	36/138,393	36/26,262,527	189.82	2.92e-62	1.64e-59
Bladder\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8182232	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
GRP gene\|GRP\|\|PART_OF\|\|Prostate:17235092	11/138,393	18/26,262,527	115.98	2.60e-18	3.34e-16
Lymphoma\|\|ISA\|\|leukemia:41519	20/138,393	298/26,262,527	12.74	1.38e-15	1.40e-13
Glutamate Carboxypeptidase II\|\|INHIBITS\|\|Glutamate Carboxypeptidase II:9717442	5/138,393	9/26,262,527	105.43	7.62e-09	3.62e-07
Upper Extremity\|\|LOCATION_OF\|\|Biopsy:3111914	16/138,393	47/26,262,527	64.61	9.43e-23	1.57e-20
Flutamide\|\|TREATS\|\|Prostate cancer metastatic:3382880	16/138,393	17/26,262,527	178.63	3.48e-28	7.27e-26
MSMB gene\|MSMB\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:6943771	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
Biopsy\|\|USES\|\|Maps:3184145	23/138,393	66/26,262,527	66.14	2.97e-32	7.52e-30
zoledronic acid\|\|TREATS\|\|Cancer Patient:9102122	5/138,393	20/26,262,527	47.44	1.93e-07	6.79e-06
Proton beam\|\|PROCESS_OF\|\|Proton beam:663477	13/138,393	380/26,262,527	6.49	2.50e-07	8.66e-06
STAT3 gene\|STAT3\|\|INHIBITS\|\|STAT3 gene\|STAT3:7872260	10/138,393	131/26,262,527	14.49	5.18e-09	2.50e-07
hepsin\|HPN\|\|ISA\|\|Endopeptidases\|ERVK-10:10739022	5/138,393	9/26,262,527	105.43	7.62e-09	3.62e-07
Fibroblasts\|\|PART_OF\|\|Prostate:1082589	58/138,393	123/26,262,527	89.52	3.59e-85	2.94e-82
Vasoactive Intestinal Peptide\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:4216843	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Oat cell carcinoma\|\|PART_OF\|\|Prostate:3569795	40/138,393	63/26,262,527	120.52	2.65e-63	1.53e-60
Adenocarcinoma Cell\|\|PART_OF\|\|Prostate:1244984	138/138,393	160/26,262,527	163.84	8.28e-228	2.06e-224
Osteoblasts\|\|PART_OF\|\|Malignant neoplasm of prostate:8340656	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Xenograft procedure\|\|TREATS\|\|tumor growth:9330878	6/138,393	38/26,262,527	29.96	1.23e-07	4.49e-06
Invasive Carcinoma\|\|PART_OF\|\|Prostate:3821832	15/138,393	17/26,262,527	167.46	3.22e-26	6.27e-24
Scanning\|\|USES\|\|Reagents, Immunoassay, Tumor Marker, Enzyme, Prostate Specific Antigen:5728932	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Autophagy\|\|AFFECTS\|\|Malignant neoplasm of prostate:14930771	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Cyproterone Acetate\|\|COEXISTS_WITH\|\|Testosterone:2575794	5/138,393	8/26,262,527	118.61	4.92e-09	2.37e-07
Tumor Markers\|\|ASSOCIATED_WITH\|\|Prostate carcinoma:1291403	13/138,393	14/26,262,527	176.23	4.22e-23	7.15e-21
melanoma\|\|PART_OF\|\|Breast:257790	23/138,393	85/26,262,527	51.36	4.18e-30	9.59e-28
Prostate specific antigen measurement\|\|USES\|\|Periodicals:3375193	57/138,393	63/26,262,527	171.76	6.10e-96	5.94e-93
Androgen Receptor\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:1913900	25/138,393	25/26,262,527	189.80	1.08e-43	4.10e-41
KLK3 gene\|KLK3\|\|ASSOCIATED_WITH\|\|Neoplasm Metastasis:6802702	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Dutasteride\|\|ISA\|\|5-Alpha reductase inhibitor:11741600	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Refractory Neoplasm\|\|PART_OF\|\|Prostate:11063839	7/138,393	9/26,262,527	147.60	1.19e-12	9.12e-11
Cyclin E\|\|STIMULATES\|\|AR protein, human\|AR:8741907	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Brachytherapy\|\|PRECEDES\|\|Prostatectomy:10104893	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
AR gene\|AR\|\|ASSOCIATED_WITH\|\|Specimen from prostate:10442967	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Selenium\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:7947125	24/138,393	27/26,262,527	168.71	3.71e-41	1.30e-38
Human Glandular Kallikrein 2\|HK2\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:7548024	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Malignant neoplasm of prostate\|\|COEXISTS_WITH\|\|Prostate carcinoma:4083036	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
PTEN gene\|PTEN\|\|INTERACTS_WITH\|\|PTEN gene\|PTEN:7551462	10/138,393	94/26,262,527	20.19	2.61e-10	1.56e-08
Single Nucleotide Polymorphism\|\|COEXISTS_WITH\|\|KLK3 gene\|KLK3:13431838	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Carcinoma in Situ\|\|PART_OF\|\|Prostatic duct:201135	4/138,393	3/26,262,527	253.03	2.61e-08	1.17e-06
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Population at Risk:7983161	11/138,393	11/26,262,527	189.78	5.49e-20	7.78e-18
prostatitis\|\|ASSOCIATED_WITH\|\|Prostate:1196268	8/138,393	17/26,262,527	89.31	5.69e-13	4.59e-11
Radioimmunodetection\|\|USES\|\|Capromab Pendetide:7626813	9/138,393	13/26,262,527	131.39	1.40e-15	1.41e-13
Anorexia\|\|PROCESS_OF\|\|sibling:125912	23/138,393	4/26,262,527	1091.35	6.07e-49	2.64e-46
Transurethral Resection of Prostate\|\|TREATS\|\|Urinary tract obstruction:1284783	7/138,393	10/26,262,527	132.84	2.02e-12	1.52e-10
Carcinoma, Non-Small-Cell Lung\|\|ISA\|\|Solid tumor:2746332	8/138,393	69/26,262,527	22.00	8.70e-09	4.11e-07
Arsenal\|\|ISA\|\|Cancer Treatment:11212220	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Gonadotropin releasing hormone antagonist\|\|TREATS\|\|Malignant neoplasm of prostate:8604155	11/138,393	11/26,262,527	189.78	5.49e-20	7.78e-18
Mammalian Cell\|\|LOCATION_OF\|\|Amino Acid Transporter:1212276	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Gonadotropin-Releasing Hormone Analog\|\|TREATS\|\|Prostate carcinoma:2122259	16/138,393	19/26,262,527	159.82	1.20e-27	2.46e-25
Prostatic Intraepithelial Neoplasias\|\|PROCESS_OF\|\|Areae:5651052	12/138,393	15/26,262,527	151.83	6.95e-21	1.04e-18
Estramustine\|\|TREATS\|\|Prostate carcinoma:2999180	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Insulin-Like Growth Factor Binding Protein 3\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:7713861	21/138,393	22/26,262,527	181.17	1.21e-36	3.64e-34
Manipulation procedure\|\|USES\|\|Androgens:2419798	16/138,393	50/26,262,527	60.73	2.17e-22	3.57e-20
Ultrasonography, Doppler, Color\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:8721739	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Cytostatic Agents\|\|USES\|\|Cytostatic Agents:92503	34/138,393	1,997/26,262,527	3.23	8.48e-09	4.02e-07
Clinical Trials, Phase II\|\|USES\|\|Health care facility:2933618	16/138,393	230/26,262,527	13.20	5.45e-13	4.40e-11
Numbers\|\|ISA\|\|Common Terminology Criteria for Adverse Events:6215126	16/138,393	114/26,262,527	26.64	2.25e-17	2.65e-15
Bone Diseases\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:6790562	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Mitoxantrone\|\|ISA\|\|Antineoplastic Agents:2356486	12/138,393	115/26,262,527	19.80	5.30e-12	3.89e-10
Acid Phosphatase\|\|PART_OF\|\|Bone Marrow:817341	25/138,393	44/26,262,527	107.84	3.22e-39	1.06e-36
Clone Cells\|\|PART_OF\|\|Malignant neoplasm of prostate:2590606	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Flutamide\|\|ISA\|\|Nonsteroidal antiandrogen:922712	28/138,393	63/26,262,527	84.36	2.27e-41	8.01e-39
Pesticides\|\|CAUSES\|\|Malignant neoplasm of prostate:10279166	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
therapeutic protein\|\|TREATS\|\|Malignant neoplasm of prostate:12829130	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Bombesin Receptor\|\|PART_OF\|\|Malignant neoplasm of prostate:12174385	9/138,393	8/26,262,527	213.50	6.99e-17	8.04e-15
CHEK2 gene\|CHEK2\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:10388107	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Nutrients\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:3401859	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Testosterone\|\|AUGMENTS\|\|Prostate:550099	8/138,393	21/26,262,527	72.30	2.22e-12	1.66e-10
Tomography, Emission-Computed\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:13610971	17/138,393	15/26,262,527	215.10	8.94e-31	2.11e-28
Neoplasm Metastasis\|\|PART_OF\|\|soft tissue:47591	75/138,393	417/26,262,527	34.15	8.59e-83	6.83e-80
Adenocarcinoma\|\|ASSOCIATED_WITH\|\|Prostate:1147724	79/138,393	82/26,262,527	182.93	7.90e-134	1.15e-130
Clinical Trials, Phase II\|\|USES\|\|Longitudinal Studies:1462855	50/138,393	687/26,262,527	13.82	3.86e-38	1.23e-35
Androgens\|\|AUGMENTS\|\|[M]Unspecified tumor cell NOS:3820645	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
beta catenin\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:7711941	32/138,393	42/26,262,527	144.62	7.60e-53	3.52e-50
Androgen Receptor\|AR\|\|AFFECTS\|\|Neoplasm progression:9689849	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Androgen Antagonists\|\|STIMULATES\|\|Gonadorelin\|GNRH1:2523852	7/138,393	11/26,262,527	120.77	3.29e-12	2.43e-10
IODINE,I-125\|\|ASSOCIATED_WITH\|\|Prostate carcinoma:7189500	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
MCF7\|\|PART_OF\|\|Breast:4313400	8/138,393	41/26,262,527	37.03	2.12e-10	1.28e-08
Candidate Disease Gene\|\|TREATS\|\|Malignant neoplasm of prostate:7039295	53/138,393	56/26,262,527	179.67	4.79e-90	4.24e-87
Gonadorelin\|GNRH1\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:3082281	11/138,393	11/26,262,527	189.78	5.49e-20	7.78e-18
Prostate carcinoma\|\|LOCATION_OF\|\|Tumor cells, malignant:1147136	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Erythrocytes\|\|PART_OF\|\|Sheep:6851	5/138,393	10,022/26,262,527	0.09	1.20e-16	1.37e-14
Prostatic Intraepithelial Neoplasias\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:7110129	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Heme Oxygenase-1\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:13767965	5/138,393	8/26,262,527	118.61	4.92e-09	2.37e-07
Androgen therapy\|\|AFFECTS\|\|Cardiovascular morbidity:12565201	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Cyclophosphamide\|\|TREATS\|\|Prostate cancer metastatic:1507534	8/138,393	10/26,262,527	151.82	2.38e-14	2.15e-12
Hormone Antagonists\|\|TREATS\|\|Malignant neoplasm of prostate:8798018	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Disseminated Malignant Neoplasm\|\|PART_OF\|\|Prostate:2864065	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Serine Protease\|\|PART_OF\|\|integral to membrane:5544827	36/138,393	301/26,262,527	22.70	6.52e-35	1.82e-32
Glutamate Carboxypeptidase II\|\|COEXISTS_WITH\|\|Glutamate Carboxypeptidase II:16120205	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Seed Implantation\|\|USES\|\|IODINE,I-125:4696947	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Ions\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9139679	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Prostate carcinoma\|\|PART_OF\|\|Bladder:1561110	6/138,393	8/26,262,527	142.33	6.01e-11	3.76e-09
Prostate\|\|LOCATION_OF\|\|Calcitriol:8801379	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Malignant neoplasm of lung\|\|PART_OF\|\|Prostate:3122625	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Oncogene Proteins\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:14687839	4/138,393	3/26,262,527	253.03	2.61e-08	1.17e-06
IMMUNOHISTOCHEMICAL\|\|DIAGNOSES\|\|Adenocarcinoma of prostate:8366790	6/138,393	8/26,262,527	142.33	6.01e-11	3.76e-09
Imatinib mesylate\|\|TREATS\|\|Malignant neoplasm of prostate:10669382	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
Choline\|\|TREATS\|\|Malignant neoplasm of prostate:10633796	27/138,393	29/26,262,527	176.71	1.70e-46	6.90e-44
Vinblastine\|\|TREATS\|\|Hormone-refractory prostate cancer:2911087	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Androgen Antagonists\|\|INTERACTS_WITH\|\|Androgens:1062414	11/138,393	31/26,262,527	67.34	3.03e-16	3.19e-14
agonists\|\|AFFECTS\|\|Malignant neoplasm of prostate:3748158	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Teleradiotherapy procedure\|\|TREATS\|\|High-Risk Cancer:10217400	25/138,393	37/26,262,527	128.24	1.19e-40	4.12e-38
Clusterin\|CLU\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:10457474	11/138,393	12/26,262,527	173.97	1.05e-19	1.44e-17
% uptake\|\|ISA\|\|Percent (qualifier value):257535	12/138,393	289/26,262,527	7.88	9.86e-08	3.61e-06
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Electromagnetic Energy:7809986	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Diphosphonates\|\|TREATS\|\|Bone pain:5780401	13/138,393	42/26,262,527	58.74	2.67e-18	3.41e-16
Neoplasm Metastasis\|\|COEXISTS_WITH\|\|Neoplasm progression:4097296	5/138,393	15/26,262,527	63.26	5.75e-08	2.23e-06
Diet\|\|CAUSES\|\|Malignant neoplasm of prostate:7029246	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
silybin\|\|DISRUPTS\|\|Cell Proliferation:9125693	5/138,393	14/26,262,527	67.78	4.33e-08	1.92e-06
Bombesin\|\|ISA\|\|Peptides:901390	9/138,393	44/26,262,527	38.82	1.08e-11	7.73e-10
Androgen Receptor\|AR\|\|AUGMENTS\|\|Malignant neoplasm of prostate:9048785	15/138,393	14/26,262,527	203.34	4.49e-27	9.03e-25
Entire neck\|\|PART_OF\|\|Bladder:32722	35/138,393	259/26,262,527	25.65	1.17e-35	3.37e-33
Polyunsaturated Fatty Acids\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:11740945	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Radical prostatectomy\|\|compared_with\|\|Radical retropubic prostatectomy:6307088	23/138,393	48/26,262,527	90.95	7.34e-35	2.04e-32
Radical prostatectomy\|\|METHOD_OF\|\|Dissection:10933888	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
agonists\|\|PREDISPOSES\|\|Fracture:10792185	10/138,393	20/26,262,527	94.89	4.28e-16	4.50e-14
Hydroxymethylglutaryl-CoA Reductase Inhibitors\|\|AFFECTS\|\|Malignant neoplasm of prostate:11520521	5/138,393	4/26,262,527	237.22	4.90e-10	2.87e-08
Sectioning technique\|\|USES\|\|Mounts:9000606	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
polyestradiol phosphate\|\|USES\|\|polyestradiol phosphate:1271423	5/138,393	10/26,262,527	94.89	1.14e-08	5.31e-07
Radiotherapy, Intensity-Modulated\|\|TREATS\|\|AIDS related complex:11187021	16/138,393	128/26,262,527	23.72	1.19e-16	1.36e-14
High-Grade Prostatic Intraepithelial Neoplasia\|\|PRECEDES\|\|Malignant neoplasm of prostate:8267112	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Adenocarcinoma\|\|PART_OF\|\|Colon:50875	82/138,393	3,638/26,262,527	4.28	3.30e-26	6.42e-24
Anti-Anxiety Agents\|\|TREATS\|\|Malignant neoplasm of prostate:11691955	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Ethnic group\|\|LOCATION_OF\|\|Prostate-Specific Antigen:10413802	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Angiogenesis\|\|PROCESS_OF\|\|Breast:6423604	7/138,393	10/26,262,527	132.84	2.02e-12	1.52e-10
Radioimmunoassay\|\|METHOD_OF\|\|Prostate specific antigen measurement:2789310	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Clinical Trials\|\|USES\|\|Health care facility:1507532	20/138,393	374/26,262,527	10.15	7.75e-14	6.82e-12
Testosterone\|\|PART_OF\|\|Prostate:265428	9/138,393	29/26,262,527	58.90	4.25e-13	3.43e-11
Combination Drug Therapy\|\|USES\|\|Estramustine phosphate:9676825	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
IODINE,I-125\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:6974428	13/138,393	13/26,262,527	189.79	2.20e-23	3.82e-21
Radical prostatectomy\|\|TREATS\|\|Observation parameter:6287326	11/138,393	12/26,262,527	173.97	1.05e-19	1.44e-17
Radical prostatectomy\|\|TREATS\|\|Prostate carcinoma:117488	135/138,393	151/26,262,527	169.82	2.17e-224	5.25e-221
[M]Unspecified tumor cell NOS\|\|LOCATION_OF\|\|Androgen Receptor\|AR:3879217	7/138,393	9/26,262,527	147.60	1.19e-12	9.12e-11
Brachytherapy\|\|TREATS\|\|Toxic effect:8700000	9/138,393	25/26,262,527	68.32	1.39e-13	1.21e-11
Prostate\|\|LOCATION_OF\|\|Adenocarcinoma of prostate:4641059	6/138,393	8/26,262,527	142.33	6.01e-11	3.76e-09
MSMB gene\|MSMB\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:7202874	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Epithelium\|\|LOCATION_OF\|\|Prostate carcinoma:3569760	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
melanoma\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:7233415	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostatic Tissue\|\|LOCATION_OF\|\|Acid Phosphatase:1199453	11/138,393	20/26,262,527	104.38	6.31e-18	7.68e-16
Acetate\|\|compared_with\|\|Prednisone:15881829	6/138,393	5/26,262,527	227.73	9.37e-12	6.74e-10
Cancer Registry\|\|ISA\|\|Databases:3416237	26/138,393	325/26,262,527	15.18	1.42e-21	2.22e-19
Ibuprofen\|\|STIMULATES\|\|CUX1\|HCLS1\|TNFRSF1B\|PSIP1\|SIGLEC7:12301364	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Proto-Oncogene Proteins c-akt\|AKT1\|\|INTERACTS_WITH\|\|Androgen Receptor\|AR:8898032	10/138,393	12/26,262,527	158.15	9.56e-18	1.15e-15
Soy Proteins\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:8811240	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Benign prostatic hypertrophy\|\|PROCESS_OF\|\|Japanese Population:8497855	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|European American:11174931	11/138,393	12/26,262,527	173.97	1.05e-19	1.44e-17
Prostate\|\|LOCATION_OF\|\|Microarray Analysis:9915042	7/138,393	10/26,262,527	132.84	2.02e-12	1.52e-10
Polymorphism, Genetic\|\|ASSOCIATED_WITH\|\|E-Cadherin:10267410	5/138,393	13/26,262,527	72.99	3.20e-08	1.43e-06
Prostate\|\|LOCATION_OF\|\|Digital Rectal Examination:321460	41/138,393	59/26,262,527	131.91	4.67e-66	2.81e-63
Ambulatory Care Facilities\|\|LOCATION_OF\|\|Digital Rectal Examination:3855784	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Prostate-Specific Antigen\|\|PART_OF\|\|Prostatic epithelium:6427075	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
IMMUNOHISTOCHEMICAL\|\|DIAGNOSES\|\|Prostate carcinoma:2779503	14/138,393	17/26,262,527	156.30	2.88e-24	5.18e-22
Testosterone\|\|STIMULATES\|\|Gonadorelin\|GNRH1:1335483	8/138,393	64/26,262,527	23.72	5.06e-09	2.44e-07
Prostate\|\|LOCATION_OF\|\|Epithelial Cells:910134	56/138,393	131/26,262,527	81.15	2.34e-80	1.80e-77
Tumor-Associated Vasculature\|\|PART_OF\|\|Solid tumor:3185824	37/138,393	45/26,262,527	156.07	9.54e-62	5.28e-59
Bladder\|\|LOCATION_OF\|\|Magnetic Resonance Imaging:2970614	8/138,393	34/26,262,527	44.65	5.74e-11	3.64e-09
Cytotoxic agent\|\|TREATS\|\|Malignant neoplasm of prostate:2043806	16/138,393	17/26,262,527	178.63	3.48e-28	7.27e-26
Immunotherapy\|\|TREATS\|\|Malignant neoplasm of urinary bladder:1528914	10/138,393	129/26,262,527	14.71	4.51e-09	2.21e-07
glycosylation\|\|PROCESS_OF\|\|Malignant neoplasm of prostate:10198475	8/138,393	7/26,262,527	216.89	3.55e-15	3.52e-13
Growth Factor\|\|CAUSES\|\|Malignant neoplasm of prostate:3882875	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Support, device\|\|TREATS\|\|Fever:236684	38/138,393	4/26,262,527	1803.29	2.39e-82	1.89e-79
Biopsy of prostate\|\|ISA\|\|Procedures:10597631	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Prostate\|\|LOCATION_OF\|\|Atrophic:4890	35/138,393	122/26,262,527	54.46	9.34e-46	3.73e-43
KLK3 gene\|KLK3\|\|INTERACTS_WITH\|\|Prostate-Specific Antigen:8025361	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Prostatectomy\|\|METHOD_OF\|\|Prostatectomy:4510982	11/138,393	18/26,262,527	115.98	2.60e-18	3.34e-16
Prostate\|\|LOCATION_OF\|\|Neurovascular bundle:6312314	6/138,393	13/26,262,527	87.59	5.31e-10	3.10e-08
Chemoprevention\|\|USES\|\|Anti-Inflammatory Agents, Non-Steroidal:5364729	8/138,393	90/26,262,527	16.87	5.90e-08	2.29e-06
Androgens\|\|STIMULATES\|\|Reactive Oxygen Species:8344493	7/138,393	9/26,262,527	147.60	1.19e-12	9.12e-11
Caucasoid Race\|\|LOCATION_OF\|\|KLK3 gene\|KLK3:8525692	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Androgen therapy\|\|AFFECTS\|\|Adverse effects:9616937	17/138,393	17/26,262,527	189.79	3.65e-30	8.38e-28
External Beam Radiation Therapy\|\|TREATS\|\|Adenocarcinoma of prostate:4688431	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Prostate\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of urinary bladder:7741067	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Radical prostatectomy\|\|USES\|\|Robotic Systems:10201845	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Epidermal Growth Factor Receptor\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:4173460	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Pelvis\|\|LOCATION_OF\|\|Enlargement of lymph nodes:112043	10/138,393	48/26,262,527	39.54	6.50e-13	5.23e-11
Neoadjuvant Therapy\|\|TREATS\|\|Malignant neoplasm of prostate:5385295	94/138,393	110/26,262,527	162.27	1.80e-155	2.98e-152
External Beam Radiation Therapy\|\|TREATS\|\|Secondary malignant neoplasm of bone:9707656	5/138,393	15/26,262,527	63.26	5.75e-08	2.23e-06
Tissue specimen\|\|PART_OF\|\|Malignant neoplasm of prostate:3931624	41/138,393	43/26,262,527	180.99	4.13e-70	2.68e-67
Basal Cell\|\|PART_OF\|\|Prostatic Intraepithelial Neoplasias:5410417	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Prostate\|\|PART_OF\|\|Stroma:1841723	6/138,393	16/26,262,527	71.17	1.44e-09	7.58e-08
Calcium\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:7983164	22/138,393	23/26,262,527	181.55	2.47e-38	7.86e-36
Solid tumor\|\|PART_OF\|\|Breast:996655	7/138,393	42/26,262,527	31.63	7.70e-09	3.65e-07
ELAC2\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:9809203	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Dysplasia\|\|ASSOCIATED_WITH\|\|Prostate:3071560	10/138,393	16/26,262,527	118.61	7.71e-17	8.83e-15
Malignant neoplasm of prostate\|\|COEXISTS_WITH\|\|Neoplasm progression:7027913	15/138,393	16/26,262,527	177.93	1.72e-26	3.38e-24
Gonadotropin-Releasing Hormone Receptor\|\|PART_OF\|\|Malignant neoplasm of prostate:8001477	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Radiotherapy, Intensity-Modulated\|\|compared_with\|\|Radiotherapy, Intensity-Modulated:8879244	6/138,393	41/26,262,527	27.77	1.85e-07	6.54e-06
RASSF1A\|RASSF1\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9790568	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
CDK2 gene\|CDK2\|\|STIMULATES\|\|IFI27\|PSMD9\|SSSCA1\|DCTN6\|TMED7:7420733	7/138,393	29/26,262,527	45.81	7.95e-10	4.59e-08
Tissue specimen\|\|LOCATION_OF\|\|Immunohistochemistry:2918277	14/138,393	267/26,262,527	9.95	5.06e-10	2.96e-08
in vitro Model\|\|METHOD_OF\|\|Carcinogenesis Mechanism:9383628	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Carcinoma in Situ\|\|ASSOCIATED_WITH\|\|Prostatic Urethra:3382877	15/138,393	19/26,262,527	149.83	1.05e-25	2.00e-23
Serum testosterone measurement\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:10957601	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Magnetic Resonance Imaging\|\|METHOD_OF\|\|Biopsy:3142777	50/138,393	146/26,262,527	65.01	6.27e-68	3.91e-65
Benign prostatic hypertrophy\|\|COEXISTS_WITH\|\|Prostate carcinoma:4188175	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
docetaxel\|\|compared_with\|\|Prednisone:10882546	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Androgen Antagonists\|\|INHIBITS\|\|Androgens:1204767	68/138,393	83/26,262,527	155.55	4.76e-112	5.50e-109
GSTP1 gene\|GSTP1\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:7717718	15/138,393	19/26,262,527	149.83	1.05e-25	2.00e-23
Malignant neoplasm of prostate\|\|AFFECTS\|\|Tumorigenicity:8025363	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostate\|\|LOCATION_OF\|\|tomography:251172	28/138,393	38/26,262,527	139.86	3.93e-46	1.58e-43
Doxorubicin\|\|TREATS\|\|Hormone-refractory prostate cancer:5167689	7/138,393	10/26,262,527	132.84	2.02e-12	1.52e-10
Castration, Male\|\|USES\|\|agonists:9976611	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Androgens\|\|ASSOCIATED_WITH\|\|Pathogenesis:1184943	12/138,393	74/26,262,527	30.78	4.60e-14	4.09e-12
Female\|\|PROCESS_OF\|\|Workers:50272	7/138,393	8,076/26,262,527	0.16	4.54e-11	2.90e-09
Xenograft procedure\|\|TREATS\|\|Malignant neoplasm of prostate:7081705	12/138,393	12/26,262,527	189.78	1.10e-21	1.72e-19
Stanolone\|\|COEXISTS_WITH\|\|Stanolone:1170379	8/138,393	31/26,262,527	48.98	3.03e-11	2.01e-09
Tea\|\|ISA\|\|Beverages:891835	16/138,393	517/26,262,527	5.87	4.12e-08	1.84e-06
Polymerase Chain Reaction\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:5717664	21/138,393	21/26,262,527	189.80	6.22e-37	1.90e-34
enzyme therapy\|\|TREATS\|\|Malignant neoplasm of prostate:11763992	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Interleukin-6\|IL6\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:4569473	5/138,393	4/26,262,527	237.22	4.90e-10	2.87e-08
Medical Imaging\|\|USES\|\|Imaging Device:2679843	8/138,393	67/26,262,527	22.66	7.04e-09	3.38e-07
Prostate\|\|LOCATION_OF\|\|Hypoxia:9458229	6/138,393	10/26,262,527	113.87	1.59e-10	9.61e-09
docetaxel\|\|TREATS\|\|Neoplasm Metastasis:5968405	9/138,393	41/26,262,527	41.66	6.17e-12	4.50e-10
taxane\|\|TREATS\|\|Hormone-refractory prostate cancer:8067680	12/138,393	12/26,262,527	189.78	1.10e-21	1.72e-19
Tumor cells, malignant\|\|LOCATION_OF\|\|targeting:5614807	16/138,393	291/26,262,527	10.44	1.55e-11	1.10e-09
Acetate\|\|INHIBITS\|\|CYP17A1 gene\|CYP17A1:13614152	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
rodent cell line\|\|PART_OF\|\|Malignant neoplasm of prostate:6411840	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Male gender\|\|PROCESS_OF\|\|African American:1104435	40/138,393	411/26,262,527	18.47	2.21e-35	6.31e-33
Malignant neoplasm of prostate\|\|PART_OF\|\|Solid organ:14677504	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Prostate cancer recurrent\|\|PROCESS_OF\|\|cohort:14566664	8/138,393	7/26,262,527	216.89	3.55e-15	3.52e-13
inhibitors\|\|TREATS\|\|Malignant neoplasm of prostate:15928675	16/138,393	1/26,262,527	3036.63	5.49e-36	1.61e-33
Charts\|\|TREATS\|\|Malignant neoplasm of prostate:9551880	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Clinic\|\|USES\|\|urology:160752	52/138,393	198/26,262,527	49.86	1.87e-65	1.12e-62
Prostate\|\|LOCATION_OF\|\|Positron-Emission Tomography:9720150	10/138,393	11/26,262,527	172.53	5.24e-18	6.40e-16
Monoclonal Antibodies\|\|STIMULATES\|\|NF-kappa B:5925787	9/138,393	43/26,262,527	39.72	8.97e-12	6.51e-10
Prostate\|\|LOCATION_OF\|\|Doxorubicin:11252379	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Stanolone\|\|CAUSES\|\|Cell Proliferation:2361229	5/138,393	8/26,262,527	118.61	4.92e-09	2.37e-07
Osteoblasts\|\|LOCATION_OF\|\|Prostate cancer metastatic:6381276	11/138,393	12/26,262,527	173.97	1.05e-19	1.44e-17
Immunohistochemistry\|\|DIAGNOSES\|\|Adenocarcinoma of prostate:6088400	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Candidate Disease Gene\|\|PART_OF\|\|Malignant neoplasm of prostate:10419317	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostatic Tissue\|\|LOCATION_OF\|\|estramustine-binding protein:3761339	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Head and neck structure\|\|LOCATION_OF\|\|Malignant neoplasm of prostate:7852745	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Prostatectomy\|\|TREATS\|\|Prostate cancer recurrent:8606649	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Prostatectomy\|\|ADMINISTERED_TO\|\|Surgeon:6308792	19/138,393	21/26,262,527	171.72	5.53e-33	1.43e-30
Prostate carcinoma\|\|COEXISTS_WITH\|\|Benign prostatic hypertrophy:3837664	10/138,393	11/26,262,527	172.53	5.24e-18	6.40e-16
Chemotherapy-Oncologic Procedure\|\|USES\|\|docetaxel:6880382	7/138,393	53/26,262,527	25.06	3.29e-08	1.47e-06
Cardiopulmonary\|\|LOCATION_OF\|\|Exercise stress test:2761148	1/138,393	4,165/26,262,527	0.05	1.79e-08	8.21e-07
Tamoxifen\|\|TREATS\|\|Hormone-refractory prostate cancer:6313569	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Metastatic malignant neoplasm to brain\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:9600506	4/138,393	3/26,262,527	253.03	2.61e-08	1.17e-06
Immunotherapy, Active\|\|TREATS\|\|Malignant neoplasm of prostate:6484163	10/138,393	10/26,262,527	189.78	2.76e-18	3.46e-16
Prostate\|\|LOCATION_OF\|\|Zinc measurement:1791727	5/138,393	16/26,262,527	59.30	7.51e-08	2.91e-06
Mouse Pancreatic Intraepithelial Neoplasia-2\|\|PART_OF\|\|Prostate:1514910	18/138,393	20/26,262,527	170.81	2.71e-31	6.53e-29
Radical retropubic prostatectomy\|\|ADMINISTERED_TO\|\|Surgeon:4834698	25/138,393	31/26,262,527	153.07	4.62e-42	1.68e-39
Casodex\|\|USES\|\|Casodex:5114433	12/138,393	13/26,262,527	175.19	2.10e-21	3.22e-19
External Beam Radiation Therapy\|\|METHOD_OF\|\|Implantation procedure:7212592	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Brachytherapy implant\|\|TREATS\|\|Malignant neoplasm of prostate:2742104	9/138,393	12/26,262,527	142.33	8.30e-16	8.48e-14
Prostate Rhabdomyosarcoma\|\|PROCESS_OF\|\|Boys:3031746	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Endocrine therapy\|\|TREATS\|\|Prostatic Neoplasms:144187	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Gonadotropin-Releasing Hormone Analog\|\|TREATS\|\|Carcinoma:3133331	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Diagnostic Neoplasm Staging\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:4328979	8/138,393	7/26,262,527	216.89	3.55e-15	3.52e-13
Cyclosporine\|\|USES\|\|Cyclosporine:1431739	3/138,393	5,145/26,262,527	0.11	1.16e-08	5.40e-07
lymph nodes\|\|LOCATION_OF\|\|Prostate cancer metastatic:2109890	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Cancer Vaccines\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:13311867	4/138,393	3/26,262,527	253.03	2.61e-08	1.17e-06
Endocrine therapy\|\|TREATS\|\|Malignant neoplasm of prostate:100742	547/138,393	650/26,262,527	160.33	0.00e+00	0.00e+00
Testosterone measurement\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:904238	11/138,393	13/26,262,527	160.59	1.92e-19	2.59e-17
Life Style\|\|PROCESS_OF\|\|Cancer Survivor:10863803	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
lymph nodes\|\|LOCATION_OF\|\|Malignant neoplasm of prostate:6522773	5/138,393	4/26,262,527	237.22	4.90e-10	2.87e-08
Malignant neoplasm of prostate\|\|PART_OF\|\|Prostatic Tissue:2758267	12/138,393	13/26,262,527	175.19	2.10e-21	3.22e-19
ZEB1\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:12952761	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostate\|\|LOCATION_OF\|\|Antigen assay:3137098	7/138,393	9/26,262,527	147.60	1.19e-12	9.12e-11
Prostate\|\|PART_OF\|\|American:9844660	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
R-1881\|\|STIMULATES\|\|Prostate-Specific Antigen:5049578	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Cyclin D1\|CCND1\|\|STIMULATES\|\|IFI27\|PSMD9\|SSSCA1\|DCTN6\|TMED7:8751709	7/138,393	39/26,262,527	34.06	4.87e-09	2.37e-07
Image analysis\|\|USES\|\|Video:2710001	13/138,393	252/26,262,527	9.79	2.51e-09	1.26e-07
Proteome\|\|PART_OF\|\|Malignant neoplasm of prostate:10456820	11/138,393	10/26,262,527	208.76	2.76e-20	4.03e-18
Insulin-Like Growth Factor I\|\|ISA\|\|Somatomedins:2021055	68/138,393	2,634/26,262,527	4.90	3.95e-25	7.44e-23
Prostatectomy, Retropubic\|\|compared_with\|\|Radical prostatectomy:12992679	14/138,393	15/26,262,527	177.13	8.52e-25	1.56e-22
Cyst\|\|LOCATION_OF\|\|Malignant neoplasm of prostate:9332360	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
BRCA2 gene\|BRCA2\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:8329707	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
Prostate-Specific Antigen\|\|PART_OF\|\|cohort:8009415	11/138,393	10/26,262,527	208.76	2.76e-20	4.03e-18
BRCA1 gene\|BRCA1\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:8329706	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
CA2\|\|PART_OF\|\|Protoplasm:610549	24/138,393	12,611/26,262,527	0.36	3.69e-09	1.81e-07
Malignant neoplasm of prostate\|\|MANIFESTATION_OF\|\|Malignant neoplasm of prostate:6356611	55/138,393	55/26,262,527	189.84	2.74e-94	2.62e-91
Solid tumor\|\|ISA\|\|Malignant neoplasm of prostate:9913557	18/138,393	18/26,262,527	189.79	7.40e-32	1.83e-29
TWIST1 gene\|TWIST1\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:13079561	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Biopsy\|\|DIAGNOSES\|\|prostatitis:8801294	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Stem cells\|\|PART_OF\|\|Prostate:6173381	79/138,393	161/26,262,527	93.17	1.76e-116	2.14e-113
Hormone Receptor\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:3725290	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Chromosomal Rearrangement\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:12485775	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
PSCA gene\|PSCA\|\|PREDISPOSES\|\|Malignant neoplasm of stomach:14517126	6/138,393	8/26,262,527	142.33	6.01e-11	3.76e-09
Heat shock proteins\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8748118	9/138,393	11/26,262,527	155.27	4.76e-16	4.94e-14
Teleradiotherapy procedure\|\|TREATS\|\|Prostate cancer recurrent:10487737	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Androgen Suppression\|\|TREATS\|\|High-Risk Cancer:10780503	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Gene Silencing\|\|PROCESS_OF\|\|Cancer Model:15200496	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Prostatic Tissue\|\|LOCATION_OF\|\|Estrogens:2703103	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
GSTT1 gene\|GSTT1\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:10883509	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
2-(4-isothiocyanatobenzyl)-6-methyldiethylenetriaminepentaacetic acid\|\|ISA\|\|Acids:11796389	5/138,393	13/26,262,527	72.99	3.20e-08	1.43e-06
CD44 gene\|CD44\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:6732670	10/138,393	12/26,262,527	158.15	9.56e-18	1.15e-15
Testosterone\|\|AFFECTS\|\|Prostate:526268	6/138,393	35/26,262,527	32.53	7.97e-08	3.08e-06
Tea\|\|AFFECTS\|\|Malignant neoplasm of prostate:11498065	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Polymorphism, Genetic\|\|ASSOCIATED_WITH\|\|Steroid 17-alpha-monooxygenase:8402637	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostate\|\|LOCATION_OF\|\|Premalignant Change:839926	8/138,393	7/26,262,527	216.89	3.55e-15	3.52e-13
Cell surface\|\|PART_OF\|\|Malignant neoplasm of prostate:12416721	4/138,393	3/26,262,527	253.03	2.61e-08	1.17e-06
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Animal Model:1333486	52/138,393	55/26,262,527	179.48	2.32e-88	1.99e-85
Rectum\|\|LOCATION_OF\|\|PROTECTION:4689322	5/138,393	8/26,262,527	118.61	4.92e-09	2.37e-07
Fatty-acid synthase\|\|PART_OF\|\|Malignant neoplasm of prostate:8785205	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Androgens\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:4299591	25/138,393	28/26,262,527	169.47	7.61e-43	2.83e-40
adenoma\|\|PART_OF\|\|Prostate:60311	53/138,393	153/26,262,527	65.76	3.99e-72	2.72e-69
Screening procedure\|\|TREATS\|\|Normal pregnancy:4551673	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Brachytherapy\|\|METHOD_OF\|\|Teleradiotherapy procedure:4399181	8/138,393	40/26,262,527	37.96	1.78e-10	1.08e-08
Radical prostatectomy\|\|PRECEDES\|\|Radiotherapy, Intensity-Modulated:13795881	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Multiple Myeloma\|\|PART_OF\|\|Entire lip:3049683	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
bicalutamide\|\|compared_with\|\|Flutamide:6307067	15/138,393	20/26,262,527	142.34	1.82e-25	3.46e-23
Castration\|\|USES\|\|Androgen Antagonists:1186994	11/138,393	16/26,262,527	130.48	9.91e-19	1.30e-16
Magnetic Resonance Imaging\|\|DIAGNOSES\|\|Secondary malignant neoplasm of bone:4358476	14/138,393	83/26,262,527	32.01	2.20e-16	2.40e-14
Prostate carcinoma\|\|PROCESS_OF\|\|Black race:910165	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
DNA Sequence\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:5046147	12/138,393	13/26,262,527	175.19	2.10e-21	3.22e-19
Vaccine Therapy\|\|TREATS\|\|Malignant neoplasm of prostate:6272348	11/138,393	12/26,262,527	173.97	1.05e-19	1.44e-17
Primary Neoplasm\|\|ASSOCIATED_WITH\|\|Bladder:1238445	6/138,393	26/26,262,527	43.79	1.67e-08	7.69e-07
cyclooxygenase 2\|\|ASSOCIATED_WITH\|\|Prostate:8547105	6/138,393	11/26,262,527	103.51	2.44e-10	1.46e-08
Vitamin D3 Receptor\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:7643370	11/138,393	12/26,262,527	173.97	1.05e-19	1.44e-17
Photochemotherapy\|\|TREATS\|\|Prostate carcinoma:8000664	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Salvage Therapy\|\|TREATS\|\|Prostate cancer recurrent:7923188	32/138,393	32/26,262,527	189.81	1.64e-55	8.04e-53
Prostate\|\|LOCATION_OF\|\|Autopsy:1976536	5/138,393	9/26,262,527	105.43	7.62e-09	3.62e-07
Prostate\|\|LOCATION_OF\|\|Polymerase Chain Reaction:4288634	9/138,393	15/26,262,527	113.87	3.64e-15	3.60e-13
Down-Regulation\|\|AFFECTS\|\|Malignant neoplasm of prostate:9632120	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Brachytherapy\|\|compared_with\|\|Prostatectomy:9295806	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Phyllodes Tumor\|\|PART_OF\|\|Prostate:3143332	30/138,393	66/26,262,527	86.28	1.88e-44	7.32e-42
Androgen Receptor\|AR\|\|INTERACTS_WITH\|\|Regulatory Sequences, Nucleic Acid:12230102	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Androgens\|\|AUGMENTS\|\|androgen receptor activity:8842442	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Polyamines\|\|DISRUPTS\|\|Cell Growth:5683571	6/138,393	17/26,262,527	66.98	1.94e-09	9.82e-08
Prostate\|\|LOCATION_OF\|\|Neodymium:5914621	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Epithelial Cells\|\|LOCATION_OF\|\|Cell Transformation, Neoplastic:849058	8/138,393	101/26,262,527	15.03	1.35e-07	4.92e-06
Honvan\|\|ISA\|\|fosfestrol:283248	8/138,393	12/26,262,527	126.52	6.79e-14	6.00e-12
CAP - NOS\|\|PREDISPOSES\|\|CAP - NOS:9831509	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
Cytotoxic Chemotherapy\|\|USES\|\|docetaxel:8514682	5/138,393	8/26,262,527	118.61	4.92e-09	2.37e-07
Prostate-Specific Antigen\|\|PART_OF\|\|Mice, Transgenic:7242672	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
ERBB2\|NEU1\|NEURL1\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:5210899	15/138,393	21/26,262,527	135.56	3.11e-25	5.86e-23
Needle biopsy procedure\|\|DIAGNOSES\|\|Prostate carcinoma:156373	21/138,393	23/26,262,527	173.29	2.30e-36	6.86e-34
Transrectal Ultrasound\|\|ISA\|\|Scanning:1872500	10/138,393	30/26,262,527	63.26	1.15e-14	1.09e-12
Pelvic lymph node group\|\|ASSOCIATED_WITH\|\|High-Risk Cancer:7392922	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Breast\|\|ASSOCIATED_WITH\|\|Secondary malignant neoplasm of bone:6395939	19/138,393	22/26,262,527	163.91	1.03e-32	2.63e-30
Prostate-Specific Antigen\|\|ASSOCIATED_WITH\|\|Upper Extremity:6279093	10/138,393	11/26,262,527	172.53	5.24e-18	6.40e-16
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Author:4659160	10/138,393	10/26,262,527	189.78	2.76e-18	3.46e-16
Dependence\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:7990828	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Gonadotropin-Releasing Hormone Analog\|\|INHIBITS\|\|Androgens:3866395	23/138,393	27/26,262,527	161.68	3.33e-39	1.09e-36
Tumor cells, malignant\|\|LOCATION_OF\|\|Androgen Receptor\|AR:7776724	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Biopsy\|\|METHOD_OF\|\|Prostate specific antigen measurement:3433319	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
ERBB2\|NEU1\|NEURL1\|\|PART_OF\|\|Malignant neoplasm of prostate:6679346	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
PSCA gene\|PSCA\|\|PART_OF\|\|Malignant neoplasm of prostate:7569684	10/138,393	11/26,262,527	172.53	5.24e-18	6.40e-16
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Family member:8083024	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
Needle biopsy procedure\|\|METHOD_OF\|\|Biopsy:1019485	9/138,393	33/26,262,527	51.76	1.14e-12	8.83e-11
Cyproterone Acetate\|\|compared_with\|\|Diethylstilbestrol:2838627	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Androgens\|\|AUGMENTS\|\|Cell Growth:2322767	5/138,393	9/26,262,527	105.43	7.62e-09	3.62e-07
Brachytherapy\|\|compared_with\|\|Brachytherapy:2411203	13/138,393	50/26,262,527	49.34	1.85e-17	2.19e-15
Cystography\|\|DIAGNOSES\|\|Extravasation:3054279	6/138,393	38/26,262,527	29.96	1.23e-07	4.49e-06
Stanolone\|\|AUGMENTS\|\|Cell Proliferation:2083627	7/138,393	11/26,262,527	120.77	3.29e-12	2.43e-10
Neuroectodermal Tumors\|\|PART_OF\|\|Prostate:10157673	6/138,393	14/26,262,527	81.33	7.55e-10	4.37e-08
estramustine-binding protein\|\|ASSOCIATED_WITH\|\|Prostate carcinoma:3844676	5/138,393	9/26,262,527	105.43	7.62e-09	3.62e-07
Antineoplastic Agents\|\|TREATS\|\|Prostate carcinoma:1280739	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Cytoplasm\|\|PART_OF\|\|Columnar epithelial cell:496362	8/138,393	77/26,262,527	19.72	1.92e-08	8.79e-07
Hodgkin Disease\|\|PART_OF\|\|Entire lip:3049686	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Reconstructive Surgical Procedures\|\|TREATS\|\|Malignant neoplasm of prostate:8172156	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
Prostate-Specific Antigen\|\|PART_OF\|\|Single Nucleotide Polymorphism:13318398	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
S100P gene\|S100P\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:7599816	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Selenium\|\|ISA\|\|Antioxidants:1202933	11/138,393	250/26,262,527	8.35	1.92e-07	6.77e-06
Positron-Emission Tomography\|\|USES\|\|Acetate:4705939	14/138,393	130/26,262,527	20.44	6.16e-14	5.47e-12
Carcinogenesis\|\|PROCESS_OF\|\|Animal Model:1202942	20/138,393	165/26,262,527	23.01	3.36e-20	4.88e-18
Epithelial Cells\|\|LOCATION_OF\|\|Benign prostatic hypertrophy:3803868	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Benign Neoplasm\|\|PART_OF\|\|Prostate:165052	13/138,393	14/26,262,527	176.23	4.22e-23	7.15e-21
calcium acetate\|\|USES\|\|calcium acetate:174168	6/138,393	15/26,262,527	75.91	1.05e-09	5.56e-08
RNA, Messenger\|\|PART_OF\|\|Prostatic Tissue:6898598	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Grains\|\|LOCATION_OF\|\|Somatotropin:109021	242/138,393	1/26,262,527	46004.24	0.00e+00	0.00e+00
leukemia\|\|PART_OF\|\|Pancreas:1821679	5/138,393	11/26,262,527	86.26	1.65e-08	7.59e-07
Basal cell carcinoma\|\|PART_OF\|\|Prostate:6856418	15/138,393	21/26,262,527	135.56	3.11e-25	5.86e-23
Testosterone\|\|TREATS\|\|Prostate cancer metastatic:3239572	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Prostatic Neoplasms\|\|PROCESS_OF\|\|Mice, Transgenic:7606941	14/138,393	14/26,262,527	189.79	4.43e-25	8.24e-23
Rat Cell Line\|\|PART_OF\|\|Adenocarcinoma:1675233	8/138,393	34/26,262,527	44.65	5.74e-11	3.64e-09
Prostate-Specific Antigen\|\|ASSOCIATED_WITH\|\|Prostatic Intraepithelial Neoplasias:5391603	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Malignant neoplasm of prostate\|\|AFFECTS\|\|Disease Progression:2572973	13/138,393	14/26,262,527	176.23	4.22e-23	7.15e-21
parathyroid hormone-related protein\|\|PART_OF\|\|Malignant neoplasm of prostate:7014398	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Estrogens\|\|ASSOCIATED_WITH\|\|Benign prostatic hypertrophy:1134006	9/138,393	25/26,262,527	68.32	1.39e-13	1.21e-11
Proto-Oncogene Proteins c-akt\|AKT1\|\|PART_OF\|\|targeting:9630153	7/138,393	69/26,262,527	19.25	1.73e-07	6.12e-06
Malignant neoplasm of prostate\|\|COEXISTS_WITH\|\|Prostatic Neoplasms:1853884	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Androgen Receptor\|AR\|\|CAUSES\|\|Down-Regulation:8315270	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Growth Factor\|\|ASSOCIATED_WITH\|\|Prostate:1561122	19/138,393	37/26,262,527	97.46	1.65e-29	3.66e-27
Integral Membrane Proteins\|\|PART_OF\|\|Malignant neoplasm of prostate:9776262	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Stanolone\|\|INTERACTS_WITH\|\|Stanolone:906819	11/138,393	84/26,262,527	24.85	4.28e-12	3.15e-10
Androgen Receptor\|AR\|\|PART_OF\|\|Prostatic Tissue:1280719	7/138,393	11/26,262,527	120.77	3.29e-12	2.43e-10
Bladder\|\|LOCATION_OF\|\|Toxic effect:319548	46/138,393	212/26,262,527	41.19	9.11e-55	4.38e-52
Glutamate Carboxypeptidase II\|\|ISA\|\|Surface Antigens:8791686	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Neoplasm Metastasis\|\|PROCESS_OF\|\|cohort:5896464	12/138,393	83/26,262,527	27.44	1.57e-13	1.37e-11
TGFBR2 protein, human\|TGFBR2\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:7077000	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Androgens\|\|AFFECTS\|\|Prostate:511735	40/138,393	92/26,262,527	82.53	4.12e-58	2.13e-55
BTG1 gene\|BTG1\|PPBP\|\|INTERACTS_WITH\|\|docetaxel:13074069	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
ERG gene\|ERG\|\|ASSOCIATED_WITH\|\|Prostatic Neoplasms:13407288	4/138,393	2/26,262,527	379.55	1.12e-08	5.27e-07
Prostate\|\|PART_OF\|\|Benign prostatic hypertrophy:1626556	7/138,393	25/26,262,527	53.14	3.26e-10	1.94e-08
steroid hormone receptor\|\|ASSOCIATED_WITH\|\|Prostate:1599811	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Bladder\|\|LOCATION_OF\|\|Preservation, Biological:1638710	30/138,393	627/26,262,527	9.08	1.03e-18	1.35e-16
Prostate\|\|LOCATION_OF\|\|Estramustine:1504875	5/138,393	9/26,262,527	105.43	7.62e-09	3.62e-07
Compartments\|\|LOCATION_OF\|\|Malignant neoplasm of prostate:12622004	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Malignant neoplasm of prostate\|\|AFFECTS\|\|Neoplasm Metastasis:5651474	8/138,393	7/26,262,527	216.89	3.55e-15	3.52e-13
atrasentan\|\|TREATS\|\|Hormone-refractory prostate cancer:9676810	9/138,393	13/26,262,527	131.39	1.40e-15	1.41e-13
Radiotherapy, Adjuvant\|\|TREATS\|\|Locally Advanced Malignant Neoplasm:6927097	11/138,393	15/26,262,527	139.17	5.90e-19	7.80e-17
Prostate cancer metastatic\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:4705242	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Androgen Suppression\|\|TREATS\|\|Neoplasm Metastasis:9501436	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Prostate\|\|LOCATION_OF\|\|Pathogenesis:4815869	9/138,393	11/26,262,527	155.27	4.76e-16	4.94e-14
Supernatant\|\|LOCATION_OF\|\|Prostate-Specific Antigen:7870505	8/138,393	10/26,262,527	151.82	2.38e-14	2.15e-12
Radical perineal prostatectomy\|\|METHOD_OF\|\|Lymph Node Dissection:5906892	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
bicalutamide\|\|TREATS\|\|advanced disease:9882537	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
Prostate cancer metastatic\|\|ASSOCIATED_WITH\|\|Skeletal bone:8264277	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
caveolin 1\|\|AUGMENTS\|\|Cell Survival:8128686	6/138,393	8/26,262,527	142.33	6.01e-11	3.76e-09
ursolic acid\|\|TREATS\|\|Malignant neoplasm of prostate:13605062	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Estramustine\|\|ISA\|\|Estradiol:1236588	8/138,393	11/26,262,527	138.02	4.09e-14	3.65e-12
Monoclonal Antibodies\|\|PART_OF\|\|Malignant neoplasm of prostate:3375197	11/138,393	11/26,262,527	189.78	5.49e-20	7.78e-18
cytotoxicity\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:4610793	12/138,393	12/26,262,527	189.78	1.10e-21	1.72e-19
Universities\|\|LOCATION_OF\|\|Genome Scan:10380244	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Biopsy\|\|METHOD_OF\|\|Antigen assay:7251982	11/138,393	12/26,262,527	173.97	1.05e-19	1.44e-17
alpha 2-Glucoproteins\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:6690954	9/138,393	16/26,262,527	106.75	5.66e-15	5.57e-13
Prostate cancer metastatic\|\|LOCATION_OF\|\|Prostate-Specific Antigen:5565310	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostate\|\|LOCATION_OF\|\|Serum specimen:14013669	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Tissue specimen\|\|LOCATION_OF\|\|Prostate-Specific Antigen:4363468	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Transrectal Ultrasound\|\|DIAGNOSES\|\|Prostate carcinoma:4095639	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
Spermidine/Spermine N1-Acetyltransferase\|SAT1\|\|ISA\|\|Acetyltransferase:8350729	10/138,393	108/26,262,527	17.57	9.12e-10	5.17e-08
Radical prostatectomy\|\|lower_than\|\|Radical prostatectomy:12005988	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Patient observation\|\|TREATS\|\|Malignant neoplasm of prostate:5840171	114/138,393	145/26,262,527	149.32	3.40e-185	6.29e-182
Androgens\|\|INTERACTS_WITH\|\|Androgen Receptor\|AR:1720953	47/138,393	116/26,262,527	76.91	8.18e-67	4.95e-64
Genistein\|\|DISRUPTS\|\|Cancer Cell Growth:8620825	6/138,393	14/26,262,527	81.33	7.55e-10	4.37e-08
Seminal fluid\|\|LOCATION_OF\|\|Prostate-Specific Antigen:3861992	30/138,393	90/26,262,527	63.27	4.12e-41	1.44e-38
Carcinoma\|\|ASSOCIATED_WITH\|\|lymph nodes:294069	6/138,393	29/26,262,527	39.26	2.96e-08	1.33e-06
Androgens\|\|AFFECTS\|\|Transcription, Genetic:1639033	7/138,393	27/26,262,527	49.20	5.17e-10	3.02e-08
Radical prostatectomy\|\|TREATS\|\|Erectile dysfunction:7545837	13/138,393	15/26,262,527	164.48	7.85e-23	1.31e-20
Androgen therapy\|\|TREATS\|\|Locally Advanced Malignant Neoplasm:9070342	25/138,393	34/26,262,527	139.56	2.47e-41	8.72e-39
VEGF protein, human\|VEGFA\|\|ASSOCIATED_WITH\|\|Prostate carcinoma:9070405	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Prednisone\|\|compared_with\|\|Prednisone:288063	54/138,393	178/26,262,527	57.59	8.13e-71	5.36e-68
Prostate\|\|LOCATION_OF\|\|Stanolone:627188	52/138,393	158/26,262,527	62.48	8.05e-70	5.20e-67
Perineal prostatectomy\|\|TREATS\|\|Malignant neoplasm of prostate:1455331	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Docosahexaenoic Acids\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:8045606	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Serine Protease\|\|PART_OF\|\|Malignant neoplasm of prostate:9873533	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Fatty Acids\|\|AFFECTS\|\|Malignant neoplasm of prostate:7449736	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Cancer Detection\|\|TREATS\|\|Atypical proliferation:11236211	7/138,393	10/26,262,527	132.84	2.02e-12	1.52e-10
Radical prostatectomy\|\|PRECEDES\|\|Cancer Treatment:6720063	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Health care facility\|\|LOCATION_OF\|\|Validation:2206146	8/138,393	63/26,262,527	24.10	4.52e-09	2.21e-07
Solid tumor\|\|ASSOCIATED_WITH\|\|Prostate:12030685	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|cohort:1949503	289/138,393	306/26,262,527	179.60	0.00e+00	0.00e+00
Androgens\|\|INTERACTS_WITH\|\|VEGF protein, human\|VEGFA:7529954	7/138,393	11/26,262,527	120.77	3.29e-12	2.43e-10
Rhabdomyosarcoma\|\|ASSOCIATED_WITH\|\|Prostate:830978	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Prostatectomy\|\|compared_with\|\|Prostatectomy:839551	15/138,393	22/26,262,527	129.40	5.21e-25	9.65e-23
Localized Malignant Neoplasm\|\|PART_OF\|\|Prostate:850491	120/138,393	126/26,262,527	180.89	5.75e-202	1.26e-198
Phytoestrogens\|\|PREVENTS\|\|Malignant neoplasm of prostate:8251386	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Estradiol\|\|TREATS\|\|Malignant neoplasm of prostate:1247877	13/138,393	13/26,262,527	189.79	2.20e-23	3.82e-21
Angiogenesis Inhibitors\|\|USES\|\|Angiogenesis Inhibitors:4741274	82/138,393	3,199/26,262,527	4.87	9.56e-30	2.15e-27
Breast\|\|LOCATION_OF\|\|[M]Unspecified tumor cell NOS:1363585	15/138,393	41/26,262,527	69.43	8.23e-22	1.32e-19
Glutamate Carboxypeptidase II\|\|PART_OF\|\|Cell surface:10387319	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Benign prostatic hypertrophy\|\|PART_OF\|\|Prostatic Tissue:2644853	6/138,393	11/26,262,527	103.51	2.44e-10	1.46e-08
Chemotherapy, Adjuvant\|\|TREATS\|\|Malignant neoplasm of prostate:1891964	7/138,393	6/26,262,527	221.41	1.82e-13	1.56e-11
Transrectal Ultrasound\|\|DIAGNOSES\|\|Adenocarcinoma of prostate:5064561	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
VEGF protein, human\|VEGFA\|\|PART_OF\|\|Malignant neoplasm of prostate:7212932	12/138,393	13/26,262,527	175.19	2.10e-21	3.22e-19
Skin tag\|\|PART_OF\|\|Prostatic Urethra:6084561	6/138,393	10/26,262,527	113.87	1.59e-10	9.61e-09
docetaxel\|\|CAUSES\|\|Growth retardation:10319931	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Endocrine therapy\|\|TREATS\|\|advanced disease:1215536	19/138,393	49/26,262,527	73.59	1.23e-27	2.52e-25
Calcium\|\|ASSOCIATED_WITH\|\|Prostate:1475509	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
secretion product\|\|PART_OF\|\|Prostate:2006399	5/138,393	16/26,262,527	59.30	7.51e-08	2.91e-06
Prostascint\|\|ISA\|\|Capromab Pendetide:7868762	21/138,393	28/26,262,527	142.35	4.36e-35	1.23e-32
Androgen Receptor\|AR\|\|ASSOCIATED_WITH\|\|Prostate cancer recurrent:10255269	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Testosterone\|\|NEG_ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:4299595	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Benign prostatic hypertrophy\|\|PROCESS_OF\|\|Cancer Patient:3732733	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Estrogen Receptor alpha\|\|ASSOCIATED_WITH\|\|Prostate:7582668	6/138,393	18/26,262,527	63.26	2.58e-09	1.30e-07
Malignant neoplasm of prostate\|\|ASSOCIATED_WITH\|\|Stroma:8837669	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
African American\|\|LOCATION_OF\|\|Prostate-Specific Antigen:7078469	11/138,393	12/26,262,527	173.97	1.05e-19	1.44e-17
Immunotherapy\|\|TREATS\|\|Asymptomatic:6782846	8/138,393	10/26,262,527	151.82	2.38e-14	2.15e-12
Neoplasm Metastasis\|\|LOCATION_OF\|\|[M]Unspecified tumor cell NOS:1005504	9/138,393	106/26,262,527	16.11	1.27e-08	5.93e-07
Insulin-Like Growth-Factor-Binding Proteins\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8043003	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Prostate-Specific Antigen\|\|AFFECTS\|\|Decision Making:6874967	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Acetate\|\|USES\|\|Acetate:103919	21/138,393	419/26,262,527	9.51	6.19e-14	5.50e-12
Prostate-Specific Antigen\|\|PART_OF\|\|Human Cell Line:6039876	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Areae:1990196	58/138,393	63/26,262,527	174.78	6.67e-98	6.62e-95
Prostate\|\|LOCATION_OF\|\|Biopsy interpretation:8425582	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
[M]Unspecified tumor cell NOS\|\|LOCATION_OF\|\|Stanolone:3314695	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
Deoxycorticosterone\|\|ASSOCIATED_WITH\|\|Diabetes Mellitus:104950	4/138,393	2/26,262,527	379.55	1.12e-08	5.27e-07
Biopsy\|\|DIAGNOSES\|\|High-Grade Prostatic Intraepithelial Neoplasia:7620694	22/138,393	23/26,262,527	181.55	2.47e-38	7.86e-36
Epithelial Cells\|\|PRODUCES\|\|Serine Protease:4722362	8/138,393	18/26,262,527	84.35	8.19e-13	6.38e-11
Androgens\|\|PREDISPOSES\|\|Neoplasm progression:8527628	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Stanolone\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:1113276	20/138,393	22/26,262,527	172.54	1.13e-34	3.12e-32
Cadmium\|\|CAUSES\|\|Malignant neoplasm of prostate:1990198	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
X-Ray Computed Tomography\|\|ISA\|\|Medical Imaging:1344473	23/138,393	1,077/26,262,527	4.05	4.41e-08	1.96e-06
Cell Cycle Arrest\|\|PROCESS_OF\|\|S Phase:4154971	12/138,393	297/26,262,527	7.67	1.31e-07	4.76e-06
research study\|\|USES\|\|Tissue Recombination:3052654	7/138,393	59/26,262,527	22.52	6.46e-08	2.51e-06
Taxanes\|\|ISA\|\|Antineoplastic Agents:6681292	15/138,393	85/26,262,527	33.49	1.03e-17	1.24e-15
Androgen Receptor\|AR\|\|INTERACTS_WITH\|\|Prostate-Specific Antigen:5542065	15/138,393	17/26,262,527	167.46	3.22e-26	6.27e-24
Cyclophosphamide\|\|TREATS\|\|Malignant neoplasm of prostate:910146	13/138,393	16/26,262,527	154.20	1.42e-22	2.34e-20
Multiple Myeloma\|\|ISA\|\|Lymphoma, Non-Hodgkin's:1800250	9/138,393	45/26,262,527	37.96	1.28e-11	9.18e-10
Neoplasm Metastasis\|\|PROCESS_OF\|\|Mice, Nude:1393208	15/138,393	127/26,262,527	22.42	2.27e-15	2.28e-13
Proto-Oncogene Proteins c-akt\|AKT1\|\|DISRUPTS\|\|Phosphorylation:7819640	13/138,393	230/26,262,527	10.73	8.79e-10	5.08e-08
Strontium-89\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:5540173	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Hospitals, University\|\|LOCATION_OF\|\|Biopsy:854033	8/138,393	73/26,262,527	20.80	1.30e-08	6.06e-07
Vasectomy\|\|METHOD_OF\|\|Vasectomy:1320585	7/138,393	42/26,262,527	31.63	7.70e-09	3.65e-07
Prostate\|\|LOCATION_OF\|\|Acute inflammation:8643758	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
High-Grade Prostatic Intraepithelial Neoplasia\|\|ASSOCIATED_WITH\|\|Prostate:5576854	23/138,393	29/26,262,527	150.53	1.08e-38	3.49e-36
Chemoprevention\|\|PREVENTS\|\|Malignant neoplasm of prostate:8267060	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Prostate-Specific Antigen\|\|ASSOCIATED_WITH\|\|Neoplasm progression:10004513	9/138,393	11/26,262,527	155.27	4.76e-16	4.94e-14
Prostate\|\|LOCATION_OF\|\|Malignant Epithelial Cell:4301631	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Linomide\|\|INHIBITS\|\|Angiogenesis:5493437	5/138,393	9/26,262,527	105.43	7.62e-09	3.62e-07
KLK3\|PLAG1\|PROS1\|NPEPPS\|PSAT1\|\|higher_than\|\|KLK3\|PLAG1\|PROS1\|NPEPPS\|PSAT1:9185843	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Breast\|\|PART_OF\|\|Participant:6673151	10/138,393	35/26,262,527	54.22	4.23e-14	3.77e-12
CD44 gene\|CD44\|\|ASSOCIATED_WITH\|\|Neoplasm Metastasis:5063676	6/138,393	40/26,262,527	28.47	1.62e-07	5.75e-06
Tumor necrosis factor receptor 11b\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9319451	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Malignant neoplasm of prostate\|\|PRODUCES\|\|Prostate-Specific Antigen:9138733	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Interleukin-6\|\|INTERACTS_WITH\|\|Androgens:6458941	5/138,393	10/26,262,527	94.89	1.14e-08	5.31e-07
MicroRNAs\|\|INTERACTS_WITH\|\|AR gene\|AR:14563878	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Estramustine phosphate\|\|USES\|\|Estramustine phosphate:927415	20/138,393	27/26,262,527	140.59	2.09e-33	5.56e-31
KLK3 gene\|KLK3\|\|PART_OF\|\|cohort:8502616	5/138,393	8/26,262,527	118.61	4.92e-09	2.37e-07
Hypermethylation\|\|AFFECTS\|\|Malignant neoplasm of prostate:10679070	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Normal cell\|\|PART_OF\|\|Prostate:992340	188/138,393	241/26,262,527	148.23	9.31e-304	3.44e-300
Tumor cells, malignant\|\|PART_OF\|\|Prostate carcinoma:3423803	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Prostate specific antigen measurement\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:3306478	89/138,393	93/26,262,527	181.72	2.25e-150	3.64e-147
Biopsy\|\|DIAGNOSES\|\|Small cell carcinoma of lung:2541072	10/138,393	73/26,262,527	26.00	2.69e-11	1.78e-09
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Rosa:5916822	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Androgens\|\|ISA\|\|Steroids:152983	22/138,393	177/26,262,527	23.59	2.77e-22	4.52e-20
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Older Population:5445040	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
5-Alpha reductase inhibitor\|\|TREATS\|\|Benign prostatic hypertrophy:3787848	11/138,393	59/26,262,527	35.38	1.34e-13	1.17e-11
Growth Factor\|\|INTERACTS_WITH\|\|Androgen Receptor\|AR:6510679	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
KLK3 gene\|KLK3\|\|AUGMENTS\|\|Malignant neoplasm of prostate:6053470	12/138,393	12/26,262,527	189.78	1.10e-21	1.72e-19
Prostate\|\|LOCATION_OF\|\|Adenoma of large intestine:11385521	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Pancreas\|\|LOCATION_OF\|\|Head:23599	6/138,393	6,351/26,262,527	0.18	1.58e-08	7.30e-07
Clinical Trials\|\|USES\|\|Longitudinal Studies:449058	370/138,393	13,546/26,262,527	5.19	9.32e-136	1.37e-132
Racemases\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:11883579	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Seed Implantation\|\|TREATS\|\|Carcinoma:887142	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
tumor growth\|\|COEXISTS_WITH\|\|Prostate carcinoma:6547002	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Radical cystectomy\|\|TREATS\|\|Invasive bladder cancer:1511455	29/138,393	480/26,262,527	11.47	1.00e-20	1.50e-18
Prostate-Specific Antigen\|\|ISA\|\|Kininogenase\|KLK4:1724585	21/138,393	32/26,262,527	124.55	3.48e-34	9.53e-32
Androgens\|\|INTERACTS_WITH\|\|Testosterone:608633	8/138,393	83/26,262,527	18.29	3.29e-08	1.47e-06
Androgen Receptor\|AR\|\|DISRUPTS\|\|Cell Proliferation:8788031	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
Prostate\|\|LOCATION_OF\|\|Prostate carcinoma:4731153	11/138,393	14/26,262,527	149.11	3.42e-19	4.56e-17
Cancer-Predisposing Gene\|\|PART_OF\|\|Prostate:6614040	76/138,393	96/26,262,527	150.31	3.27e-124	4.29e-121
Prostate\|\|LOCATION_OF\|\|Early Diagnosis:5771439	11/138,393	12/26,262,527	173.97	1.05e-19	1.44e-17
Biological Products\|\|TREATS\|\|Malignant neoplasm of prostate:9918976	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Microtubule-Associated Proteins\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9650957	4/138,393	1/26,262,527	759.09	3.76e-09	1.84e-07
Biopsy\|\|AFFECTS\|\|Malignant neoplasm of prostate:136835	22/138,393	21/26,262,527	198.84	6.37e-39	2.07e-36
[X]Malignant melanoma of skin, unspecified\|\|PART_OF\|\|Prostate:5285489	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Estramustine phosphate\|\|ASSOCIATED_WITH\|\|Hormone-refractory prostate cancer:5276097	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Jaw\|\|LOCATION_OF\|\|Bone necrosis:93399	136/138,393	3,121/26,262,527	8.28	5.00e-74	3.52e-71
Diagnosis, Computer-Assisted\|\|METHOD_OF\|\|Radionuclide Imaging:15577556	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Oncogene Proteins\|\|PART_OF\|\|Malignant neoplasm of prostate:6776559	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
TP53 gene\|TP53\|\|ASSOCIATED_WITH\|\|Prostate cancer metastatic:6634509	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostate-Specific Antigen\|\|PART_OF\|\|targeting:12236390	8/138,393	15/26,262,527	101.22	2.61e-13	2.22e-11
G-Protein-Coupled Receptors\|\|ASSOCIATED_WITH\|\|Prostate:7514654	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Prostatic epithelium\|\|LOCATION_OF\|\|TP53 gene\|TP53:7909912	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Cold Therapy\|\|TREATS\|\|Adenocarcinoma:8026142	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Androsterone\|\|INHIBITS\|\|17beta-hydroxysteroid dehydrogenase type 3:14791579	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
hepsin\|HPN\|\|AUGMENTS\|\|Malignant neoplasm of prostate:10817663	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
maspin\|SERPINB5\|\|DISRUPTS\|\|tumor growth:8894841	6/138,393	17/26,262,527	66.98	1.94e-09	9.82e-08
Gonadorelin\|GNRH1\|\|INHIBITS\|\|Androgens:2196838	5/138,393	12/26,262,527	79.07	2.32e-08	1.06e-06
Prostate\|\|LOCATION_OF\|\|Necrosis:400398	10/138,393	22/26,262,527	86.26	9.10e-16	9.28e-14
Prostate\|\|LOCATION_OF\|\|Nodule:1806567	19/138,393	22/26,262,527	163.91	1.03e-32	2.63e-30
Metalloproteases\|\|ASSOCIATED_WITH\|\|Neoplasm progression:5801819	6/138,393	21/26,262,527	54.22	5.59e-09	2.69e-07
Interleukin-6\|\|AUGMENTS\|\|androgen receptor activity:7866573	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Stromal Cells\|\|PART_OF\|\|Malignant neoplasm of prostate:11442212	10/138,393	13/26,262,527	145.99	1.68e-17	1.99e-15
Prostate\|\|LOCATION_OF\|\|Tissue Microarray:8009424	42/138,393	46/26,262,527	173.32	3.12e-71	2.07e-68
Sildenafil citrate\|\|TREATS\|\|Erectile dysfunction:7915282	15/138,393	235/26,262,527	12.11	9.06e-12	6.57e-10
BRCA1 gene\|BRCA1\|\|ASSOCIATED_WITH\|\|Breast:5448485	11/138,393	152/26,262,527	13.73	1.51e-09	7.97e-08
Chromogranin A\|\|ASSOCIATED_WITH\|\|Prostate:6241529	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Radical prostatectomy\|\|ADMINISTERED_TO\|\|Surgeon:8460292	62/138,393	95/26,262,527	123.90	8.85e-98	8.74e-95
Radical retropubic prostatectomy\|\|TREATS\|\|Local disease:6422797	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Estrogens\|\|TREATS\|\|Prostate cancer metastatic:2948244	11/138,393	13/26,262,527	160.59	1.92e-19	2.59e-17
Diphosphonates\|\|TREATS\|\|Multiple Myeloma:1842827	17/138,393	145/26,262,527	22.25	3.56e-17	4.16e-15
lymph nodes\|\|PART_OF\|\|Bone structure of ilium:4771	24/138,393	415/26,262,527	10.98	5.10e-17	5.91e-15
research study\|\|USES\|\|Tissue Microarray:10659823	6/138,393	22/26,262,527	51.76	7.08e-09	3.39e-07
Carcinoma\|\|PART_OF\|\|Prostate:8651	2,759/138,393	3,476/26,262,527	153.67	0.00e+00	0.00e+00
RNA\|\|DISRUPTS\|\|tumor growth:652028	6/138,393	32/26,262,527	35.58	4.96e-08	2.03e-06
Sensitized cell\|\|PART_OF\|\|Malignant neoplasm of prostate:9345578	24/138,393	26/26,262,527	175.20	1.97e-41	6.98e-39
PCA3\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:12782761	13/138,393	15/26,262,527	164.48	7.85e-23	1.31e-20
Cancer Cell Growth\|\|PART_OF\|\|Breast:3150016	20/138,393	684/26,262,527	5.55	2.27e-09	1.15e-07
Bombesin\|\|ISA\|\|Neuropeptides\|NPS:4772002	6/138,393	22/26,262,527	51.76	7.08e-09	3.39e-07
Proton therapy\|\|TREATS\|\|Malignant neoplasm of prostate:6193605	80/138,393	138/26,262,527	110.07	1.66e-122	2.11e-119
Prostate-Specific Antigen\|\|PART_OF\|\|Neoplasm Metastasis:6679627	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Transforming Growth Factor beta\|\|AFFECTS\|\|Malignant neoplasm of prostate:4074544	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Radiographic\|\|PROCESS_OF\|\|Neoplasm Metastasis:3535278	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Horns\|\|LOCATION_OF\|\|Biopsy:8244551	6/138,393	9/26,262,527	126.52	9.97e-11	6.13e-09
Prostate\|\|LOCATION_OF\|\|Needle device:5050764	15/138,393	15/26,262,527	189.79	8.93e-27	1.77e-24
Prostate specific antigen measurement\|\|METHOD_OF\|\|Early Diagnosis:4705551	26/138,393	26/26,262,527	189.80	2.21e-45	8.73e-43
Lymph Node Dissection\|\|TREATS\|\|Prostate cancer recurrent:13902727	10/138,393	13/26,262,527	145.99	1.68e-17	1.99e-15
Immunotherapy\|\|TREATS\|\|Prostate cancer metastatic:2006377	37/138,393	39/26,262,527	180.08	2.29e-63	1.32e-60
Estrogen Antagonists\|\|TREATS\|\|Malignant neoplasm of prostate:1826886	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Androgens\|\|AUGMENTS\|\|Gene Expression:3318865	6/138,393	10/26,262,527	113.87	1.59e-10	9.61e-09
Tomography, Emission-Computed, Single-Photon\|\|DIAGNOSES\|\|Secondary malignant neoplasm of bone:7424194	5/138,393	18/26,262,527	52.72	1.23e-07	4.49e-06
Prostate\|\|LOCATION_OF\|\|Ectopic Tissue:3987013	8/138,393	21/26,262,527	72.30	2.22e-12	1.66e-10
Interstitial brachytherapy\|\|TREATS\|\|High-Risk Cancer:9729149	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Racial group\|\|LOCATION_OF\|\|Prostate-Specific Antigen:10228658	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
KLK3\|PLAG1\|PROS1\|NPEPPS\|PSAT1\|\|higher_than\|\|Prostate-Specific Antigen:5986973	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Neoplasm Metastasis\|\|PART_OF\|\|penis:160460	44/138,393	166/26,262,527	50.32	8.51e-56	4.21e-53
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Japanese Population:7583892	44/138,393	57/26,262,527	146.53	2.95e-72	2.01e-69
Testosterone\|\|ISA\|\|Androgens:491569	67/138,393	731/26,262,527	17.40	1.55e-56	7.86e-54
Biopsy\|\|ISA\|\|diagnostic procedure:1035314	16/138,393	166/26,262,527	18.29	5.03e-15	4.96e-13
Prostate\|\|LOCATION_OF\|\|Adenocarcinoma:404142	20/138,393	23/26,262,527	165.04	2.10e-34	5.75e-32
Isoflavones\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:13219932	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Genistein\|\|PREVENTS\|\|Malignant neoplasm of prostate:9421966	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Estrogens\|\|compared_with\|\|Orchiectomy:1355207	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Cancer Treatment\|\|AFFECTS\|\|Sexual function:8044793	5/138,393	12/26,262,527	79.07	2.32e-08	1.06e-06
Brachytherapy\|\|NEG_TREATS\|\|Malignant neoplasm of prostate:11818130	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
organic disorders\|\|PROCESS_OF\|\|cohort:10230819	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Toxic effect\|\|COEXISTS_WITH\|\|Prostate cancer metastatic:14072175	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
ERG gene\|ERG\|\|INTERACTS_WITH\|\|TMPRSS2 gene\|TMPRSS2:15879938	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Surgical margins\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:6368688	24/138,393	25/26,262,527	182.21	1.03e-41	3.68e-39
bicalutamide\|\|CAUSES\|\|Gynecomastia:11074218	4/138,393	3/26,262,527	253.03	2.61e-08	1.17e-06
Polymorphism, Genetic\|\|ASSOCIATED_WITH\|\|GSTM1 gene\|GSTM1:6388716	11/138,393	192/26,262,527	10.87	1.50e-08	6.94e-07
VTN gene\|VTN\|\|PART_OF\|\|Bladder:16060235	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Androgen therapy\|\|METHOD_OF\|\|Androgen therapy:12430075	15/138,393	15/26,262,527	189.79	8.93e-27	1.77e-24
Medical Imaging\|\|METHOD_OF\|\|Biopsy:3061728	13/138,393	55/26,262,527	44.86	5.41e-17	6.26e-15
Prostate\|\|LOCATION_OF\|\|Fibrosing adenosis:3380959	7/138,393	23/26,262,527	57.76	1.99e-10	1.20e-08
Prostate\|\|LOCATION_OF\|\|Needle biopsy procedure:106970	641/138,393	1,070/26,262,527	114.21	0.00e+00	0.00e+00
Adenocarcinoma of prostate\|\|ASSOCIATED_WITH\|\|Bladder:8478330	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Prostatic Neoplasms\|\|PROCESS_OF\|\|Mice, Inbred C57BL:11863129	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
High-Grade Prostatic Intraepithelial Neoplasia\|\|ISA\|\|Prostatic Intraepithelial Neoplasias:5596964	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Malignant neoplasm of prostate\|\|COEXISTS_WITH\|\|Precancerous lesions:9150062	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Human tissue\|\|LOCATION_OF\|\|Immunohistochemistry:2326047	9/138,393	119/26,262,527	14.35	3.25e-08	1.45e-06
Fibronectins\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:1724426	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
epitheliasin\|TMPRSS2\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:12284618	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
TOOKAD\|\|ISA\|\|palladium-bacteriopheophorbide:10037244	5/138,393	11/26,262,527	86.26	1.65e-08	7.59e-07
Endometrial Carcinoma\|\|PART_OF\|\|Entire utricle:497220	8/138,393	10/26,262,527	151.82	2.38e-14	2.15e-12
Androgens\|\|COEXISTS_WITH\|\|Androgens:1180178	11/138,393	51/26,262,527	40.93	3.26e-14	2.93e-12
Zinc\|\|PREVENTS\|\|Malignant neoplasm of prostate:8251388	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Radiotherapy, Conformal\|\|TREATS\|\|High-Risk Cancer:10487235	8/138,393	13/26,262,527	116.79	1.09e-13	9.55e-12
Nerve Block\|\|USES\|\|Lidocaine:930852	10/138,393	101/26,262,527	18.79	4.99e-10	2.92e-08
National Cancer Institute\|\|LOCATION_OF\|\|Clinical Trials:1217585	11/138,393	110/26,262,527	18.98	6.18e-11	3.86e-09
Gonadal Steroid Hormones\|\|AFFECTS\|\|Prostate:36987	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Alpha-hemolytic streptococcus\|\|CAUSES\|\|Arthritis, Experimental:105029	13/138,393	1/26,262,527	2467.21	3.14e-29	6.90e-27
Secondary malignant neoplasm of lung\|\|PART_OF\|\|Prostate:89437	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Beta Carotene\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:4398720	7/138,393	9/26,262,527	147.60	1.19e-12	9.12e-11
Intraepithelial Neoplasia\|\|PART_OF\|\|Prostate:5478294	11/138,393	12/26,262,527	173.97	1.05e-19	1.44e-17
Cold Therapy\|\|TREATS\|\|Malignant neoplasm of prostate:800583	75/138,393	90/26,262,527	158.22	8.29e-124	1.08e-120
Benign prostatic hypertrophy\|\|LOCATION_OF\|\|Fibroblasts:2105232	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
METHYLATE\|\|TREATS\|\|Malignant neoplasm of prostate:12317810	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Transrectal Ultrasound\|\|ISA\|\|Assessment procedure:5108287	9/138,393	15/26,262,527	113.87	3.64e-15	3.60e-13
Ketoconazole\|\|USES\|\|Ketoconazole:1806083	37/138,393	503/26,262,527	13.96	8.21e-29	1.78e-26
Diethylstilbestrol\|\|TREATS\|\|Metastatic Carcinoma:1351919	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
maspin\|SERPINB5\|\|DISRUPTS\|\|Neoplasm progression:9223941	5/138,393	15/26,262,527	63.26	5.75e-08	2.23e-06
Carcinoma, Endometrioid\|\|PART_OF\|\|Prostate:3544440	16/138,393	23/26,262,527	132.03	1.09e-26	2.16e-24
Biopsy\|\|METHOD_OF\|\|Ultrasonography:1433239	6/138,393	42/26,262,527	27.11	2.11e-07	7.41e-06
FOXO3A gene\|FOXO3\|\|INHIBITS\|\|Proto-Oncogene Proteins c-akt\|AKT1:13453246	5/138,393	19/26,262,527	49.94	1.55e-07	5.48e-06
Human Glandular Kallikrein 2\|HK2\|\|ISA\|\|Serine Protease:8025358	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Benign prostatic hypertrophy\|\|LOCATION_OF\|\|KLK3 gene\|KLK3:7570981	9/138,393	11/26,262,527	155.27	4.76e-16	4.94e-14
Free prostate-specific antigen\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:6793959	48/138,393	51/26,262,527	178.67	1.27e-81	9.82e-79
Androgen therapy\|\|TREATS\|\|Hormone-refractory prostate cancer:6016884	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
Estracyt\|\|ISA\|\|Estramustine phosphate:831179	56/138,393	75/26,262,527	141.75	6.31e-91	5.74e-88
Prostate carcinoma\|\|PROCESS_OF\|\|Mice, Nude:2166781	20/138,393	24/26,262,527	158.16	3.83e-34	1.04e-31
IFI27\|PSMD9\|SSSCA1\|DCTN6\|TMED7\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:7529905	17/138,393	19/26,262,527	169.81	1.33e-29	2.97e-27
abarelix\|\|TREATS\|\|Malignant neoplasm of prostate:8924052	10/138,393	13/26,262,527	145.99	1.68e-17	1.99e-15
Endothelin receptor antagonist\|\|TREATS\|\|Malignant neoplasm of prostate:9292771	10/138,393	13/26,262,527	145.99	1.68e-17	1.99e-15
Androgen therapy\|\|TREATS\|\|advanced disease:7473412	16/138,393	16/26,262,527	189.79	1.80e-28	3.82e-26
Zinc measurement\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:8329716	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Androgen Receptor\|AR\|\|ISA\|\|Receptors, Nuclear\|AR:7282511	9/138,393	12/26,262,527	142.33	8.30e-16	8.48e-14
Biopsy\|\|PRECEDES\|\|Radical prostatectomy:11457838	11/138,393	11/26,262,527	189.78	5.49e-20	7.78e-18
tumor growth\|\|ASSOCIATED_WITH\|\|Tail:5047645	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
bicalutamide\|\|CAUSES\|\|Mastodynia:11074217	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Phytoestrogens\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:7540133	7/138,393	9/26,262,527	147.60	1.19e-12	9.12e-11
Human Cell Line\|\|PART_OF\|\|Carcinoma:578006	33/138,393	1,366/26,262,527	4.59	2.72e-12	2.04e-10
prostate cancer screening\|\|TREATS\|\|Raised prostate specific antigen:6457138	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Tomatoes\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:6515903	11/138,393	15/26,262,527	139.17	5.90e-19	7.80e-17
Ultrasonography, Doppler\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:7853916	9/138,393	16/26,262,527	106.75	5.66e-15	5.57e-13
CHRFAM7A\|\|PART_OF\|\|Urethra:8569357	10/138,393	11/26,262,527	172.53	5.24e-18	6.40e-16
Glycine max\|\|LOCATION_OF\|\|Genistein:6730424	6/138,393	39/26,262,527	29.20	1.42e-07	5.16e-06
Immunotherapy, Active\|\|TREATS\|\|Prostate cancer metastatic:12747485	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
Acid Phosphatase\|\|ASSOCIATED_WITH\|\|Benign prostatic hypertrophy:383876	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
vitamin therapy\|\|TREATS\|\|Malignant neoplasm of prostate:13715376	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Digital Rectal Examination\|\|METHOD_OF\|\|Prostate specific antigen measurement:5316579	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
caveolin 1\|\|PART_OF\|\|Malignant neoplasm of prostate:8043972	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Endocrine therapy\|\|TREATS\|\|Adenocarcinoma of prostate:2150287	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Han Chinese:15709724	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Patient Selection\|\|METHOD_OF\|\|Radical prostatectomy:4011389	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Etidronate\|\|TREATS\|\|Neoplasm Metastasis:5072420	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Orchiectomy\|\|USES\|\|Gonadotropin-Releasing Hormone Analog:3654225	10/138,393	13/26,262,527	145.99	1.68e-17	1.99e-15
Prophylactic treatment\|\|AFFECTS\|\|Malignant neoplasm of prostate:7698384	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Proto-Oncogene Proteins c-akt\|AKT1\|\|TREATS\|\|Malignant neoplasm of prostate:14227580	4/138,393	2/26,262,527	379.55	1.12e-08	5.27e-07
Loss of Heterozygosity\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:4562256	34/138,393	37/26,262,527	174.42	5.01e-58	2.59e-55
Cancer Treatment\|\|METHOD_OF\|\|Cancer Treatment:3736192	9/138,393	108/26,262,527	15.81	1.48e-08	6.87e-07
Chronic inflammation\|\|AFFECTS\|\|Malignant neoplasm of prostate:12352157	10/138,393	10/26,262,527	189.78	2.76e-18	3.46e-16
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Latinos:11574099	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Reactive Oxygen Species\|\|ASSOCIATED_WITH\|\|Prostate:8044136	6/138,393	8/26,262,527	142.33	6.01e-11	3.76e-09
Chemoprevention\|\|USES\|\|Finasteride:6435545	19/138,393	25/26,262,527	144.24	5.81e-32	1.46e-29
KLK3 gene\|KLK3\|\|CAUSES\|\|Malignant neoplasm of prostate:8270062	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Cell Adhesion Molecules\|\|AFFECTS\|\|cell motility:3011436	9/138,393	106/26,262,527	16.11	1.27e-08	5.93e-07
Osteoblasts\|\|PART_OF\|\|Secondary malignant neoplasm of bone:8485407	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
Androgen Receptor\|AR\|\|DISRUPTS\|\|Cell Growth:7952947	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
HIGH SENSITIVITY\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:6177217	10/138,393	10/26,262,527	189.78	2.76e-18	3.46e-16
Immobilization\|\|TREATS\|\|Malignant neoplasm of prostate:6638561	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
ERBB2\|NEU1\|NEURL1\|\|ASSOCIATED_WITH\|\|Prostate carcinoma:9387916	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
AR gene\|AR\|\|AFFECTS\|\|Signal Transduction:14433378	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Elevation procedure\|\|TREATS\|\|Malignant neoplasm of prostate:4718183	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
PLAU gene\|PLAU\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:6514168	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
External radiotherapy NOS\|\|TREATS\|\|Malignant neoplasm of prostate:826523	40/138,393	44/26,262,527	172.57	7.30e-68	4.53e-65
Gelatinase A\|\|ASSOCIATED_WITH\|\|Prostate:5439854	5/138,393	12/26,262,527	79.07	2.32e-08	1.06e-06
Phosphoric Monoester Hydrolases\|\|ASSOCIATED_WITH\|\|Metastatic Carcinoma:724087	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostatectomy, Retropubic\|\|PRECEDES\|\|Prostatectomy, Retropubic:11154020	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Urokinase\|PLAU\|PRAP1\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:7236678	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Chemoprevention\|\|TREATS\|\|cohort:7061328	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Weighing patient\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:8702867	19/138,393	21/26,262,527	171.72	5.53e-33	1.43e-30
Cell Adhesion Molecules\|\|AFFECTS\|\|Tissue Integrity:10070489	8/138,393	48/26,262,527	31.63	6.47e-10	3.76e-08
Treatment Protocols\|\|TREATS\|\|Prostate cancer metastatic:4230220	18/138,393	18/26,262,527	189.79	7.40e-32	1.83e-29
Interferon-alpha\|\|TREATS\|\|Malignant neoplasm of prostate:4599417	6/138,393	8/26,262,527	142.33	6.01e-11	3.76e-09
Prostate-Specific Antigen\|\|PART_OF\|\|Protoplasm:7310730	7/138,393	10/26,262,527	132.84	2.02e-12	1.52e-10
Prostate-Specific Antigen\|\|ASSOCIATED_WITH\|\|organic disorders:5547882	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Growth Factor\|\|AFFECTS\|\|Malignant neoplasm of prostate:4235547	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Digital Rectal Examination\|\|DIAGNOSES\|\|Nodule:5993105	9/138,393	12/26,262,527	142.33	8.30e-16	8.48e-14
Malignant neoplasm of prostate\|\|PART_OF\|\|Human tissue:10832153	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Carcinoma of the Large Intestine\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:11143647	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Epithelial Cells\|\|PART_OF\|\|Stroma:1726987	6/138,393	36/26,262,527	31.63	9.26e-08	3.42e-06
Pelvis\|\|LOCATION_OF\|\|Lymph Node Involvement:110778	57/138,393	253/26,262,527	42.77	2.84e-68	1.78e-65
Biopsy\|\|USES\|\|Health care facility:3806874	6/138,393	22/26,262,527	51.76	7.08e-09	3.39e-07
Osteoblasts\|\|LOCATION_OF\|\|Neoplasm Metastasis:263069	104/138,393	259/26,262,527	76.26	2.09e-145	3.33e-142
Endopeptidases\|\|ASSOCIATED_WITH\|\|Neoplasm progression:5001630	7/138,393	26/26,262,527	51.09	4.12e-10	2.44e-08
R-1881\|\|ISA\|\|Metribolone:1306829	29/138,393	159/26,262,527	34.62	3.38e-33	8.91e-31
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Migrants:10344248	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
SIRT1\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:13321910	5/138,393	4/26,262,527	237.22	4.90e-10	2.87e-08
Meningitis\|\|COMPLICATES\|\|Abortion, Septic:234814	5/138,393	1/26,262,527	948.87	2.36e-11	1.58e-09
Finasteride\|\|AFFECTS\|\|Malignant neoplasm of prostate:5622884	10/138,393	10/26,262,527	189.78	2.76e-18	3.46e-16
lenalidomide\|\|TREATS\|\|Malignant neoplasm of prostate:13830081	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Estramustine phosphate\|\|ISA\|\|Nitrogen Mustard Compounds:979061	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Adrenergic alpha-Antagonists\|\|TREATS\|\|OBSTRUCTIVE SYMPTOM:1139273	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Diethylstilbestrol\|\|TREATS\|\|Adenocarcinoma:1147725	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Alkaline Phosphatase\|\|PART_OF\|\|Animalia:256236	6/138,393	2/26,262,527	569.33	5.76e-13	4.63e-11
zoledronic acid\|\|INHIBITS\|\|Bone Resorption:8963092	8/138,393	31/26,262,527	48.98	3.03e-11	2.01e-09
probasin\|\|PART_OF\|\|Prostate:8662004	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Scanning\|\|DIAGNOSES\|\|Bone lesion:787121	5/138,393	20/26,262,527	47.44	1.93e-07	6.79e-06
Psychotherapy, Multiple\|\|USES\|\|bicalutamide:11757132	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Androgen therapy\|\|ISA\|\|Endocrine therapy:2143103	12/138,393	14/26,262,527	162.67	3.88e-21	5.87e-19
Detrusor\|\|LOCATION_OF\|\|Apron:9300002	5/138,393	10/26,262,527	94.89	1.14e-08	5.31e-07
Supplementation\|\|USES\|\|Testosterone:1207256	46/138,393	679/26,262,527	12.86	6.03e-34	1.63e-31
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Caucasoid Race:1413217	115/138,393	133/26,262,527	164.22	3.15e-190	5.98e-187
Magnetic Resonance Imaging\|\|AFFECTS\|\|Malignant neoplasm of prostate:12529608	14/138,393	13/26,262,527	204.39	2.22e-25	4.21e-23
Cigarette Smoking\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:3688551	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
Biopsy\|\|DIAGNOSES\|\|[M]Adenocarcinoma, metastatic, NOS:1590876	8/138,393	63/26,262,527	24.10	4.52e-09	2.21e-07
Prostatic Neoplasms\|\|LOCATION_OF\|\|Tumor cells, malignant:10040184	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Hepatitis C, Chronic\|\|ISA\|\|Virus Diseases:4398300	3/138,393	5,768/26,262,527	0.10	7.56e-10	4.38e-08
docetaxel\|\|ISA\|\|Taxanes:6681293	9/138,393	138/26,262,527	12.38	1.07e-07	3.92e-06
Adenocarcinoma of prostate\|\|PART_OF\|\|Prostate:1282476	15/138,393	19/26,262,527	149.83	1.05e-25	2.00e-23
Secondary malignant neoplasm of bone\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:362215	155/138,393	162/26,262,527	181.77	1.45e-260	4.41e-257
Radical prostatectomy\|\|TREATS\|\|Age:5782952	24/138,393	26/26,262,527	175.20	1.97e-41	6.98e-39
zoledronic acid\|\|TREATS\|\|Advanced cancer:10689336	6/138,393	11/26,262,527	103.51	2.44e-10	1.46e-08
Prostate carcinoma\|\|PROCESS_OF\|\|Voluntary Workers:2790884	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
lymph nodes\|\|LOCATION_OF\|\|Metastatic Lesion:753679	12/138,393	168/26,262,527	13.56	3.17e-10	1.89e-08
educational intervention\|\|METHOD_OF\|\|prostate cancer screening:12602741	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Medroxyprogesterone 17-Acetate\|\|TREATS\|\|Malignant neoplasm of prostate:3074877	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Prostate\|\|LOCATION_OF\|\|Core needle biopsy:3267090	289/138,393	421/26,262,527	130.54	0.00e+00	0.00e+00
Estrogens\|\|STIMULATES\|\|Androgens:878788	7/138,393	41/26,262,527	32.40	6.63e-09	3.19e-07
zoledronic acid\|\|TREATS\|\|Secondary malignant neoplasm of bone:10425104	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
The science and art of healing\|\|TREATS\|\|Malignant neoplasm of prostate:7559392	19/138,393	19/26,262,527	189.79	1.50e-33	4.01e-31
Core needle biopsy\|\|ISA\|\|Procedures:2355889	9/138,393	61/26,262,527	28.00	1.46e-10	8.91e-09
Choline\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8958477	19/138,393	20/26,262,527	180.30	2.92e-33	7.71e-31
Intestines\|\|LOCATION_OF\|\|Toxic effect:237116	48/138,393	582/26,262,527	15.66	5.11e-39	1.67e-36
AR gene\|AR\|\|PART_OF\|\|targeting:12589464	8/138,393	11/26,262,527	138.02	4.09e-14	3.65e-12
Receptor Gene\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:8689901	13/138,393	15/26,262,527	164.48	7.85e-23	1.31e-20
Smoking\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:5432923	18/138,393	21/26,262,527	162.68	5.01e-31	1.19e-28
extranodal lymphoma\|\|PART_OF\|\|Prostate:2979027	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Tumor Suppressor Genes\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:7205951	20/138,393	18/26,262,527	210.88	7.52e-36	2.19e-33
Chromosomal translocation\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:12317844	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Fossa\|\|PART_OF\|\|Prostate:6673588	16/138,393	33/26,262,527	92.02	9.24e-25	1.69e-22
HCT116 Cells\|\|PART_OF\|\|Malignant tumor of colon:6121643	20/138,393	661/26,262,527	5.74	1.30e-09	6.85e-08
Prostatic Tissue\|\|PART_OF\|\|Malignant neoplasm of prostate:6421410	25/138,393	25/26,262,527	189.80	1.08e-43	4.10e-41
MicroRNAs\|\|ASSOCIATED_WITH\|\|Prostate:13060521	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
RNA\|\|INHIBITS\|\|Androgen Receptor\|AR:13284711	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
NOS3 protein, human\|NOS3\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:7317497	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Up-Regulation (Physiology)\|\|AFFECTS\|\|Malignant neoplasm of prostate:9988671	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Mice, Nude:2077823	64/138,393	76/26,262,527	159.88	4.18e-106	4.47e-103
Prostatic Neoplasms\|\|PROCESS_OF\|\|Mice, Nude:4610870	36/138,393	36/26,262,527	189.82	2.92e-62	1.64e-59
Ductal Carcinoma\|\|PART_OF\|\|Prostate:717009	20/138,393	29/26,262,527	130.89	5.99e-33	1.54e-30
Radical prostatectomy\|\|METHOD_OF\|\|adjuvant therapy:8193298	7/138,393	6/26,262,527	221.41	1.82e-13	1.56e-11
Hydrocortisone\|\|TREATS\|\|Malignant neoplasm of prostate:3400809	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Malignant neoplasm of prostate\|\|LOCATION_OF\|\|KLK3 gene\|KLK3:7578062	23/138,393	25/26,262,527	174.62	9.63e-40	3.20e-37
Radiation Therapy Oncology Group\|\|LOCATION_OF\|\|Clinical Trials:919208	21/138,393	114/26,262,527	34.96	1.50e-24	2.73e-22
Buserelin\|\|ASSOCIATED_WITH\|\|Prostate cancer metastatic:2610479	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Clusterin\|CLU\|\|INHIBITS\|\|Clusterin\|CLU:8536440	5/138,393	8/26,262,527	118.61	4.92e-09	2.37e-07
lycopene\|\|compared_with\|\|Orchiectomy:10273672	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Prostate\|\|PART_OF\|\|Outpatients:6030678	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Coagulation procedure\|\|TREATS\|\|Rectal hemorrhage:8770123	5/138,393	12/26,262,527	79.07	2.32e-08	1.06e-06
Orchiectomy\|\|METHOD_OF\|\|Castration:5158773	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
small molecule\|\|INTERACTS_WITH\|\|Glutamate Carboxypeptidase II:12487250	6/138,393	5/26,262,527	227.73	9.37e-12	6.74e-10
Strontium-89\|\|ASSOCIATED_WITH\|\|Secondary malignant neoplasm of bone:3416017	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Radical prostatectomy\|\|PRECEDES\|\|Antiandrogen therapy:4926596	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Cyclin D1\|CCND1\|\|STIMULATES\|\|CDKN1A\|TCEAL1\|NSG1\|H3F3AP6:6716667	8/138,393	77/26,262,527	19.72	1.92e-08	8.79e-07
KLK3 gene\|KLK3\|\|ASSOCIATED_WITH\|\|Adenocarcinoma:5882007	6/138,393	5/26,262,527	227.73	9.37e-12	6.74e-10
Castration\|\|compared_with\|\|Castration:154727	6/138,393	17/26,262,527	66.98	1.94e-09	9.82e-08
MLH1 gene\|MLH1\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9142302	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
External Beam Radiation Therapy\|\|METHOD_OF\|\|Brachytherapy:7411869	9/138,393	21/26,262,527	81.33	3.87e-14	3.47e-12
Membrane\|\|LOCATION_OF\|\|Vesicle:275222	12/138,393	8,691/26,262,527	0.26	7.12e-09	3.41e-07
Neoplasm Metastasis\|\|PROCESS_OF\|\|Animal Model:3438117	9/138,393	78/26,262,527	21.90	1.06e-09	5.60e-08
Mandible\|\|LOCATION_OF\|\|Bone necrosis:187393	13/138,393	149/26,262,527	16.56	5.66e-12	4.14e-10
Benign prostatic hypertrophy\|\|LOCATION_OF\|\|Stromal Cells:5372103	14/138,393	21/26,262,527	126.52	2.47e-23	4.27e-21
Selenium\|\|ASSOCIATED_WITH\|\|Prostate:5858875	13/138,393	20/26,262,527	123.36	1.17e-21	1.83e-19
Magnetic Resonance Imaging\|\|DIAGNOSES\|\|Prostatic Neoplasms:3540110	11/138,393	13/26,262,527	160.59	1.92e-19	2.59e-17
Cell Transformation, Neoplastic\|\|ASSOCIATED_WITH\|\|Prostate:5349360	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostatic Tissue\|\|LOCATION_OF\|\|Immunohistochemistry:3460567	13/138,393	15/26,262,527	164.48	7.85e-23	1.31e-20
Prostatic Intraepithelial Neoplasias\|\|PROCESS_OF\|\|Mice, Transgenic:6948576	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Wall of rectum\|\|LOCATION_OF\|\|PROTECTION:8288293	7/138,393	12/26,262,527	110.70	5.19e-12	3.80e-10
Vitamin E\|\|PREVENTS\|\|Malignant neoplasm of prostate:7605907	37/138,393	40/26,262,527	175.58	4.38e-63	2.51e-60
Suramin\|\|TREATS\|\|Prostate cancer metastatic:5064534	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
Lymph Node Dissection\|\|TREATS\|\|High-Risk Cancer:10376139	13/138,393	14/26,262,527	176.23	4.22e-23	7.15e-21
Magnetic Resonance Spectroscopy\|\|ISA\|\|Medical Imaging:4482911	13/138,393	80/26,262,527	30.84	3.96e-15	3.92e-13
Dairy Products\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:7394328	20/138,393	29/26,262,527	130.89	5.99e-33	1.54e-30
Proto-Oncogene Proteins c-akt\|AKT1\|\|ASSOCIATED_WITH\|\|Prostate:8654497	12/138,393	18/26,262,527	126.52	3.41e-20	4.96e-18
Hydroxymethylglutaryl-CoA Reductase Inhibitors\|\|INTERACTS_WITH\|\|Prostate-Specific Antigen:13369155	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Posterior mediastinum\|\|LOCATION_OF\|\|Benign Neoplasm:190303	5/138,393	18/26,262,527	52.72	1.23e-07	4.49e-06
melanoma\|\|PART_OF\|\|Colon:1512702	8/138,393	59/26,262,527	25.73	2.82e-09	1.42e-07
Diabetes Insipidus\|\|COMPLICATES\|\|Brill-Zinsser Disease:158372	9/138,393	1/26,262,527	1708.02	2.97e-20	4.33e-18
Malignant neoplasm of prostate\|\|PART_OF\|\|Cancer Survivor:13823461	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Epithelium\|\|PART_OF\|\|Prostatic Intraepithelial Neoplasias:8096487	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
chromatin immunoprecipitation\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:14977361	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Magnetic resonance imaging guided biopsy\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:13897380	11/138,393	13/26,262,527	160.59	1.92e-19	2.59e-17
Inactivation\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:7851523	21/138,393	21/26,262,527	189.80	6.22e-37	1.90e-34
R-1881\|\|INTERACTS_WITH\|\|Androgen Receptor\|AR:1213592	5/138,393	17/26,262,527	55.82	9.68e-08	3.54e-06
Interleukin-8\|\|ASSOCIATED_WITH\|\|Neoplasm progression:7372716	5/138,393	14/26,262,527	67.78	4.33e-08	1.92e-06
Gonadotropin-Releasing Hormone Analog\|\|USES\|\|Gonadotropin-Releasing Hormone Analog:2004868	131/138,393	712/26,262,527	34.95	2.18e-144	3.44e-141
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Modulus:6786542	15/138,393	16/26,262,527	177.93	1.72e-26	3.38e-24
Prostate-Specific Antigen\|\|ISA\|\|Tumor Markers:3137099	126/138,393	134/26,262,527	178.60	1.73e-211	3.99e-208
Brachytherapy\|\|CAUSES\|\|Erectile dysfunction:10074204	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Division (procedure)\|\|USES\|\|Mounts:156075	81/138,393	251/26,262,527	61.28	3.33e-107	3.61e-104
antisense therapy\|\|TREATS\|\|Malignant neoplasm of prostate:8393061	6/138,393	8/26,262,527	142.33	6.01e-11	3.76e-09
Estrogens\|\|TREATS\|\|Adenocarcinoma of prostate:2375648	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Diphosphonates\|\|TREATS\|\|Hormone-refractory prostate cancer:8951456	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Cell surface\|\|LOCATION_OF\|\|HSPA5:7998789	9/138,393	31/26,262,527	55.10	7.06e-13	5.52e-11
Subcapsular orchidectomy\|\|TREATS\|\|Malignant neoplasm of prostate:2286211	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Brachytherapy\|\|METHOD_OF\|\|External Beam Radiation Therapy:4869470	11/138,393	27/26,262,527	77.32	8.67e-17	9.92e-15
Gonadotropin-Releasing Hormone Analog\|\|TREATS\|\|Prostate cancer metastatic:2364924	17/138,393	18/26,262,527	179.25	7.06e-30	1.59e-27
Prostatic Intraepithelial Neoplasias\|\|ASSOCIATED_WITH\|\|Lobe:9323534	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Casodex\|\|compared_with\|\|Flutamide:6514157	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Rectal examination\|\|DIAGNOSES\|\|Carcinoma:1863230	5/138,393	4/26,262,527	237.22	4.90e-10	2.87e-08
diagnostic procedure\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:61046	11/138,393	11/26,262,527	189.78	5.49e-20	7.78e-18
Fish intake\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:10962624	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
caveolin 1\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8128687	21/138,393	27/26,262,527	147.62	2.50e-35	7.11e-33
Prostatic epithelium\|\|LOCATION_OF\|\|Malignant neoplasm of prostate:8342129	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Radical cystoprostatectomy\|\|TREATS\|\|Malignant neoplasm of urinary bladder:3396234	45/138,393	71/26,262,527	120.31	5.48e-71	3.62e-68
DNA Modification Methylases\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9277694	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Benign prostatic hypertrophy\|\|LOCATION_OF\|\|Basal Cell:3462026	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
SLC5A5 gene\|SLC5A5\|\|PART_OF\|\|Adenoviruses:9345462	5/138,393	8/26,262,527	118.61	4.92e-09	2.37e-07
maspin\|SERPINB5\|\|ASSOCIATED_WITH\|\|Prostate:13015103	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Fibroblast Growth Factor\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:7922744	11/138,393	12/26,262,527	173.97	1.05e-19	1.44e-17
Endocrine therapy\|\|TREATS\|\|High-Risk Cancer:9683577	21/138,393	28/26,262,527	142.35	4.36e-35	1.23e-32
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|inpatient:7570914	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Prostate\|\|PART_OF\|\|Mice, Inbred C57BL:7226927	7/138,393	9/26,262,527	147.60	1.19e-12	9.12e-11
PCA3 gene\|PCA3\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:15165049	6/138,393	10/26,262,527	113.87	1.59e-10	9.61e-09
Proto-Oncogene Protein pp60 (c-src)\|SRC\|\|ISA\|\|Phosphotransferases:2260490	19/138,393	515/26,262,527	7.00	1.43e-10	8.74e-09
TWIST1 gene\|TWIST1\|\|PART_OF\|\|Prostate:15103175	4/138,393	3/26,262,527	253.03	2.61e-08	1.17e-06
Prostate-Specific Antigen\|\|CAUSES\|\|overdiagnosis:9663469	8/138,393	7/26,262,527	216.89	3.55e-15	3.52e-13
Estrogens\|\|TREATS\|\|Carcinoma:65749	15/138,393	22/26,262,527	129.40	5.21e-25	9.65e-23
High-Grade Prostatic Intraepithelial Neoplasia\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:7943163	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Glycoproteins\|\|PART_OF\|\|integral to membrane:1146512	55/138,393	2,126/26,262,527	4.91	1.09e-20	1.62e-18
Anogenital region\|\|LOCATION_OF\|\|Needle biopsy procedure:153238	14/138,393	16/26,262,527	166.06	1.59e-24	2.88e-22
Malignant neoplasm of prostate\|\|CAUSES\|\|Bladder outlet obstruction:5114412	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Endocrine therapy\|\|TREATS\|\|Hormone-refractory prostate cancer:7831324	7/138,393	9/26,262,527	147.60	1.19e-12	9.12e-11
External radiotherapy NOS\|\|TREATS\|\|Prostate carcinoma:2037419	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
zoledronic acid\|\|PREVENTS\|\|loss; bone:9976612	21/138,393	80/26,262,527	49.82	2.22e-27	4.49e-25
Bladder\|\|LOCATION_OF\|\|V 70:12548651	8/138,393	10/26,262,527	151.82	2.38e-14	2.15e-12
docetaxel\|\|ISA\|\|Chemotherapy-Oncologic Procedure:6028045	7/138,393	58/26,262,527	22.90	5.80e-08	2.25e-06
Cancer Treatment\|\|USES\|\|Androgen Antagonists:14225231	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Prostate-Specific Antigen\|\|PREDISPOSES\|\|Adenocarcinoma:4020594	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Compartments\|\|PART_OF\|\|Stroma:541987	84/138,393	936/26,262,527	17.04	9.84e-70	6.34e-67
Prostate-Specific Antigen\|\|ASSOCIATED_WITH\|\|Hyperplasia:5870635	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Cell Surface Proteins\|\|PART_OF\|\|Malignant neoplasm of prostate:9071728	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Castration\|\|USES\|\|Estrogens:126478	5/138,393	9/26,262,527	105.43	7.62e-09	3.62e-07
Adenocarcinoma, Endometrioid\|\|PART_OF\|\|Prostate:4668428	10/138,393	16/26,262,527	118.61	7.71e-17	8.83e-15
Myocytes, Smooth Muscle\|\|PART_OF\|\|Stroma:2143316	7/138,393	27/26,262,527	49.20	5.17e-10	3.02e-08
Radical cystectomy\|\|TREATS\|\|Carcinoma, Transitional Cell:1578224	35/138,393	456/26,262,527	14.57	6.37e-28	1.32e-25
Prostate\|\|LOCATION_OF\|\|IMMUNOHISTOCHEMICAL:3569784	5/138,393	8/26,262,527	118.61	4.92e-09	2.37e-07
Malignant neoplasm of prostate\|\|COEXISTS_WITH\|\|Carcinogenesis:6053469	10/138,393	10/26,262,527	189.78	2.76e-18	3.46e-16
Secondary malignant neoplasm of bone\|\|COEXISTS_WITH\|\|Prostate cancer metastatic:4246220	5/138,393	3/26,262,527	316.29	2.19e-10	1.31e-08
Transrectal Ultrasound\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:2920569	104/138,393	124/26,262,527	159.28	3.22e-171	5.65e-168
Magnetic Resonance Imaging\|\|DIAGNOSES\|\|Prostate carcinoma:3066872	17/138,393	18/26,262,527	179.25	7.06e-30	1.59e-27
Chromosomes, Human, Pair 10\|\|LOCATION_OF\|\|Phosphoric Monoester Hydrolases:7409004	63/138,393	838/26,262,527	14.27	2.13e-48	9.09e-46
Endocrine therapy\|\|USES\|\|Ketoconazole:10456830	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Fine needle aspiration biopsy\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:3757210	14/138,393	18/26,262,527	147.61	5.10e-24	9.12e-22
Prostate carcinoma\|\|PROCESS_OF\|\|Xenograft Model:10052312	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
docetaxel\|\|TREATS\|\|Xenograft Model:9480600	9/138,393	34/26,262,527	50.24	1.43e-12	1.09e-10
ETV4 gene\|ETV4\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:12037000	11/138,393	12/26,262,527	173.97	1.05e-19	1.44e-17
Hormone manipulation\|\|TREATS\|\|Prostate cancer metastatic:5391590	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Testosterone\|\|ASSOCIATED_WITH\|\|Prostate cancer metastatic:7446442	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Stromal Cells\|\|LOCATION_OF\|\|AR gene\|AR:13098796	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Specimen\|\|LOCATION_OF\|\|Immunoreactivity:1062364	17/138,393	317/26,262,527	10.18	5.28e-12	3.87e-10
Immunohistochemistry\|\|METHOD_OF\|\|Biopsy:2484013	16/138,393	430/26,262,527	7.06	3.49e-09	1.71e-07
Androgens\|\|AUGMENTS\|\|Transcription, Genetic:3385068	6/138,393	17/26,262,527	66.98	1.94e-09	9.82e-08
Stabilization\|\|TREATS\|\|Malignant neoplasm of prostate:9350606	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Prophylactic treatment\|\|USES\|\|Diphosphonates:2784209	26/138,393	168/26,262,527	29.37	2.83e-28	5.98e-26
Genistein\|\|ASSOCIATED_WITH\|\|Prostate:7800273	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Human Cell Line\|\|LOCATION_OF\|\|Glutamate Carboxypeptidase II:15308910	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Polymorphism, Genetic\|\|ASSOCIATED_WITH\|\|AR gene\|AR:7094948	9/138,393	29/26,262,527	58.90	4.25e-13	3.43e-11
Carcinoma\|\|PART_OF\|\|lymph nodes:511048	24/138,393	45/26,262,527	101.23	3.40e-37	1.05e-34
Radical prostatectomy\|\|TREATS\|\|Urinary Incontinence:944158	10/138,393	14/26,262,527	135.56	2.87e-17	3.37e-15
Radiosurgery\|\|TREATS\|\|Malignant neoplasm of prostate:7313478	6/138,393	9/26,262,527	126.52	9.97e-11	6.13e-09
Neoplasm Metastasis\|\|PART_OF\|\|Bladder:62889	12/138,393	229/26,262,527	9.94	8.63e-09	4.09e-07
serine repeat antigen, Plasmodium\|\|PART_OF\|\|Prostate:1996842	11/138,393	22/26,262,527	94.89	1.43e-17	1.71e-15
[M]Unspecified tumor cell NOS\|\|PRODUCES\|\|Prostate-Specific Antigen:6415191	11/138,393	13/26,262,527	160.59	1.92e-19	2.59e-17
Toremifene\|\|ISA\|\|Selective Estrogen Receptor Modulators:8180807	14/138,393	36/26,262,527	73.81	9.29e-21	1.39e-18
Carcinosarcoma\|\|PART_OF\|\|Prostate:476098	33/138,393	56/26,262,527	111.85	1.11e-51	5.02e-49
Prostate-Specific Antigen\|\|PART_OF\|\|Upper Extremity:7003744	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Bladder\|\|LOCATION_OF\|\|Cancer Diagnosis:1751125	12/138,393	174/26,262,527	13.09	4.62e-10	2.73e-08
Histologic\|\|ISA\|\|Beginning:196735	24/138,393	407/26,262,527	11.19	3.38e-17	3.94e-15
Multiple Myeloma\|\|PART_OF\|\|Colon:3459483	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Proton therapy\|\|TREATS\|\|AIDS related complex:7302541	5/138,393	21/26,262,527	45.18	2.37e-07	8.32e-06
Urologist\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:5935327	38/138,393	38/26,262,527	189.82	1.24e-65	7.41e-63
Stroma\|\|PART_OF\|\|Malignant neoplasm of prostate:8279463	36/138,393	38/26,262,527	179.83	1.11e-61	6.10e-59
Teleradiotherapy procedure\|\|compared_with\|\|Radical prostatectomy:7178133	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
EP300 protein, human\|EP300\|\|INTERACTS_WITH\|\|Androgen Receptor\|AR:8684203	6/138,393	8/26,262,527	142.33	6.01e-11	3.76e-09
Casodex\|\|TREATS\|\|Malignant neoplasm of prostate:4252370	20/138,393	25/26,262,527	151.84	6.86e-34	1.85e-31
BRCA1 gene\|BRCA1\|\|ISA\|\|Tumor Suppressor Genes:5774053	14/138,393	424/26,262,527	6.27	1.33e-07	4.83e-06
Prostatectomy, Retropubic\|\|TREATS\|\|Prostate carcinoma:4558194	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Prostatic Tissue\|\|LOCATION_OF\|\|Testosterone:662941	12/138,393	33/26,262,527	69.01	1.05e-17	1.27e-15
Androgens\|\|PART_OF\|\|Protoplasm:867742	8/138,393	14/26,262,527	108.44	1.71e-13	1.48e-11
Stroma\|\|LOCATION_OF\|\|Epithelial Cells:954259	11/138,393	86/26,262,527	24.27	5.40e-12	3.95e-10
Phototherapy\|\|TREATS\|\|Malignant neoplasm of prostate:2198093	19/138,393	18/26,262,527	200.34	7.55e-34	2.03e-31
Steroids\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:103261	16/138,393	15/26,262,527	202.44	9.06e-29	1.96e-26
Radical prostatectomy\|\|higher_than\|\|Radical prostatectomy:8452357	13/138,393	16/26,262,527	154.20	1.42e-22	2.34e-20
Benign prostatic hypertrophy\|\|COEXISTS_WITH\|\|Chronic inflammation:12891843	5/138,393	8/26,262,527	118.61	4.92e-09	2.37e-07
[M]Unspecified tumor cell NOS\|\|PRODUCES\|\|Glutamate Carboxypeptidase II:9441495	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Prostate\|\|ASSOCIATED_WITH\|\|Secondary malignant neoplasm of bone:6395940	15/138,393	15/26,262,527	189.79	8.93e-27	1.77e-24
Androgen Receptor\|AR\|\|INTERACTS_WITH\|\|AR:9284328	5/138,393	4/26,262,527	237.22	4.90e-10	2.87e-08
External Beam Radiation Therapy\|\|TREATS\|\|Locally Advanced Malignant Neoplasm:1231880	21/138,393	30/26,262,527	132.86	1.26e-34	3.49e-32
alpha-methylacyl-CoA racemase\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:10388252	12/138,393	14/26,262,527	162.67	3.88e-21	5.87e-19
Death (finding)\|\|PROCESS_OF\|\|Caucasoid Race:1180372	8/138,393	61/26,262,527	24.89	3.59e-09	1.76e-07
Transrectal Ultrasound\|\|ISA\|\|Medical Imaging:4633805	112/138,393	191/26,262,527	111.37	3.13e-171	5.54e-168
Needle biopsy procedure\|\|DIAGNOSES\|\|High-Grade Prostatic Intraepithelial Neoplasia:5543175	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Human tissue\|\|LOCATION_OF\|\|Androgen Receptor\|AR:2723445	5/138,393	12/26,262,527	79.07	2.32e-08	1.06e-06
Lower urinary tract symptoms\|\|ASSOCIATED_WITH\|\|Erectile dysfunction:10708487	6/138,393	40/26,262,527	28.47	1.62e-07	5.75e-06
Adriamycin\|\|TREATS\|\|Malignant neoplasm of prostate:910152	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
5-Alpha reductase inhibitor\|\|PREVENTS\|\|Malignant neoplasm of prostate:10993695	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
Stroma\|\|PART_OF\|\|Prostate:1271268	47/138,393	144/26,262,527	61.96	3.99e-63	2.29e-60
bicalutamide\|\|INTERACTS_WITH\|\|Androgen Receptor\|AR:8519123	7/138,393	9/26,262,527	147.60	1.19e-12	9.12e-11
Prostatic Diseases\|\|ISA\|\|Malignant neoplasm of prostate:8020072	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Malignant neoplasm of prostate\|\|COEXISTS_WITH\|\|Malignant neoplasm of stomach:6945641	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Lymph Node Dissection\|\|TREATS\|\|Prostate carcinoma:5881839	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
Radical prostatectomy\|\|TREATS\|\|Detected:8539882	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Antibodies, Anti-Idiotypic\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:3757351	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
MYC gene\|MYC\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:12799360	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
lenalidomide\|\|TREATS\|\|Prostate cancer metastatic:13882732	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Radiation Therapy Oncology Group\|\|LOCATION_OF\|\|Clinical Trials, Phase III:1918191	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
beta catenin\|\|COEXISTS_WITH\|\|Androgens:12615468	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
NKX3-1 gene\|NKX3-1\|\|PART_OF\|\|Prostate:7620699	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
parathyroid hormone-related protein\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:5493378	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Androgens\|\|AFFECTS\|\|Neoplasm progression:12050408	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Prostate-Specific Antigen\|\|PREDISPOSES\|\|Prostate carcinoma:3626767	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Photochemotherapy\|\|TREATS\|\|Malignant neoplasm of prostate:4053827	61/138,393	81/26,262,527	142.97	4.61e-99	4.67e-96
Immunotherapy, Active\|\|STIMULATES\|\|Immune response:2640547	6/138,393	11/26,262,527	103.51	2.44e-10	1.46e-08
5-Alpha reductase inhibitor\|\|TREATS\|\|Malignant neoplasm of prostate:10527710	12/138,393	12/26,262,527	189.78	1.10e-21	1.72e-19
Antigen assay\|\|METHOD_OF\|\|Radical prostatectomy:9742429	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
UVRAG\|TP63\|CKAP4\|\|ASSOCIATED_WITH\|\|Prostate carcinoma:10932066	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Cytotoxic Chemotherapy\|\|AFFECTS\|\|Malignant neoplasm of prostate:3586549	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Receptor Gene\|\|AFFECTS\|\|Malignant neoplasm of prostate:8052038	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Malignant neoplasm of prostate\|\|COEXISTS_WITH\|\|Neoplasm Metastasis:1858325	24/138,393	23/26,262,527	198.05	2.66e-42	9.70e-40
PTGS2 gene\|PTGS2\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9415069	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
KLK3\|PLAG1\|PROS1\|NPEPPS\|PSAT1\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:7981031	10/138,393	13/26,262,527	145.99	1.68e-17	1.99e-15
Flutamide\|\|INTERACTS_WITH\|\|Androgen Receptor\|AR:3108498	6/138,393	12/26,262,527	94.89	3.65e-10	2.16e-08
Flutamide\|\|compared_with\|\|Gonadotropin-Releasing Hormone Analog:5728923	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Zoladex\|\|ISA\|\|Gonadotropin-Releasing Hormone Analog:2892838	23/138,393	38/26,262,527	114.88	1.09e-36	3.32e-34
Prostate\|\|PRODUCES\|\|Citrate:2204687	6/138,393	14/26,262,527	81.33	7.55e-10	4.37e-08
zoledronic acid\|\|TREATS\|\|Multiple Myeloma:9824591	11/138,393	58/26,262,527	35.99	1.13e-13	9.90e-12
Prostate-Specific Antigen\|\|INHIBITS\|\|Androgens:6088399	27/138,393	32/26,262,527	160.15	1.10e-45	4.36e-43
Prostate\|\|PRODUCES\|\|Prostate-Specific Antigen:2003061	17/138,393	21/26,262,527	153.64	4.41e-29	9.64e-27
Radical cystoprostatectomy\|\|TREATS\|\|Invasive bladder cancer:4806785	15/138,393	29/26,262,527	98.17	1.23e-23	2.18e-21
Radiotherapy Systems, Linear Accelerator\|\|USES\|\|Collimator:1102038	7/138,393	48/26,262,527	27.68	1.77e-08	8.13e-07
Androgen Receptor\|AR\|\|COEXISTS_WITH\|\|Androgens:1932745	8/138,393	18/26,262,527	84.35	8.19e-13	6.38e-11
Diet, Fat-Restricted\|\|TREATS\|\|Malignant neoplasm of prostate:10296456	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Tumor Markers\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:2533976	36/138,393	37/26,262,527	184.69	5.74e-62	3.21e-59
Prednisone\|\|TREATS\|\|Prostate cancer metastatic:4007402	40/138,393	47/26,262,527	161.55	4.70e-67	2.88e-64
Clusterin\|CLU\|\|AUGMENTS\|\|Cell Survival:9231534	6/138,393	11/26,262,527	103.51	2.44e-10	1.46e-08
Round Ligament\|\|LOCATION_OF\|\|Thickened:108859	7/138,393	1/26,262,527	1328.44	8.66e-16	8.84e-14
Gland structure\|\|PART_OF\|\|Gland structure:678833	9/138,393	88/26,262,527	19.41	2.82e-09	1.42e-07
Magnetic Resonance Imaging\|\|ISA\|\|Medical Imaging:1559207	53/138,393	2,398/26,262,527	4.20	3.39e-17	3.96e-15
Malignant neoplasm of prostate\|\|AFFECTS\|\|receptor expression:6676168	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Pathologic stage\|\|ASSOCIATED_WITH\|\|Prostate carcinoma:5795173	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Prostate\|\|LOCATION_OF\|\|Atypical hyperplasia:4439929	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
prostate cancer prevention\|\|USES\|\|Finasteride:11925218	10/138,393	10/26,262,527	189.78	2.76e-18	3.46e-16
Androgen Receptor\|AR\|\|PREDISPOSES\|\|Neoplasm progression:11069897	7/138,393	6/26,262,527	221.41	1.82e-13	1.56e-11
Estradiol\|\|ASSOCIATED_WITH\|\|Prostate carcinoma:765404	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Androgen therapy\|\|TREATS\|\|Cardiovascular Diseases:13108457	10/138,393	10/26,262,527	189.78	2.76e-18	3.46e-16
VAV3 gene\|VAV3\|\|PART_OF\|\|Malignant neoplasm of prostate:12993305	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Diet, Mediterranean\|\|PREVENTS\|\|Malignant neoplasm of prostate:13347465	7/138,393	6/26,262,527	221.41	1.82e-13	1.56e-11
Urinalysis\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:9266090	5/138,393	9/26,262,527	105.43	7.62e-09	3.62e-07
TFF1 gene\|TFF1\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:6396803	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
atrasentan\|\|TREATS\|\|Malignant neoplasm of prostate:9227944	12/138,393	14/26,262,527	162.67	3.88e-21	5.87e-19
Thermal techniques\|\|USES\|\|Applicator - device:7008067	7/138,393	15/26,262,527	88.56	1.73e-11	1.23e-09
KLK3\|PLAG1\|PROS1\|NPEPPS\|PSAT1\|\|compared_with\|\|KLK3 gene\|KLK3:8401096	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
Biopsy\|\|DIAGNOSES\|\|Prostate cancer recurrent:10918160	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Glutamate Carboxypeptidase II\|\|ASSOCIATED_WITH\|\|Carcinogenesis:15807986	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Supplementation\|\|PREVENTS\|\|Malignant neoplasm of prostate:8760157	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
Brachytherapy\|\|PRECEDES\|\|Transurethral Resection of Prostate:7614915	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Epithelium\|\|PART_OF\|\|Prostatic Neoplasms:6245150	21/138,393	25/26,262,527	159.43	7.87e-36	2.27e-33
Acetate\|\|INHIBITS\|\|Androgens:14114398	12/138,393	13/26,262,527	175.19	2.10e-21	3.22e-19
Pelvis\|\|LOCATION_OF\|\|Magnetic Resonance Imaging:2726896	66/138,393	941/26,262,527	13.32	7.67e-49	3.32e-46
Emcyt\|\|ISA\|\|Estramustine phosphate:1925187	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Tumor cells, malignant\|\|LOCATION_OF\|\|Tumor Suppressor Genes:5756191	8/138,393	99/26,262,527	15.34	1.17e-07	4.28e-06
Gene Expression\|\|AFFECTS\|\|Malignant neoplasm of prostate:7368487	5/138,393	4/26,262,527	237.22	4.90e-10	2.87e-08
Androgen Receptor\|AR\|\|ASSOCIATED_WITH\|\|Neoplasm progression:7171269	13/138,393	13/26,262,527	189.79	2.20e-23	3.82e-21
Hydrocortisone\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:4485658	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Leptin\|LEP\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:7617165	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Triptorelin\|TYRP1\|\|TREATS\|\|Malignant neoplasm of prostate:3097154	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
DERIVED\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:11274022	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Secretory Vesicles\|\|PART_OF\|\|Prostate:2920388	8/138,393	41/26,262,527	37.03	2.12e-10	1.28e-08
Stanolone\|\|STIMULATES\|\|Androgens:1247463	6/138,393	19/26,262,527	59.93	3.37e-09	1.66e-07
Androgen Receptor\|AR\|\|PART_OF\|\|Tumor cells, malignant:4092108	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
host\|\|LOCATION_OF\|\|Toxic effect:145784	20/138,393	484/26,262,527	7.84	6.87e-12	5.01e-10
Physical activity\|\|TREATS\|\|Survivors:2147489	13/138,393	196/26,262,527	12.59	1.38e-10	8.47e-09
Androgen Receptor\|AR\|\|DISRUPTS\|\|Phosphorylation:12616163	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Phantoms, Imaging\|\|TREATS\|\|Malignant neoplasm of prostate:3459586	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
Malignant neoplasm of prostate\|\|LOCATION_OF\|\|Tumor cells, malignant:3507216	13/138,393	13/26,262,527	189.79	2.20e-23	3.82e-21
AR gene\|AR\|\|ASSOCIATED_WITH\|\|Carcinogenesis:13006211	10/138,393	20/26,262,527	94.89	4.28e-16	4.50e-14
Cardiovascular Diseases\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:16078754	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostatic Tissue\|\|LOCATION_OF\|\|Prostate carcinoma:944160	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
Malignant neoplasm of prostate\|\|AFFECTS\|\|Drug resistance:10637271	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Cessation of life\|\|PROCESS_OF\|\|American:2213387	7/138,393	62/26,262,527	21.43	8.83e-08	3.41e-06
FOLH1 gene\|FOLH1\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:12617018	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Goserelin Acetate\|\|USES\|\|Goserelin Acetate:6785244	8/138,393	22/26,262,527	69.01	3.01e-12	2.24e-10
CXCR4 gene\|CXCR4\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:14150483	7/138,393	9/26,262,527	147.60	1.19e-12	9.12e-11
Virus\|\|INTERACTS_WITH\|\|Bombyx:123267	5/138,393	2/26,262,527	474.44	8.24e-11	5.13e-09
Cell Line, Tumor\|\|PART_OF\|\|Breast:840562	15/138,393	365/26,262,527	7.80	2.97e-09	1.49e-07
Prostate\|\|LOCATION_OF\|\|Ultrasonography:1214652	140/138,393	261/26,262,527	101.89	2.45e-209	5.59e-206
Diphosphonates\|\|DISRUPTS\|\|Secondary malignant neoplasm of bone:6962777	5/138,393	13/26,262,527	72.99	3.20e-08	1.43e-06
Supernatant\|\|LOCATION_OF\|\|KLK3 gene\|KLK3:6244535	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Behavior\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:2530336	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Breast\|\|LOCATION_OF\|\|Secondary malignant neoplasm of bone:2771875	23/138,393	36/26,262,527	121.26	4.24e-37	1.31e-34
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Workers:1393773	15/138,393	17/26,262,527	167.46	3.22e-26	6.27e-24
Prostatic epithelium\|\|PART_OF\|\|Bladder:2748463	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Androgen Receptor\|AR\|\|AFFECTS\|\|Cell Proliferation:1125378	10/138,393	19/26,262,527	99.88	2.86e-16	3.02e-14
Insulin-Like Growth-Factor-Binding Proteins\|\|ASSOCIATED_WITH\|\|Prostate:7554357	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Stanolone\|\|AUGMENTS\|\|Transcription, Genetic:9677970	6/138,393	9/26,262,527	126.52	9.97e-11	6.13e-09
Cell Line, Transformed\|\|PART_OF\|\|Malignant neoplasm of prostate:12425710	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
long-term care\|\|USES\|\|Estrogens:354993	10/138,393	139/26,262,527	13.65	8.82e-09	4.17e-07
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Physicians:6032481	16/138,393	16/26,262,527	189.79	1.80e-28	3.82e-26
Prostate\|\|LOCATION_OF\|\|Anatomic structures:559	83/138,393	143/26,262,527	110.21	4.54e-127	6.08e-124
Estramustine phosphate\|\|ISA\|\|Estramustine:1511431	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
Knee\|\|LOCATION_OF\|\|Degenerative polyarthritis:45720	1/138,393	5,393/26,262,527	0.04	2.38e-11	1.59e-09
Androgen Receptor\|AR\|\|STIMULATES\|\|Cell Growth:9490596	7/138,393	9/26,262,527	147.60	1.19e-12	9.12e-11
Surrogate Endpoints\|\|ISA\|\|Biological Markers:5664777	33/138,393	298/26,262,527	21.02	3.81e-31	9.14e-29
Doxorubicin\|\|TREATS\|\|Malignant neoplasm of prostate:2212204	19/138,393	22/26,262,527	163.91	1.03e-32	2.63e-30
Malignant neoplasm of prostate\|\|ISA\|\|Prostatic Neoplasms:5875302	9/138,393	7/26,262,527	244.00	3.31e-17	3.87e-15
Prostatectomy\|\|TREATS\|\|Large prostate:2781250	5/138,393	17/26,262,527	55.82	9.68e-08	3.54e-06
Gland structure\|\|PART_OF\|\|Prostate:2088201	11/138,393	28/26,262,527	74.56	1.20e-16	1.37e-14
Transforming Growth Factor beta\|\|PART_OF\|\|Stroma:5618274	8/138,393	29/26,262,527	52.35	1.92e-11	1.28e-09
Prostate\|\|LOCATION_OF\|\|Receptors, Nuclear:2005035	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Radical prostatectomy\|\|TREATS\|\|Prostate cancer recurrent:6237241	32/138,393	41/26,262,527	148.15	4.34e-53	2.02e-50
AR gene\|AR\|\|ASSOCIATED_WITH\|\|Benign prostatic hypertrophy:1342091	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
Pheochromocytoma\|\|PART_OF\|\|Prostate:3269659	5/138,393	9/26,262,527	105.43	7.62e-09	3.62e-07
Androgens\|\|ASSOCIATED_WITH\|\|Neoplasm progression:4739498	20/138,393	23/26,262,527	165.04	2.10e-34	5.75e-32
lycopene\|\|STIMULATES\|\|lycopene:8632190	6/138,393	24/26,262,527	47.44	1.11e-08	5.20e-07
Androgen Receptor\|AR\|\|STIMULATES\|\|Prostate-Specific Antigen:7443338	10/138,393	12/26,262,527	158.15	9.56e-18	1.15e-15
Prostatic epithelium\|\|LOCATION_OF\|\|Prostate-Specific Antigen:5046454	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Alkaline Phosphatase\|\|compared_with\|\|Prostate-Specific Antigen:4915714	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Transurethral Resection of Prostate\|\|TREATS\|\|Benign prostatic hypertrophy:957057	63/138,393	459/26,262,527	26.06	3.26e-63	1.88e-60
Malignant neoplasm of prostate\|\|PART_OF\|\|Organ:2252587	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Fibroblasts\|\|PRODUCES\|\|Laminin:5359383	8/138,393	56/26,262,527	27.11	1.94e-09	9.82e-08
procollagen type I carboxy terminal peptide\|\|ISA\|\|Procollagen:4453193	19/138,393	274/26,262,527	13.16	4.01e-15	3.97e-13
PARP1\|COL11A2\|\|STIMULATES\|\|caspase-3:6717516	9/138,393	149/26,262,527	11.46	1.99e-07	6.99e-06
Malignant neoplasm of prostate\|\|ISA\|\|Urologic Diseases:2780940	11/138,393	11/26,262,527	189.78	5.49e-20	7.78e-18
maspin\|SERPINB5\|\|ISA\|\|Tumor Suppressor Genes:6354458	13/138,393	67/26,262,527	36.82	5.13e-16	5.31e-14
Androgen therapy\|\|CAUSES\|\|Hypogonadism:11938271	5/138,393	4/26,262,527	237.22	4.90e-10	2.87e-08
Prostate-Specific Antigen\|\|AFFECTS\|\|tumor growth:7132180	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Therapeutic agent (substance)\|\|TREATS\|\|Hormone-refractory prostate cancer:7039297	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Manganese Superoxide Dismutase\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:10286606	5/138,393	4/26,262,527	237.22	4.90e-10	2.87e-08
Fusion Gene\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:11778261	14/138,393	14/26,262,527	189.79	4.43e-25	8.24e-23
selective intervention\|\|TREATS\|\|Malignant neoplasm of prostate:9531072	10/138,393	10/26,262,527	189.78	2.76e-18	3.46e-16
Prostate\|\|ASSOCIATED_WITH\|\|Adenocarcinoma:204054	14/138,393	14/26,262,527	189.79	4.43e-25	8.24e-23
Single Nucleotide Polymorphism\|\|COEXISTS_WITH\|\|PSCA gene\|PSCA:13782946	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Androgen Receptor\|\|INTERACTS_WITH\|\|Androgen Receptor:3920557	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Prostate cancer metastatic\|\|COEXISTS_WITH\|\|Secondary malignant neoplasm of bone:10672532	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Palliative Care\|\|USES\|\|Diphosphonates:2740131	5/138,393	13/26,262,527	72.99	3.20e-08	1.43e-06
Epithelial Cells\|\|LOCATION_OF\|\|Glutamate Carboxypeptidase II:6676182	4/138,393	3/26,262,527	253.03	2.61e-08	1.17e-06
Transrectal Ultrasound\|\|METHOD_OF\|\|Magnetic Resonance Imaging:6159679	5/138,393	11/26,262,527	86.26	1.65e-08	7.59e-07
Prostate\|\|LOCATION_OF\|\|Very low:620815	5/138,393	9/26,262,527	105.43	7.62e-09	3.62e-07
MicroRNAs\|\|AFFECTS\|\|Neoplasm progression:13617618	8/138,393	58/26,262,527	26.18	2.50e-09	1.26e-07
Estrogens\|\|ASSOCIATED_WITH\|\|Carcinogenesis:106642	16/138,393	124/26,262,527	24.49	7.52e-17	8.63e-15
Chemotherapy, Adjuvant\|\|TREATS\|\|High-Risk Cancer:3959341	7/138,393	52/26,262,527	25.55	2.92e-08	1.31e-06
Intracranial\|\|LOCATION_OF\|\|Neoplasm Metastasis:33853	17/138,393	580/26,262,527	5.56	3.37e-08	1.51e-06
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|spouse:9587741	4/138,393	3/26,262,527	253.03	2.61e-08	1.17e-06
TNF protein, human\|TNF\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8568333	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
CHEK2 gene\|CHEK2\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9973068	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostate\|\|LOCATION_OF\|\|Cancer Diagnosis:3826937	979/138,393	1,180/26,262,527	158.56	0.00e+00	0.00e+00
Methylnitrosourea\|\|CAUSES\|\|Malignant neoplasm of prostate:6648859	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Anemia\|\|COEXISTS_WITH\|\|Iron deficiency anemia:300471	9/138,393	8/26,262,527	213.50	6.99e-17	8.04e-15
Cytosol\|\|PART_OF\|\|Prostate:673956	22/138,393	179/26,262,527	23.33	3.46e-22	5.64e-20
Stanolone\|\|AFFECTS\|\|Cell Proliferation:3963364	9/138,393	15/26,262,527	113.87	3.64e-15	3.60e-13
Specimen from prostate\|\|LOCATION_OF\|\|AR gene\|AR:15445012	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Compete\|\|TREATS\|\|Malignant neoplasm of prostate:7321173	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
Testing\|\|USES\|\|Pads:1203147	35/138,393	874/26,262,527	7.60	3.11e-19	4.17e-17
Diethylstilbestrol\|\|ISA\|\|Estrogens:57053	19/138,393	219/26,262,527	16.47	8.81e-17	1.01e-14
adult stem cell\|\|PART_OF\|\|Prostate:13195542	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Acid Phosphatase\|\|INTERACTS_WITH\|\|Androgens:2280245	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
fosfestrol\|\|USES\|\|fosfestrol:299649	13/138,393	16/26,262,527	154.20	1.42e-22	2.34e-20
FLVCR1\|\|compared_with\|\|FLVCR1:2455929	9/138,393	25/26,262,527	68.32	1.39e-13	1.21e-11
Prostate\|\|LOCATION_OF\|\|Biological Models:2075120	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
Combined radiotherapy NOS\|\|TREATS\|\|Malignant neoplasm of prostate:9647149	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Brachytherapy\|\|compared_with\|\|Radical prostatectomy:8514684	21/138,393	26/26,262,527	153.30	1.42e-35	4.06e-33
Seminoma\|\|PART_OF\|\|Prostate:6425621	9/138,393	15/26,262,527	113.87	3.64e-15	3.60e-13
CpG Islands\|\|ASSOCIATED_WITH\|\|Prostate:8719726	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
zoledronate\|\|ISA\|\|Diphosphonates:7341809	10/138,393	139/26,262,527	13.65	8.82e-09	4.17e-07
Transurethral Resection of Prostate\|\|TREATS\|\|Lower urinary tract symptoms:7391081	11/138,393	59/26,262,527	35.38	1.34e-13	1.17e-11
Diphosphonates\|\|AFFECTS\|\|Secondary malignant neoplasm of bone:7779767	10/138,393	17/26,262,527	111.64	1.22e-16	1.38e-14
Benign prostatic hypertrophy\|\|PROCESS_OF\|\|Areae:3338618	6/138,393	10/26,262,527	113.87	1.59e-10	9.61e-09
Prostate\|\|LOCATION_OF\|\|Carcinoma:211598	35/138,393	38/26,262,527	174.83	1.03e-59	5.46e-57
HSP90 Heat-Shock Proteins\|HSP90AA1\|\|INTERACTS_WITH\|\|Androgen Receptor\|AR:9517848	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
GSTP1 gene\|GSTP1\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:7717721	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Recurrent Carcinoma\|\|PART_OF\|\|Prostate:28323	79/138,393	100/26,262,527	150.00	5.39e-129	7.41e-126
Androgen Receptor\|AR\|\|AFFECTS\|\|Receptor Signaling:9178856	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Androgens\|\|DISRUPTS\|\|tumor growth:3756979	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Malignant neoplasm of prostate\|\|ASSOCIATED_WITH\|\|Rectum:173260	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostate-Specific Antigen\|\|compared_with\|\|Glutamate Carboxypeptidase II:6277879	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prednisone\|\|TREATS\|\|Hormone-refractory prostate cancer:4543156	28/138,393	37/26,262,527	143.64	2.27e-46	9.20e-44
MSR1 gene\|MSR1\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9942467	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Entire autonomic nerve\|\|LOCATION_OF\|\|Preservation, Biological:3749016	12/138,393	184/26,262,527	12.38	8.41e-10	4.86e-08
retinoic acid receptor beta 2\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:10195158	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Tomography, Emission-Computed\|\|USES\|\|Choline:13266343	6/138,393	10/26,262,527	113.87	1.59e-10	9.61e-09
Insulin-Like Growth-Factor-Binding Proteins\|\|ISA\|\|Binding Protein:3989079	19/138,393	351/26,262,527	10.27	2.61e-13	2.23e-11
Immunohistochemistry\|\|METHOD_OF\|\|Radical prostatectomy:6390102	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Endocrine therapy\|\|USES\|\|agonists:5060804	10/138,393	19/26,262,527	99.88	2.86e-16	3.02e-14
Androgen therapy\|\|TREATS\|\|Osteoporosis:8439742	9/138,393	13/26,262,527	131.39	1.40e-15	1.41e-13
Suppression treatment\|\|USES\|\|Androgens:7809956	11/138,393	15/26,262,527	139.17	5.90e-19	7.80e-17
Prostatic Intraepithelial Neoplasias\|\|PROCESS_OF\|\|Mice, Knockout:10572421	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Digital Rectal Examination\|\|DIAGNOSES\|\|Large prostate:7630462	13/138,393	14/26,262,527	176.23	4.22e-23	7.15e-21
Cancer Relapse\|\|PART_OF\|\|Prostate:6252771	52/138,393	60/26,262,527	164.53	5.55e-87	4.66e-84
lymph nodes\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:2876136	24/138,393	27/26,262,527	168.71	3.71e-41	1.30e-38
Neoplasm progression\|\|PROCESS_OF\|\|Animal Model:4392503	7/138,393	37/26,262,527	35.90	3.52e-09	1.73e-07
prostate cancer screening\|\|TREATS\|\|African American:11020671	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Radiotherapy Systems, Linear Accelerator\|\|TREATS\|\|AIDS related complex:11113411	7/138,393	20/26,262,527	66.42	8.81e-11	5.47e-09
Radical prostatectomy\|\|TREATS\|\|Large prostate:13073017	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Somatostatin\|\|TREATS\|\|Malignant neoplasm of prostate:7316298	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Cisplatin\|\|TREATS\|\|Malignant neoplasm of prostate:1646807	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Prostate-Specific Antigen\|\|COEXISTS_WITH\|\|KLK3 gene\|KLK3:8298153	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
External Beam Radiation Therapy\|\|TREATS\|\|Prostate cancer metastatic:10716029	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Androgen therapy\|\|TREATS\|\|Prostate carcinoma:5880742	24/138,393	30/26,262,527	151.84	2.23e-40	7.66e-38
Physical activity\|\|TREATS\|\|Cancer Survivor:10357911	10/138,393	91/26,262,527	20.86	1.95e-10	1.18e-08
External Beam Radiation Therapy\|\|TREATS\|\|High-Risk Cancer:8416775	27/138,393	32/26,262,527	160.15	1.10e-45	4.36e-43
Prostatectomy\|\|TREATS\|\|High-Risk Cancer:10551460	10/138,393	9/26,262,527	210.87	1.39e-18	1.80e-16
Cystoprostatectomy\|\|TREATS\|\|Malignant neoplasm of prostate:6712191	5/138,393	8/26,262,527	118.61	4.92e-09	2.37e-07
Carcinogens\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:6690955	35/138,393	34/26,262,527	195.40	7.14e-61	3.85e-58
Implantation procedure\|\|TREATS\|\|Mice, Nude:1676737	12/138,393	117/26,262,527	19.46	6.39e-12	4.66e-10
Prostate\|\|LOCATION_OF\|\|dehydroepiandrosterone:3773162	7/138,393	15/26,262,527	88.56	1.73e-11	1.23e-09
Mitoxantrone\|\|TREATS\|\|Malignant neoplasm of prostate:2495335	13/138,393	14/26,262,527	176.23	4.22e-23	7.15e-21
Adenocarcinoma\|\|PART_OF\|\|Bladder:104182	28/138,393	405/26,262,527	13.12	1.60e-21	2.49e-19
Human Cell Line\|\|LOCATION_OF\|\|Cell Cycle:1469015	8/138,393	78/26,262,527	19.46	2.10e-08	9.64e-07
Gonadotropin-Releasing Hormone Analog\|\|TREATS\|\|Malignant neoplasm of prostate:2129624	116/138,393	134/26,262,527	164.41	6.56e-192	1.28e-188
[M]Unspecified tumor cell NOS\|\|PART_OF\|\|Prostate:578777	551/138,393	685/26,262,527	153.25	0.00e+00	0.00e+00
Thermal techniques\|\|TREATS\|\|Malignant neoplasm of prostate:8599265	13/138,393	17/26,262,527	145.13	2.49e-22	4.06e-20
Diet\|\|AFFECTS\|\|Malignant neoplasm of prostate:3394128	18/138,393	18/26,262,527	189.79	7.40e-32	1.83e-29
Autophagy\|\|CAUSES\|\|Cell Death:2370105	12/138,393	212/26,262,527	10.74	3.81e-09	1.87e-07
Human tissue\|\|LOCATION_OF\|\|Malignant neoplasm of prostate:6259026	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
epigallocatechin gallate\|\|USES\|\|epigallocatechin gallate:6408121	17/138,393	529/26,262,527	6.10	9.29e-09	4.38e-07
Malignant neoplasm of prostate\|\|COEXISTS_WITH\|\|Aggressive behavior:9461183	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Tretinoin\|\|TREATS\|\|Malignant neoplasm of prostate:6126058	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Acid Phosphatase\|\|ASSOCIATED_WITH\|\|Carcinoma:87098	7/138,393	9/26,262,527	147.60	1.19e-12	9.12e-11
cohort\|\|LOCATION_OF\|\|Single Nucleotide Polymorphism:9030258	23/138,393	715/26,262,527	6.11	2.46e-11	1.64e-09
Malignant neoplasm of prostate\|\|PART_OF\|\|Bone Marrow:13604922	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostatic Neoplasms\|\|COEXISTS_WITH\|\|Prostatic Neoplasms:4452884	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Disseminated carcinoma\|\|PART_OF\|\|Prostate:885662	11/138,393	12/26,262,527	173.97	1.05e-19	1.44e-17
cyclooxygenase 2\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:7846390	28/138,393	32/26,262,527	166.08	1.23e-47	5.12e-45
prognostic\|\|ISA\|\|Additional values:1370622	17/138,393	343/26,262,527	9.41	1.71e-11	1.22e-09
Radical prostatectomy\|\|TREATS\|\|Secondary malignant neoplasm of lymph node:5140063	14/138,393	16/26,262,527	166.06	1.59e-24	2.88e-22
Diethylstilbestrol\|\|USES\|\|Diethylstilbestrol:37116	49/138,393	556/26,262,527	16.73	4.61e-41	1.61e-38
DNMT1\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9277701	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Prostate\|\|LOCATION_OF\|\|Diffusion Magnetic Resonance Imaging:14602479	15/138,393	19/26,262,527	149.83	1.05e-25	2.00e-23
Stanolone\|\|STIMULATES\|\|Prostate-Specific Antigen:4539603	9/138,393	12/26,262,527	142.33	8.30e-16	8.48e-14
Pedicles\|\|PART_OF\|\|Prostate:6656711	7/138,393	13/26,262,527	102.19	7.94e-12	5.78e-10
Radiotherapy, Intensity-Modulated\|\|TREATS\|\|Malignant neoplasm of prostate:8523976	186/138,393	269/26,262,527	131.39	2.54e-293	9.07e-290
Androgen therapy\|\|TREATS\|\|Menopausal hot flushes:10931680	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
RNA\|\|PART_OF\|\|Prostate:810693	6/138,393	25/26,262,527	45.55	1.36e-08	6.33e-07
Valproic Acid\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:12046161	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Hospitals\|\|LOCATION_OF\|\|Biopsy:213799	42/138,393	311/26,262,527	25.64	1.90e-42	6.98e-40
Androgen Receptor\|AR\|\|STIMULATES\|\|c-myc Genes\|MYC:14668408	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Electromagnetic Energy\|\|PROCESS_OF\|\|Malignant neoplasm of prostate:3851430	14/138,393	14/26,262,527	189.79	4.43e-25	8.24e-23
prednisolone\|\|TREATS\|\|Malignant neoplasm of prostate:7686054	11/138,393	13/26,262,527	160.59	1.92e-19	2.59e-17
Breast\|\|ASSOCIATED_WITH\|\|Neoplasm Metastasis:152784	11/138,393	25/26,262,527	83.50	4.37e-17	5.09e-15
Testosterone\|\|AUGMENTS\|\|Malignant neoplasm of prostate:12922409	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Testosterone\|\|CAUSES\|\|Carcinogenesis:10400440	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
zoledronic acid\|\|TREATS\|\|Prostate cancer metastatic:9789973	30/138,393	32/26,262,527	177.95	1.47e-51	6.63e-49
Proto-Oncogene Proteins c-akt\|AKT1\|\|ASSOCIATED_WITH\|\|Neoplasm progression:8719559	10/138,393	35/26,262,527	54.22	4.23e-14	3.77e-12
Colon\|\|PART_OF\|\|Prostate:11794613	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
IFI27\|PSMD9\|SSSCA1\|DCTN6\|TMED7\|\|INHIBITS\|\|Cyclin D1\|CCND1:7463723	7/138,393	59/26,262,527	22.52	6.46e-08	2.51e-06
Creatine Kinase\|\|ASSOCIATED_WITH\|\|Prostate:1013981	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Seed Implantation\|\|TREATS\|\|Prostate carcinoma:4167217	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
Calcium\|\|PART_OF\|\|Protoplasm:27315	37/138,393	15,252/26,262,527	0.46	1.18e-07	4.30e-06
Prostate\|\|LOCATION_OF\|\|Suspected malignancy:8504641	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Biopsy\|\|ISA\|\|Procedures:130413	130/138,393	1,236/26,262,527	19.98	5.69e-115	6.81e-112
Gastrointestinal Stromal Tumors\|\|PART_OF\|\|Prostate:8903537	6/138,393	9/26,262,527	126.52	9.97e-11	6.13e-09
Chondroblasts\|\|PRODUCES\|\|Proteoglycan:16361249	8/138,393	48/26,262,527	31.63	6.47e-10	3.76e-08
External Beam Radiation Therapy\|\|PRECEDES\|\|Brachytherapy:7214343	5/138,393	20/26,262,527	47.44	1.93e-07	6.79e-06
Curcumin\|\|PREVENTS\|\|Malignant neoplasm of prostate:12760505	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Chromosomes, Human, Pair 13\|\|LOCATION_OF\|\|BRCA2 gene\|BRCA2:6024341	5/138,393	15/26,262,527	63.26	5.75e-08	2.23e-06
Secondary malignant neoplasm of bone\|\|COEXISTS_WITH\|\|Hormone-refractory prostate cancer:7435035	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
Supplementation\|\|USES\|\|alpha Tocopherol:930925	17/138,393	567/26,262,527	5.69	2.46e-08	1.12e-06
Prostate\|\|LOCATION_OF\|\|Human cells:1280695	7/138,393	11/26,262,527	120.77	3.29e-12	2.43e-10
Prostate\|\|PART_OF\|\|Rats, Sprague-Dawley:2105279	5/138,393	18/26,262,527	52.72	1.23e-07	4.49e-06
BTG1 gene\|BTG1\|PPBP\|\|PART_OF\|\|Prostate:4894168	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Testosterone\|\|NEG_PREDISPOSES\|\|Malignant neoplasm of prostate:14710257	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Selenium\|\|TREATS\|\|Malignant neoplasm of prostate:9888127	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
CDKN2A gene\|CDKN2A\|\|ISA\|\|Tumor Suppressor Genes:5938538	27/138,393	1,348/26,262,527	3.80	1.15e-08	5.35e-07
Pathologic Neovascularization\|\|COEXISTS_WITH\|\|Prostate carcinoma:6296450	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostate-Specific Antigen\|\|ASSOCIATED_WITH\|\|Salivary Glands:6769752	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Zinc\|\|ASSOCIATED_WITH\|\|Prostate:122993	36/138,393	93/26,262,527	73.48	5.71e-51	2.56e-48
Needle biopsy procedure\|\|ISA\|\|Diagnosis:88141	32/138,393	187/26,262,527	32.48	1.12e-35	3.22e-33
Milk intake\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:11208947	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Hypoxia\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:10545489	25/138,393	30/26,262,527	158.17	2.57e-42	9.41e-40
Fibroblast Growth Factor Receptors\|\|ASSOCIATED_WITH\|\|Neoplasm progression:6965594	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Stroma\|\|PART_OF\|\|Prostatic Neoplasms:8699904	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Prostatic epithelium\|\|PART_OF\|\|Adenomatous Polyps:2009650	8/138,393	12/26,262,527	126.52	6.79e-14	6.00e-12
Transrectal Ultrasound\|\|ISA\|\|Ultrasonography:5285940	6/138,393	8/26,262,527	142.33	6.01e-11	3.76e-09
liarozole\|\|TREATS\|\|Malignant neoplasm of prostate:5435254	6/138,393	8/26,262,527	142.33	6.01e-11	3.76e-09
Androgen Receptor\|AR\|\|ASSOCIATED_WITH\|\|Prostate carcinoma:2029751	10/138,393	11/26,262,527	172.53	5.24e-18	6.40e-16
Androgen therapy\|\|ADMINISTERED_TO\|\|Survivors:10757865	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
PIN1\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:10349136	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Chromogranin A\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:6785150	23/138,393	26/26,262,527	167.90	1.81e-39	5.98e-37
Neprilysin\|\|PART_OF\|\|Malignant neoplasm of prostate:10314159	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Orchiectomy\|\|USES\|\|Diethylstilbestrol:3737456	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Radical prostatectomy\|\|METHOD_OF\|\|Endocrine therapy:7018589	8/138,393	10/26,262,527	151.82	2.38e-14	2.15e-12
Androgens\|\|AFFECTS\|\|[M]Unspecified tumor cell NOS:5697269	7/138,393	6/26,262,527	221.41	1.82e-13	1.56e-11
NKX3-1 gene\|NKX3-1\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8514700	17/138,393	19/26,262,527	169.81	1.33e-29	2.97e-27
Zinc\|\|PART_OF\|\|Protoplasm:913866	14/138,393	403/26,262,527	6.59	7.31e-08	2.83e-06
Radiation-Sensitizing Agents\|\|TREATS\|\|Malignant neoplasm of prostate:10240037	17/138,393	18/26,262,527	179.25	7.06e-30	1.59e-27
Prostatic Tissue\|\|LOCATION_OF\|\|Zinc:938569	5/138,393	9/26,262,527	105.43	7.62e-09	3.62e-07
satraplatin\|\|ISA\|\|Platinum Compounds:11878617	6/138,393	8/26,262,527	142.33	6.01e-11	3.76e-09
Radioimmunotherapy\|\|TREATS\|\|Malignant neoplasm of prostate:7461212	12/138,393	11/26,262,527	207.04	5.52e-22	8.86e-20
Medical Castration\|\|USES\|\|Gonadorelin\|GNRH1:4166521	6/138,393	9/26,262,527	126.52	9.97e-11	6.13e-09
Prostate specific antigen measurement\|\|DIAGNOSES\|\|Benign prostatic hypertrophy:3490284	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Benign prostatic hypertrophy\|\|PART_OF\|\|Stroma:1402016	12/138,393	27/26,262,527	84.35	1.48e-18	1.91e-16
Protein p53\|TP53\|\|ASSOCIATED_WITH\|\|Adenocarcinoma of prostate:5954572	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Suicide Gene Therapy\|\|TREATS\|\|Malignant neoplasm of prostate:8653093	17/138,393	19/26,262,527	169.81	1.33e-29	2.97e-27
Brachytherapy\|\|PRECEDES\|\|Teleradiotherapy procedure:7558131	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Radical prostatectomy\|\|compared_with\|\|Prostate-Specific Antigen:7559389	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Fibroblast Growth Factor\|\|PART_OF\|\|Malignant neoplasm of prostate:7922745	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Entire genitourinary tract\|\|LOCATION_OF\|\|Magnetic Resonance Imaging:2993070	5/138,393	10/26,262,527	94.89	1.14e-08	5.31e-07
Paraganglioma\|\|PART_OF\|\|Prostate:7462310	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Sex Hormone-Binding Globulin\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:12472056	6/138,393	9/26,262,527	126.52	9.97e-11	6.13e-09
Malignant neoplasm of prostate\|\|AFFECTS\|\|Racial group:7791126	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
Prostatic Tissue\|\|PART_OF\|\|Adenocarcinoma:1046008	23/138,393	24/26,262,527	181.89	5.04e-40	1.70e-37
Human Papillomavirus\|\|CAUSES\|\|Malignant neoplasm of prostate:7564983	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Carbohydrates\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:7531116	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Stromal Cells\|\|LOCATION_OF\|\|Androgen Receptor\|AR:4750031	6/138,393	20/26,262,527	56.93	4.37e-09	2.14e-07
Precancerous lesions\|\|PART_OF\|\|Prostate:83987	36/138,393	40/26,262,527	170.84	4.02e-61	2.18e-58
Prostate\|\|LOCATION_OF\|\|X-Ray Computed Tomography:2610480	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
Genes, rRNA\|\|PART_OF\|\|16s:1368658	3/138,393	10,626/26,262,527	0.05	4.08e-20	5.90e-18
Diagnosis\|\|TREATS\|\|Cancer Patient:90079	11/138,393	109/26,262,527	19.15	5.64e-11	3.58e-09
Testosterone\|\|INHIBITS\|\|Testosterone:867745	16/138,393	121/26,262,527	25.10	5.29e-17	6.12e-15
Digital Rectal Examination\|\|ADMINISTERED_TO\|\|Participant:6546008	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
MSMB gene\|MSMB\|\|ASSOCIATED_WITH\|\|Prostate:2064180	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Proto-Oncogene Proteins c-akt\|AKT1\|\|AFFECTS\|\|Neoplasm progression:8719558	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Bone Density\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:13641126	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Cadherins\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:5235809	8/138,393	11/26,262,527	138.02	4.09e-14	3.65e-12
Radical prostatectomy\|\|TREATS\|\|Racial group:7916931	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Genistein\|\|AFFECTS\|\|Malignant neoplasm of prostate:9678612	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Malignant neoplasm of prostate\|\|COEXISTS_WITH\|\|Chronic inflammation:12236963	8/138,393	7/26,262,527	216.89	3.55e-15	3.52e-13
Androgen Receptor\|AR\|\|STIMULATES\|\|Androgens:1746824	26/138,393	35/26,262,527	141.00	5.18e-43	1.94e-40
Ketoconazole\|\|TREATS\|\|Prostate cancer metastatic:3526506	13/138,393	17/26,262,527	145.13	2.49e-22	4.06e-20
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Elderly man:13783287	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Protein-Serine-Threonine Kinases\|\|AFFECTS\|\|Cell Growth:5790163	9/138,393	108/26,262,527	15.81	1.48e-08	6.87e-07
External Beam Radiation Therapy\|\|compared_with\|\|Radical prostatectomy:4740337	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
PROSTATE SPECIFIC\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9212113	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Gonadotropin-Releasing Hormone Receptor\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:3756969	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Secretory Cell\|\|PART_OF\|\|Prostate:1157887	21/138,393	65/26,262,527	61.32	5.33e-29	1.16e-26
Alkaline Phosphatase\|\|INHIBITS\|\|Androgens:7644801	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Prostate-Specific Antigen\|\|NEG_PREDISPOSES\|\|Malignant neoplasm of prostate:3920608	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
leiomyosarcoma\|\|PART_OF\|\|Prostate:89505	53/138,393	77/26,262,527	130.67	9.43e-85	7.61e-82
Malignant neoplasm of prostate\|\|COEXISTS_WITH\|\|Disease Progression:8782150	12/138,393	12/26,262,527	189.78	1.10e-21	1.72e-19
Renal Cell Carcinoma\|\|PART_OF\|\|Prostate:1190952	8/138,393	13/26,262,527	116.79	1.09e-13	9.55e-12
FOLH1 gene\|FOLH1\|\|INTERACTS_WITH\|\|FOLH1 gene\|FOLH1:5855908	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
degarelix\|\|INHIBITS\|\|Gonadotropin-Releasing Hormone Receptor:12228946	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Androgens\|\|STIMULATES\|\|Prostate-Specific Antigen:4789011	25/138,393	38/26,262,527	124.87	1.95e-40	6.73e-38
Zinc\|\|ASSOCIATED_WITH\|\|Carcinogenesis:48582	5/138,393	21/26,262,527	45.18	2.37e-07	8.32e-06
Epithelium\|\|PART_OF\|\|Breast:47395	9/138,393	55/26,262,527	31.05	6.35e-11	3.97e-09
Prostatic Tissue\|\|LOCATION_OF\|\|In Situ Hybridization:2346282	10/138,393	11/26,262,527	172.53	5.24e-18	6.40e-16
Immunohistochemistry\|\|USES\|\|Tissue Microarray:9337952	31/138,393	323/26,262,527	18.22	1.28e-27	2.61e-25
Prophylactic treatment\|\|USES\|\|zoledronic acid:10005626	17/138,393	53/26,262,527	60.88	1.03e-23	1.83e-21
IFI27\|PSMD9\|SSSCA1\|DCTN6\|TMED7\|\|ASSOCIATED_WITH\|\|Prostate:8020737	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Cancer-Predisposing Gene\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:7363873	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
racial differences\|\|PROCESS_OF\|\|African American:5939750	6/138,393	30/26,262,527	37.96	3.53e-08	1.58e-06
CANCER END STAGE\|\|PART_OF\|\|Prostate:6291993	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Neoplasm progression\|\|PROCESS_OF\|\|Mice, Transgenic:4040281	8/138,393	36/26,262,527	42.17	8.54e-11	5.31e-09
epitheliasin\|TMPRSS2\|\|ISA\|\|Serine Protease:8414625	8/138,393	31/26,262,527	48.98	3.03e-11	2.01e-09
sorafenib\|\|TREATS\|\|Malignant neoplasm of prostate:12744901	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
Stroma\|\|ASSOCIATED_WITH\|\|Prostate carcinoma:840216	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Epithelial Cells\|\|PRODUCES\|\|Glycoproteins:2022432	12/138,393	73/26,262,527	31.20	3.97e-14	3.56e-12
Free testosterone\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:10803200	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Gonadotropin-Releasing Hormone Analog\|\|STIMULATES\|\|Chlormadinone Acetate:6360119	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
bicalutamide\|\|INHIBITS\|\|Androgen Receptor\|AR:6651317	13/138,393	16/26,262,527	154.20	1.42e-22	2.34e-20
C-reactive protein\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:13412674	7/138,393	9/26,262,527	147.60	1.19e-12	9.12e-11
Tumor Suppressor Genes\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:6067966	192/138,393	202/26,262,527	180.62	6.08e-322	2.47e-318
Consumption-archaic term for TB\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:8760154	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Prostatic Urethra\|\|LOCATION_OF\|\|Biopsy:3382874	27/138,393	39/26,262,527	131.40	5.36e-44	2.07e-41
Protons\|\|PART_OF\|\|Prostate:7136468	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Osteoblasts\|\|PRODUCES\|\|Laminin:16361248	8/138,393	48/26,262,527	31.63	6.47e-10	3.76e-08
Neoplasm Metastasis\|\|ASSOCIATED_WITH\|\|Prostate:6460130	20/138,393	22/26,262,527	172.54	1.13e-34	3.12e-32
Therapies, Investigational\|\|TREATS\|\|Malignant neoplasm of prostate:9771172	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Laboratory\|\|LOCATION_OF\|\|Needle biopsy procedure:4997247	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Prostate\|\|LOCATION_OF\|\|Citrate:1195115	11/138,393	29/26,262,527	71.99	1.65e-16	1.80e-14
Androgen Receptor\|\|ASSOCIATED_WITH\|\|Benign prostatic hypertrophy:679337	5/138,393	11/26,262,527	86.26	1.65e-08	7.59e-07
Epirubicin\|\|TREATS\|\|Hormone-refractory prostate cancer:4145319	7/138,393	11/26,262,527	120.77	3.29e-12	2.43e-10
Germ-Line Mutation\|\|ASSOCIATED_WITH\|\|BRCA2 gene\|BRCA2:6715561	29/138,393	360/26,262,527	15.29	5.86e-24	1.04e-21
Antimetastatic Agent\|\|TREATS\|\|Malignant neoplasm of prostate:5047646	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Epithelial Cells\|\|PART_OF\|\|Malignant neoplasm of prostate:7477529	97/138,393	110/26,262,527	167.46	2.56e-161	4.31e-158
Prostatic Tissue\|\|LOCATION_OF\|\|lycopene:9543151	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Primary Carcinoma\|\|PART_OF\|\|Prostate:4829	44/138,393	60/26,262,527	139.21	1.55e-71	1.03e-68
Human Cell Line\|\|PART_OF\|\|Hormone-refractory prostate cancer:6514324	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Surgical margins\|\|ASSOCIATED_WITH\|\|organic disorders:7410786	5/138,393	8/26,262,527	118.61	4.92e-09	2.37e-07
Professional Organization or Group\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:7793032	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
ETS1 gene\|ETS1\|\|ISA\|\|Transcription factor genes:7505708	7/138,393	17/26,262,527	78.14	3.48e-11	2.23e-09
Adenocarcinoma of prostate\|\|ASSOCIATED_WITH\|\|Prostate:3508253	12/138,393	15/26,262,527	151.83	6.95e-21	1.04e-18
Bladder\|\|LOCATION_OF\|\|Cancer Model:2542197	11/138,393	170/26,262,527	12.28	4.55e-09	2.23e-07
[M]Unspecified tumor cell NOS\|\|PART_OF\|\|Breast:94302	28/138,393	1,148/26,262,527	4.63	9.37e-11	5.82e-09
Prostate\|\|LOCATION_OF\|\|Tumor Burden:9074752	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Pharmacologic Substance\|\|TREATS\|\|Malignant neoplasm of prostate:5888568	11/138,393	11/26,262,527	189.78	5.49e-20	7.78e-18
Brachytherapy\|\|TREATS\|\|Local disease:7756533	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
CDKN1A\|TCEAL1\|NSG1\|H3F3AP6\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:6216562	12/138,393	14/26,262,527	162.67	3.88e-21	5.87e-19
Estramustine\|\|TREATS\|\|Prostate cancer metastatic:6984336	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Stromal Cells\|\|PART_OF\|\|Prostate:3202482	148/138,393	449/26,262,527	62.62	1.63e-195	3.31e-192
TNF-related apoptosis-inducing ligand\|TNFSF10\|\|STIMULATES\|\|caspase-8:8548109	6/138,393	32/26,262,527	35.58	4.96e-08	2.03e-06
Androgens\|\|INTERACTS_WITH\|\|Transcript:6001718	9/138,393	13/26,262,527	131.39	1.40e-15	1.41e-13
Prostate\|\|LOCATION_OF\|\|Brachytherapy implant:5089640	25/138,393	39/26,262,527	121.67	3.19e-40	1.09e-37
External Beam Radiation Therapy\|\|TREATS\|\|advanced disease:4110614	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Interstitial brachytherapy\|\|TREATS\|\|Male gender:5232531	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Vitamins\|\|PREVENTS\|\|Malignant neoplasm of prostate:8010169	10/138,393	10/26,262,527	189.78	2.76e-18	3.46e-16
Prostate-Specific Antigen\|\|ASSOCIATED_WITH\|\|Seminal Vesicles:5122037	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Intervention regimes\|\|TREATS\|\|Cancer Survivor:8405614	13/138,393	132/26,262,527	18.69	1.37e-12	1.05e-10
Ultrasonic Therapy\|\|TREATS\|\|Malignant neoplasm of prostate:12091043	11/138,393	12/26,262,527	173.97	1.05e-19	1.44e-17
Pelvic Exenteration\|\|TREATS\|\|Cancer of Rectum:277814	7/138,393	60/26,262,527	22.14	7.18e-08	2.78e-06
Carcinoma, Cribriform\|\|PART_OF\|\|Prostate:1891959	4/138,393	3/26,262,527	253.03	2.61e-08	1.17e-06
Fibroid Tumor\|\|PART_OF\|\|Prostate:64324	29/138,393	45/26,262,527	122.32	1.82e-46	7.38e-44
Screening procedure\|\|TREATS\|\|Cancer Survivor:11180591	5/138,393	18/26,262,527	52.72	1.23e-07	4.49e-06
Isoflavones\|\|COEXISTS_WITH\|\|Soy Proteins:6284037	11/138,393	105/26,262,527	19.88	3.89e-11	2.49e-09
AR gene\|AR\|\|ASSOCIATED_WITH\|\|Prostate carcinoma:1342092	7/138,393	9/26,262,527	147.60	1.19e-12	9.12e-11
Prostate\|\|LOCATION_OF\|\|Endothelial Cells:9406646	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Combined Modality Therapy\|\|TREATS\|\|Prostate cancer metastatic:5718523	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
PubMed\|\|ISA\|\|Databases:8065116	129/138,393	5,895/26,262,527	4.16	5.91e-39	1.93e-36
Diphosphonates\|\|TREATS\|\|Prostate carcinoma:7421726	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Hematologic Neoplasms\|\|PART_OF\|\|Colon:6634567	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Radical prostatectomy\|\|NEG_TREATS\|\|Malignant neoplasm of prostate:538874	7/138,393	6/26,262,527	221.41	1.82e-13	1.56e-11
Basal Cell\|\|PART_OF\|\|Prostatic Tissue:9285276	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
targeting\|\|PROCESS_OF\|\|Mice, Nude:3168476	7/138,393	40/26,262,527	33.21	5.69e-09	2.74e-07
Diagnosis\|\|METHOD_OF\|\|Radical prostatectomy:4395851	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
membrane fraction\|\|PART_OF\|\|Mammary Carcinoma, Human:2517566	9/138,393	18/26,262,527	94.89	1.29e-14	1.21e-12
Breast\|\|PART_OF\|\|Cancer Patient:5944252	8/138,393	16/26,262,527	94.89	3.89e-13	3.15e-11
Preservation, Biological\|\|METHOD_OF\|\|Radical prostatectomy:6373110	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostate-Specific Antigen\|\|INTERACTS_WITH\|\|Tumor Markers:3375194	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
docetaxel\|\|AUGMENTS\|\|Phosphorylation:8777237	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Diethylstilbestrol\|\|ISA\|\|Estrogens, Synthetic:51919	12/138,393	281/26,262,527	8.10	7.37e-08	2.85e-06
Pelvic lymphadenectomy\|\|TREATS\|\|Prostate carcinoma:1540541	16/138,393	16/26,262,527	189.79	1.80e-28	3.82e-26
Bromocriptine\|\|TREATS\|\|Malignant neoplasm of prostate:910149	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Transurethral Resection\|\|TREATS\|\|Male gender:1599767	9/138,393	26/26,262,527	65.69	1.87e-13	1.60e-11
Human Cell Line\|\|LOCATION_OF\|\|Cell Growth:2335617	9/138,393	146/26,262,527	11.70	1.69e-07	5.97e-06
Androgen therapy\|\|TREATS\|\|Carcinoma:78037	6/138,393	5/26,262,527	227.73	9.37e-12	6.74e-10
Smoker\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:13666223	11/138,393	11/26,262,527	189.78	5.49e-20	7.78e-18
Prostate\|\|LOCATION_OF\|\|Pathologic Processes:1271971	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Breast\|\|ASSOCIATED_WITH\|\|Tumorigenesis:5201459	6/138,393	18/26,262,527	63.26	2.58e-09	1.30e-07
Neoadjuvant Therapy\|\|USES\|\|Androgen Antagonists:7466552	10/138,393	11/26,262,527	172.53	5.24e-18	6.40e-16
KLK3 gene\|KLK3\|\|AFFECTS\|\|Antimicrobial susceptibility:7193201	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Surgical Patients:11492838	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Carcinoma\|\|NEG_PART_OF\|\|Prostate:2906520	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Androgen Receptor\|AR\|\|INTERACTS_WITH\|\|Androgen Response Element:4688568	21/138,393	34/26,262,527	117.23	9.12e-34	2.44e-31
GALACTOSYLGALACTOSYLGLUCOSYLCERAMIDASE\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8745985	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Hormone manipulation\|\|TREATS\|\|Malignant neoplasm of prostate:3739575	30/138,393	32/26,262,527	177.95	1.47e-51	6.63e-49
Ultrasonography\|\|DIAGNOSES\|\|Large prostate:2621934	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Malignant transformation\|\|PART_OF\|\|Prostatic epithelium:3993345	18/138,393	18/26,262,527	189.79	7.40e-32	1.83e-29
III\|\|ISA\|\|contextual factors:991365	14/138,393	96/26,262,527	27.68	1.36e-15	1.38e-13
Androgens\|\|PREVENTS\|\|Malignant neoplasm of prostate:9987013	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
[M]Unspecified tumor cell NOS\|\|LOCATION_OF\|\|Acid Phosphatase:632217	6/138,393	11/26,262,527	103.51	2.44e-10	1.46e-08
leukemia\|\|PART_OF\|\|Prostate:594779	14/138,393	18/26,262,527	147.61	5.10e-24	9.12e-22
Prostate\|\|LOCATION_OF\|\|fMRI:13304888	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Peptide Hydrolases\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8526121	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Pathologic stage\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:7607220	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
Prostate-Specific Antigen\|\|INTERACTS_WITH\|\|Acid Phosphatase:2994332	16/138,393	18/26,262,527	168.70	6.55e-28	1.35e-25
Vasectomy\|\|TREATS\|\|Malignant neoplasm of prostate:2286273	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
Aggressive behavior\|\|PROCESS_OF\|\|European American:15694948	4/138,393	3/26,262,527	253.03	2.61e-08	1.17e-06
Adenocarcinoma of prostate\|\|ISA\|\|Malignant neoplasm of prostate:1280720	11/138,393	12/26,262,527	173.97	1.05e-19	1.44e-17
Fluorouracil\|\|TREATS\|\|Prostate cancer metastatic:1339354	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Zinc\|\|AFFECTS\|\|Malignant neoplasm of prostate:10700931	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Androgens\|\|INTERACTS_WITH\|\|Androgens:584043	30/138,393	217/26,262,527	26.24	4.62e-31	1.11e-28
External Beam Radiation Therapy\|\|compared_with\|\|External Beam Radiation Therapy:6834336	8/138,393	20/26,262,527	75.91	1.61e-12	1.23e-10
vinorelbine\|\|TREATS\|\|Prostate cancer metastatic:8816825	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
KLK3 gene\|KLK3\|\|ASSOCIATED_WITH\|\|Benign prostatic hypertrophy:4260964	29/138,393	40/26,262,527	137.61	1.42e-47	5.88e-45
Linoleic Acid\|\|INTERACTS_WITH\|\|Fatty Acids, Unsaturated:305014	5/138,393	3/26,262,527	316.29	2.19e-10	1.31e-08
Radical prostatectomy\|\|METHOD_OF\|\|Brachytherapy:9811705	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Author\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:3076438	27/138,393	27/26,262,527	189.80	4.52e-47	1.86e-44
beta catenin\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:9877706	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Ablation\|\|TREATS\|\|Prostate cancer recurrent:6509001	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Milk Thistle\|\|LOCATION_OF\|\|Flavonolignans:7611069	7/138,393	57/26,262,527	23.31	5.20e-08	2.03e-06
Androgen Receptor\|AR\|\|AFFECTS\|\|Drug Interactions:8722122	6/138,393	15/26,262,527	75.91	1.05e-09	5.56e-08
Malignant neoplasm of prostate\|\|ISA\|\|Prostatic Diseases:3523522	31/138,393	33/26,262,527	178.31	3.02e-53	1.41e-50
Prostate\|\|PART_OF\|\|Adenocarcinoma:4483895	8/138,393	10/26,262,527	151.82	2.38e-14	2.15e-12
Transurethral Resection of Prostate\|\|TREATS\|\|OBSTRUCTIVE SYMPTOM:2572972	10/138,393	13/26,262,527	145.99	1.68e-17	1.99e-15
Benign prostatic hypertrophy\|\|ISA\|\|Prostatic Diseases:3280642	34/138,393	44/26,262,527	146.67	3.33e-56	1.67e-53
docetaxel\|\|TREATS\|\|Malignant neoplasm of prostate:8514680	242/138,393	303/26,262,527	151.83	0.00e+00	0.00e+00
Pelvic lymphadenectomy\|\|TREATS\|\|Adenocarcinoma of prostate:1238870	6/138,393	5/26,262,527	227.73	9.37e-12	6.74e-10
Prostate\|\|LOCATION_OF\|\|Epithelial proliferation:863691	20/138,393	31/26,262,527	122.45	1.63e-32	4.16e-30
Apigenin\|\|TREATS\|\|Malignant neoplasm of prostate:9613997	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Iodine 125 brachytherapy\|\|TREATS\|\|Prostate cancer recurrent:16857461	4/138,393	3/26,262,527	253.03	2.61e-08	1.17e-06
Renal Cell Carcinoma\|\|ASSOCIATED_WITH\|\|Prostate:9035190	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Transforming Growth Factor beta\|TGFB1\|\|ASSOCIATED_WITH\|\|Prostate:6894755	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Organ\|\|LOCATION_OF\|\|Micrometastasis:3109663	8/138,393	29/26,262,527	52.35	1.92e-11	1.28e-09
Interleukin-6\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:5345151	33/138,393	38/26,262,527	164.84	8.51e-56	4.21e-53
Prostate\|\|LOCATION_OF\|\|Basal Cell:3460568	10/138,393	21/26,262,527	90.37	6.28e-16	6.50e-14
Cryosurgery\|\|TREATS\|\|Prostate cancer recurrent:8125866	23/138,393	32/26,262,527	136.42	5.61e-38	1.77e-35
receptor expression\|\|ASSOCIATED_WITH\|\|Androgen Receptor\|AR:6848550	6/138,393	10/26,262,527	113.87	1.59e-10	9.61e-09
Prostate\|\|LOCATION_OF\|\|Testosterone:240986	39/138,393	146/26,262,527	50.71	9.31e-50	4.11e-47
VEGFA\|\|PART_OF\|\|Malignant neoplasm of prostate:12530171	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
E-Cadherin\|\|ASSOCIATED_WITH\|\|Neoplasm progression:5235811	9/138,393	48/26,262,527	35.58	2.14e-11	1.43e-09
amidronate\|\|TREATS\|\|Prostate cancer metastatic:4701613	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Tumor cells, malignant\|\|LOCATION_OF\|\|Malignant neoplasm of prostate:11363089	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Bone necrosis\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:13161418	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Endocrine therapy\|\|TREATS\|\|Metastatic Carcinoma:432798	6/138,393	20/26,262,527	56.93	4.37e-09	2.14e-07
taxane\|\|TREATS\|\|Prostate cancer metastatic:12287463	7/138,393	6/26,262,527	221.41	1.82e-13	1.56e-11
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|husband:13140212	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Mouse Cell Line\|\|PART_OF\|\|Malignant neoplasm of prostate:6724434	12/138,393	12/26,262,527	189.78	1.10e-21	1.72e-19
Diphosphonates\|\|TREATS\|\|Cancer Patient:7051447	11/138,393	60/26,262,527	34.79	1.57e-13	1.37e-11
Radical prostatectomy\|\|TREATS\|\|Surgeon:9149069	15/138,393	24/26,262,527	118.62	1.38e-24	2.52e-22
Dopa\|\|STIMULATES\|\|Norepinephrine:116393	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
RNA\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:11746197	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Androgen Receptor\|\|ASSOCIATED_WITH\|\|Prostate:712282	8/138,393	53/26,262,527	28.65	1.31e-09	6.91e-08
NKX3-1 gene\|NKX3-1\|\|ASSOCIATED_WITH\|\|Prostate:8240653	9/138,393	11/26,262,527	155.27	4.76e-16	4.94e-14
Transforming Growth Factor beta\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:5420070	22/138,393	24/26,262,527	173.98	4.71e-38	1.49e-35
Dinucleotide Repeats\|\|COEXISTS_WITH\|\|3' Untranslated Regions:4629036	5/138,393	15/26,262,527	63.26	5.75e-08	2.23e-06
PTEN gene\|PTEN\|\|ASSOCIATED_WITH\|\|Prostate carcinoma:7573885	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Androgen Receptor\|AR\|\|ISA\|\|Hormone Receptor:4201262	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
ESR1 protein, human\|ESR1\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:2847764	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Endothelin-1\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8592983	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Gonadotropin-Releasing Hormone Analog\|\|INHIBITS\|\|Testosterone:1974407	11/138,393	19/26,262,527	109.87	4.09e-18	5.11e-16
zoledronic acid\|\|ISA\|\|Diphosphonates:8853014	107/138,393	411/26,262,527	49.44	1.84e-132	2.60e-129
tomography\|\|DIAGNOSES\|\|Large prostate:13357735	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Free prostate-specific antigen\|\|DIAGNOSES\|\|Benign prostatic hypertrophy:6769720	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Oxidative Stress\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:10579114	19/138,393	21/26,262,527	171.72	5.53e-33	1.43e-30
Prostate\|\|PART_OF\|\|Rectum:793117	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Carcinoma\|\|PART_OF\|\|Seminal Vesicles:160464	12/138,393	40/26,262,527	56.94	7.31e-17	8.40e-15
Androgen Antagonists\|\|COEXISTS_WITH\|\|Gonadotropin-Releasing Hormone Analog:4643519	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
8q24\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9588198	16/138,393	20/26,262,527	151.83	2.15e-27	4.37e-25
Flutamide\|\|INHIBITS\|\|Androgens:4232683	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Chemoprevention\|\|USES\|\|Dutasteride:11026103	7/138,393	10/26,262,527	132.84	2.02e-12	1.52e-10
Endocrine therapy\|\|USES\|\|bicalutamide:8801300	6/138,393	5/26,262,527	227.73	9.37e-12	6.74e-10
Coagulation procedure\|\|TREATS\|\|Radiation proctitis:8225491	6/138,393	39/26,262,527	29.20	1.42e-07	5.16e-06
Osteoblasts\|\|PRODUCES\|\|Glycoproteins:6582077	8/138,393	56/26,262,527	27.11	1.94e-09	9.82e-08
Prostate\|\|LOCATION_OF\|\|Prognosis bad:9244783	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Magnetic Resonance Spectroscopy\|\|ISA\|\|Magnetic Resonance Imaging:3675896	14/138,393	186/26,262,527	14.28	5.61e-12	4.11e-10
Oestrogen therapy\|\|TREATS\|\|Prostate cancer metastatic:811030	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Malignant neoplasm of prostate\|\|PART_OF\|\|cohort:5967692	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Cell Proliferation\|\|AFFECTS\|\|Malignant neoplasm of prostate:7433353	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
External Beam Radiation Therapy\|\|TREATS\|\|Carcinoma:394011	12/138,393	39/26,262,527	58.40	5.65e-17	6.54e-15
E-Cadherin\|\|PART_OF\|\|Malignant neoplasm of prostate:7607219	13/138,393	14/26,262,527	176.23	4.22e-23	7.15e-21
abiraterone\|\|INHIBITS\|\|Steroid 17-alpha-monooxygenase\|CYP17A1:13282062	19/138,393	20/26,262,527	180.30	2.92e-33	7.71e-31
Dutasteride\|\|AFFECTS\|\|Malignant neoplasm of prostate:11998986	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
dietary intervention\|\|PREVENTS\|\|Malignant neoplasm of prostate:7427273	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Growth Factor\|\|AFFECTS\|\|Cell Proliferation:1528830	13/138,393	330/26,262,527	7.48	5.27e-08	2.06e-06
Fibroblast Growth Factor 2\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9332623	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
Prostate\|\|LOCATION_OF\|\|High-Grade Prostatic Intraepithelial Neoplasia:7444963	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostate\|\|LOCATION_OF\|\|Puncture biopsy:131754	43/138,393	73/26,262,527	111.82	7.44e-67	4.52e-64
Gland structure\|\|PART_OF\|\|Malignant neoplasm of prostate:8083071	19/138,393	20/26,262,527	180.30	2.92e-33	7.71e-31
Prostate-Specific Antigen\|\|PART_OF\|\|Epithelial Cells:4539599	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Carcinoma\|\|PART_OF\|\|Salivary Glands:57343	9/138,393	115/26,262,527	14.85	2.46e-08	1.12e-06
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Rodent Model:13336383	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Binding Sites\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:6371530	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Epithelial Cells\|\|PRODUCES\|\|Prostate-Specific Antigen:4712392	16/138,393	21/26,262,527	144.60	3.77e-27	7.61e-25
Plasticity\|\|PROCESS_OF\|\|Malignant neoplasm of prostate:14065107	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Malignant neoplasm of prostate\|\|AFFECTS\|\|African American:7094938	7/138,393	6/26,262,527	221.41	1.82e-13	1.56e-11
Digital Rectal Examination\|\|ISA\|\|Assessment procedure:6906683	6/138,393	12/26,262,527	94.89	3.65e-10	2.16e-08
Stanolone\|\|USES\|\|Stanolone:406780	49/138,393	569/26,262,527	16.35	1.27e-40	4.40e-38
Gonadotropin-Releasing Hormone Analog\|\|ISA\|\|Gonadorelin\|GNRH1:2818328	8/138,393	26/26,262,527	58.39	9.17e-12	6.65e-10
abiraterone\|\|TREATS\|\|Malignant neoplasm of prostate:11597994	54/138,393	52/26,262,527	197.14	3.32e-93	3.10e-90
Urinary Diversion\|\|TREATS\|\|Malignant neoplasm of urinary bladder:1271257	8/138,393	108/26,262,527	14.06	2.19e-07	7.70e-06
Prostate\|\|LOCATION_OF\|\|Palpation:120779	13/138,393	22/26,262,527	112.15	2.99e-21	4.57e-19
Prostatic Tissue\|\|LOCATION_OF\|\|Medical Imaging:6967136	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Hospitals, Private\|\|USES\|\|Health care facility:109805	5/138,393	3/26,262,527	316.29	2.19e-10	1.31e-08
Oxidoreductase\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:365879	12/138,393	11/26,262,527	207.04	5.52e-22	8.86e-20
X-Ray Computed Tomography\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:7988548	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Digital Rectal Examination\|\|ADMINISTERED_TO\|\|Urologist:4162333	9/138,393	13/26,262,527	131.39	1.40e-15	1.41e-13
Malignant neoplasm of prostate\|\|PRODUCES\|\|parathyroid hormone-related protein:7765394	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Stanolone\|\|STIMULATES\|\|Androgen Receptor\|AR:2511033	20/138,393	37/26,262,527	102.59	2.46e-31	5.99e-29
Tissue specimen\|\|PART_OF\|\|Benign prostatic hypertrophy:2505315	24/138,393	33/26,262,527	138.04	1.18e-39	3.91e-37
Endocrine therapy\|\|TREATS\|\|Prostate cancer stage IV:1599820	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Seed Implantation\|\|TREATS\|\|Malignant neoplasm of prostate:2403540	62/138,393	72/26,262,527	163.48	2.86e-103	3.00e-100
Androgens\|\|TREATS\|\|tumor growth:4610871	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Specific antigen\|\|PART_OF\|\|Prostate:4262339	9/138,393	14/26,262,527	122.00	2.29e-15	2.30e-13
Endometrial Carcinoma\|\|PART_OF\|\|Prostate:1478540	7/138,393	10/26,262,527	132.84	2.02e-12	1.52e-10
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Voluntary Workers:5452685	12/138,393	11/26,262,527	207.04	5.52e-22	8.86e-20
Isoflavones\|\|INTERACTS_WITH\|\|Isoflavones:8168937	7/138,393	44/26,262,527	30.19	1.03e-08	4.85e-07
Radical prostatectomy\|\|METHOD_OF\|\|Radical prostatectomy:1236583	54/138,393	73/26,262,527	140.43	1.41e-87	1.20e-84
Serine Protease\|\|PART_OF\|\|Prostate:7113507	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
hydroxyflutamide\|\|STIMULATES\|\|Androgen Receptor\|AR:7410501	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Prostate\|\|PART_OF\|\|SCID Mice:7828187	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
tadalafil\|\|TREATS\|\|Sexual function:14759069	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Cyclophosphamide\|\|TREATS\|\|Carcinoma:311799	6/138,393	33/26,262,527	34.50	5.84e-08	2.27e-06
Prostatic Neoplasms\|\|PROCESS_OF\|\|Xenograft Model:6838251	16/138,393	16/26,262,527	189.79	1.80e-28	3.82e-26
Androgens\|\|STIMULATES\|\|Growth Factor:6386983	6/138,393	10/26,262,527	113.87	1.59e-10	9.61e-09
BRCA1 gene\|BRCA1\|\|PART_OF\|\|Malignant neoplasm of prostate:7861451	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Blood supply aspects\|\|PART_OF\|\|Prostate:8232375	10/138,393	20/26,262,527	94.89	4.28e-16	4.50e-14
Casodex\|\|DISRUPTS\|\|Cell Growth:9266053	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|father:4567102	39/138,393	51/26,262,527	145.16	4.13e-64	2.42e-61
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Variation (Genetics):14846854	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prognostic Factor\|\|ASSOCIATED_WITH\|\|Prostate carcinoma:2988430	12/138,393	12/26,262,527	189.78	1.10e-21	1.72e-19
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Mice, Transgenic:6286552	20/138,393	24/26,262,527	158.16	3.83e-34	1.04e-31
Immunoassay\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:1996823	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Malignant neoplasm of urinary bladder\|\|PROCESS_OF\|\|cohort:2837340	9/138,393	81/26,262,527	21.09	1.44e-09	7.58e-08
Oligonucleotides, Antisense\|\|INTERACTS_WITH\|\|Regulatory Protein:15536848	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Casodex\|\|ISA\|\|Nonsteroidal antiandrogen:5193795	9/138,393	13/26,262,527	131.39	1.40e-15	1.41e-13
Dissection\|\|TREATS\|\|Malignant neoplasm of prostate:1284735	24/138,393	26/26,262,527	175.20	1.97e-41	6.98e-39
Prostate\|\|LOCATION_OF\|\|KLK3 gene\|KLK3:7242903	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Diethylstilbestrol\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:1147723	9/138,393	11/26,262,527	155.27	4.76e-16	4.94e-14
docetaxel\|\|DISRUPTS\|\|tumor growth:8914199	10/138,393	37/26,262,527	51.29	6.80e-14	6.00e-12
DNA Damage\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:15875051	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Malignant neoplasm of prostate\|\|AFFECTS\|\|Tumorigenesis:8668840	11/138,393	11/26,262,527	189.78	5.49e-20	7.78e-18
Brachytherapy\|\|ISA\|\|Cancer Treatment:9702495	6/138,393	15/26,262,527	75.91	1.05e-09	5.56e-08
Tissue specimen\|\|LOCATION_OF\|\|Malignant neoplasm of prostate:15941969	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Prostatic Tissue\|\|LOCATION_OF\|\|AR gene\|AR:1691753	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Phosphoric Monoester Hydrolases\|\|PART_OF\|\|Prostate:79316	6/138,393	14/26,262,527	81.33	7.55e-10	4.37e-08
Adrenergic alpha-Antagonists\|\|TREATS\|\|Benign prostatic hypertrophy:1511718	14/138,393	209/26,262,527	12.71	2.42e-11	1.61e-09
Genistein\|\|ISA\|\|Chemopreventive Agent:6254097	5/138,393	15/26,262,527	63.26	5.75e-08	2.23e-06
Kininogenase\|KLK4\|\|TREATS\|\|Malignant neoplasm of prostate:14081744	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Prostate\|\|LOCATION_OF\|\|Able:4522567	5/138,393	9/26,262,527	105.43	7.62e-09	3.62e-07
Cyproterone Acetate\|\|ISA\|\|Androgen Antagonists:457722	62/138,393	320/26,262,527	36.78	1.58e-70	1.03e-67
Fatty-acid synthase\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9097212	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
[M]Unspecified tumor cell NOS\|\|LOCATION_OF\|\|Pretreatment:684202	9/138,393	121/26,262,527	14.12	3.72e-08	1.66e-06
Angiogenesis\|\|AFFECTS\|\|Malignant neoplasm of prostate:11143029	10/138,393	10/26,262,527	189.78	2.76e-18	3.46e-16
Prostate-Specific Antigen\|\|AUGMENTS\|\|specific immunity:7900450	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostate\|\|PRODUCES\|\|Serine Protease:8046741	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
BRCA2 gene\|BRCA2\|\|PART_OF\|\|Malignant neoplasm of prostate:7861450	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Specimen from prostate\|\|PART_OF\|\|Adenocarcinoma:1708004	14/138,393	14/26,262,527	189.79	4.43e-25	8.24e-23
Candidate Disease Gene\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8480028	23/138,393	27/26,262,527	161.68	3.33e-39	1.09e-36
Testosterone\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:818961	46/138,393	46/26,262,527	189.83	4.02e-79	3.05e-76
Epidermal Growth Factor\|\|TREATS\|\|Malignant neoplasm of prostate:4059689	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Neoplasm progression\|\|PROCESS_OF\|\|Transgenic Model:6596429	19/138,393	43/26,262,527	83.86	1.62e-28	3.47e-26
Epithelial Cells\|\|PART_OF\|\|Prostatic Intraepithelial Neoplasias:8338918	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Biopsy\|\|DIAGNOSES\|\|stage, prostate cancer:6421409	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostate specific antigen measurement\|\|USES\|\|Stains:4234864	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Benign prostatic hypertrophy\|\|LOCATION_OF\|\|Prostate-Specific Antigen:4332715	21/138,393	25/26,262,527	159.43	7.87e-36	2.27e-33
Tumor Suppressor Genes\|\|ASSOCIATED_WITH\|\|Prostate carcinoma:5064558	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
Androgen Antagonists\|\|STIMULATES\|\|Androgens:1989701	6/138,393	11/26,262,527	103.51	2.44e-10	1.46e-08
docetaxel\|\|TREATS\|\|Prostate cancer metastatic:9438101	28/138,393	19/26,262,527	279.71	8.84e-52	4.02e-49
Prostatic Intraepithelial Neoplasias\|\|ISA\|\|Carcinoma:6499835	6/138,393	8/26,262,527	142.33	6.01e-11	3.76e-09
Prostate\|\|PART_OF\|\|Papio:536960	7/138,393	20/26,262,527	66.42	8.81e-11	5.47e-09
Anti-Inflammatory Agents, Non-Steroidal\|\|ISA\|\|Aspirin:1027424	20/138,393	514/26,262,527	7.38	1.92e-11	1.28e-09
Radionuclide therapy\|\|TREATS\|\|Malignant neoplasm of prostate:8301034	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Combined Modality Therapy\|\|TREATS\|\|Malignant neoplasm of prostate:352255	68/138,393	69/26,262,527	187.11	6.85e-116	8.30e-113
Androgen therapy\|\|TREATS\|\|Local disease:6786541	12/138,393	13/26,262,527	175.19	2.10e-21	3.22e-19
Zoladex\|\|TREATS\|\|Malignant neoplasm of prostate:2948239	16/138,393	18/26,262,527	168.70	6.55e-28	1.35e-25
lycopene\|\|DISRUPTS\|\|Malignant neoplasm of prostate:10808044	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Malignant neoplasm of prostate\|\|AFFECTS\|\|member:8649184	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Estrogens\|\|CAUSES\|\|Benign prostatic hypertrophy:1468544	7/138,393	18/26,262,527	73.80	4.81e-11	3.06e-09
TP53 gene\|TP53\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8101437	8/138,393	7/26,262,527	216.89	3.55e-15	3.52e-13
ras Oncogene\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:5158768	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Flutamide\|\|compared_with\|\|Castration, Male:4491275	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Regional Cancer\|\|PART_OF\|\|Prostate:6713782	17/138,393	17/26,262,527	189.79	3.65e-30	8.38e-28
Radioimmunoassay\|\|METHOD_OF\|\|Serum acid phosphatase measurement:1516197	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Immunohistochemistry\|\|ISA\|\|Diagnosis:1733283	14/138,393	414/26,262,527	6.42	1.00e-07	3.68e-06
Serum specimen\|\|LOCATION_OF\|\|Prostate-Specific Antigen:3375190	56/138,393	79/26,262,527	134.57	5.45e-90	4.80e-87
Androgen therapy\|\|TREATS\|\|CAP - NOS:9616936	16/138,393	24/26,262,527	126.53	1.81e-26	3.55e-24
Blood Cells\|\|LOCATION_OF\|\|Prostate-Specific Antigen:7025166	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Castration\|\|PRECEDES\|\|Castration:993535	23/138,393	136/26,262,527	32.10	5.54e-26	1.07e-23
Prostatic Tissue\|\|LOCATION_OF\|\|Prostatic Neoplasms:11032447	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Hip Joint\|\|LOCATION_OF\|\|Arthrogryposis:105609	20/138,393	2/26,262,527	1897.95	5.60e-44	2.16e-41
Specific antigen\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:910130	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Endocrine therapy\|\|AFFECTS\|\|Adverse effects:1020617	5/138,393	11/26,262,527	86.26	1.65e-08	7.59e-07
Oxidoreductase\|\|INHIBITS\|\|Oxidoreductase:850848	8/138,393	76/26,262,527	19.98	1.74e-08	8.02e-07
MicroRNAs\|\|ASSOCIATED_WITH\|\|Carcinogenesis:12278441	16/138,393	384/26,262,527	7.91	7.41e-10	4.31e-08
Papillary adenoma\|\|PART_OF\|\|Prostatic Urethra:2334865	6/138,393	11/26,262,527	103.51	2.44e-10	1.46e-08
Biopsy\|\|DIAGNOSES\|\|Residual Cancer:5092048	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Prostatectomy\|\|PRECEDES\|\|Salvage Therapy:10547399	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
Testosterone\|\|USES\|\|Testosterone:44192	168/138,393	4,130/26,262,527	7.73	1.06e-86	8.83e-84
Prostate-Specific Antigen\|\|PART_OF\|\|Prostate:4363465	5/138,393	4/26,262,527	237.22	4.90e-10	2.87e-08
Estramustine\|\|ISA\|\|Antineoplastic Agents:3615285	7/138,393	14/26,262,527	94.89	1.19e-11	8.48e-10
tumor growth\|\|PART_OF\|\|Prostate:2041756	310/138,393	362/26,262,527	162.87	0.00e+00	0.00e+00
Angiogenesis\|\|AFFECTS\|\|tumor growth:2862022	17/138,393	277/26,262,527	11.65	6.94e-13	5.44e-11
Implantation procedure\|\|METHOD_OF\|\|Brachytherapy:2622802	10/138,393	26/26,262,527	72.99	3.52e-15	3.52e-13
Taxotere\|\|TREATS\|\|Hormone-refractory prostate cancer:8063033	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Taxotere\|\|TREATS\|\|Hormone-refractory prostate cancer:8063032	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
degarelix\|\|compared_with\|\|Leuprolide:12228950	11/138,393	14/26,262,527	149.11	3.42e-19	4.56e-17
sulforafan\|\|USES\|\|sulforafan:8621959	13/138,393	184/26,262,527	13.41	6.64e-11	4.14e-09
Prostate\|\|ASSOCIATED_WITH\|\|Carcinoma:241505	26/138,393	30/26,262,527	164.50	2.90e-44	1.12e-41
Prostate\|\|LOCATION_OF\|\|Cell Count:1561125	6/138,393	10/26,262,527	113.87	1.59e-10	9.61e-09
Radical cystectomy\|\|TREATS\|\|Malignant neoplasm of prostate:6779735	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Human tissue\|\|PART_OF\|\|Prostate:420879	241/138,393	387/26,262,527	118.38	0.00e+00	0.00e+00
Leuprolide\|\|USES\|\|Leuprolide:2706011	32/138,393	151/26,262,527	40.22	2.60e-38	8.28e-36
Biopsy sample\|\|LOCATION_OF\|\|Antigen assay:2511113	6/138,393	12/26,262,527	94.89	3.65e-10	2.16e-08
Prostate carcinoma\|\|LOCATION_OF\|\|Stromal Cells:6362928	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Carcinoma\|\|PART_OF\|\|Pancreas:11675	29/138,393	1,617/26,262,527	3.40	3.46e-08	1.54e-06
polyestradiol phosphate\|\|TREATS\|\|Malignant neoplasm of prostate:2242280	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Zoladex\|\|ISA\|\|Gonadorelin:2892841	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Prostate\|\|LOCATION_OF\|\|Edema:2862052	38/138,393	75/26,262,527	96.18	2.55e-57	1.31e-54
Adrenal Cortex Hormones\|\|TREATS\|\|Malignant neoplasm of prostate:9110107	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Endocrine therapy\|\|TREATS\|\|Adenocarcinoma:659915	11/138,393	16/26,262,527	130.48	9.91e-19	1.30e-16
Androgen Antagonists\|\|TREATS\|\|Prostatic hypertrophy:1200546	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Supplementation\|\|USES\|\|Soy Proteins:2461238	10/138,393	99/26,262,527	19.17	4.16e-10	2.47e-08
Phosphotransferases\|\|PART_OF\|\|Malignant neoplasm of prostate:14499144	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Acid Phosphatase\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:200493	31/138,393	29/26,262,527	202.90	1.98e-54	9.50e-52
Prostate\|\|LOCATION_OF\|\|Rectal Fistula:776692	6/138,393	24/26,262,527	47.44	1.11e-08	5.20e-07
Free prostate-specific antigen\|\|METHOD_OF\|\|Biopsy:7570982	10/138,393	10/26,262,527	189.78	2.76e-18	3.46e-16
Fluorescent in Situ Hybridization\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:5926668	13/138,393	12/26,262,527	205.60	1.11e-23	1.96e-21
Malignant neoplasm of prostate\|\|OCCURS_IN\|\|Ethnic group:11094664	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Pelvis\|\|LOCATION_OF\|\|Lymphatic vessel:30791	22/138,393	59/26,262,527	70.77	1.86e-31	4.53e-29
Diagnostic\|\|ISA\|\|Purpose:2921	66/138,393	4,932/26,262,527	2.54	4.70e-11	3.00e-09
ERG gene\|ERG\|\|PART_OF\|\|Family member:11727702	8/138,393	10/26,262,527	151.82	2.38e-14	2.15e-12
GSTP1 gene\|GSTP1\|\|ASSOCIATED_WITH\|\|Adenocarcinoma:9266049	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Prostate\|\|LOCATION_OF\|\|Tuberculosis:20857	7/138,393	68/26,262,527	19.54	1.58e-07	5.60e-06
Vaccines\|\|TREATS\|\|Malignant neoplasm of prostate:8224268	52/138,393	56/26,262,527	176.28	4.44e-88	3.80e-85
Cancer Vaccines\|\|PART_OF\|\|Prostate:6648868	68/138,393	80/26,262,527	161.38	7.89e-113	9.23e-110
Neoplastic Epithelial Cell\|\|PART_OF\|\|Prostate:4665509	25/138,393	25/26,262,527	189.80	1.08e-43	4.10e-41
Vaccines\|\|TREATS\|\|Hormone-refractory prostate cancer:11308551	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Fossa\|\|LOCATION_OF\|\|Biopsy:378985	12/138,393	22/26,262,527	103.52	2.12e-19	2.85e-17
Testosterone\|\|INHIBITS\|\|Androgens:1078517	9/138,393	31/26,262,527	55.10	7.06e-13	5.52e-11
Retreatment\|\|USES\|\|docetaxel:12712789	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Prostatectomy\|\|compared_with\|\|Open prostatectomy:8037227	6/138,393	8/26,262,527	142.33	6.01e-11	3.76e-09
Estrogens\|\|ASSOCIATED_WITH\|\|Pathogenesis:498393	13/138,393	162/26,262,527	15.23	1.50e-11	1.07e-09
Prognostic Factor\|\|PROCESS_OF\|\|cohort:2843135	18/138,393	265/26,262,527	12.89	2.92e-14	2.62e-12
Cancer Promoting Genes\|\|PART_OF\|\|Malignant neoplasm of prostate:8023390	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostate-Specific Antigen\|\|CAUSES\|\|Malignant neoplasm of prostate:3920605	14/138,393	16/26,262,527	166.06	1.59e-24	2.88e-22
Urine\|\|LOCATION_OF\|\|PCA3:12782760	21/138,393	27/26,262,527	147.62	2.50e-35	7.11e-33
Radical cystectomy\|\|PRECEDES\|\|Urinary Diversion:885645	8/138,393	86/26,262,527	17.65	4.25e-08	1.89e-06
Epithelium\|\|PART_OF\|\|Benign prostatic hypertrophy:2207180	19/138,393	79/26,262,527	45.65	2.73e-24	4.94e-22
Taxotere\|\|TREATS\|\|Prostate cancer metastatic:15355105	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
silybin\|\|USES\|\|silybin:1258469	17/138,393	163/26,262,527	19.79	2.14e-16	2.33e-14
Genistein\|\|USES\|\|Genistein:4116891	32/138,393	464/26,262,527	13.09	2.44e-24	4.42e-22
Lymphocyte antigen CD66A\|\|DISRUPTS\|\|Tumorigenicity:7201824	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Stratum germinativum\|\|PART_OF\|\|Gland structure:4235888	6/138,393	13/26,262,527	87.59	5.31e-10	3.10e-08
Biopsy\|\|DIAGNOSES\|\|Prostate carcinoma:316160	47/138,393	60/26,262,527	148.70	2.72e-77	2.04e-74
Prostate-Specific Antigen\|\|STIMULATES\|\|Prostate-Specific Antigen:4666523	54/138,393	63/26,262,527	162.72	4.42e-90	3.93e-87
Pain management\|\|TREATS\|\|Malignant neoplasm of prostate:9338661	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Single Nucleotide Polymorphism\|\|PART_OF\|\|Single Nucleotide Polymorphism:3006220	17/138,393	479/26,262,527	6.74	2.26e-09	1.14e-07
cohort\|\|LOCATION_OF\|\|PCA3 gene\|PCA3:15766901	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Vaccines, DNA\|\|TREATS\|\|Malignant neoplasm of prostate:12480672	10/138,393	13/26,262,527	145.99	1.68e-17	1.99e-15
Prostate\|\|LOCATION_OF\|\|Driving While Intoxicated:9946210	6/138,393	9/26,262,527	126.52	9.97e-11	6.13e-09
Epithelial Cells\|\|LOCATION_OF\|\|Malignant neoplasm of prostate:6522774	10/138,393	9/26,262,527	210.87	1.39e-18	1.80e-16
Oxidoreductase\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:11559234	4/138,393	3/26,262,527	253.03	2.61e-08	1.17e-06
Hormones\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:5337276	4/138,393	3/26,262,527	253.03	2.61e-08	1.17e-06
Androgen Receptor\|AR\|\|DISRUPTS\|\|Drug Interactions:6466122	5/138,393	9/26,262,527	105.43	7.62e-09	3.62e-07
Radical prostatectomy\|\|AFFECTS\|\|Recovery:11556767	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Cisplatin\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:2142767	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Diagnosis\|\|TREATS\|\|Caucasoid Race:2843651	8/138,393	71/26,262,527	21.38	1.07e-08	5.03e-07
Organ\|\|LOCATION_OF\|\|Epithelial Cells:368855	7/138,393	72/26,262,527	18.45	2.27e-07	7.96e-06
Prostatic Neoplasms\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:3356426	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
ERG gene\|ERG\|\|compared_with\|\|PTEN gene\|PTEN:17559895	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
lycopene\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:4398719	13/138,393	13/26,262,527	189.79	2.20e-23	3.82e-21
Prostate-Specific Antigen\|\|PART_OF\|\|Cancer Patient:4668413	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Estrogen Receptor alpha\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:10314175	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Chemoprevention\|\|USES\|\|Genistein:6797111	6/138,393	10/26,262,527	113.87	1.59e-10	9.61e-09
Image analysis\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:5961632	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
MicroRNAs\|\|AUGMENTS\|\|Malignant neoplasm of prostate:12844226	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Polymorphism, Genetic\|\|ASSOCIATED_WITH\|\|Prostate-Specific Antigen:7109660	16/138,393	22/26,262,527	138.03	6.48e-27	1.30e-24
c-myc Genes\|MYC\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8483450	17/138,393	18/26,262,527	179.25	7.06e-30	1.59e-27
docetaxel\|\|INHIBITS\|\|KLK3 gene\|KLK3:10824174	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
prednisolone\|\|TREATS\|\|Prostate cancer metastatic:14928072	12/138,393	15/26,262,527	151.83	6.95e-21	1.04e-18
Estrogen Receptor beta\|\|PART_OF\|\|Malignant neoplasm of prostate:8860711	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Brachytherapy\|\|TREATS\|\|Prostate carcinoma:5615242	37/138,393	48/26,262,527	146.32	5.37e-61	2.90e-58
Carcinoma\|\|PART_OF\|\|Prostatic duct:439444	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
VEGF gene\|VEGFA\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8748122	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Glutamate Carboxypeptidase II\|\|PART_OF\|\|Prostatic Tissue:7348994	5/138,393	4/26,262,527	237.22	4.90e-10	2.87e-08
Androgen therapy\|\|TREATS\|\|loss; bone:10433119	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Diphosphonates\|\|TREATS\|\|Osteoporosis:682285	24/138,393	1,027/26,262,527	4.44	4.35e-09	2.13e-07
Integrins\|\|PART_OF\|\|Malignant neoplasm of prostate:11607841	7/138,393	9/26,262,527	147.60	1.19e-12	9.12e-11
Buserelin\|\|TREATS\|\|Prostate carcinoma:2134591	11/138,393	12/26,262,527	173.97	1.05e-19	1.44e-17
Testosterone\|\|TREATS\|\|Prostate carcinoma:781662	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Cytoplasm\|\|PART_OF\|\|[M]Unspecified tumor cell NOS:63881	22/138,393	1,047/26,262,527	3.99	1.12e-07	4.08e-06
Flutamide\|\|INTERACTS_WITH\|\|Flutamide:922714	7/138,393	25/26,262,527	53.14	3.26e-10	1.94e-08
Avodart\|\|ISA\|\|Dutasteride:9898112	5/138,393	13/26,262,527	72.99	3.20e-08	1.43e-06
Androgens\|\|ISA\|\|Steroid hormone:2005337	13/138,393	77/26,262,527	32.04	2.55e-15	2.56e-13
Somatomedins\|\|AFFECTS\|\|Cell Proliferation:3372677	10/138,393	82/26,262,527	23.14	7.64e-11	4.76e-09
soy protein isolate\|\|AFFECTS\|\|Malignant neoplasm of prostate:9911851	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
PTEN gene\|PTEN\|\|PART_OF\|\|Malignant neoplasm of prostate:8414679	20/138,393	18/26,262,527	210.88	7.52e-36	2.19e-33
gene therapy\|\|METHOD_OF\|\|Cancer Treatment:5974124	8/138,393	92/26,262,527	16.50	6.91e-08	2.68e-06
Androgens\|\|ASSOCIATED_WITH\|\|Prostate cancer metastatic:12969330	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Conservative therapy\|\|TREATS\|\|Malignant neoplasm of prostate:2044133	21/138,393	24/26,262,527	166.07	4.30e-36	1.26e-33
DELETION\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:6852218	15/138,393	15/26,262,527	189.79	8.93e-27	1.77e-24
Prostate specific antigen measurement\|\|DIAGNOSES\|\|Prostate carcinoma:3544216	13/138,393	14/26,262,527	176.23	4.22e-23	7.15e-21
Implantation procedure\|\|METHOD_OF\|\|Prostatic radiotherapies:12563328	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Secondary malignant neoplasm of bone\|\|COEXISTS_WITH\|\|Advanced cancer:9378261	7/138,393	9/26,262,527	147.60	1.19e-12	9.12e-11
Tumorigenicity\|\|PROCESS_OF\|\|SCID Mice:4875195	14/138,393	118/26,262,527	22.52	1.82e-14	1.67e-12
Lymph Node Dissection\|\|TREATS\|\|Neoplasm Metastasis:1915490	7/138,393	51/26,262,527	26.05	2.59e-08	1.17e-06
Compartments\|\|PART_OF\|\|Prostate:1220086	34/138,393	74/26,262,527	87.21	2.69e-50	1.20e-47
Prostate\|\|LOCATION_OF\|\|Western Blot:3512871	7/138,393	12/26,262,527	110.70	5.19e-12	3.80e-10
Brachytherapy\|\|TREATS\|\|cohort:8072287	5/138,393	19/26,262,527	49.94	1.55e-07	5.48e-06
Ultrasonography\|\|METHOD_OF\|\|Cancer Diagnosis:10230836	5/138,393	10/26,262,527	94.89	1.14e-08	5.31e-07
Prostate\|\|LOCATION_OF\|\|Radionuclide Imaging:643610	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Wall of rectum\|\|LOCATION_OF\|\|V 70:11323575	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Locally Advanced Malignant Neoplasm\|\|PART_OF\|\|Prostate:1231881	840/138,393	1,326/26,262,527	120.94	0.00e+00	0.00e+00
Prostate\|\|LOCATION_OF\|\|Tumorigenicity:6015557	14/138,393	15/26,262,527	177.13	8.52e-25	1.56e-22
Androgen Receptor\|AR\|\|PART_OF\|\|Prostate:861740	11/138,393	74/26,262,527	28.21	1.23e-12	9.37e-11
Cell Death\|\|AFFECTS\|\|Malignant neoplasm of prostate:10008247	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostatic Tissue\|\|LOCATION_OF\|\|Androgen Receptor\|AR:1909285	8/138,393	13/26,262,527	116.79	1.09e-13	9.55e-12
Finasteride\|\|INHIBITS\|\|Testosterone 5-alpha-Reductase:4575333	9/138,393	54/26,262,527	31.63	5.48e-11	3.48e-09
Androgen therapy\|\|TREATS\|\|Advanced cancer:7242934	21/138,393	21/26,262,527	189.80	6.22e-37	1.90e-34
Selenium\|\|AFFECTS\|\|Neoplasm progression:11317081	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Cytoplasm\|\|PART_OF\|\|Malignant neoplasm of prostate:15941971	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
casein kinase II\|\|AFFECTS\|\|Cell Growth:4005871	7/138,393	23/26,262,527	57.76	1.99e-10	1.20e-08
Prostate\|\|LOCATION_OF\|\|Dihydrotestosterone Assay:970741	8/138,393	18/26,262,527	84.35	8.19e-13	6.38e-11
Androgen therapy\|\|TREATS\|\|tumor growth:5966752	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Screening procedure\|\|TREATS\|\|Local disease:1891975	5/138,393	8/26,262,527	118.61	4.92e-09	2.37e-07
Alcohol consumption\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:5432921	12/138,393	13/26,262,527	175.19	2.10e-21	3.22e-19
Androgen Receptor\|AR\|\|ASSOCIATED_WITH\|\|Benign prostatic hypertrophy:2089057	8/138,393	11/26,262,527	138.02	4.09e-14	3.65e-12
Rectal examination\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:1863229	17/138,393	16/26,262,527	201.65	1.83e-30	4.28e-28
Nerve Growth Factors\|\|ASSOCIATED_WITH\|\|Prostate:2636036	5/138,393	13/26,262,527	72.99	3.20e-08	1.43e-06
PLAB Protein\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:10281549	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
BRCA1 gene\|BRCA1\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8329286	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Urine\|\|LOCATION_OF\|\|PCA3 gene\|PCA3:13472762	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
Etidronate\|\|TREATS\|\|Secondary malignant neoplasm of bone:3845832	6/138,393	10/26,262,527	113.87	1.59e-10	9.61e-09
Polymerase chain reaction analysis\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:7576914	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
HSPA5\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:12038009	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Primary Neoplasm\|\|LOCATION_OF\|\|[M]Unspecified tumor cell NOS:1104941	13/138,393	202/26,262,527	12.21	1.96e-10	1.19e-08
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Lethe:11998899	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Bone necrosis\|\|PROCESS_OF\|\|Cancer Patient:4097239	7/138,393	57/26,262,527	23.31	5.20e-08	2.03e-06
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Xenograft Model:6748553	121/138,393	132/26,262,527	174.11	3.12e-202	6.91e-199
Solid tumor\|\|PART_OF\|\|Prostate:4778086	24/138,393	25/26,262,527	182.21	1.03e-41	3.68e-39
Biopsy\|\|DIAGNOSES\|\|Antimicrobial susceptibility:896833	10/138,393	60/26,262,527	31.63	4.67e-12	3.43e-10
Diffusion weighted imaging\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:12167209	9/138,393	7/26,262,527	244.00	3.31e-17	3.87e-15
Estramustine phosphate\|\|TREATS\|\|Carcinoma:910154	11/138,393	13/26,262,527	160.59	1.92e-19	2.59e-17
Stereotactic radiotherapy\|\|TREATS\|\|Prostate cancer recurrent:13693421	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Flutamide\|\|USES\|\|Flutamide:927447	65/138,393	326/26,262,527	37.85	1.43e-74	1.02e-71
Radiotherapy, Interstitial\|\|TREATS\|\|Malignant neoplasm of prostate:2029037	8/138,393	10/26,262,527	151.82	2.38e-14	2.15e-12
Adenocarcinoma\|\|PART_OF\|\|Prostate:129573	3,301/138,393	4,414/26,262,527	145.36	0.00e+00	0.00e+00
Second Primary Cancers\|\|PART_OF\|\|Rectum:244793	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Insulin-Like-Growth Factor I Receptor\|\|ASSOCIATED_WITH\|\|Prostate:5347148	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Radical prostatectomy\|\|TREATS\|\|Male gender:5982598	28/138,393	29/26,262,527	183.26	1.81e-48	7.76e-46
Androgens\|\|AUGMENTS\|\|Receptor Signaling:10540727	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Nevus, Blue\|\|PART_OF\|\|Prostate:362469	12/138,393	26/26,262,527	87.59	1.03e-18	1.35e-16
Stroma\|\|LOCATION_OF\|\|Fibrosis:614182	15/138,393	434/26,262,527	6.56	2.71e-08	1.22e-06
GTPase-Activating Proteins\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8075390	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Body mass index\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:5432922	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
docetaxel\|\|AFFECTS\|\|Malignant neoplasm of prostate:14586054	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Electromagnetic Energy\|\|PROCESS_OF\|\|Prostate carcinoma:6057714	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Cytoplasm\|\|LOCATION_OF\|\|Malignant neoplasm of prostate:13225058	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Soy Proteins\|\|PREVENTS\|\|Malignant neoplasm of prostate:8409914	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
Tumor Suppressor Genes\|\|PART_OF\|\|Retinoblastoma:3971489	21/138,393	554/26,262,527	7.19	9.77e-12	7.02e-10
Androgens\|\|AUGMENTS\|\|Prostate:158276	13/138,393	28/26,262,527	88.11	3.47e-20	5.03e-18
FOLH1 gene\|FOLH1\|\|PART_OF\|\|Dendritic Cells:7027644	7/138,393	11/26,262,527	120.77	3.29e-12	2.43e-10
Androgen Antagonists\|\|INTERACTS_WITH\|\|Androgen Receptor\|AR:2945331	18/138,393	33/26,262,527	103.52	2.11e-28	4.47e-26
Vegetables\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:6515898	13/138,393	14/26,262,527	176.23	4.22e-23	7.15e-21
Diphosphonates\|\|TREATS\|\|Malignant neoplasm of prostate:5944531	57/138,393	64/26,262,527	169.08	1.15e-95	1.11e-92
Androgen Receptor\|AR\|\|ISA\|\|TRANSCRIPTION FACTOR:4575354	45/138,393	66/26,262,527	129.43	4.56e-72	3.10e-69
Fluorouracil\|\|TREATS\|\|Malignant neoplasm of prostate:910147	14/138,393	15/26,262,527	177.13	8.52e-25	1.56e-22
Malignant neoplasm of prostate\|\|AFFECTS\|\|Carcinogenesis:627850	18/138,393	18/26,262,527	189.79	7.40e-32	1.83e-29
Prostate\|\|PRODUCES\|\|Androgens:1211245	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Biopsy sample\|\|LOCATION_OF\|\|Adenocarcinoma:3177392	10/138,393	40/26,262,527	47.45	1.33e-13	1.16e-11
Malignant neoplasm of prostate\|\|AFFECTS\|\|Germ-Line Mutation:7364105	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Somatomedins\|\|ASSOCIATED_WITH\|\|Prostate:6569132	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
Androgens\|\|TREATS\|\|Malignant neoplasm of prostate:10947179	6/138,393	5/26,262,527	227.73	9.37e-12	6.74e-10
Radical retropubic prostatectomy\|\|METHOD_OF\|\|Radical retropubic prostatectomy:11094967	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Secondary malignant neoplasm of bone\|\|ISA\|\|Neoplasm Metastasis:956613	15/138,393	77/26,262,527	36.97	2.78e-18	3.49e-16
Dutasteride\|\|TREATS\|\|Benign prostatic hypertrophy:9898113	26/138,393	94/26,262,527	52.50	4.82e-34	1.31e-31
Hormonal\|\|ISA\|\|Environment:136500	25/138,393	679/26,262,527	6.99	2.05e-13	1.76e-11
Seminal fluid\|\|LOCATION_OF\|\|KLK3 gene\|KLK3:6415205	6/138,393	15/26,262,527	75.91	1.05e-09	5.56e-08
docetaxel\|\|TREATS\|\|High-Risk Cancer:7969094	23/138,393	40/26,262,527	109.13	2.71e-36	8.03e-34
Somatomedins\|\|ASSOCIATED_WITH\|\|Carcinogenesis:8058253	7/138,393	29/26,262,527	45.81	7.95e-10	4.59e-08
Receptors, Steroid\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:1353709	10/138,393	11/26,262,527	172.53	5.24e-18	6.40e-16
Prostate-Specific Antigen\|\|INTERACTS_WITH\|\|Androgens:5079915	11/138,393	15/26,262,527	139.17	5.90e-19	7.80e-17
PTEN gene\|PTEN\|\|DISRUPTS\|\|androgen receptor activity:10262138	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Brachytherapy\|\|TREATS\|\|Prostatic Neoplasms:7418085	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Cruciferous Vegetable\|\|AFFECTS\|\|Malignant neoplasm of prostate:8737186	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostate specific antigen measurement\|\|DIAGNOSES\|\|Carcinoma:3107637	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Magnetic Resonance Imaging\|\|METHOD_OF\|\|Diagnostic Neoplasm Staging:3924858	6/138,393	42/26,262,527	27.11	2.11e-07	7.41e-06
Transitional cell carcinoma of bladder\|\|ASSOCIATED_WITH\|\|Prostate:9407328	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Chlormadinone Acetate\|\|INHIBITS\|\|Androgens:6429273	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Biopsy\|\|USES\|\|Antibiotics:1795090	5/138,393	12/26,262,527	79.07	2.32e-08	1.06e-06
High-Grade Prostatic Intraepithelial Neoplasia\|\|PROCESS_OF\|\|Areae:6925294	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
CDK2 gene\|CDK2\|\|STIMULATES\|\|CDKN1A\|TCEAL1\|NSG1\|H3F3AP6:7699387	7/138,393	39/26,262,527	34.06	4.87e-09	2.37e-07
zoledronic acid\|\|TREATS\|\|Neoplasm Metastasis:9048274	21/138,393	55/26,262,527	72.47	2.83e-30	6.58e-28
Prostate-Specific Antigen\|\|ASSOCIATED_WITH\|\|Secondary malignant neoplasm of bone:7126559	11/138,393	12/26,262,527	173.97	1.05e-19	1.44e-17
Hypophysectomy\|\|TREATS\|\|Prostate carcinoma:607457	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Androgen Receptor\|AR\|\|INTERACTS_WITH\|\|Proto-Oncogene Proteins c-akt\|AKT1:12553421	6/138,393	8/26,262,527	142.33	6.01e-11	3.76e-09
Prostatectomy\|\|PRECEDES\|\|Elevation procedure:5112831	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Epidermal Growth Factor\|EGF\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:4055351	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Erectile dysfunction\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:11824029	5/138,393	4/26,262,527	237.22	4.90e-10	2.87e-08
Prostate-Specific Antigen\|\|compared_with\|\|Prostate-Specific Antigen:3274172	145/138,393	181/26,262,527	152.18	6.35e-236	1.62e-232
Metabolic syndrome\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:13557573	6/138,393	5/26,262,527	227.73	9.37e-12	6.74e-10
Androgens\|\|STIMULATES\|\|Androgen Receptor\|AR:3668750	58/138,393	103/26,262,527	106.90	1.02e-88	8.89e-86
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Cancer Model:8679720	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
Prostate\|\|LOCATION_OF\|\|Probes:1884823	12/138,393	19/26,262,527	119.86	5.54e-20	7.83e-18
UVRAG\|TP63\|CKAP4\|\|ASSOCIATED_WITH\|\|Prostate:9559167	5/138,393	8/26,262,527	118.61	4.92e-09	2.37e-07
abiraterone\|\|TREATS\|\|Prostate cancer metastatic:14703998	74/138,393	90/26,262,527	156.11	7.19e-122	9.09e-119
TNF-related apoptosis-inducing ligand\|TNFSF10\|\|ISA\|\|Cancer Treatment:9381013	10/138,393	49/26,262,527	38.73	7.79e-13	6.09e-11
Samarium SM 153 lexidronam\|\|TREATS\|\|Secondary malignant neoplasm of bone:5130158	8/138,393	26/26,262,527	58.39	9.17e-12	6.65e-10
KLK3 gene\|KLK3\|\|TREATS\|\|Malignant neoplasm of prostate:17304948	21/138,393	2/26,262,527	1992.86	3.22e-46	1.30e-43
Prostatic Neoplasms\|\|AFFECTS\|\|Malignant neoplasm of prostate:7351732	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Tumor cells, malignant\|\|PRODUCES\|\|Prostate-Specific Antigen:6811518	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Specimen from prostate\|\|LOCATION_OF\|\|Tissue Microarray:12050410	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
cofactor\|\|INTERACTS_WITH\|\|Androgen Receptor\|AR:9587767	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
High dose brachytherapy\|\|TREATS\|\|Malignant neoplasm of prostate:10608183	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Androgen therapy\|\|compared_with\|\|Castration:11577677	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
B-Cell Lymphomas\|\|PART_OF\|\|Prostate:5324528	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Primary Neoplasm\|\|COEXISTS_WITH\|\|Prostate cancer metastatic:16556133	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Cyclin D1\|LMOD1\|BBS9\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:7648540	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Gland structure\|\|PART_OF\|\|High-Grade Prostatic Intraepithelial Neoplasia:7262629	20/138,393	36/26,262,527	105.44	1.61e-31	3.92e-29
Androgen Receptor\|AR\|\|PART_OF\|\|targeting:8927005	21/138,393	38/26,262,527	104.89	5.51e-33	1.43e-30
TACSTD2 protein, human\|TACSTD2\|\|PART_OF\|\|Malignant neoplasm of prostate:14032596	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Prostate\|\|LOCATION_OF\|\|Ultrasound examination:1444903	12/138,393	27/26,262,527	84.35	1.48e-18	1.91e-16
Induction\|\|USES\|\|Stanolone:775365	7/138,393	19/26,262,527	69.92	6.56e-11	4.09e-09
GSTT1 gene\|GSTT1\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:11045622	10/138,393	11/26,262,527	172.53	5.24e-18	6.40e-16
Androgens\|\|CAUSES\|\|Malignant neoplasm of prostate:4225118	34/138,393	35/26,262,527	184.39	1.36e-58	7.06e-56
Radiopharmaceuticals\|\|TREATS\|\|Bone pain:8728425	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Prostate\|\|LOCATION_OF\|\|Extravasation:6219380	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Upper arm\|\|LOCATION_OF\|\|Toxic effect:2033038	14/138,393	252/26,262,527	10.54	2.48e-10	1.48e-08
Transurethral Resection of Prostate\|\|TREATS\|\|Bladder outlet obstruction:3612961	13/138,393	37/26,262,527	66.68	6.68e-19	8.82e-17
Gleason pattern\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:10330637	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Biopsy\|\|METHOD_OF\|\|Digital Rectal Examination:5993104	20/138,393	23/26,262,527	165.04	2.10e-34	5.75e-32
Aconitate Hydratase\|\|INTERACTS_WITH\|\|Citrate:5699410	9/138,393	14/26,262,527	122.00	2.29e-15	2.30e-13
Cell Line, Tumor\|\|PART_OF\|\|Prostate:2418434	156/138,393	203/26,262,527	145.99	1.26e-251	3.62e-248
hepsin\|HPN\|\|ASSOCIATED_WITH\|\|Neoplasm progression:11727785	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
lycopene\|\|COEXISTS_WITH\|\|lycopene:3649170	6/138,393	28/26,262,527	40.67	2.46e-08	1.12e-06
MICE\|\|PART_OF\|\|Adenocarcinoma of prostate:8791625	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Ketoconazole\|\|TREATS\|\|Disseminated Intravascular Coagulation:3412208	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Androgen Receptor\|AR\|\|PART_OF\|\|Cytosol:812545	7/138,393	65/26,262,527	20.44	1.19e-07	4.34e-06
Androgen Receptor\|AR\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:5961629	143/138,393	155/26,262,527	175.26	5.91e-239	1.63e-235
Cytotoxic Chemotherapy\|\|TREATS\|\|Hormone-refractory prostate cancer:7665491	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Androgenetic Alopecia\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:8619438	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Epidermal Growth Factor Receptor\|EGFR\|\|PART_OF\|\|Malignant neoplasm of prostate:4673426	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Glioblastoma\|\|PART_OF\|\|Prostate:2142831	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Glutamate Carboxypeptidase II\|\|PART_OF\|\|Recombinants:10310374	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Biopsy\|\|DIAGNOSES\|\|Carcinoma:69980	46/138,393	235/26,262,527	37.16	5.96e-53	2.76e-50
CYP17A1 gene\|CYP17A1\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8053803	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
Biopsy\|\|METHOD_OF\|\|Magnetic Resonance Imaging:3411666	24/138,393	80/26,262,527	56.94	2.87e-32	7.28e-30
tamsulosin\|\|ISA\|\|Sulfonamides:8829476	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Rectum\|\|LOCATION_OF\|\|Toxic effect:9555084	12/138,393	25/26,262,527	91.10	7.06e-19	9.30e-17
HISTORY OF SYMPTOMS & DISEASES:FINDING:POINT IN TIME:HEREDITARY:NOMINAL\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:6391527	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
Endocrine therapy\|\|PRECEDES\|\|Radical prostatectomy:6837064	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
CANADIAN\|\|PROCESS_OF\|\|Urologist:7879499	9/138,393	36/26,262,527	47.44	2.23e-12	1.67e-10
Carcinoma, Transitional Cell\|\|ASSOCIATED_WITH\|\|Prostatic duct:2588085	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Radical prostatectomy\|\|PRECEDES\|\|Rehabilitation therapy:11078423	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Phosphodiesterase 5 inhibitor\|\|TREATS\|\|Erectile dysfunction:8640910	21/138,393	611/26,262,527	6.52	5.54e-11	3.52e-09
Stroma\|\|LOCATION_OF\|\|Xenograft Model:9616787	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Finasteride\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:9817634	10/138,393	10/26,262,527	189.78	2.76e-18	3.46e-16
Phantoms, Imaging\|\|TREATS\|\|AIDS related complex:3587429	8/138,393	24/26,262,527	63.26	5.36e-12	3.93e-10
Gelatinase B\|\|PART_OF\|\|Malignant neoplasm of prostate:13170017	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
KLK3 gene\|KLK3\|\|COEXISTS_WITH\|\|Zonal:6619400	9/138,393	16/26,262,527	106.75	5.66e-15	5.57e-13
Lesion, pre malignant\|\|PART_OF\|\|Prostate:10143359	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Androgen Receptor\|AR\|\|AUGMENTS\|\|Phosphorylation:8273617	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Vaccination\|\|ISA\|\|Immunotherapy:2904752	7/138,393	55/26,262,527	24.15	4.16e-08	1.85e-06
Antigen assay\|\|USES\|\|Digital Rectal Examination:7288232	8/138,393	11/26,262,527	138.02	4.09e-14	3.65e-12
Carcinogens\|\|AFFECTS\|\|Malignant neoplasm of prostate:12302312	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Bone structure of tibia\|\|PART_OF\|\|Mice, Nude:10041236	10/138,393	19/26,262,527	99.88	2.86e-16	3.02e-14
GATA3\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:15683088	4/138,393	3/26,262,527	253.03	2.61e-08	1.17e-06
Plasminogen Activator Inhibitor 1\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:7846229	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Reader\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:8014745	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Tissue specimen\|\|PART_OF\|\|Prostate carcinoma:6089068	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Proto-Oncogene Proteins c-akt\|AKT1\|\|COEXISTS_WITH\|\|PTEN gene\|PTEN:9072369	6/138,393	26/26,262,527	43.79	1.67e-08	7.69e-07
Spectrum Analysis\|\|USES\|\|Biopsy:7252493	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
High-Grade Prostatic Intraepithelial Neoplasia\|\|ASSOCIATED_WITH\|\|Duct (organ) structure:8453299	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
ZD1839\|\|ISA\|\|Epidermal growth factor receptor inhibitor:8888212	10/138,393	104/26,262,527	18.25	6.49e-10	3.77e-08
Carotenoids\|\|COEXISTS_WITH\|\|Plasma Proteins:129410	7/138,393	1/26,262,527	1328.44	8.66e-16	8.84e-14
gene therapy\|\|AFFECTS\|\|Malignant neoplasm of prostate:6272351	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Dexamethasone\|\|TREATS\|\|Prostate carcinoma:9976564	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Polymerase Chain Reaction\|\|DIAGNOSES\|\|Micrometastasis:5505334	6/138,393	32/26,262,527	35.58	4.96e-08	2.03e-06
Osteoblasts\|\|PRODUCES\|\|Proteoglycan:7546112	9/138,393	49/26,262,527	34.86	2.52e-11	1.67e-09
alpha 2-Glucoproteins\|\|INTERACTS_WITH\|\|HSPA5:11308208	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Radical prostatectomy\|\|AFFECTS\|\|Sexual function:8517100	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Lobe\|\|PART_OF\|\|Prostate:2301	279/138,393	857/26,262,527	61.90	0.00e+00	0.00e+00
Mitochondria\|\|LOCATION_OF\|\|CYTOCHROME C:504623	35/138,393	1,356/26,262,527	4.90	9.91e-14	8.71e-12
Insulin-Like Growth Factor II\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:8856002	7/138,393	11/26,262,527	120.77	3.29e-12	2.43e-10
degarelix\|\|compared_with\|\|Gonadotropin-Releasing Hormone Analog:15237918	6/138,393	9/26,262,527	126.52	9.97e-11	6.13e-09
Reverse Transcriptase Polymerase Chain Reaction\|\|METHOD_OF\|\|Radical prostatectomy:7002163	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Males:4577836	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
CAP - NOS\|\|PROCESS_OF\|\|African American:8575709	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Nuclear Proteins\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9097219	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Complementary therapies\|\|TREATS\|\|Malignant neoplasm of prostate:8232357	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
Invasive Carcinoma\|\|PART_OF\|\|Bladder:312821	18/138,393	418/26,262,527	8.17	3.98e-11	2.54e-09
Needle biopsy procedure\|\|DIAGNOSES\|\|Adenocarcinoma:3840441	36/138,393	46/26,262,527	148.55	1.46e-59	7.68e-57
Digital Rectal Examination\|\|DIAGNOSES\|\|Antimicrobial susceptibility:9561393	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Radical prostatectomy\|\|PRECEDES\|\|External Beam Radiation Therapy:7586423	10/138,393	10/26,262,527	189.78	2.76e-18	3.46e-16
Ovarian Carcinoma\|\|ASSOCIATED_WITH\|\|Prostate:13104559	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
agonists\|\|TREATS\|\|Prostate cancer metastatic:2610477	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
lycopene\|\|AFFECTS\|\|Malignant neoplasm of prostate:9842121	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Biopsy\|\|USES\|\|Calculators:13759600	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Glutamate Carboxypeptidase II\|\|INTERACTS_WITH\|\|N-acetyl-aspartyl-glutamate:13558026	10/138,393	12/26,262,527	158.15	9.56e-18	1.15e-15
Prostate carcinoma\|\|PROCESS_OF\|\|cohort:7302922	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Physiologic Function\|\|PROCESS_OF\|\|Prostate:4649876	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Vasectomy\|\|ISA\|\|Contraceptive methods:1441293	7/138,393	45/26,262,527	29.52	1.18e-08	5.51e-07
estramustine-binding protein\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:3725296	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
17q\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:6134904	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
prostate cancer screening\|\|TREATS\|\|Malignant neoplasm of prostate:7022203	32/138,393	31/26,262,527	195.93	8.24e-56	4.10e-53
Immunotherapy\|\|USES\|\|Vaccines:340185	16/138,393	347/26,262,527	8.75	1.82e-10	1.10e-08
Carcinoma, Transitional Cell\|\|PART_OF\|\|Bladder:89875	334/138,393	6,667/26,262,527	9.53	1.75e-196	3.59e-193
Genomic Instability\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:6317187	12/138,393	11/26,262,527	207.04	5.52e-22	8.86e-20
Secondary malignant neoplasm of bone\|\|LOCATION_OF\|\|Osteoblasts:8936388	6/138,393	9/26,262,527	126.52	9.97e-11	6.13e-09
Vascular Endothelial Growth Factor C\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:11369169	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Radionuclide Imaging\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:827990	17/138,393	20/26,262,527	161.32	2.45e-29	5.41e-27
Radical prostatectomy\|\|TREATS\|\|Lower urinary tract symptoms:8193288	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Prostate-Specific Antigen\|\|ASSOCIATED_WITH\|\|Surgical margins:5122038	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
dietary intervention\|\|TREATS\|\|Malignant neoplasm of prostate:9222469	13/138,393	14/26,262,527	176.23	4.22e-23	7.15e-21
Diagnostic tests\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:4067719	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Combination Drug Therapy\|\|USES\|\|Estramustine:6984338	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Radical retropubic prostatectomy\|\|compared_with\|\|Radical retropubic prostatectomy:7894839	7/138,393	10/26,262,527	132.84	2.02e-12	1.52e-10
SPOP gene\|SPOP\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:16029735	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Gonadotropin-Releasing Hormone Analog\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:2810107	29/138,393	31/26,262,527	177.56	7.15e-50	3.16e-47
Aneuploidy\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:6738913	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Glutamate Carboxypeptidase II\|\|PART_OF\|\|Malignant neoplasm of prostate:7256048	25/138,393	26/26,262,527	182.50	2.11e-43	7.93e-41
MicroRNAs\|\|AFFECTS\|\|Gene Expression:9667125	60/138,393	3,036/26,262,527	3.75	4.43e-17	5.15e-15
Intestines\|\|LOCATION_OF\|\|Dental caries:202092	9/138,393	55/26,262,527	31.05	6.35e-11	3.97e-09
Benign prostatic hypertrophy\|\|ISA\|\|Urologic Diseases:3884749	8/138,393	19/26,262,527	79.91	1.16e-12	8.96e-11
Seed Implantation\|\|TREATS\|\|Adenocarcinoma:6363510	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
PREDICTED\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:6373108	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Cell Line, Tumor\|\|PART_OF\|\|Bladder:1581348	9/138,393	134/26,262,527	12.75	8.47e-08	3.27e-06
Neoplasm Metastasis\|\|PART_OF\|\|Bone structure of spine:196018	40/138,393	538/26,262,527	14.11	3.52e-31	8.45e-29
Anesthesia procedures\|\|METHOD_OF\|\|Radical prostatectomy:6004097	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Diffusion Magnetic Resonance Imaging\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:12742535	35/138,393	39/26,262,527	170.35	1.95e-59	1.02e-56
Copper\|\|INHIBITS\|\|multicatalytic endopeptidase complex:10572231	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Operation on prostate\|\|TREATS\|\|Malignant neoplasm of prostate:6514162	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Teleradiotherapy procedure\|\|PRECEDES\|\|Salvage Therapy:12312376	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Buserelin\|\|compared_with\|\|Orchiectomy:3028172	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Vitamin E\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:7947124	14/138,393	15/26,262,527	177.13	8.52e-25	1.56e-22
Malignant neoplasm of prostate\|\|ASSOCIATED_WITH\|\|Lobe:4934350	10/138,393	11/26,262,527	172.53	5.24e-18	6.40e-16
Urine specimen\|\|PART_OF\|\|Sediment:1667868	6/138,393	17/26,262,527	66.98	1.94e-09	9.82e-08
Implants\|\|TREATS\|\|Malignant neoplasm of prostate:2150286	34/138,393	38/26,262,527	169.83	9.44e-58	4.85e-55
Endocrine therapy\|\|TREATS\|\|Prostate carcinoma:159037	53/138,393	62/26,262,527	162.28	2.13e-88	1.83e-85
Medical therapy\|\|TREATS\|\|Malignant neoplasm of prostate:3990275	19/138,393	18/26,262,527	200.34	7.55e-34	2.03e-31
Castration, Male\|\|TREATS\|\|Prostate cancer metastatic:5315699	10/138,393	14/26,262,527	135.56	2.87e-17	3.37e-15
trichostatin A\|\|USES\|\|trichostatin A:6036283	17/138,393	601/26,262,527	5.37	5.52e-08	2.15e-06
GLUCOCORTICOID THERAPY\|\|TREATS\|\|Malignant neoplasm of prostate:11928851	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Radical retropubic prostatectomy\|\|TREATS\|\|Malignant neoplasm of prostate:668162	346/138,393	397/26,262,527	165.80	0.00e+00	0.00e+00
Prostate\|\|PART_OF\|\|Adenocarcinoma of prostate:5938679	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostate\|\|LOCATION_OF\|\|Disease Progression:7910473	10/138,393	11/26,262,527	172.53	5.24e-18	6.40e-16
Androgen therapy\|\|TREATS\|\|Prostate cancer recurrent:12051490	16/138,393	16/26,262,527	189.79	1.80e-28	3.82e-26
Prostatic Diseases\|\|ASSOCIATED_WITH\|\|Prostate:5913345	11/138,393	15/26,262,527	139.17	5.90e-19	7.80e-17
Androgens\|\|AFFECTS\|\|Gene Expression:3115526	11/138,393	51/26,262,527	40.93	3.26e-14	2.93e-12
GRP gene\|GRP\|\|PART_OF\|\|Malignant neoplasm of pancreas:17235087	11/138,393	18/26,262,527	115.98	2.60e-18	3.34e-16
beta catenin\|\|PART_OF\|\|Malignant neoplasm of prostate:9503090	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Primary Neoplasm\|\|ASSOCIATED_WITH\|\|Prostate:2917832	9/138,393	12/26,262,527	142.33	8.30e-16	8.48e-14
Peptides\|\|ASSOCIATED_WITH\|\|Neoplasm Metastasis:8801685	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Prostate-Specific Antigen\|\|ASSOCIATED_WITH\|\|Prostatic Diseases:3624443	16/138,393	17/26,262,527	178.63	3.48e-28	7.27e-26
Diphosphonates\|\|TREATS\|\|loss; bone:3676963	10/138,393	68/26,262,527	27.91	1.42e-11	1.02e-09
Systemic Therapy\|\|TREATS\|\|Malignant neoplasm of prostate:2624126	50/138,393	58/26,262,527	163.65	1.29e-83	1.03e-80
Testosterone\|\|ASSOCIATED_WITH\|\|Prostate carcinoma:452484	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Leuprolide\|\|TREATS\|\|Malignant neoplasm of prostate:2722228	28/138,393	30/26,262,527	177.15	3.48e-48	1.48e-45
Estrogen Receptors\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:5247272	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Mechlorethamine\|\|TREATS\|\|Malignant neoplasm of prostate:1105285	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
AR gene\|AR\|\|AFFECTS\|\|Cell Proliferation:12819397	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Interleukin-8\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:7559395	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
[M]Unspecified tumor cell NOS\|\|LOCATION_OF\|\|PTEN gene\|PTEN:8676250	5/138,393	21/26,262,527	45.18	2.37e-07	8.32e-06
Treatment Protocols\|\|USES\|\|Suramin:4759831	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Metallothionein\|\|ASSOCIATED_WITH\|\|Prostate:3286708	10/138,393	40/26,262,527	47.45	1.33e-13	1.16e-11
osteopontin\|\|ASSOCIATED_WITH\|\|Prostate:8278893	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
melanoma\|\|PART_OF\|\|Pancreas:1935586	5/138,393	17/26,262,527	55.82	9.68e-08	3.54e-06
Folate\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:11597829	11/138,393	12/26,262,527	173.97	1.05e-19	1.44e-17
Integrins\|\|ASSOCIATED_WITH\|\|Prostate cancer metastatic:9421711	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Malignant neoplasm of prostate\|\|AFFECTS\|\|Polymorphism, Genetic:8067591	22/138,393	22/26,262,527	189.80	1.27e-38	4.06e-36
Prostate-Specific Antigen\|\|ASSOCIATED_WITH\|\|Secondary malignant neoplasm of lymph node:7504251	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Radical prostatectomy\|\|PRECEDES\|\|Endocrine therapy:4481719	25/138,393	32/26,262,527	148.28	8.19e-42	2.94e-39
Estramustine\|\|ASSOCIATED_WITH\|\|Hormone-refractory prostate cancer:6045253	24/138,393	24/26,262,527	189.80	5.28e-42	1.91e-39
Phosphotransferases\|\|AFFECTS\|\|androgen receptor activity:10645801	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostatic Tissue\|\|LOCATION_OF\|\|Prostate-Specific Antigen:3484974	25/138,393	28/26,262,527	169.47	7.61e-43	2.83e-40
Pain relief\|\|TREATS\|\|Secondary malignant neoplasm of bone:4626514	11/138,393	41/26,262,527	50.92	4.07e-15	4.02e-13
Suprapubic\|\|LOCATION_OF\|\|Ultrasonography:1574176	14/138,393	54/26,262,527	49.20	1.12e-18	1.46e-16
Secondary malignant neoplasm of bone\|\|ASSOCIATED_WITH\|\|Bone Marrow:2293133	5/138,393	10/26,262,527	94.89	1.14e-08	5.31e-07
Histone Deacetylase\|\|PART_OF\|\|Malignant neoplasm of prostate:10971221	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
STAT3 gene\|STAT3\|\|AUGMENTS\|\|Malignant neoplasm of prostate:9531128	6/138,393	5/26,262,527	227.73	9.37e-12	6.74e-10
Biological Response Modifiers\|\|TREATS\|\|Malignant neoplasm of prostate:4156939	4/138,393	3/26,262,527	253.03	2.61e-08	1.17e-06
Bombesin\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:13609809	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Open approach\|\|TREATS\|\|Malignant neoplasm of prostate:9808044	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
degarelix\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:13821511	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Specimen from prostate\|\|LOCATION_OF\|\|Fluorescent in Situ Hybridization:8012456	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Estramustine phosphate\|\|TREATS\|\|Prostate cancer metastatic:2624149	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
BRCA1 gene\|BRCA1\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:6644597	18/138,393	26/26,262,527	131.39	8.07e-30	1.81e-27
Chemoprevention\|\|USES\|\|Tea:7387224	7/138,393	18/26,262,527	73.80	4.81e-11	3.06e-09
Neoadjuvant Therapy\|\|TREATS\|\|Prostate carcinoma:6018449	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Prostate-Specific Antigen\|\|PART_OF\|\|Prostate cancer metastatic:8362111	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Mucin-1 Staining Method\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:10402131	9/138,393	12/26,262,527	142.33	8.30e-16	8.48e-14
Signal Pathways\|\|AFFECTS\|\|Neoplasm progression:8891226	10/138,393	60/26,262,527	31.63	4.67e-12	3.43e-10
Interleukin-6\|\|STIMULATES\|\|Androgen Receptor\|AR:7866579	8/138,393	13/26,262,527	116.79	1.09e-13	9.55e-12
Adrenal Cortex Hormones\|\|USES\|\|Adrenal Cortex Hormones:46817	7/138,393	8,192/26,262,527	0.16	2.29e-11	1.53e-09
Prostatic secretions\|\|LOCATION_OF\|\|Specimen:1284808	8/138,393	28/26,262,527	54.22	1.51e-11	1.08e-09
Therapeutic agent (substance)\|\|TREATS\|\|Prostate cancer metastatic:13033619	7/138,393	6/26,262,527	221.41	1.82e-13	1.56e-11
Castration\|\|TREATS\|\|Prostate cancer metastatic:2364925	25/138,393	29/26,262,527	163.62	1.41e-42	5.19e-40
paracrine\|\|PROCESS_OF\|\|Prostate:7818513	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Prostate carcinoma\|\|LOCATION_OF\|\|Epithelial Cells:910135	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Peptide Hydrolases\|\|PART_OF\|\|Cell surface:973334	10/138,393	146/26,262,527	13.00	1.37e-08	6.35e-07
Prostate-Specific Antigen\|\|PART_OF\|\|Prostate carcinoma:3461741	19/138,393	21/26,262,527	171.72	5.53e-33	1.43e-30
Androgens\|\|AUGMENTS\|\|Malignant neoplasm of prostate:3053811	25/138,393	25/26,262,527	189.80	1.08e-43	4.10e-41
Radical prostatectomy\|\|TREATS\|\|Carcinoma:76399	57/138,393	67/26,262,527	161.51	7.31e-95	7.02e-92
magnetic resonance spectroscopic imaging\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:6774798	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Lymphoma\|\|ASSOCIATED_WITH\|\|Prostate:2861049	14/138,393	24/26,262,527	110.71	1.02e-22	1.69e-20
Paneth Cells\|\|PART_OF\|\|Adenocarcinoma of prostate:3508252	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Castration\|\|TREATS\|\|Locally Advanced Malignant Neoplasm:7548032	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Squamous cell carcinoma\|\|ASSOCIATED_WITH\|\|Prostate:4576673	6/138,393	9/26,262,527	126.52	9.97e-11	6.13e-09
HSP90 Heat-Shock Proteins\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:10359256	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Antigen assay\|\|METHOD_OF\|\|Antigen assay:5830465	7/138,393	14/26,262,527	94.89	1.19e-11	8.48e-10
Disseminated Intravascular Coagulation\|\|COEXISTS_WITH\|\|Prostate carcinoma:2096672	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
AR gene\|AR\|\|ASSOCIATED_WITH\|\|Prostate:7625338	21/138,393	25/26,262,527	159.43	7.87e-36	2.27e-33
Tumor Antigens\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:910176	13/138,393	15/26,262,527	164.48	7.85e-23	1.31e-20
Mucin-producing adenocarcinoma\|\|PART_OF\|\|Prostate:243562	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
Androgens\|\|CAUSES\|\|Cell Proliferation:6669098	5/138,393	9/26,262,527	105.43	7.62e-09	3.62e-07
External Beam Radiation Therapy\|\|TREATS\|\|Toxic effect:7269474	8/138,393	10/26,262,527	151.82	2.38e-14	2.15e-12
Eligard\|\|ISA\|\|Leuprolide Acetate:10060197	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
Biopsy of prostate\|\|DIAGNOSES\|\|Carcinoma:6141003	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Stroma\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8332943	27/138,393	34/26,262,527	150.73	3.54e-45	1.39e-42
Malignant neoplasm of urinary bladder\|\|ASSOCIATED_WITH\|\|Prostate:6030941	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Bladder\|\|LOCATION_OF\|\|Biopsy:33596	38/138,393	894/26,262,527	8.07	1.38e-21	2.16e-19
Cytoplasm\|\|LOCATION_OF\|\|Androgen Receptor\|AR:597424	19/138,393	39/26,262,527	92.46	3.65e-29	7.99e-27
Lower urinary tract symptoms\|\|PROCESS_OF\|\|cohort:7832088	7/138,393	27/26,262,527	49.20	5.17e-10	3.02e-08
2,3-bis(3'-hydroxybenzyl)butyrolactone\|\|ISA\|\|Lignans:2201651	13/138,393	154/26,262,527	16.02	8.33e-12	6.05e-10
Malignant neoplasm of prostate\|\|COEXISTS_WITH\|\|Oxidative Stress:14680843	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Entire tibia\|\|PART_OF\|\|SCID Mice:9608812	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Radioisotope scan of bone\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:1911951	7/138,393	5/26,262,527	265.69	8.42e-14	7.41e-12
Proteome\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:10307043	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Diethylstilbestrol\|\|TREATS\|\|Prostate cancer metastatic:72075	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Androgen Antagonists\|\|INTERACTS_WITH\|\|agonists:3376033	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Malignant Epithelial Cell\|\|PART_OF\|\|Prostate:1996827	83/138,393	90/26,262,527	175.11	2.01e-139	3.01e-136
Diphosphonates\|\|INHIBITS\|\|Bone Resorption:769156	36/138,393	467/26,262,527	14.63	9.83e-29	2.13e-26
Zinc\|\|PART_OF\|\|Prostatic Tissue:2219904	7/138,393	13/26,262,527	102.19	7.94e-12	5.78e-10
EZH2 protein, human\|EZH2\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9801661	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
MET\|RNMT\|SLTM\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:7855862	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
Secondary malignant neoplasm of lymph node\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:1230905	59/138,393	63/26,262,527	177.79	7.22e-100	7.39e-97
Flutamide\|\|compared_with\|\|Orchiectomy:2972617	16/138,393	16/26,262,527	189.79	1.80e-28	3.82e-26
Homologous Gene\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9337924	9/138,393	8/26,262,527	213.50	6.99e-17	8.04e-15
Prostate\|\|LOCATION_OF\|\|Prostate-Specific Antigen:5304227	16/138,393	26/26,262,527	116.79	4.76e-26	9.21e-24
Malignant neoplasm of prostate\|\|NEG_COEXISTS_WITH\|\|Consumption-archaic term for TB:5577643	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Gonadorelin\|\|TREATS\|\|Prostate carcinoma:2621932	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
S-Phase Fraction\|\|DIAGNOSES\|\|Benign prostatic hypertrophy:7724923	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Prostatic Intraepithelial Neoplasias\|\|ISA\|\|Dysplasia:5418999	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
PTRF\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:16181600	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Fibroblasts\|\|PRODUCES\|\|Proteoglycan:1506088	8/138,393	69/26,262,527	22.00	8.70e-09	4.11e-07
PLAU gene\|PLAU\|\|AFFECTS\|\|Tumor Cell Invasion:6549746	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Combined Modality Therapy\|\|TREATS\|\|High-Risk Cancer:8755776	18/138,393	24/26,262,527	142.34	2.80e-30	6.50e-28
Biopsy sample\|\|LOCATION_OF\|\|Carcinoma:1875543	8/138,393	32/26,262,527	47.44	3.78e-11	2.41e-09
Malignant neoplasm of prostate\|\|AFFECTS\|\|Angiogenesis:9822743	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
Epirubicin\|\|TREATS\|\|Prostate cancer metastatic:3578734	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
CD80 gene\|CD80\|\|PART_OF\|\|Malignant neoplasm of prostate:12502573	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
advanced disease\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:10435293	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
leukemia\|\|PART_OF\|\|Entire lip:3049685	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Caucasoid Race\|\|ISA\|\|Racial group:714868	24/138,393	865/26,262,527	5.27	1.68e-10	1.01e-08
Genistein\|\|INHIBITS\|\|Prostate-Specific Antigen:8620824	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Malignant neoplasm of prostate\|\|COEXISTS_WITH\|\|Consumption-archaic term for TB:9238781	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
cohort\|\|LOCATION_OF\|\|ERG gene\|ERG:12750061	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Testosterone\|\|INHIBITS\|\|Prostate-Specific Antigen:7811984	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Body mass index procedure\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:12183128	12/138,393	10/26,262,527	227.74	2.65e-22	4.33e-20
Androgens\|\|AFFECTS\|\|telomerase activity:6992011	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
antitumor agent\|\|TREATS\|\|Malignant neoplasm of prostate:5520925	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Stimulation procedure\|\|USES\|\|Stanolone:1489233	24/138,393	41/26,262,527	111.10	5.98e-38	1.88e-35
Radiopharmaceuticals\|\|TREATS\|\|Neoplasm Metastasis:3540350	7/138,393	16/26,262,527	83.03	2.48e-11	1.64e-09
Plants\|\|LOCATION_OF\|\|Flavones:235914	11/138,393	81/26,262,527	25.77	2.99e-12	2.23e-10
Free testosterone\|\|ISA\|\|Testosterone:1179689	16/138,393	286/26,262,527	10.62	1.21e-11	8.65e-10
Estracyt\|\|TREATS\|\|Prostate carcinoma:679160	11/138,393	11/26,262,527	189.78	5.49e-20	7.78e-18
Prostatic Tissue\|\|LOCATION_OF\|\|Tissue Microarray:9912457	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
PTEN gene\|PTEN\|\|INHIBITS\|\|AR gene\|AR:9134455	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Prostate cancer recurrent\|\|ISA\|\|Malignant neoplasm of prostate:12952682	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Protein p53\|TP53\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:5047643	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
Vitamin A\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:4351362	16/138,393	19/26,262,527	159.82	1.20e-27	2.46e-25
Primary Neoplasm\|\|LOCATION_OF\|\|Human Cell Line:3445806	6/138,393	37/26,262,527	30.77	1.07e-07	3.92e-06
Radical prostatectomy\|\|PRECEDES\|\|Ablation:8284107	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Androgen therapy\|\|USES\|\|Gonadotropin-Releasing Hormone Analog:8308956	20/138,393	21/26,262,527	180.76	5.94e-35	1.66e-32
Radical prostatectomy\|\|higher_than\|\|Prostatectomy, Retropubic:13481252	6/138,393	4/26,262,527	284.66	4.28e-12	3.15e-10
Endothelium\|\|PART_OF\|\|Bone Marrow:19420	17/138,393	95/26,262,527	33.96	5.71e-20	8.07e-18
Human tissue\|\|PART_OF\|\|Benign prostatic hypertrophy:1113275	18/138,393	89/26,262,527	38.38	6.65e-22	1.07e-19
Prostate\|\|LOCATION_OF\|\|Basal cell hyperplasia:2251313	14/138,393	21/26,262,527	126.52	2.47e-23	4.27e-21
Malignant neoplasm of prostate\|\|AFFECTS\|\|Gammaretrovirus:14095901	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
ETV1 gene\|ETV1\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:11474229	19/138,393	23/26,262,527	156.79	1.86e-32	4.75e-30
Ultrasonography\|\|METHOD_OF\|\|Prostate specific antigen measurement:5751822	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Androgen Receptor\|AR\|\|DISRUPTS\|\|tumor growth:12502658	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
[M]Unspecified tumor cell NOS\|\|LOCATION_OF\|\|Integrins:4725155	11/138,393	126/26,262,527	16.57	2.37e-10	1.42e-08
Chemoprevention\|\|TREATS\|\|Malignant neoplasm of prostate:5391588	46/138,393	48/26,262,527	181.92	1.54e-78	1.17e-75
Vitamin D\|\|PREVENTS\|\|Malignant neoplasm of prostate:7427272	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
targeting\|\|PROCESS_OF\|\|Transcription, Genetic:4946317	11/138,393	221/26,262,527	9.45	5.87e-08	2.28e-06
Prostatic Tissue\|\|LOCATION_OF\|\|Compartments:7358556	5/138,393	9/26,262,527	105.43	7.62e-09	3.62e-07
Prophylactic treatment\|\|PREVENTS\|\|Malignant neoplasm of prostate:6813101	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostatic Tissue\|\|LOCATION_OF\|\|Stanolone:938570	29/138,393	61/26,262,527	90.24	1.78e-43	6.69e-41
Needle biopsy procedure\|\|DIAGNOSES\|\|Adenocarcinoma of prostate:7360191	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
disease stage\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:5132352	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Seminal Vesicles\|\|LOCATION_OF\|\|Biopsy:4079940	60/138,393	169/26,262,527	67.40	5.79e-82	4.50e-79
Xenograft procedure\|\|compared_with\|\|Xenograft procedure:2720508	10/138,393	115/26,262,527	16.50	1.61e-09	8.44e-08
Ablation\|\|TREATS\|\|Neoplasm Metastasis:214365	8/138,393	55/26,262,527	27.60	1.71e-09	8.98e-08
beta catenin\|\|ASSOCIATED_WITH\|\|Prostate:10450114	14/138,393	25/26,262,527	106.28	1.58e-22	2.60e-20
KLK3 gene\|KLK3\|\|PART_OF\|\|Malignant neoplasm of prostate:4799852	68/138,393	72/26,262,527	179.31	5.06e-115	6.10e-112
Beta Carotene\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:7605913	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Angiogenesis\|\|PROCESS_OF\|\|Xenograft Model:9103800	7/138,393	65/26,262,527	20.44	1.19e-07	4.34e-06
Transurethral Resection of Prostate\|\|PREDISPOSES\|\|Incontinence:6785157	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Treatment Protocols\|\|TREATS\|\|Malignant neoplasm of prostate:3366167	83/138,393	84/26,262,527	187.62	3.79e-141	5.76e-138
Radical prostatectomy\|\|ADMINISTERED_TO\|\|cohort:6323615	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
HSPB1 gene\|HSPB1\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8748112	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Xenograft procedure\|\|TREATS\|\|Immunologic Deficiency Syndromes:1610153	8/138,393	109/26,262,527	13.93	2.34e-07	8.21e-06
Adenoid Cystic Carcinoma\|\|PART_OF\|\|Prostate:840381	24/138,393	37/26,262,527	123.11	9.12e-39	2.96e-36
Endocrine therapy\|\|TREATS\|\|Locally Advanced Malignant Neoplasm:2394367	42/138,393	72/26,262,527	110.73	3.36e-65	2.00e-62
Epithelial Cells\|\|PART_OF\|\|Prostate:297645	1,274/138,393	2,326/26,262,527	104.90	0.00e+00	0.00e+00
Brachytherapy\|\|TREATS\|\|Prostate cancer recurrent:8834305	19/138,393	23/26,262,527	156.79	1.86e-32	4.75e-30
Positron-Emission Tomography\|\|USES\|\|Choline:7104687	40/138,393	120/26,262,527	63.27	2.80e-54	1.33e-51
Aspirin\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:9549348	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Intravenous therapy\|\|USES\|\|Diphosphonates:5944442	9/138,393	140/26,262,527	12.20	1.20e-07	4.40e-06
docetaxel\|\|DISRUPTS\|\|apoptogenic cytochrome c release channel activity:10920099	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
rhenium-186 HEDP\|\|ISA\|\|Diphosphonates:6003564	5/138,393	10/26,262,527	94.89	1.14e-08	5.31e-07
Prostate\|\|LOCATION_OF\|\|Crosstalk:7757252	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Androgen therapy\|\|METHOD_OF\|\|Castration:14917829	4/138,393	3/26,262,527	253.03	2.61e-08	1.17e-06
Stem cells\|\|PART_OF\|\|Malignant neoplasm of prostate:11495865	155/138,393	318/26,262,527	92.60	1.96e-226	4.80e-223
cyclooxygenase 2\|\|PART_OF\|\|Malignant neoplasm of prostate:8453320	12/138,393	13/26,262,527	175.19	2.10e-21	3.22e-19
Invasive Malignant Neoplasm\|\|PART_OF\|\|Prostate:5478299	15/138,393	15/26,262,527	189.79	8.93e-27	1.77e-24
Androgen Antagonists\|\|INTERACTS_WITH\|\|AR gene\|AR:4602601	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
PRUNE2\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:13401619	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostate\|\|LOCATION_OF\|\|Transrectal Ultrasound:2826051	88/138,393	156/26,262,527	107.12	9.08e-134	1.30e-130
Breast\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:5345150	14/138,393	15/26,262,527	177.13	8.52e-25	1.56e-22
DNA analysis\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:5189694	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Cisplatin\|\|TREATS\|\|Prostate cancer metastatic:2318810	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Infiltration\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:5597443	9/138,393	7/26,262,527	244.00	3.31e-17	3.87e-15
Brachytherapy\|\|TREATS\|\|Age:6797492	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Myocytes, Smooth Muscle\|\|PART_OF\|\|Prostate:442283	14/138,393	83/26,262,527	32.01	2.20e-16	2.40e-14
JAZF1\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:13579275	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Proscar\|\|ISA\|\|Finasteride:5108286	7/138,393	43/26,262,527	30.89	8.92e-09	4.21e-07
Enzyme-Linked Immunosorbent Assay\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:6908932	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Interleukin-8\|\|PART_OF\|\|Malignant neoplasm of prostate:11252364	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Prostate carcinoma\|\|LOCATION_OF\|\|Neuroendocrine Cell:3868861	12/138,393	14/26,262,527	162.67	3.88e-21	5.87e-19
Adenocarcinoma\|\|PART_OF\|\|Seminal Vesicles:387572	10/138,393	37/26,262,527	51.29	6.80e-14	6.00e-12
KLK3 gene\|KLK3\|\|COEXISTS_WITH\|\|FLVCR1:8929667	6/138,393	5/26,262,527	227.73	9.37e-12	6.74e-10
Phosphatidylethanolamine Binding Protein\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:11610258	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Japanese Population\|\|LOCATION_OF\|\|Prostate-Specific Antigen:7041428	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Clusterin\|CLU\|\|PART_OF\|\|targeting:11200714	5/138,393	9/26,262,527	105.43	7.62e-09	3.62e-07
Carcinoma in Situ\|\|PART_OF\|\|Prostatic Urethra:201134	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
Xenograft procedure\|\|TREATS\|\|SCID Mice:5418005	33/138,393	326/26,262,527	19.21	5.50e-30	1.26e-27
Cytosol\|\|PART_OF\|\|Mammary Neoplasms:890301	11/138,393	96/26,262,527	21.75	1.60e-11	1.14e-09
Single Nucleotide Polymorphism\|\|PART_OF\|\|8q24:12895563	13/138,393	28/26,262,527	88.11	3.47e-20	5.03e-18
Upper Extremity\|\|PART_OF\|\|Prostate:7428640	34/138,393	36/26,262,527	179.27	2.62e-58	1.36e-55
equol\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:13516827	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Selenium\|\|ISA\|\|Micronutrients:2588743	8/138,393	73/26,262,527	20.80	1.30e-08	6.06e-07
Hyperthermia, Local\|\|TREATS\|\|Malignant neoplasm of prostate:4598241	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Bone Marrow\|\|PART_OF\|\|Cancer Patient:635770	7/138,393	45/26,262,527	29.52	1.18e-08	5.51e-07
FAVOR\|\|TREATS\|\|Malignant neoplasm of prostate:3030395	13/138,393	12/26,262,527	205.60	1.11e-23	1.96e-21
Cisplatin\|\|TREATS\|\|Hormone-refractory prostate cancer:2315795	6/138,393	9/26,262,527	126.52	9.97e-11	6.13e-09
Prostatic radiotherapies\|\|TREATS\|\|Malignant neoplasm of prostate:8837525	4/138,393	3/26,262,527	253.03	2.61e-08	1.17e-06
Neck\|\|LOCATION_OF\|\|Prostate:1163318	12/138,393	21/26,262,527	108.45	1.38e-19	1.88e-17
daidzein\|\|ISA\|\|Isoflavones:1838775	20/138,393	417/26,262,527	9.10	5.21e-13	4.21e-11
Phosphotransferases\|\|INTERACTS_WITH\|\|Androgen Receptor\|AR:2708638	5/138,393	9/26,262,527	105.43	7.62e-09	3.62e-07
Pneumoencephalography\|\|AFFECTS\|\|Epilepsy:271926	6/138,393	2/26,262,527	569.33	5.76e-13	4.63e-11
Urine\|\|LOCATION_OF\|\|KLK3 gene\|KLK3:6733771	11/138,393	15/26,262,527	139.17	5.90e-19	7.80e-17
Anti-Inflammatory Agents, Non-Steroidal\|\|PREVENTS\|\|Malignant neoplasm of prostate:9514117	14/138,393	17/26,262,527	156.30	2.88e-24	5.18e-22
Endorectal\|\|LOCATION_OF\|\|Ultrasonography:2449855	35/138,393	627/26,262,527	10.60	1.29e-23	2.27e-21
Casodex\|\|INHIBITS\|\|Androgens:5854188	8/138,393	10/26,262,527	151.82	2.38e-14	2.15e-12
Androgen therapy\|\|AFFECTS\|\|Sexual function:12067052	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
Zoladex\|\|TREATS\|\|Carcinoma:2892840	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Androgen Receptor\|AR\|\|ISA\|\|steroid hormone receptor:2531116	13/138,393	22/26,262,527	112.15	2.99e-21	4.57e-19
Alar\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:10605180	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Lymph Node Dissection\|\|compared_with\|\|Lymph Node Dissection:3549310	8/138,393	45/26,262,527	33.74	4.10e-10	2.43e-08
Lipids\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:1684764	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
KLK3 gene\|KLK3\|\|PART_OF\|\|Adenocarcinoma:3547207	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Antigen assay\|\|METHOD_OF\|\|Cancer Diagnosis:12523753	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Radical retropubic prostatectomy\|\|TREATS\|\|Male gender:5315618	8/138,393	10/26,262,527	151.82	2.38e-14	2.15e-12
Prostate-Specific Antigen\|\|AFFECTS\|\|Cell Proliferation:7147558	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Germ-Line Mutation\|\|ASSOCIATED_WITH\|\|HOXB13:15114280	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Mitoxantrone\|\|compared_with\|\|Prednisone:6005331	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Androgen Receptor\|AR\|\|NEG_INTERACTS_WITH\|\|Androgen Receptor\|AR:4610835	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Prostate\|\|LOCATION_OF\|\|Anatomical zone:2369999	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Male gender\|\|PROCESS_OF\|\|American:83151	43/138,393	102/26,262,527	80.02	7.07e-62	3.94e-59
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Polymorphism, Genetic:7154517	12/138,393	12/26,262,527	189.78	1.10e-21	1.72e-19
Physicians\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:3444762	30/138,393	30/26,262,527	189.81	3.89e-52	1.78e-49
Microtubule-Associated Proteins\|\|PART_OF\|\|Prostate:9518290	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Laboratory\|\|LOCATION_OF\|\|Prostate specific antigen measurement:6251321	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
antiangiogenesis therapy\|\|TREATS\|\|Malignant neoplasm of prostate:8912575	10/138,393	11/26,262,527	172.53	5.24e-18	6.40e-16
Glutamate Carboxypeptidase II\|\|STIMULATES\|\|Glutamate Carboxypeptidase II:9837255	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Genome\|\|PART_OF\|\|Malignant neoplasm of prostate:5618267	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Plasma specimen\|\|LOCATION_OF\|\|Prostate-Specific Antigen:6418934	7/138,393	11/26,262,527	120.77	3.29e-12	2.43e-10
Stanolone\|\|AFFECTS\|\|Prostate:2178705	7/138,393	16/26,262,527	83.03	2.48e-11	1.64e-09
Prostate-Specific Antigen\|\|PREDISPOSES\|\|Secondary malignant neoplasm of bone:5804295	10/138,393	11/26,262,527	172.53	5.24e-18	6.40e-16
Signaling Molecule\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:11262759	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Cytosol\|\|LOCATION_OF\|\|Androgen Receptor\|AR:834126	10/138,393	89/26,262,527	21.32	1.60e-10	9.66e-09
Prostatic duct\|\|LOCATION_OF\|\|Hyperplasia:564981	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Chromosome 8 Short Arm\|\|PART_OF\|\|Upper Extremity:5295495	8/138,393	44/26,262,527	34.51	3.49e-10	2.08e-08
NDRG1 gene\|NDRG1\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:10514930	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Adenocarcinoma of prostate\|\|PROCESS_OF\|\|Mice, Nude:1891958	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostatic Diseases\|\|COEXISTS_WITH\|\|Prostatic Diseases:3407481	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Zoladex\|\|TREATS\|\|Prostate carcinoma:3569796	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Functional RNA\|\|AFFECTS\|\|Gene Expression:16155073	5/138,393	1/26,262,527	948.87	2.36e-11	1.58e-09
Prostatic Tissue\|\|PART_OF\|\|Prostatic Intraepithelial Neoplasias:10585272	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Human Cell Line\|\|PART_OF\|\|Prostate cancer metastatic:8116239	15/138,393	15/26,262,527	189.79	8.93e-27	1.77e-24
Castration\|\|TREATS\|\|Prostate carcinoma:46264	16/138,393	20/26,262,527	151.83	2.15e-27	4.37e-25
Prostate-Specific Antigen\|\|AUGMENTS\|\|Malignant neoplasm of prostate:5893850	23/138,393	23/26,262,527	189.80	2.59e-40	8.82e-38
Epidermal Growth Factor Receptor\|EGFR\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:5047644	22/138,393	27/26,262,527	154.65	2.92e-37	9.04e-35
Chromosomes, Human, Pair 10\|\|LOCATION_OF\|\|Homologous Gene:2685257	63/138,393	892/26,262,527	13.41	7.16e-47	2.94e-44
APEX1 protein, human\|APEX1\|\|PART_OF\|\|Prostate:119361	120/138,393	214/26,262,527	106.50	1.63e-181	2.99e-178
Androgen therapy\|\|NEG_TREATS\|\|Malignant neoplasm of prostate:7418088	15/138,393	13/26,262,527	218.99	2.18e-27	4.41e-25
Radical prostatectomy\|\|PRECEDES\|\|Androgen therapy:8001890	19/138,393	24/26,262,527	150.25	3.32e-32	8.35e-30
Implantation procedure\|\|TREATS\|\|Localized Carcinoma:1434673	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Prostate carcinoma\|\|ISA\|\|Carcinoma:944156	20/138,393	21/26,262,527	180.76	5.94e-35	1.66e-32
Prostatectomy\|\|AFFECTS\|\|Malignant neoplasm of prostate:8987828	5/138,393	4/26,262,527	237.22	4.90e-10	2.87e-08
Lymph node excision\|\|AFFECTS\|\|Malignant neoplasm of prostate:10777014	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Stanolone\|\|ASSOCIATED_WITH\|\|Carcinoma:1158261	4/138,393	3/26,262,527	253.03	2.61e-08	1.17e-06
Fibroblasts\|\|PART_OF\|\|Synovial:710330	2/138,393	4,566/26,262,527	0.08	2.65e-08	1.19e-06
Screening procedure\|\|ISA\|\|Physical Examination:586691	20/138,393	332/26,262,527	11.43	9.44e-15	8.94e-13
Monoclonal Antibodies\|\|ASSOCIATED_WITH\|\|Prostate:2108889	6/138,393	11/26,262,527	103.51	2.44e-10	1.46e-08
Stromal Cells\|\|PART_OF\|\|Benign prostatic hypertrophy:5383038	10/138,393	37/26,262,527	51.29	6.80e-14	6.00e-12
Prostate carcinoma\|\|ISA\|\|Malignant neoplasm of prostate:7868310	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Proto-Oncogene Proteins c-akt\|AKT1\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:13275561	4/138,393	2/26,262,527	379.55	1.12e-08	5.27e-07
cohort\|\|LOCATION_OF\|\|Insulin-Like Growth Factor I:5651860	8/138,393	44/26,262,527	34.51	3.49e-10	2.08e-08
Hodgkin Disease\|\|PART_OF\|\|Prostate:3156154	10/138,393	10/26,262,527	189.78	2.76e-18	3.46e-16
Racemases\|\|PART_OF\|\|Prostate carcinoma:11117365	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Cancer Cell Growth Regulation\|\|PART_OF\|\|Prostate:5080744	4/138,393	3/26,262,527	253.03	2.61e-08	1.17e-06
Radical therapy\|\|TREATS\|\|Malignant neoplasm of prostate:3714320	29/138,393	29/26,262,527	189.81	1.90e-50	8.49e-48
Human Cell Line\|\|PART_OF\|\|Cancer of Urinary Tract:1724413	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Prostate\|\|LOCATION_OF\|\|Primary Neoplasm:2964960	9/138,393	8/26,262,527	213.50	6.99e-17	8.04e-15
Diabetes Mellitus\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:9819163	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
BTG1 gene\|BTG1\|PPBP\|\|PART_OF\|\|Malignant neoplasm of prostate:12731098	20/138,393	18/26,262,527	210.88	7.52e-36	2.19e-33
Carcinogenesis\|\|PART_OF\|\|Prostate:1101843	1,100/138,393	1,403/26,262,527	149.97	0.00e+00	0.00e+00
mucosa-associated lymphoid tissue lymphoma\|\|PART_OF\|\|Prostate:2468663	8/138,393	22/26,262,527	69.01	3.01e-12	2.24e-10
Radiotherapy, Intensity-Modulated\|\|TREATS\|\|Toxic effect:10295018	11/138,393	35/26,262,527	59.65	9.25e-16	9.43e-14
tumor growth\|\|PROCESS_OF\|\|Xenograft Model:6613326	88/138,393	881/26,262,527	18.97	1.19e-76	8.84e-74
Scanning\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:1373012	24/138,393	25/26,262,527	182.21	1.03e-41	3.68e-39
Insulin-Like Growth Factor II\|\|ASSOCIATED_WITH\|\|Cancer Cell Growth:6714860	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Anandron\|\|ISA\|\|Androgen Antagonists:3134321	5/138,393	10/26,262,527	94.89	1.14e-08	5.31e-07
Slide\|\|USES\|\|Mounts:1259211	6/138,393	26/26,262,527	43.79	1.67e-08	7.69e-07
Solitary fibrous tumor\|\|PART_OF\|\|Prostate:7421968	15/138,393	30/26,262,527	94.89	1.84e-23	3.24e-21
PTEN gene\|PTEN\|\|ASSOCIATED_WITH\|\|Neoplasm progression:7881874	11/138,393	29/26,262,527	71.99	1.65e-16	1.80e-14
Secondary malignant neoplasm of bone\|\|OCCURS_IN\|\|Cancer Patient:9262425	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Ultrasonography\|\|DIAGNOSES\|\|Carcinoma:1432805	11/138,393	80/26,262,527	26.10	2.64e-12	1.98e-10
Strontium-89\|\|TREATS\|\|Secondary malignant neoplasm of bone:5193556	16/138,393	28/26,262,527	108.45	1.18e-25	2.24e-23
Integrins\|\|AFFECTS\|\|Cell Adhesion:3637515	13/138,393	322/26,262,527	7.66	4.01e-08	1.79e-06
Zinc\|\|TREATS\|\|Malignant neoplasm of prostate:9847172	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Raised prostate specific antigen\|\|PROCESS_OF\|\|Participant:6725131	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Malignant neoplasm of prostate\|\|AFFECTS\|\|Cell Survival:9655508	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Oestrogen therapy\|\|TREATS\|\|Malignant neoplasm of prostate:65225	53/138,393	50/26,262,527	201.23	7.92e-92	7.26e-89
trefoil factor\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:11651047	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
probasin\|\|INTERACTS_WITH\|\|Transgenes:7278504	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Hydroxymethylglutaryl-CoA Reductase Inhibitors\|\|PREVENTS\|\|Malignant neoplasm of prostate:11344879	21/138,393	23/26,262,527	173.29	2.30e-36	6.86e-34
Malignant neoplasm of endocrine gland\|\|PART_OF\|\|Prostate:4609475	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Brachytherapy\|\|TREATS\|\|organic disorders:7996430	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Malignant neoplasm of prostate\|\|ISA\|\|Cancer of Urinary Tract:2006381	6/138,393	5/26,262,527	227.73	9.37e-12	6.74e-10
Binding Protein\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:910388	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Iron\|\|ASSOCIATED_WITH\|\|Prostate:7333245	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
[M]Unspecified tumor cell NOS\|\|PART_OF\|\|Malignant neoplasm of prostate:5821122	27/138,393	29/26,262,527	176.71	1.70e-46	6.90e-44
Pelvis\|\|LOCATION_OF\|\|Medical Imaging:412888	33/138,393	276/26,262,527	22.69	3.90e-32	9.79e-30
cancer angiogenesis\|\|PART_OF\|\|Prostate:10204412	17/138,393	17/26,262,527	189.79	3.65e-30	8.38e-28
KLK3 gene\|KLK3\|\|PART_OF\|\|Participant:12453323	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
UVRAG\|TP63\|CKAP4\|\|PART_OF\|\|Basal Cell:8058839	9/138,393	31/26,262,527	55.10	7.06e-13	5.52e-11
Androgen Receptor\|AR\|\|COEXISTS_WITH\|\|Stanolone:9456807	5/138,393	8/26,262,527	118.61	4.92e-09	2.37e-07
Vitamin D\|\|TREATS\|\|Malignant neoplasm of prostate:6407675	28/138,393	30/26,262,527	177.15	3.48e-48	1.48e-45
Peptides\|\|AFFECTS\|\|Contraction:17287266	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Magnetic Resonance Imaging\|\|ISA\|\|tomography:1712472	35/138,393	2,100/26,262,527	3.16	8.68e-09	4.11e-07
Neoplasm progression\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:5402835	58/138,393	56/26,262,527	196.63	6.06e-100	6.23e-97
Steroid 17-alpha-monooxygenase\|CYP17A1\|\|ISA\|\|Cytochrome P450:8402638	5/138,393	11/26,262,527	86.26	1.65e-08	7.59e-07
Positron-Emission Tomography\|\|ISA\|\|Medical Imaging:1926056	32/138,393	2,091/26,262,527	2.90	2.31e-07	8.12e-06
KLK3 gene\|KLK3\|\|ASSOCIATED_WITH\|\|Prostate:5680995	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
CDKN1B gene\|CDKN1B\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:10103581	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Neck\|\|LOCATION_OF\|\|Preservation, Biological:3628060	57/138,393	201/26,262,527	53.84	3.18e-73	2.22e-70
Teleradiotherapy procedure\|\|TREATS\|\|Localized Carcinoma:4476552	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Radical prostatectomy\|\|METHOD_OF\|\|Cancer Treatment:6047408	11/138,393	10/26,262,527	208.76	2.76e-20	4.03e-18
TP53 gene\|TP53\|\|ISA\|\|Tumor Suppressor Genes:4143675	113/138,393	4,025/26,262,527	5.33	7.42e-44	2.85e-41
Androgens\|\|TREATS\|\|Neoplasm progression:4739497	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Castration\|\|TREATS\|\|advanced disease:9231518	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
ATM gene\|ATM\|\|PART_OF\|\|Prostatic Neoplasms:4860963	7/138,393	10/26,262,527	132.84	2.02e-12	1.52e-10
Spheroids, Cellular\|\|PART_OF\|\|Prostatic Neoplasms:7477645	14/138,393	20/26,262,527	132.85	1.49e-23	2.62e-21
Prostate\|\|LOCATION_OF\|\|Biopsy:116711	3,989/138,393	7,852/26,262,527	99.24	0.00e+00	0.00e+00
Antigen assay\|\|USES\|\|Biopsy:6239449	12/138,393	12/26,262,527	189.78	1.10e-21	1.72e-19
ID-1\|\|AUGMENTS\|\|Tumor cells, malignant:8420663	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
leukemia\|\|PART_OF\|\|Ovary:594780	7/138,393	18/26,262,527	73.80	4.81e-11	3.06e-09
Protoplasm\|\|LOCATION_OF\|\|Signal Pathways:3409668	59/138,393	4,897/26,262,527	2.29	1.88e-08	8.64e-07
Alleles\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:11521696	12/138,393	16/26,262,527	142.34	1.21e-20	1.80e-18
Pelvic lymphadenectomy\|\|TREATS\|\|Adenocarcinoma:1222282	21/138,393	27/26,262,527	147.62	2.50e-35	7.11e-33
Positron-Emission Tomography\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:7755556	40/138,393	50/26,262,527	151.86	2.78e-66	1.68e-63
Metastatic Carcinoma\|\|PART_OF\|\|Prostate:107816	188/138,393	217/26,262,527	164.63	6.07e-310	2.33e-306
Antigen assay\|\|ISA\|\|Diagnosis:2723221	16/138,393	63/26,262,527	48.20	5.13e-21	7.74e-19
alpha Catenin\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:5592261	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Cancer Promoting Genes\|\|PART_OF\|\|Breast:4302384	10/138,393	197/26,262,527	9.63	1.96e-07	6.90e-06
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Racial group:2876411	24/138,393	24/26,262,527	189.80	5.28e-42	1.91e-39
Age\|\|ASSOCIATED_WITH\|\|Erectile dysfunction:8054539	8/138,393	72/26,262,527	21.09	1.18e-08	5.50e-07
Anandron\|\|TREATS\|\|Malignant neoplasm of prostate:3526513	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
KLK3\|PLAG1\|PROS1\|NPEPPS\|PSAT1\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8439722	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Blast Cell\|\|LOCATION_OF\|\|Neoplasm Metastasis:2064796	5/138,393	21/26,262,527	45.18	2.37e-07	8.32e-06
HK2 gene\|HK2\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:7004581	8/138,393	11/26,262,527	138.02	4.09e-14	3.65e-12
Etoposide\|\|TREATS\|\|Hormone-refractory prostate cancer:5539106	16/138,393	18/26,262,527	168.70	6.55e-28	1.35e-25
Estrogenic\|\|TREATS\|\|Malignant neoplasm of prostate:422199	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
cohort\|\|LOCATION_OF\|\|FOLH1 gene\|FOLH1:16602208	4/138,393	3/26,262,527	253.03	2.61e-08	1.17e-06
bone sialoprotein\|\|PART_OF\|\|Breast:8608033	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Linoleic Acid\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:5875193	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Flutamide\|\|TREATS\|\|Neoplasm Metastasis:2972620	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
lymph nodes\|\|LOCATION_OF\|\|Neoplasm Metastasis:444072	15/138,393	132/26,262,527	21.57	3.82e-15	3.78e-13
Malignant neoplasm of prostate\|\|AFFECTS\|\|network:14167949	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
HIF1alpha protein\|\|AUGMENTS\|\|Hypoxia:9574989	5/138,393	17/26,262,527	55.82	9.68e-08	3.54e-06
Prostate\|\|LOCATION_OF\|\|Xenograft Model:8143308	13/138,393	17/26,262,527	145.13	2.49e-22	4.06e-20
Prostatic epithelium\|\|LOCATION_OF\|\|PTEN gene\|PTEN:13320808	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Radiotherapy, Intensity-Modulated\|\|METHOD_OF\|\|Radiotherapy, Intensity-Modulated:9844560	7/138,393	39/26,262,527	34.06	4.87e-09	2.37e-07
Oxidoreductase\|\|INHIBITS\|\|Stanolone:5202566	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Toxic effect\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:1393784	45/138,393	44/26,262,527	194.14	9.80e-78	7.39e-75
Pelvic lymphadenectomy\|\|TREATS\|\|Malignant neoplasm of prostate:833305	115/138,393	132/26,262,527	165.46	1.70e-190	3.26e-187
Prostate\|\|LOCATION_OF\|\|Atypical proliferation:7886336	13/138,393	16/26,262,527	154.20	1.42e-22	2.34e-20
caveolin 1\|\|PART_OF\|\|Caveolae:8491093	8/138,393	87/26,262,527	17.45	4.62e-08	2.03e-06
Advice\|\|METHOD_OF\|\|Radical prostatectomy:14470404	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Transgenic Model:6913536	55/138,393	59/26,262,527	176.97	3.94e-93	3.64e-90
Growth Factor\|\|AFFECTS\|\|Cell Growth:768776	10/138,393	196/26,262,527	9.68	1.87e-07	6.61e-06
Tumor Angiogenesis\|\|PART_OF\|\|Prostate:7358588	18/138,393	19/26,262,527	179.80	1.43e-31	3.50e-29
KLK3 gene\|KLK3\|\|higher_than\|\|KLK3 gene\|KLK3:1568378	15/138,393	22/26,262,527	129.40	5.21e-25	9.65e-23
Goserelin\|\|TREATS\|\|Locally Advanced Malignant Neoplasm:7285696	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Prostate carcinoma\|\|PART_OF\|\|Prostatic Tissue:7095851	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
RNA, Small Interfering\|\|INHIBITS\|\|Androgen Receptor\|AR:11204165	10/138,393	13/26,262,527	145.99	1.68e-17	1.99e-15
ERG gene\|ERG\|\|COEXISTS_WITH\|\|ERG gene\|ERG:14008549	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
VEGF protein, human\|VEGFA\|\|ASSOCIATED_WITH\|\|Neoplasm progression:7424967	7/138,393	69/26,262,527	19.25	1.73e-07	6.12e-06
Glutamate Carboxypeptidase II\|\|PART_OF\|\|Endothelial Cells:9883524	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Screening procedure\|\|TREATS\|\|Raised prostate specific antigen:10528820	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Large T-Antigen\|\|PART_OF\|\|Simian virus 40:1463046	45/138,393	2,570/26,262,527	3.32	1.59e-11	1.14e-09
Dissection\|\|TREATS\|\|Prostate carcinoma:1853879	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Alkaline Phosphatase\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:2105247	11/138,393	11/26,262,527	189.78	5.49e-20	7.78e-18
antibody conjugate\|\|INTERACTS_WITH\|\|Glutamate Carboxypeptidase II:10919320	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
PSCA gene\|PSCA\|\|ASSOCIATED_WITH\|\|Carcinogenesis:11943035	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Radical retropubic prostatectomy\|\|PRECEDES\|\|Radical retropubic prostatectomy:6639578	11/138,393	13/26,262,527	160.59	1.92e-19	2.59e-17
Epithelial Cells\|\|PART_OF\|\|Breast:314900	41/138,393	1,507/26,262,527	5.16	1.49e-16	1.63e-14
Glutathione S-Transferase\|\|ASSOCIATED_WITH\|\|Prostate:1837237	6/138,393	10/26,262,527	113.87	1.59e-10	9.61e-09
Radical prostatectomy\|\|TREATS\|\|Disease recurrence:8270865	9/138,393	8/26,262,527	213.50	6.99e-17	8.04e-15
Prostate\|\|ASSOCIATED_WITH\|\|Benign prostatic hypertrophy:833068	34/138,393	104/26,262,527	62.05	3.87e-46	1.56e-43
Prostate-Specific Antigen\|\|PART_OF\|\|Adenocarcinoma:5398585	14/138,393	14/26,262,527	189.79	4.43e-25	8.24e-23
Biopsy\|\|DIAGNOSES\|\|Suspected prostate cancer:1891961	5/138,393	3/26,262,527	316.29	2.19e-10	1.31e-08
Prostatectomy\|\|TREATS\|\|Locally Advanced Malignant Neoplasm:9069917	5/138,393	9/26,262,527	105.43	7.62e-09	3.62e-07
Fine needle aspiration biopsy\|\|DIAGNOSES\|\|Prostate carcinoma:1895212	11/138,393	11/26,262,527	189.78	5.49e-20	7.78e-18
Testosterone\|\|AFFECTS\|\|Malignant neoplasm of prostate:11805164	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Secretory Cell\|\|PART_OF\|\|Prostatic epithelium:6950933	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Dutasteride\|\|compared_with\|\|Finasteride:10506132	9/138,393	27/26,262,527	63.26	2.48e-13	2.12e-11
BTG1 gene\|BTG1\|PPBP\|\|PART_OF\|\|Prostate carcinoma:2805733	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Thalidomide\|\|TREATS\|\|Prostate cancer metastatic:9186650	8/138,393	10/26,262,527	151.82	2.38e-14	2.15e-12
Lymphatic vessel\|\|PART_OF\|\|Prostate:445268	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Hospitals\|\|USES\|\|urology:79300	8/138,393	33/26,262,527	46.01	4.67e-11	2.98e-09
Radical prostatectomy\|\|TREATS\|\|Local disease:4161410	71/138,393	73/26,262,527	184.66	1.19e-120	1.49e-117
Radical retropubic prostatectomy\|\|TREATS\|\|cohort:9407050	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Cancer Cell Growth\|\|PART_OF\|\|Prostate:4164654	543/138,393	641/26,262,527	161.38	0.00e+00	0.00e+00
Prostate\|\|LOCATION_OF\|\|Underweight:12356343	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Carcinoma\|\|COEXISTS_WITH\|\|Carcinoma:83683	14/138,393	310/26,262,527	8.57	3.15e-09	1.55e-07
Prostate\|\|LOCATION_OF\|\|calcification:20856	7/138,393	25/26,262,527	53.14	3.26e-10	1.94e-08
Neoplasm Metastasis\|\|ASSOCIATED_WITH\|\|Organ:19559	14/138,393	379/26,262,527	7.01	3.54e-08	1.58e-06
Radical prostatectomy\|\|PRECEDES\|\|Reconstructive Surgical Procedures:3639753	11/138,393	29/26,262,527	71.99	1.65e-16	1.80e-14
Duodenal Ulcer\|\|PROCESS_OF\|\|Mice, Nude:3292002	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
alitretinoin\|\|DISRUPTS\|\|Carcinogenesis:5993413	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
AR gene\|AR\|\|CAUSES\|\|Malignant neoplasm of prostate:9301096	5/138,393	4/26,262,527	237.22	4.90e-10	2.87e-08
Human Cell Line\|\|PART_OF\|\|Adenocarcinoma:1210089	41/138,393	1,034/26,262,527	7.53	4.22e-22	6.85e-20
Advanced cancer\|\|PART_OF\|\|Prostate:138066	370/138,393	416/26,262,527	169.23	0.00e+00	0.00e+00
Tongue\|\|PART_OF\|\|Laboratory mice:144997	8/138,393	1/26,262,527	1518.23	5.11e-18	6.36e-16
Malignant neoplasm of prostate\|\|AFFECTS\|\|establishment and maintenance of substrate location:12906251	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Acne\|\|ASSOCIATED_WITH\|\|Prostate:11999483	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Chlormadinone Acetate\|\|ISA\|\|Androgen Antagonists:1702038	8/138,393	29/26,262,527	52.35	1.92e-11	1.28e-09
Calcitriol\|\|TREATS\|\|Malignant neoplasm of prostate:7676009	10/138,393	11/26,262,527	172.53	5.24e-18	6.40e-16
Prostate\|\|LOCATION_OF\|\|Fine needle aspiration biopsy:1105182	57/138,393	81/26,262,527	133.59	1.97e-91	1.79e-88
Signal Pathways\|\|AFFECTS\|\|Malignant neoplasm of prostate:11838533	9/138,393	8/26,262,527	213.50	6.99e-17	8.04e-15
Etoposide\|\|COEXISTS_WITH\|\|Estramustine:7319787	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Human Cell Line\|\|PART_OF\|\|Malignant neoplasm of urinary bladder:1407984	21/138,393	505/26,262,527	7.89	1.86e-12	1.41e-10
cohort\|\|USES\|\|Gleason grading system for prostatic cancer:11092876	12/138,393	12/26,262,527	189.78	1.10e-21	1.72e-19
Human Cell Line\|\|PART_OF\|\|Malignant neoplasm of prostate:1900323	1,092/138,393	1,253/26,262,527	166.69	0.00e+00	0.00e+00
Castration Cell\|\|LOCATION_OF\|\|Androgen Receptor\|AR:14912051	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Pelvic lymphadenectomy\|\|TREATS\|\|Carcinoma:172752	15/138,393	45/26,262,527	63.26	2.64e-21	4.04e-19
MicroRNAs\|\|ASSOCIATED_WITH\|\|Specimen from prostate:14098167	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Malignant neoplasm of prostate\|\|COEXISTS_WITH\|\|DELETION:12056138	4/138,393	3/26,262,527	253.03	2.61e-08	1.17e-06
Prostatectomy\|\|TREATS\|\|organic disorders:7394059	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Lymph Node Dissection\|\|TREATS\|\|Malignant neoplasm of prostate:2256143	179/138,393	224/26,262,527	151.84	1.14e-290	3.99e-287
General Population\|\|LOCATION_OF\|\|Prostate-Specific Antigen:5824453	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
lymph nodes\|\|ASSOCIATED_WITH\|\|Prostate cancer metastatic:11482123	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Transforming Growth Factor beta\|\|ASSOCIATED_WITH\|\|Neoplasm progression:5746630	11/138,393	87/26,262,527	24.00	6.05e-12	4.42e-10
Chronic inflammation\|\|AFFECTS\|\|Carcinogenesis:1980556	13/138,393	41/26,262,527	60.18	2.05e-18	2.64e-16
TRANSCRIPTION FACTOR\|\|ASSOCIATED_WITH\|\|Prostate:8788028	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Prostate\|\|LOCATION_OF\|\|FAVOR:8053521	5/138,393	9/26,262,527	105.43	7.62e-09	3.62e-07
NKX3-1 gene\|NKX3-1\|\|ASSOCIATED_WITH\|\|Carcinogenesis:8782763	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Tumor cells, malignant\|\|LOCATION_OF\|\|Adhesions:1236647	11/138,393	224/26,262,527	9.32	6.68e-08	2.59e-06
Urine\|\|LOCATION_OF\|\|Prostate-Specific Antigen:3435518	18/138,393	53/26,262,527	64.46	2.13e-25	4.04e-23
Radical prostatectomy\|\|TREATS\|\|Urologist:13815460	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Androgen therapy\|\|PREDISPOSES\|\|Osteoporosis:11055627	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Flow Cytometry\|\|DIAGNOSES\|\|Adenocarcinoma of prostate:3802317	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|High Risk Populations:6122605	18/138,393	18/26,262,527	189.79	7.40e-32	1.83e-29
Biopsy sample\|\|PART_OF\|\|Prostate:1256244	123/138,393	163/26,262,527	143.33	4.56e-198	9.67e-195
Biopsy\|\|USES\|\|Biopsy gun:4015906	6/138,393	42/26,262,527	27.11	2.11e-07	7.41e-06
Penile Prosthesis\|\|TREATS\|\|Erectile dysfunction:2855735	8/138,393	104/26,262,527	14.60	1.67e-07	5.91e-06
interstitial\|\|LOCATION_OF\|\|Stroma:1094134	8/138,393	106/26,262,527	14.32	1.92e-07	6.76e-06
maspin\|SERPINB5\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:7559256	10/138,393	11/26,262,527	172.53	5.24e-18	6.40e-16
Somatomedins\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:9433342	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Cyproterone Acetate\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:1740801	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
CpG Islands\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:10520151	6/138,393	5/26,262,527	227.73	9.37e-12	6.74e-10
Testosterone\|\|ASSOCIATED_WITH\|\|Neoplasm progression:13998615	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Biopsy\|\|DIAGNOSES\|\|Prostatic Neoplasms:1412670	11/138,393	13/26,262,527	160.59	1.92e-19	2.59e-17
Prostate\|\|LOCATION_OF\|\|Magnetic Resonance Elastography:14509416	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
bicalutamide\|\|STIMULATES\|\|Androgen Receptor\|AR:8108574	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Entire pelvic lymph node\|\|LOCATION_OF\|\|Biopsy:1280727	7/138,393	18/26,262,527	73.80	4.81e-11	3.06e-09
Immunotherapy, Adoptive\|\|TREATS\|\|Malignant neoplasm of prostate:2624124	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
lycopene\|\|TREATS\|\|Malignant neoplasm of prostate:8301085	18/138,393	24/26,262,527	142.34	2.80e-30	6.50e-28
Carcinogenesis\|\|PROCESS_OF\|\|Rats, Inbred F344:1159595	16/138,393	457/26,262,527	6.64	7.94e-09	3.76e-07
Polysaccharides\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:12708189	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Primary Carcinoma\|\|PART_OF\|\|Seminal Vesicles:65669	8/138,393	24/26,262,527	63.26	5.36e-12	3.93e-10
Androgen therapy\|\|compared_with\|\|agonists:14684398	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
kallikrein 4\|\|PART_OF\|\|Prostate:9220706	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
prostate stem cell antigen\|\|PART_OF\|\|Malignant neoplasm of prostate:9212104	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Brachytherapy\|\|TREATS\|\|Localized Malignant Neoplasm:3993319	7/138,393	15/26,262,527	88.56	1.73e-11	1.23e-09
therapeutic use\|\|TREATS\|\|Malignant neoplasm of prostate:4992656	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
day\|\|ISA\|\|Time:19158	138/138,393	15,041/26,262,527	1.74	2.71e-09	1.36e-07
Aggressive cancer\|\|PART_OF\|\|Prostate:7211314	143/138,393	152/26,262,527	178.72	8.38e-240	2.33e-236
Alkaline Phosphatase\|\|PREDISPOSES\|\|Secondary malignant neoplasm of bone:4651606	8/138,393	17/26,262,527	89.31	5.69e-13	4.59e-11
Malignant neoplasm of prostate\|\|COEXISTS_WITH\|\|Pathologic Neovascularization:11218091	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Aggressive behavior\|\|PROCESS_OF\|\|African American:9259805	7/138,393	10/26,262,527	132.84	2.02e-12	1.52e-10
ERG gene\|ERG\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:11474230	65/138,393	80/26,262,527	154.26	5.19e-107	5.59e-104
[M]Unspecified tumor cell NOS\|\|PART_OF\|\|Prostate carcinoma:8635664	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Epithelial Cells\|\|LOCATION_OF\|\|Prostate-Specific Antigen:4017055	12/138,393	17/26,262,527	133.97	2.06e-20	3.04e-18
Malignant neoplasm of prostate\|\|LOCATION_OF\|\|Neuroendocrine Cell:5765041	22/138,393	28/26,262,527	149.13	5.19e-37	1.60e-34
PSCA gene\|PSCA\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8538828	11/138,393	12/26,262,527	173.97	1.05e-19	1.44e-17
Raised prostate specific antigen\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:8009414	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Digital Rectal Examination\|\|METHOD_OF\|\|Transrectal Ultrasound:3863910	15/138,393	16/26,262,527	177.93	1.72e-26	3.38e-24
Teleradiotherapy procedure\|\|compared_with\|\|Teleradiotherapy procedure:4151777	7/138,393	33/26,262,527	40.26	1.74e-09	9.03e-08
established cell line\|\|PART_OF\|\|Malignant neoplasm of prostate:5847711	29/138,393	30/26,262,527	183.48	3.71e-50	1.65e-47
Human Age Group\|\|LOCATION_OF\|\|Prostate-Specific Antigen:6084058	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
NKX3-1 gene\|NKX3-1\|\|PART_OF\|\|Malignant neoplasm of prostate:8848760	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Basal Cell\|\|PART_OF\|\|Prostate:458828	70/138,393	103/26,262,527	129.03	4.16e-111	4.75e-108
Prednisone\|\|NEG_TREATS\|\|Prostate cancer metastatic:14275754	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Stanolone\|\|INTERACTS_WITH\|\|Androgens:681038	12/138,393	67/26,262,527	33.99	1.59e-14	1.46e-12
Radical prostatectomy\|\|PRECEDES\|\|Lymph Node Dissection:12785722	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
Radical prostatectomy\|\|PRECEDES\|\|Radiotherapy, Conformal:9982598	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|cohort:14736127	14/138,393	2/26,262,527	1328.51	1.40e-30	3.31e-28
Finasteride\|\|INTERACTS_WITH\|\|Prostate-Specific Antigen:5433318	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Carcinogenesis\|\|PROCESS_OF\|\|Transgenic Model:7518194	11/138,393	19/26,262,527	109.87	4.09e-18	5.11e-16
Vacuum Pump\|\|TREATS\|\|Erectile dysfunction:4132717	11/138,393	71/26,262,527	29.40	8.17e-13	6.38e-11
MED12\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:15350211	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Laser Therapy, Low-Level\|\|TREATS\|\|Malignant neoplasm of prostate:3329080	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Testosterone\|\|INTERACTS_WITH\|\|Prostate-Specific Antigen:3987033	5/138,393	8/26,262,527	118.61	4.92e-09	2.37e-07
long-term care\|\|USES\|\|bicalutamide:12580959	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Endocrine therapy\|\|AFFECTS\|\|Prostate carcinoma:2365553	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Iodine 125 brachytherapy\|\|TREATS\|\|Malignant neoplasm of prostate:4980090	38/138,393	42/26,262,527	171.74	1.71e-64	1.01e-61
Therapeutic vaccine\|\|PART_OF\|\|Malignant neoplasm of prostate:12782872	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Enucleation procedure\|\|USES\|\|Holmium:YAG laser device:8583517	22/138,393	387/26,262,527	10.79	1.39e-15	1.41e-13
Chemoprevention\|\|USES\|\|Androgen Antagonists:8730511	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Flutamide\|\|compared_with\|\|Diethylstilbestrol:1147722	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Diethylstilbestrol\|\|STIMULATES\|\|Gonadorelin\|GNRH1:3851554	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Radical prostatectomy\|\|compared_with\|\|Prostatectomy, Retropubic:11356749	32/138,393	55/26,262,527	110.44	5.02e-50	2.22e-47
PPAR gamma\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8785635	9/138,393	12/26,262,527	142.33	8.30e-16	8.48e-14
capecitabine\|\|TREATS\|\|Hormone-refractory prostate cancer:11520516	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
NF-kappa B\|\|ASSOCIATED_WITH\|\|Neoplasm progression:9529301	7/138,393	27/26,262,527	49.20	5.17e-10	3.02e-08
Tumor tissue sample\|\|PART_OF\|\|Prostate:6782710	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Gelatinase A\|\|PART_OF\|\|Malignant neoplasm of prostate:6908931	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Neoadjuvant Therapy\|\|USES\|\|Gonadorelin:5795169	5/138,393	12/26,262,527	79.07	2.32e-08	1.06e-06
Pelvic lymph node group\|\|PART_OF\|\|Malignant neoplasm of prostate:2666122	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Chemoprevention\|\|METHOD_OF\|\|Chemoprevention:5856005	6/138,393	25/26,262,527	45.55	1.36e-08	6.33e-07
Prostate\|\|LOCATION_OF\|\|Stromal Cells:3126810	28/138,393	60/26,262,527	88.58	7.52e-42	2.71e-39
Testosterone 5-alpha-Reductase\|\|ASSOCIATED_WITH\|\|Prostate:755113	12/138,393	53/26,262,527	42.97	1.34e-15	1.36e-13
Neck\|\|LOCATION_OF\|\|Malignant neoplasm of prostate:7022295	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Lycopersicon esculentum\|\|LOCATION_OF\|\|Carotenoids:36492	6/138,393	40/26,262,527	28.47	1.62e-07	5.75e-06
Nuclear Matrix-Associated Proteins\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:7435054	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
PSA Velocity\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:5739358	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
Vitamin D\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:4553143	32/138,393	31/26,262,527	195.93	8.24e-56	4.10e-53
Follicle Stimulating Hormone\|\|TREATS\|\|Malignant neoplasm of prostate:3614401	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Radical perineal prostatectomy\|\|TREATS\|\|Malignant neoplasm of prostate:1208451	38/138,393	40/26,262,527	180.33	4.72e-65	2.80e-62
Bombesin\|\|INTERACTS_WITH\|\|Bombesin Receptor:3017100	25/138,393	44/26,262,527	107.84	3.22e-39	1.06e-36
Biopsy\|\|METHOD_OF\|\|Early Diagnosis:67959	18/138,393	153/26,262,527	22.33	4.03e-18	5.04e-16
Polymorphism, Genetic\|\|ASSOCIATED_WITH\|\|Vitamin D3 Receptor:6171982	21/138,393	250/26,262,527	15.94	4.01e-18	5.03e-16
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Brothers:2824306	38/138,393	55/26,262,527	131.15	2.87e-61	1.56e-58
Pes\|\|LOCATION_OF\|\|Lymphangiography:451675	12/138,393	52/26,262,527	43.80	1.10e-15	1.12e-13
Risk Reduction\|\|TREATS\|\|Malignant neoplasm of prostate:11127351	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
prostatitis\|\|ISA\|\|Prostatic Diseases:3454213	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
Radical retropubic prostatectomy\|\|TREATS\|\|Carcinoma:177785	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
BRCA2 gene\|BRCA2\|\|ISA\|\|Tumor Suppressor Genes:6486483	10/138,393	149/26,262,527	12.74	1.64e-08	7.59e-07
Prostatic epithelium\|\|PART_OF\|\|Prostate:6796236	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Chlormadinone Acetate\|\|USES\|\|Chlormadinone Acetate:1067633	10/138,393	37/26,262,527	51.29	6.80e-14	6.00e-12
Gastrectomy\|\|USES\|\|Sleeves:7797286	1/138,393	7,179/26,262,527	0.03	2.63e-15	2.63e-13
alpha-methylacyl-CoA racemase\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9854885	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
Biopsy sample\|\|LOCATION_OF\|\|Adenocarcinoma of prostate:3068941	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Receptors, Nuclear\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:5699760	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Ketoconazole\|\|ISA\|\|Antifungal Agents:1806078	13/138,393	244/26,262,527	10.11	1.73e-09	9.03e-08
Nerve Growth Factors\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:6509092	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Prostatic Intraepithelial Neoplasias\|\|ASSOCIATED_WITH\|\|Prostate:4834706	40/138,393	51/26,262,527	148.88	4.93e-66	2.96e-63
Prostatic Tissue\|\|LOCATION_OF\|\|epigallocatechin gallate:11837400	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Prostatectomy\|\|higher_than\|\|Prostatectomy:11084704	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostate\|\|LOCATION_OF\|\|RNA, Messenger:1373166	5/138,393	11/26,262,527	86.26	1.65e-08	7.59e-07
Rhabdomyosarcoma\|\|PART_OF\|\|Prostate:33904	57/138,393	87/26,262,527	124.38	4.21e-90	3.75e-87
5-aza-2'-deoxycytidine\|\|USES\|\|5-aza-2'-deoxycytidine:1626237	19/138,393	407/26,262,527	8.86	3.07e-12	2.29e-10
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Long-Term Survivors:10344268	18/138,393	32/26,262,527	106.76	1.37e-28	2.96e-26
Intervention regimes\|\|METHOD_OF\|\|prostate cancer screening:13575896	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Immunotherapy\|\|STIMULATES\|\|Immune response:1499274	10/138,393	139/26,262,527	13.65	8.82e-09	4.17e-07
Combined Modality Therapy\|\|USES\|\|Antineoplastic Agents:401102	11/138,393	83/26,262,527	25.15	3.80e-12	2.81e-10
Hypoxia\|\|COEXISTS_WITH\|\|Prostate carcinoma:8834292	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Clusterin\|CLU\|\|PART_OF\|\|Malignant neoplasm of prostate:10148778	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Prostate\|\|PART_OF\|\|Malignant neoplasm of prostate:2212195	23/138,393	25/26,262,527	174.62	9.63e-40	3.20e-37
Mitochondria\|\|LOCATION_OF\|\|DIABLO:8989350	9/138,393	144/26,262,527	11.86	1.51e-07	5.48e-06
Tumor stage\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:1972993	12/138,393	12/26,262,527	189.78	1.10e-21	1.72e-19
Research Personnel\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:1996845	20/138,393	20/26,262,527	189.80	3.06e-35	8.64e-33
Malignant neoplasm of prostate\|\|LOCATION_OF\|\|[M]Unspecified tumor cell NOS:9490907	56/138,393	62/26,262,527	171.47	2.94e-94	2.80e-91
Frozen Sections\|\|PART_OF\|\|Prostatic Tissue:1388297	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Prostate cancer metastatic\|\|COEXISTS_WITH\|\|Prostate cancer metastatic:9717553	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Adenocarcinoma of prostate\|\|COEXISTS_WITH\|\|Adenocarcinoma of prostate:3040812	7/138,393	10/26,262,527	132.84	2.02e-12	1.52e-10
Bombesin Receptor\|\|ISA\|\|G-Protein-Coupled Receptors:8518836	5/138,393	12/26,262,527	79.07	2.32e-08	1.06e-06
Dutasteride\|\|PREVENTS\|\|Malignant neoplasm of prostate:11805695	11/138,393	11/26,262,527	189.78	5.49e-20	7.78e-18
Cryosurgery\|\|TREATS\|\|Malignant neoplasm of prostate:527633	142/138,393	210/26,262,527	128.45	2.46e-223	5.88e-220
Radical prostatectomy\|\|TREATS\|\|Incontinence:5924354	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Prostatectomy\|\|compared_with\|\|Prostatectomy, Retropubic:14612327	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Radium\|\|TREATS\|\|Prostate cancer metastatic:16103024	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Transurethral Resection\|\|TREATS\|\|Malignant neoplasm of urinary bladder:1950221	15/138,393	141/26,262,527	20.19	9.32e-15	8.83e-13
High Grade Intraepithelial Neoplasia\|\|ASSOCIATED_WITH\|\|Prostate:8267101	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
diallyl trisulfide\|\|USES\|\|diallyl trisulfide:7478099	11/138,393	71/26,262,527	29.40	8.17e-13	6.38e-11
Biopsy\|\|ADMINISTERED_TO\|\|Urologist:5508035	23/138,393	36/26,262,527	121.26	4.24e-37	1.31e-34
Prostate-Specific Antigen\|\|AUGMENTS\|\|Antimicrobial susceptibility:4085107	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
[M]Unspecified tumor cell NOS\|\|PRODUCES\|\|Tumor necrosis factor receptor 11b:9070355	5/138,393	13/26,262,527	72.99	3.20e-08	1.43e-06
DNA Sequence\|\|PART_OF\|\|Prostate:3733191	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
multicatalytic endopeptidase complex\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:15549693	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Breast\|\|LOCATION_OF\|\|Diphosphonates:10722541	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Gonadotropin-Releasing Hormone Analog\|\|PREVENTS\|\|Flare:5718504	5/138,393	4/26,262,527	237.22	4.90e-10	2.87e-08
Scanning\|\|DIAGNOSES\|\|Prostate cancer metastatic:2568390	6/138,393	5/26,262,527	227.73	9.37e-12	6.74e-10
Digital Rectal Examination\|\|ADMINISTERED_TO\|\|Physicians:3642413	8/138,393	24/26,262,527	63.26	5.36e-12	3.93e-10
Stem cells\|\|PART_OF\|\|Prostatic epithelium:10403407	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Hispanics:5872296	15/138,393	18/26,262,527	158.16	5.88e-26	1.13e-23
Pads\|\|higher_than\|\|Pads:2175730	9/138,393	35/26,262,527	48.80	1.80e-12	1.36e-10
Polymorphism, Genetic\|\|ASSOCIATED_WITH\|\|CYP17A1 gene\|CYP17A1:7147542	12/138,393	40/26,262,527	56.94	7.31e-17	8.40e-15
Lymph Node Dissection\|\|USES\|\|Obturators:989052	5/138,393	19/26,262,527	49.94	1.55e-07	5.48e-06
AR gene\|AR\|\|AFFECTS\|\|Neoplasm progression:13854727	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Radionuclide Imaging\|\|DIAGNOSES\|\|Prostate carcinoma:809418	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Antigen assay\|\|DIAGNOSES\|\|Neoplasm Metastasis:6932322	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Radionuclide Imaging\|\|ISA\|\|Medical Imaging:459504	24/138,393	1,191/26,262,527	3.82	6.46e-08	2.51e-06
follow-up\|\|METHOD_OF\|\|Therapeutic radiology procedure:8452369	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Prostate\|\|ASSOCIATED_WITH\|\|Carcinogenesis:7226929	12/138,393	13/26,262,527	175.19	2.10e-21	3.22e-19
Malignant neoplasm of prostate\|\|OCCURS_IN\|\|cohort:3904834	19/138,393	19/26,262,527	189.79	1.50e-33	4.01e-31
[M]Unspecified tumor cell NOS\|\|PART_OF\|\|Mice, Nude:1883320	8/138,393	61/26,262,527	24.89	3.59e-09	1.76e-07
N-Cadherins\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:11591151	8/138,393	12/26,262,527	126.52	6.79e-14	6.00e-12
prostate cancer screening\|\|METHOD_OF\|\|prostate cancer screening:14688117	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Estracyt\|\|TREATS\|\|Carcinoma:1017334	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Scanning\|\|DIAGNOSES\|\|Secondary malignant neoplasm of bone:1257330	27/138,393	96/26,262,527	53.38	1.84e-35	5.27e-33
Aminoglutethimide\|\|TREATS\|\|Malignant neoplasm of prostate:2842326	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
Malignant neoplasm of prostate\|\|COEXISTS_WITH\|\|Metabolic syndrome:12073821	8/138,393	13/26,262,527	116.79	1.09e-13	9.55e-12
Biopsy sample\|\|LOCATION_OF\|\|Biopsy:1497096	6/138,393	42/26,262,527	27.11	2.11e-07	7.41e-06
Radical retropubic prostatectomy\|\|TREATS\|\|Adenocarcinoma of prostate:2109782	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Malignant neoplasm of prostate\|\|AFFECTS\|\|Gene Expression:9461184	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Malignant neoplasm of prostate\|\|COEXISTS_WITH\|\|Pathogenesis:9393884	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Malignant neoplasm of prostate\|\|LOCATION_OF\|\|Prostate-Specific Antigen:2876226	61/138,393	73/26,262,527	158.64	4.61e-101	4.76e-98
cDNA Library\|\|PART_OF\|\|Prostate:3405259	21/138,393	51/26,262,527	78.15	7.69e-31	1.82e-28
Neck\|\|LOCATION_OF\|\|Bladder stenosis:99662	16/138,393	73/26,262,527	41.60	4.00e-20	5.79e-18
Androgen Antagonists\|\|INHIBITS\|\|Prostate-Specific Antigen:6651309	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Nucleolar Organizer Region\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:5385270	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Screening procedure\|\|TREATS\|\|overdiagnosis:11825839	10/138,393	14/26,262,527	135.56	2.87e-17	3.37e-15
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Respondents:6333365	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
CDKN2A gene\|CDKN2A\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:6444911	15/138,393	21/26,262,527	135.56	3.11e-25	5.86e-23
Androgen Receptor\|AR\|\|INTERACTS_WITH\|\|Androgen Receptor\|AR:2670612	50/138,393	87/26,262,527	109.10	4.67e-77	3.48e-74
Carcinogenesis\|\|ASSOCIATED_WITH\|\|Prostate:3761372	33/138,393	36/26,262,527	174.00	2.43e-56	1.23e-53
Benign prostatic hypertrophy\|\|PROCESS_OF\|\|cohort:3523524	10/138,393	25/26,262,527	75.91	2.55e-15	2.56e-13
Adenocarcinoma, Clear Cell\|\|PART_OF\|\|Prostate:7440542	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
silybin\|\|ISA\|\|Silymarin:549982	8/138,393	42/26,262,527	36.15	2.52e-10	1.50e-08
Cystectomy\|\|TREATS\|\|Malignant neoplasm of urinary bladder:220743	38/138,393	354/26,262,527	20.38	3.75e-35	1.06e-32
Therapeutic vaccine\|\|TREATS\|\|Malignant neoplasm of prostate:5855876	13/138,393	12/26,262,527	205.60	1.11e-23	1.96e-21
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Radiation:9053070	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Prostate\|\|LOCATION_OF\|\|Estrogens:40513	19/138,393	48/26,262,527	75.13	8.89e-28	1.83e-25
Kininogenase\|\|ISA\|\|Serine Protease:646285	14/138,393	67/26,262,527	39.66	1.55e-17	1.86e-15
Biopsy\|\|ADMINISTERED_TO\|\|Voluntary Workers:1725142	7/138,393	23/26,262,527	57.76	1.99e-10	1.20e-08
PCA3\|\|PART_OF\|\|Malignant neoplasm of prostate:14154365	10/138,393	10/26,262,527	189.78	2.76e-18	3.46e-16
Prostate-Specific Antigen\|\|compared_with\|\|KLK3 gene\|KLK3:7733125	18/138,393	23/26,262,527	148.53	1.61e-30	3.77e-28
Radical retropubic prostatectomy\|\|TREATS\|\|Localized Carcinoma:4485656	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
hepsin\|HPN\|\|PREDISPOSES\|\|Neoplasm progression:10817660	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
melanoma\|\|ASSOCIATED_WITH\|\|Prostate:134434	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
osteosarcoma\|\|PART_OF\|\|Prostate:287129	7/138,393	12/26,262,527	110.70	5.19e-12	3.80e-10
Androgen Antagonists\|\|NEG_TREATS\|\|Malignant neoplasm of prostate:8832742	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Lipoxygenase\|\|ASSOCIATED_WITH\|\|Prostate:8282035	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Pelvis\|\|LOCATION_OF\|\|Malignant disease:58535	7/138,393	46/26,262,527	28.88	1.36e-08	6.30e-07
Puncture biopsy\|\|DIAGNOSES\|\|Prostate carcinoma:641780	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Proto-Oncogenes\|\|PART_OF\|\|Malignant neoplasm of prostate:3569813	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
African race\|\|ISA\|\|Racial group:946214	23/138,393	387/26,262,527	11.28	1.29e-16	1.47e-14
Clinical Trials\|\|USES\|\|Radar:13548013	8/138,393	14/26,262,527	108.44	1.71e-13	1.48e-11
Disseminated adenocarcinoma\|\|PART_OF\|\|Prostate:2301114	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Prostate\|\|LOCATION_OF\|\|Multiple malignancy:4909869	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
KLK3 gene\|KLK3\|\|INTERACTS_WITH\|\|Androgen Receptor\|AR:8413077	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Prostate\|\|PART_OF\|\|Beagle:1639136	6/138,393	25/26,262,527	45.55	1.36e-08	6.33e-07
Radiotherapy Systems, Linear Accelerator\|\|USES\|\|Multileaf collimator:5174136	7/138,393	72/26,262,527	18.45	2.27e-07	7.96e-06
survivin\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:12335618	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Genistein\|\|AFFECTS\|\|Signal Transduction:5059002	5/138,393	11/26,262,527	86.26	1.65e-08	7.59e-07
Adenocarcinoma of prostate\|\|PROCESS_OF\|\|Transgenic Model:7408967	30/138,393	42/26,262,527	135.58	5.09e-49	2.22e-46
Implantation procedure\|\|USES\|\|Probes:198055	37/138,393	393/26,262,527	17.87	2.26e-32	5.74e-30
Proto-Oncogene Proteins c-akt\|AKT1\|\|ASSOCIATED_WITH\|\|Breast:8654498	7/138,393	12/26,262,527	110.70	5.19e-12	3.80e-10
TP53 gene\|TP53\|\|ASSOCIATED_WITH\|\|Prostate:5668159	10/138,393	15/26,262,527	126.52	4.77e-17	5.53e-15
Pathologic stage\|\|PROCESS_OF\|\|cohort:9455995	5/138,393	10/26,262,527	94.89	1.14e-08	5.31e-07
KLK3 gene\|KLK3\|\|PRODUCES\|\|KLK3 gene\|KLK3:5053115	7/138,393	10/26,262,527	132.84	2.02e-12	1.52e-10
AR gene\|AR\|\|ASSOCIATED_WITH\|\|Prostatic Neoplasms:9491907	5/138,393	4/26,262,527	237.22	4.90e-10	2.87e-08
Radical prostatectomy\|\|TREATS\|\|high-risk group:12675145	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Tissue, Fresh\|\|PART_OF\|\|Prostate:578924	26/138,393	35/26,262,527	141.00	5.18e-43	1.94e-40
CYP17A1 gene\|CYP17A1\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:8827483	11/138,393	10/26,262,527	208.76	2.76e-20	4.03e-18
Stromal Cells\|\|PRODUCES\|\|Hepatocyte Growth Factor:5465180	8/138,393	33/26,262,527	46.01	4.67e-11	2.98e-09
Carcinoma\|\|PART_OF\|\|Ovary:6352	34/138,393	905/26,262,527	7.13	6.27e-18	7.64e-16
zoledronic acid\|\|TREATS\|\|Malignant neoplasm of prostate:10150099	5/138,393	2/26,262,527	474.44	8.24e-11	5.13e-09
Androgens\|\|PREDISPOSES\|\|Carcinogenesis:8344488	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Bone Marrow\|\|LOCATION_OF\|\|Acid phosphatase level:614389	7/138,393	10/26,262,527	132.84	2.02e-12	1.52e-10
Radical retropubic prostatectomy\|\|compared_with\|\|Prostatectomy:9848453	5/138,393	12/26,262,527	79.07	2.32e-08	1.06e-06
Orchiectomy\|\|METHOD_OF\|\|Androgen Suppression:4916061	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Prostatic Tissue\|\|LOCATION_OF\|\|Fatty Acids:5873473	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Androgens\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:1581301	171/138,393	188/26,262,527	172.82	1.21e-284	4.16e-281
Radical prostatectomy\|\|TREATS\|\|High-Grade Prostatic Intraepithelial Neoplasia:8267109	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Cytoplasm\|\|PART_OF\|\|Epithelial Cells:26882	31/138,393	986/26,262,527	5.97	1.74e-14	1.60e-12
Adenocarcinoma of prostate\|\|PART_OF\|\|Bladder:113282	8/138,393	13/26,262,527	116.79	1.09e-13	9.55e-12
Prostatic hypertrophy\|\|ISA\|\|Benign prostatic hypertrophy:2026998	6/138,393	16/26,262,527	71.17	1.44e-09	7.58e-08
Prostate\|\|LOCATION_OF\|\|Zinc:289918	6/138,393	8/26,262,527	142.33	6.01e-11	3.76e-09
Carcinoma in Situ\|\|PART_OF\|\|Bladder:449196	44/138,393	505/26,262,527	16.54	7.53e-37	2.30e-34
hepsin\|HPN\|\|ISA\|\|Serine Protease:3706133	27/138,393	57/26,262,527	89.91	1.50e-40	5.17e-38
Prostate\|\|LOCATION_OF\|\|Myocytes, Smooth Muscle:684933	6/138,393	21/26,262,527	54.22	5.59e-09	2.69e-07
Phosphotransferases\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:7613605	23/138,393	23/26,262,527	189.80	2.59e-40	8.82e-38
Gland structure\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8406869	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
Androgen therapy\|\|compared_with\|\|Androgen therapy:7242895	38/138,393	41/26,262,527	175.93	9.04e-65	5.33e-62
Orchiectomy\|\|METHOD_OF\|\|Orchiectomy:2350466	6/138,393	21/26,262,527	54.22	5.59e-09	2.69e-07
Prednisone\|\|COEXISTS_WITH\|\|Mitoxantrone:2704358	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Rectum\|\|LOCATION_OF\|\|V 70:12619902	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Angiogenesis Factor\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:7212934	11/138,393	13/26,262,527	160.59	1.92e-19	2.59e-17
Epidermal Growth Factor\|EGF\|\|PART_OF\|\|Prostate:7620689	5/138,393	8/26,262,527	118.61	4.92e-09	2.37e-07
KLK3 gene\|KLK3\|\|PREDISPOSES\|\|Disease Progression:7188563	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Biopsy\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:207312	628/138,393	735/26,262,527	162.88	0.00e+00	0.00e+00
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Survivors:5973740	354/138,393	609/26,262,527	110.59	0.00e+00	0.00e+00
Teleradiotherapy procedure\|\|NEG_TREATS\|\|Malignant neoplasm of prostate:9940332	5/138,393	4/26,262,527	237.22	4.90e-10	2.87e-08
small molecule\|\|INHIBITS\|\|Glutamate Carboxypeptidase II:12951073	10/138,393	11/26,262,527	172.53	5.24e-18	6.40e-16
tumor growth\|\|PROCESS_OF\|\|Cancer Model:3979381	20/138,393	92/26,262,527	41.26	1.01e-24	1.84e-22
Diphosphonates\|\|TREATS\|\|Neoplasm Metastasis:1002359	35/138,393	134/26,262,527	49.58	1.58e-44	6.18e-42
Biopsy\|\|DIAGNOSES\|\|Carcinoma, Transitional Cell:2306658	11/138,393	82/26,262,527	25.46	3.37e-12	2.49e-10
TP53 gene\|TP53\|\|PART_OF\|\|Prostate carcinoma:5433316	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Castration, Male\|\|TREATS\|\|Prostate carcinoma:2048570	8/138,393	12/26,262,527	126.52	6.79e-14	6.00e-12
Testosterone Propionate\|\|CAUSES\|\|Invasive Carcinoma:4691489	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
celecoxib\|\|ISA\|\|Cyclooxygenase 2 Inhibitors:7312701	34/138,393	1,198/26,262,527	5.39	1.67e-14	1.54e-12
Neuropeptides\|\|PART_OF\|\|Amphibia:3053343	6/138,393	10/26,262,527	113.87	1.59e-10	9.61e-09
Brachytherapy\|\|TREATS\|\|Sexual function:10058845	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Folate\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:12527099	11/138,393	10/26,262,527	208.76	2.76e-20	4.03e-18
Prostatic Tissue\|\|LOCATION_OF\|\|Gammaretrovirus:12206699	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
AR gene\|AR\|\|AFFECTS\|\|Cell Growth:7852990	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Stanolone\|\|ASSOCIATED_WITH\|\|Benign prostatic hypertrophy:1018104	9/138,393	33/26,262,527	51.76	1.14e-12	8.83e-11
docetaxel\|\|TREATS\|\|Malignant neoplasm of prostate:12238526	43/138,393	40/26,262,527	204.06	5.62e-75	4.05e-72
Consumption-archaic term for TB\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:3981404	41/138,393	47/26,262,527	165.59	5.29e-69	3.37e-66
Red meat\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:5663600	7/138,393	9/26,262,527	147.60	1.19e-12	9.12e-11
Xenograft procedure\|\|TREATS\|\|Prostate cancer metastatic:7167705	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostate\|\|LOCATION_OF\|\|Granuloma:352808	7/138,393	29/26,262,527	45.81	7.95e-10	4.59e-08
Adenocarcinoma\|\|LOCATION_OF\|\|Epithelial Cells:3231151	5/138,393	17/26,262,527	55.82	9.68e-08	3.54e-06
Chondroblasts\|\|PRODUCES\|\|Laminin:16361251	8/138,393	48/26,262,527	31.63	6.47e-10	3.76e-08
Androgens\|\|INHIBITS\|\|Prostate-Specific Antigen:5067856	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
ixabepilone\|\|ISA\|\|Epothilones:11813722	9/138,393	36/26,262,527	47.44	2.23e-12	1.67e-10
lycopene\|\|USES\|\|lycopene:6786890	13/138,393	109/26,262,527	22.63	1.46e-13	1.27e-11
TNF-related apoptosis-inducing ligand\|TNFSF10\|\|CAUSES\|\|Cell Death:8615734	8/138,393	98/26,262,527	15.49	1.09e-07	3.98e-06
Gland structure\|\|LOCATION_OF\|\|Biopsy:708326	9/138,393	39/26,262,527	43.80	4.17e-12	3.07e-10
Etidronate\|\|TREATS\|\|Bone pain:3748076	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Spectrum Analysis\|\|USES\|\|Magnetic Resonance Imaging:3971422	9/138,393	62/26,262,527	27.55	1.66e-10	1.00e-08
Seed Implantation\|\|ISA\|\|Brachytherapy:7124188	22/138,393	35/26,262,527	119.30	1.97e-35	5.63e-33
Metabolites\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:3819000	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Radical prostatectomy\|\|TREATS\|\|Prostatic Neoplasms:4538135	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Malignant neoplasm of prostate\|\|OCCURS_IN\|\|Participant:10472183	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
SOX9\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:13910081	6/138,393	5/26,262,527	227.73	9.37e-12	6.74e-10
Clinicians\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:7933930	13/138,393	15/26,262,527	164.48	7.85e-23	1.31e-20
FOXA1\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:14920938	11/138,393	12/26,262,527	173.97	1.05e-19	1.44e-17
Local Therapy\|\|PRECEDES\|\|Endocrine therapy:8832738	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Malignant neoplasm of prostate\|\|AFFECTS\|\|paracrine:7702683	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Systemic Therapy\|\|TREATS\|\|High-Risk Cancer:2779898	5/138,393	10/26,262,527	94.89	1.14e-08	5.31e-07
FRAP1 protein, human\|MTOR\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:13379945	10/138,393	10/26,262,527	189.78	2.76e-18	3.46e-16
trichostatin A\|\|ISA\|\|Histone Deacetylase Inhibitor:6037572	43/138,393	1,070/26,262,527	7.63	2.60e-23	4.48e-21
Prostatic Neoplasms\|\|PROCESS_OF\|\|Animal Model:9487704	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
KLK3 gene\|KLK3\|\|INHIBITS\|\|KLK3 gene\|KLK3:3775069	19/138,393	28/26,262,527	128.79	2.84e-31	6.82e-29
Chemotherapy-Oncologic Procedure\|\|TREATS\|\|Hormone-refractory prostate cancer:8063048	27/138,393	31/26,262,527	165.31	5.97e-46	2.39e-43
TP73\|ARHGAP24\|\|ASSOCIATED_WITH\|\|Prostate carcinoma:7683299	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Farmer, unspecified:6748535	10/138,393	14/26,262,527	135.56	2.87e-17	3.37e-15
Radical prostatectomy\|\|PRECEDES\|\|Neoadjuvant Therapy:8373159	12/138,393	14/26,262,527	162.67	3.88e-21	5.87e-19
Stanolone\|\|INTERACTS_WITH\|\|Androgen Receptor\|AR:861739	23/138,393	78/26,262,527	55.97	7.67e-31	1.82e-28
Casodex\|\|ISA\|\|bicalutamide:6514159	108/138,393	138/26,262,527	148.63	2.20e-175	3.96e-172
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Offspring:10344249	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Oestrogen therapy\|\|TREATS\|\|Prostate carcinoma:76879	20/138,393	18/26,262,527	210.88	7.52e-36	2.19e-33
Stanolone\|\|ISA\|\|Testosterone:681033	52/138,393	493/26,262,527	20.02	3.99e-47	1.65e-44
Biopsy\|\|METHOD_OF\|\|Biopsy:86572	157/138,393	589/26,262,527	50.64	7.10e-195	1.42e-191
PTEN gene\|PTEN\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:7432503	87/138,393	103/26,262,527	160.39	1.04e-143	1.63e-140
Vinblastine\|\|COEXISTS_WITH\|\|Estramustine:7319786	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Cadmium\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:5404518	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Prostatectomy\|\|TREATS\|\|cohort:13578906	8/138,393	7/26,262,527	216.89	3.55e-15	3.52e-13
Prostatic Tissue\|\|LOCATION_OF\|\|KLK3 gene\|KLK3:5320652	9/138,393	11/26,262,527	155.27	4.76e-16	4.94e-14
Prostate specific antigen measurement\|\|USES\|\|Reverse Transcriptase Polymerase Chain Reaction:6277882	16/138,393	26/26,262,527	116.79	4.76e-26	9.21e-24
Radical retropubic prostatectomy\|\|TREATS\|\|Prostate carcinoma:618267	23/138,393	33/26,262,527	132.28	9.47e-38	2.95e-35
Androgen Antagonists\|\|TREATS\|\|Hormone-refractory prostate cancer:8848559	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Insulin-Like Growth Factor II\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:7577311	5/138,393	10/26,262,527	94.89	1.14e-08	5.31e-07
Prostate-Specific Antigen\|\|PART_OF\|\|Malignant neoplasm of prostate:4799853	149/138,393	168/26,262,527	168.49	4.18e-247	1.18e-243
Toxic effect\|\|PROCESS_OF\|\|cohort:4375005	26/138,393	295/26,262,527	16.73	1.48e-22	2.44e-20
Morphometric analysis\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:4186885	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
U73122\|\|INHIBITS\|\|Phospholipase C:5634596	16/138,393	246/26,262,527	12.34	1.42e-12	1.09e-10
Prostate\|\|LOCATION_OF\|\|SMALL SIZE:6725628	13/138,393	25/26,262,527	98.69	1.08e-20	1.61e-18
Castration\|\|PREVENTS\|\|tumor growth:5974132	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Sun Exposure\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:11274150	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Osteoblasts\|\|LOCATION_OF\|\|Malignant neoplasm of prostate:10998047	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Systemic Therapy\|\|TREATS\|\|Neoplasm Metastasis:1918385	9/138,393	87/26,262,527	19.63	2.57e-09	1.30e-07
Androgen Receptor\|AR\|\|ISA\|\|Receptors, Steroid:2531786	7/138,393	20/26,262,527	66.42	8.81e-11	5.47e-09
Malignant neoplasm of prostate\|\|COEXISTS_WITH\|\|Adenocarcinoma:2034337	10/138,393	9/26,262,527	210.87	1.39e-18	1.80e-16
mibolerone\|\|ISA\|\|Androgens, Synthetic:1279274	16/138,393	44/26,262,527	69.01	3.91e-23	6.73e-21
PCA3 gene\|PCA3\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:12219310	14/138,393	17/26,262,527	156.30	2.88e-24	5.18e-22
Cancer of Urinary Tract\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:13264649	4/138,393	3/26,262,527	253.03	2.61e-08	1.17e-06
prostate cancer prevention\|\|USES\|\|lycopene:12367706	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Radionuclide Imaging\|\|USES\|\|Technetium Tc 99m Medronate:1362071	15/138,393	193/26,262,527	14.75	6.46e-13	5.19e-11
Tumor stage\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:6373107	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
prostate cancer screening\|\|TREATS\|\|cohort:8204985	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Brachytherapy\|\|METHOD_OF\|\|Brachytherapy:1563678	17/138,393	86/26,262,527	37.52	1.28e-20	1.89e-18
Cystectomy\|\|TREATS\|\|Carcinoma, Transitional Cell:1904952	10/138,393	134/26,262,527	14.16	6.35e-09	3.05e-07
follow-up\|\|METHOD_OF\|\|Radical prostatectomy:9724303	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Peplomycin\|\|TREATS\|\|Malignant neoplasm of prostate:2529014	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Brachytherapy\|\|PRECEDES\|\|Radical prostatectomy:8700004	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Carcinoma\|\|PART_OF\|\|Testis:6152	8/138,393	97/26,262,527	15.65	1.01e-07	3.70e-06
Magnetic Resonance Imaging\|\|DIAGNOSES\|\|Benign prostatic hypertrophy:4911374	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Prostatic Neoplasms\|\|PROCESS_OF\|\|SCID Mice:6318302	10/138,393	10/26,262,527	189.78	2.76e-18	3.46e-16
High-Grade Prostatic Intraepithelial Neoplasia\|\|ISA\|\|Carcinoma:6421393	11/138,393	14/26,262,527	149.11	3.42e-19	4.56e-17
MICE\|\|PART_OF\|\|Prostate:7408968	42/138,393	88/26,262,527	90.60	2.60e-62	1.48e-59
Estramustine\|\|COEXISTS_WITH\|\|docetaxel:8063041	18/138,393	24/26,262,527	142.34	2.80e-30	6.50e-28
ERG gene\|ERG\|\|AUGMENTS\|\|Malignant neoplasm of prostate:12050966	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Induction\|\|INHIBITS\|\|Cell Proliferation:1745960	15/138,393	221/26,262,527	12.88	3.98e-12	2.94e-10
Mammary Neoplasms\|\|PRODUCES\|\|Prostate-Specific Antigen:6045702	8/138,393	15/26,262,527	101.22	2.61e-13	2.22e-11
Behavior\|\|PROCESS_OF\|\|Cancer Survivor:10863802	6/138,393	22/26,262,527	51.76	7.08e-09	3.39e-07
Tamoxifen\|\|TREATS\|\|Gynecomastia:1580873	6/138,393	33/26,262,527	34.50	5.84e-08	2.27e-06
Radical prostatectomy\|\|compared_with\|\|Pelvic lymphadenectomy:7317849	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
BAX gene\|BAX\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8793184	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Metastasis Suppressor Genes\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:4789024	11/138,393	11/26,262,527	189.78	5.49e-20	7.78e-18
Endocrine therapy\|\|TREATS\|\|high-risk group:6736043	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Endocrine therapy\|\|USES\|\|Dexamethasone:1904138	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
canine cell line\|\|PART_OF\|\|Malignant neoplasm of prostate:8009274	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
host\|\|PART_OF\|\|Mice, Nude:1610152	8/138,393	38/26,262,527	39.95	1.25e-10	7.63e-09
Residual Tissues\|\|PART_OF\|\|Prostate:5812690	13/138,393	18/26,262,527	137.07	4.26e-22	6.89e-20
Prostate carcinoma\|\|LOCATION_OF\|\|Prostate-Specific Antigen:2850288	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
RNA\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9995462	11/138,393	8/26,262,527	260.95	5.97e-21	9.01e-19
Radical retropubic prostatectomy\|\|METHOD_OF\|\|Radical prostatectomy:11715816	7/138,393	9/26,262,527	147.60	1.19e-12	9.12e-11
Androgen Suppression\|\|TREATS\|\|Malignant neoplasm of prostate:2948243	118/138,393	142/26,262,527	157.83	1.10e-193	2.16e-190
Cell surface\|\|PART_OF\|\|Prostate carcinoma:2339650	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Growth Factor\|\|CAUSES\|\|Benign prostatic hypertrophy:7025148	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Primary Prevention\|\|USES\|\|Finasteride:9298466	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostatic Neoplasms\|\|PROCESS_OF\|\|Mice, Knockout:14812563	4/138,393	2/26,262,527	379.55	1.12e-08	5.27e-07
Proto-Oncogene Proteins c-akt\|AKT1\|\|STIMULATES\|\|Proto-Oncogene Proteins c-akt\|AKT1:6825414	20/138,393	442/26,262,527	8.59	1.43e-12	1.09e-10
Prostate\|\|LOCATION_OF\|\|Fluoroscopy:4778127	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Early Diagnosis\|\|USES\|\|Tool:659833	51/138,393	1,188/26,262,527	8.15	1.37e-28	2.96e-26
Tumor cells, malignant\|\|LOCATION_OF\|\|Down-Regulation:5300270	9/138,393	70/26,262,527	24.40	4.42e-10	2.61e-08
Androgen Receptor\|\|ASSOCIATED_WITH\|\|Prostate carcinoma:3373886	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Testosterone\|\|INTERACTS_WITH\|\|Stanolone:627191	82/138,393	405/26,262,527	38.44	4.30e-94	4.07e-91
Endocrine therapy\|\|TREATS\|\|Advanced cancer:138188	6/138,393	44/26,262,527	25.88	2.71e-07	9.37e-06
hepsin\|HPN\|\|PART_OF\|\|integral to membrane:7452270	13/138,393	19/26,262,527	129.85	7.14e-22	1.15e-19
Genistein\|\|ASSOCIATED_WITH\|\|Breast:9052534	6/138,393	9/26,262,527	126.52	9.97e-11	6.13e-09
Occult carcinoma\|\|PART_OF\|\|Prostate:175822	10/138,393	5/26,262,527	379.56	4.59e-20	6.65e-18
External Beam Radiation Therapy\|\|TREATS\|\|Adenocarcinoma:940843	26/138,393	43/26,262,527	114.76	2.87e-41	1.01e-38
Blotting, Western\|\|METHOD_OF\|\|Proteomics:11028109	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
bicalutamide\|\|TREATS\|\|Prostate cancer metastatic:6651306	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Prostate\|\|LOCATION_OF\|\|Immunohistochemistry:3435520	23/138,393	33/26,262,527	132.28	9.47e-38	2.95e-35
Malignant neoplasm of prostate\|\|COEXISTS_WITH\|\|Prostate cancer metastatic:12999112	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Lymph node excision\|\|TREATS\|\|Malignant neoplasm of prostate:1284671	36/138,393	39/26,262,527	175.22	2.13e-61	1.16e-58
Stricture\|\|LOCATION_OF\|\|Urethral Diseases:1114279	13/138,393	306/26,262,527	8.06	2.26e-08	1.04e-06
Second Primary Cancers\|\|PART_OF\|\|Prostate:3040049	11/138,393	13/26,262,527	160.59	1.92e-19	2.59e-17
Radical prostatectomy\|\|PRECEDES\|\|Nerve sparing:7842399	14/138,393	22/26,262,527	120.77	4.03e-23	6.92e-21
AR gene\|AR\|\|PART_OF\|\|Stroma:8968010	10/138,393	21/26,262,527	90.37	6.28e-16	6.50e-14
Oncolytic Virotherapy\|\|TREATS\|\|Malignant neoplasm of prostate:12688413	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
[M]Unspecified tumor cell NOS\|\|LOCATION_OF\|\|Malignant neoplasm of prostate:5954540	14/138,393	14/26,262,527	189.79	4.43e-25	8.24e-23
Epithelial Cells\|\|LOCATION_OF\|\|Prostatic hypertrophy:7515377	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
hip bone\|\|LOCATION_OF\|\|Anatomic structures:8251503	6/138,393	16/26,262,527	71.17	1.44e-09	7.58e-08
Androgen Receptor\|AR\|\|AFFECTS\|\|androgen receptor activity:9292779	7/138,393	10/26,262,527	132.84	2.02e-12	1.52e-10
Spectrum Analysis\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:4159154	18/138,393	19/26,262,527	179.80	1.43e-31	3.50e-29
8q24\|\|LOCATION_OF\|\|Malignant neoplasm of prostate:11987443	17/138,393	18/26,262,527	179.25	7.06e-30	1.59e-27
Neoadjuvant Therapy\|\|TREATS\|\|High-Risk Cancer:10058849	10/138,393	14/26,262,527	135.56	2.87e-17	3.37e-15
Treatment Protocols\|\|TREATS\|\|Hormone-refractory prostate cancer:5064579	36/138,393	36/26,262,527	189.82	2.92e-62	1.64e-59
Saw palmetto extract\|\|INHIBITS\|\|Oxidoreductase:8353068	5/138,393	9/26,262,527	105.43	7.62e-09	3.62e-07
Neoplasm progression\|\|COEXISTS_WITH\|\|Prostatic Neoplasms:6006543	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Malignant neoplasm of prostate\|\|PART_OF\|\|lymph nodes:8903989	4/138,393	3/26,262,527	253.03	2.61e-08	1.17e-06
Emcyt\|\|ISA\|\|Estramustine:4145311	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Pancreas\|\|PART_OF\|\|Prostate:2564614	8/138,393	14/26,262,527	108.44	1.71e-13	1.48e-11
Pelvis\|\|LOCATION_OF\|\|Neoplasm Metastasis:198469	17/138,393	219/26,262,527	14.73	1.96e-14	1.80e-12
maspin\|SERPINB5\|\|ISA\|\|Serpins:6899225	7/138,393	55/26,262,527	24.15	4.16e-08	1.85e-06
MicroRNAs\|\|ASSOCIATED_WITH\|\|Prostate cancer metastatic:14923560	9/138,393	11/26,262,527	155.27	4.76e-16	4.94e-14
Tumor Necrosis Factor-alpha\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:5609074	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Radiopharmaceuticals\|\|TREATS\|\|Malignant neoplasm of prostate:10261244	18/138,393	19/26,262,527	179.80	1.43e-31	3.50e-29
HOXB13\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:15766234	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
silybin\|\|TREATS\|\|Malignant neoplasm of prostate:9520379	10/138,393	10/26,262,527	189.78	2.76e-18	3.46e-16
Radical prostatectomy\|\|METHOD_OF\|\|Neoadjuvant Therapy:5795172	11/138,393	14/26,262,527	149.11	3.42e-19	4.56e-17
Hydroxymethylglutaryl-CoA Reductase Inhibitors\|\|TREATS\|\|Malignant neoplasm of prostate:12874462	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
Linomide\|\|ISA\|\|Angiogenesis Inhibitors:6388727	5/138,393	9/26,262,527	105.43	7.62e-09	3.62e-07
Estrogens\|\|USES\|\|Estrogens:40507	130/138,393	4,881/26,262,527	5.06	8.27e-48	3.45e-45
Male gender\|\|PROCESS_OF\|\|African race:841149	41/138,393	893/26,262,527	8.72	2.42e-24	4.38e-22
Imaging Techniques\|\|TREATS\|\|Malignant neoplasm of prostate:5233217	32/138,393	31/26,262,527	195.93	8.24e-56	4.10e-53
Estrogens\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:209706	50/138,393	49/26,262,527	193.71	3.67e-86	3.04e-83
diindolylmethane\|\|TREATS\|\|Malignant neoplasm of prostate:10958294	7/138,393	6/26,262,527	221.41	1.82e-13	1.56e-11
Cytoplasm\|\|PART_OF\|\|glandular epithelium:707662	7/138,393	17/26,262,527	78.14	3.48e-11	2.23e-09
Prostatectomy\|\|TREATS\|\|Benign prostatic hypertrophy:278408	30/138,393	166/26,262,527	34.30	3.51e-34	9.59e-32
Transurethral Resection\|\|TREATS\|\|Bladder outlet obstruction:2944632	5/138,393	20/26,262,527	47.44	1.93e-07	6.79e-06
Orchiectomy\|\|USES\|\|Flutamide:2152485	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
Prostate\|\|PART_OF\|\|cohort:12634455	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Immunotherapeutic agent\|\|TREATS\|\|Prostate cancer metastatic:14425275	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Malignant neoplasm of prostate\|\|COEXISTS_WITH\|\|Diabetes Mellitus:8252092	11/138,393	11/26,262,527	189.78	5.49e-20	7.78e-18
Acupuncture procedure\|\|TREATS\|\|Menopausal hot flushes:10411454	8/138,393	72/26,262,527	21.09	1.18e-08	5.50e-07
cyclohexylalanine\|\|ISA\|\|Amino Acids:1293614	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Ascorbic Acid\|\|TREATS\|\|Malignant neoplasm of prostate:7317485	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Prostate-Specific Antigen\|\|ASSOCIATED_WITH\|\|Mammary Neoplasms:6104028	7/138,393	11/26,262,527	120.77	3.29e-12	2.43e-10
Gland structure\|\|LOCATION_OF\|\|Basal Cell:1677526	13/138,393	17/26,262,527	145.13	2.49e-22	4.06e-20
Prostate-Specific Antigen\|\|ASSOCIATED_WITH\|\|Prostatic hypertrophy:5595206	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Stratification\|\|USES\|\|Health care facility:7783104	5/138,393	18/26,262,527	52.72	1.23e-07	4.49e-06
25-hydroxyvitamin D\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:10633133	8/138,393	7/26,262,527	216.89	3.55e-15	3.52e-13
Stereotactic radiotherapy\|\|USES\|\|CyberKnife:11797654	13/138,393	86/26,262,527	28.69	9.17e-15	8.70e-13
Oxidative Stress\|\|COEXISTS_WITH\|\|Benign prostatic hypertrophy:10142440	5/138,393	10/26,262,527	94.89	1.14e-08	5.31e-07
Acetate\|\|TREATS\|\|Prostate cancer metastatic:17947373	8/138,393	1/26,262,527	1518.23	5.11e-18	6.36e-16
Prostate\|\|LOCATION_OF\|\|Anatomical location:6365075	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
Mouse Adenocarcinoma\|\|PART_OF\|\|Prostate:9833182	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Vitamins\|\|TREATS\|\|Malignant neoplasm of prostate:4553141	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Magnetic Resonance Imaging\|\|USES\|\|Information Systems:13742897	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Glycoproteins\|\|ASSOCIATED_WITH\|\|Prostate carcinoma:4332714	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Androgen Receptor\|AR\|\|AUGMENTS\|\|Transcription, Genetic:5881535	24/138,393	42/26,262,527	108.46	9.34e-38	2.93e-35
Radical prostatectomy\|\|ISA\|\|Open prostatectomy:7025159	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Somatic mutation\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:7635319	16/138,393	17/26,262,527	178.63	3.48e-28	7.27e-26
Integral Membrane Proteins\|\|PART_OF\|\|Prostate:10107042	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Mouse Intraepithelial Neoplasia\|\|PART_OF\|\|Prostate:11040240	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
agonists\|\|TREATS\|\|Prostate carcinoma:2767393	17/138,393	19/26,262,527	169.81	1.33e-29	2.97e-27
bicalutamide\|\|INHIBITS\|\|Androgens:6651295	37/138,393	51/26,262,527	137.71	2.79e-60	1.48e-57
Magnetic Resonance Imaging\|\|USES\|\|Magnetic Resonance Imaging:3971423	7/138,393	48/26,262,527	27.68	1.77e-08	8.13e-07
Digital Rectal Examination\|\|ADMINISTERED_TO\|\|Voluntary Workers:5334854	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Cancer Diagnosis\|\|USES\|\|Tool:4253800	11/138,393	84/26,262,527	24.85	4.28e-12	3.15e-10
Finasteride\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8596322	14/138,393	14/26,262,527	189.79	4.43e-25	8.24e-23
Breast\|\|PART_OF\|\|Malignant neoplasm of lung:2158366	4/138,393	3/26,262,527	253.03	2.61e-08	1.17e-06
Prostate-Specific Antigen\|\|ASSOCIATED_WITH\|\|Localized Malignant Neoplasm:4885570	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Human Cell Line\|\|PART_OF\|\|Adenocarcinoma of prostate:1316413	13/138,393	18/26,262,527	137.07	4.26e-22	6.89e-20
Prostate-Specific Antigen\|\|ASSOCIATED_WITH\|\|Benign prostatic hypertrophy:3503102	46/138,393	65/26,262,527	134.34	3.45e-74	2.45e-71
Lobe\|\|LOCATION_OF\|\|Epithelial Cells:1142423	5/138,393	18/26,262,527	52.72	1.23e-07	4.49e-06
Fatty Acids\|\|INTERACTS_WITH\|\|Coenzyme A:210816	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Calcitriol\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9330003	9/138,393	13/26,262,527	131.39	1.40e-15	1.41e-13
docetaxel\|\|compared_with\|\|Mitoxantrone:10885396	34/138,393	35/26,262,527	184.39	1.36e-58	7.06e-56
Androgens\|\|INTERACTS_WITH\|\|NKX3-1 gene\|NKX3-1:7416432	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
histrelin\|\|TREATS\|\|Malignant neoplasm of prostate:9307546	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Ultrasonography\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:3114312	116/138,393	135/26,262,527	163.20	1.21e-191	2.35e-188
Inferior Colliculus\|\|PART_OF\|\|Prostate:932423	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Sentinel Lymph Node\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9295769	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
One\|\|ISA\|\|Purpose:117482	33/138,393	1,932/26,262,527	3.24	1.29e-08	5.99e-07
Consumption-archaic term for TB\|\|ASSOCIATED_WITH\|\|Prostate:6554269	10/138,393	17/26,262,527	111.64	1.22e-16	1.38e-14
Morphologically altered structure\|\|COEXISTS_WITH\|\|Prostate carcinoma:1514030	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Epitopes\|\|PART_OF\|\|Extracellular:2362011	12/138,393	230/26,262,527	9.90	9.04e-09	4.26e-07
Calcium\|\|PART_OF\|\|Coronary artery:1999819	1/138,393	3,824/26,262,527	0.05	6.97e-08	2.70e-06
Cyproterone Acetate\|\|INHIBITS\|\|Androgens:1204769	5/138,393	14/26,262,527	67.78	4.33e-08	1.92e-06
Androgens\|\|ASSOCIATED_WITH\|\|Benign prostatic hypertrophy:1128726	11/138,393	28/26,262,527	74.56	1.20e-16	1.37e-14
Stilphostrol\|\|ISA\|\|fosfestrol:905073	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Curcumin\|\|ISA\|\|Chemopreventive Agent:6763277	8/138,393	85/26,262,527	17.86	3.91e-08	1.74e-06
RB1 gene\|RB1\|\|ISA\|\|Tumor Suppressor Genes:3998043	10/138,393	141/26,262,527	13.46	1.00e-08	4.72e-07
Diphosphonates\|\|PREVENTS\|\|Secondary malignant neoplasm of bone:7512562	10/138,393	36/26,262,527	52.72	5.38e-14	4.79e-12
Neoplasm Metastasis\|\|PART_OF\|\|Bone structure of cranium:505241	12/138,393	97/26,262,527	23.48	8.43e-13	6.56e-11
docetaxel\|\|TREATS\|\|Prostatic Neoplasms:11964678	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Fibroblast Growth Factor Receptors\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:7922743	10/138,393	12/26,262,527	158.15	9.56e-18	1.15e-15
Prostatic Tissue\|\|LOCATION_OF\|\|Preservation, Biological:13030246	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostate\|\|LOCATION_OF\|\|Surgical biopsy:133934	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Open approach\|\|TREATS\|\|Benign prostatic hypertrophy:3327829	7/138,393	32/26,262,527	41.51	1.44e-09	7.60e-08
Rectum\|\|LOCATION_OF\|\|Maximum:2960646	5/138,393	14/26,262,527	67.78	4.33e-08	1.92e-06
Androgens\|\|AFFECTS\|\|Cell Growth:1917035	15/138,393	22/26,262,527	129.40	5.21e-25	9.65e-23
Genes, cdc\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:7288270	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Fibroblast Growth Factor\|\|AFFECTS\|\|Malignant neoplasm of prostate:5098336	4/138,393	3/26,262,527	253.03	2.61e-08	1.17e-06
Insulin-Like Growth Factor Binding Protein 3\|\|AFFECTS\|\|Cell Proliferation:7230157	5/138,393	20/26,262,527	47.44	1.93e-07	6.79e-06
ACPP gene\|ACPP\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:1900343	4/138,393	3/26,262,527	253.03	2.61e-08	1.17e-06
Clinical Trials, Phase II\|\|USES\|\|Labels:3514019	12/138,393	221/26,262,527	10.30	5.92e-09	2.85e-07
VTN gene\|VTN\|\|PART_OF\|\|Rectum:13377373	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
CYP24\|CYP24A1\|\|ISA\|\|Mixed Function Oxygenases:6382880	9/138,393	94/26,262,527	18.17	4.81e-09	2.35e-07
VEGF protein, human\|VEGFA\|\|ASSOCIATED_WITH\|\|Prostate:7730943	8/138,393	19/26,262,527	79.91	1.16e-12	8.96e-11
Malignant neoplasm of prostate\|\|PART_OF\|\|Prostate:2026977	47/138,393	51/26,262,527	174.94	1.17e-79	8.99e-77
lycopene\|\|PREVENTS\|\|Malignant neoplasm of prostate:8251387	38/138,393	49/26,262,527	147.21	1.12e-62	6.41e-60
Fibroblasts\|\|PART_OF\|\|Gingiva:711649	4/138,393	6,249/26,262,527	0.12	6.79e-10	3.94e-08
Prostatectomy\|\|TREATS\|\|Local disease:3550931	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Radical perineal prostatectomy\|\|METHOD_OF\|\|Radical perineal prostatectomy:2013031	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Brachytherapy\|\|TREATS\|\|Adenocarcinoma of prostate:3045129	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Cryosurgery\|\|TREATS\|\|Prostate carcinoma:738808	19/138,393	24/26,262,527	150.25	3.32e-32	8.35e-30
Application procedure\|\|TREATS\|\|Prostatic Diseases:546820	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Neoadjuvant Therapy\|\|USES\|\|Gonadotropin-Releasing Hormone Analog:6718766	7/138,393	11/26,262,527	120.77	3.29e-12	2.43e-10
Implantation procedure\|\|TREATS\|\|Adenocarcinoma:2418890	10/138,393	12/26,262,527	158.15	9.56e-18	1.15e-15
Androgen Receptor\|AR\|\|AFFECTS\|\|Transcription, Genetic:4972255	35/138,393	58/26,262,527	114.54	5.37e-55	2.61e-52
Prostate-Specific Antigen\|\|AFFECTS\|\|Malignant neoplasm of prostate:4232434	23/138,393	24/26,262,527	181.89	5.04e-40	1.70e-37
Steroids\|\|STIMULATES\|\|Androgen Receptor\|AR:7617321	7/138,393	10/26,262,527	132.84	2.02e-12	1.52e-10
Urine specimen\|\|LOCATION_OF\|\|GSTP1 gene\|GSTP1:10203201	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Mitogen-Activated Protein Kinases\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:10476684	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Prostate\|\|LOCATION_OF\|\|Primary Cell Culture:2225903	8/138,393	10/26,262,527	151.82	2.38e-14	2.15e-12
satraplatin\|\|TREATS\|\|Hormone-refractory prostate cancer:11453132	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
Immunotoxins\|\|TREATS\|\|Malignant neoplasm of prostate:9752463	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Biopsy\|\|METHOD_OF\|\|Cancer Diagnosis:68783	24/138,393	32/26,262,527	142.35	6.85e-40	2.30e-37
Protons\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:7866277	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Prostate\|\|ASSOCIATED_WITH\|\|Prostate carcinoma:149012	13/138,393	14/26,262,527	176.23	4.22e-23	7.15e-21
Prostate carcinoma\|\|PROCESS_OF\|\|Animal Model:5385266	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
Prostate-Specific Antigen\|\|PART_OF\|\|Participant:6206421	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
Prostate\|\|LOCATION_OF\|\|Chronic inflammation:1255566	22/138,393	54/26,262,527	77.32	3.73e-32	9.37e-30
MicroRNAs\|\|ISA\|\|Small RNA:10103902	32/138,393	1,507/26,262,527	4.03	1.36e-10	8.30e-09
DNA Methyltransferase\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9277692	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Replacement therapy\|\|TREATS\|\|Male gender:5432364	7/138,393	31/26,262,527	42.85	1.19e-09	6.28e-08
preference\|\|ASSOCIATED_WITH\|\|Prostate:3862488	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
intimacy\|\|PROCESS_OF\|\|Couples:2344037	7/138,393	52/26,262,527	25.55	2.92e-08	1.31e-06
Teleradiotherapy procedure\|\|TREATS\|\|Malignant neoplasm of prostate:2384890	454/138,393	600/26,262,527	144.06	0.00e+00	0.00e+00
amidronate\|\|TREATS\|\|Secondary malignant neoplasm of bone:4714698	12/138,393	65/26,262,527	35.04	1.15e-14	1.09e-12
Finasteride\|\|TREATS\|\|Malignant neoplasm of prostate:5278125	30/138,393	33/26,262,527	172.55	2.79e-51	1.26e-48
Endothelin\|\|ASSOCIATED_WITH\|\|Secondary malignant neoplasm of bone:10598663	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Needle biopsy procedure\|\|PRECEDES\|\|Implantation procedure:3950524	5/138,393	9/26,262,527	105.43	7.62e-09	3.62e-07
Prostate\|\|LOCATION_OF\|\|Adverse effects:4011394	11/138,393	26/26,262,527	80.29	6.19e-17	7.15e-15
Ambulatory Care Facilities\|\|USES\|\|urology:133142	104/138,393	680/26,262,527	29.04	1.46e-107	1.60e-104
Digital Rectal Examination\|\|METHOD_OF\|\|Biopsy:2758026	50/138,393	53/26,262,527	179.09	5.42e-85	4.43e-82
Chromosome 8 Short Arm\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:5618266	11/138,393	11/26,262,527	189.78	5.49e-20	7.78e-18
Angina Pectoris\|\|ASSOCIATED_WITH\|\|Heart failure:10225316	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Biopsy\|\|DIAGNOSES\|\|Atypical proliferation:9848451	6/138,393	9/26,262,527	126.52	9.97e-11	6.13e-09
Endorectal\|\|LOCATION_OF\|\|fMRI:13304887	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
CAP - NOS\|\|PROCESS_OF\|\|Survivors:12353960	6/138,393	10/26,262,527	113.87	1.59e-10	9.61e-09
[M]Unspecified tumor cell NOS\|\|LOCATION_OF\|\|Diphosphonates:8585575	5/138,393	14/26,262,527	67.78	4.33e-08	1.92e-06
Xenograft procedure\|\|TREATS\|\|Mice, Nude:927709	157/138,393	2,271/26,262,527	13.13	9.00e-113	1.05e-109
Prednisone\|\|ASSOCIATED_WITH\|\|Prostate cancer metastatic:10154110	29/138,393	38/26,262,527	144.85	4.76e-48	2.00e-45
Entire prostatic fascia\|\|LOCATION_OF\|\|Preservation, Biological:11492455	5/138,393	16/26,262,527	59.30	7.51e-08	2.91e-06
Neoplasm Metastasis\|\|PART_OF\|\|lymph nodes:171863	23/138,393	400/26,262,527	10.91	2.53e-16	2.75e-14
Digital Rectal Examination\|\|USES\|\|Periodicals:2256144	6/138,393	9/26,262,527	126.52	9.97e-11	6.13e-09
Integrins\|\|ASSOCIATED_WITH\|\|Prostate:10388811	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Comorbidity\|\|ISA\|\|Finding / disorder:2700627	31/138,393	1,512/26,262,527	3.89	5.86e-10	3.42e-08
Curcumin\|\|TREATS\|\|Malignant neoplasm of prostate:8654599	17/138,393	18/26,262,527	179.25	7.06e-30	1.59e-27
8q24\|\|PART_OF\|\|Chromosomes:12301229	5/138,393	8/26,262,527	118.61	4.92e-09	2.37e-07
Lignans\|\|AFFECTS\|\|Malignant neoplasm of prostate:10593167	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Acid Phosphatase\|\|ISA\|\|Phosphoric Monoester Hydrolases:590921	7/138,393	60/26,262,527	22.14	7.18e-08	2.78e-06
Malignant neoplasm of urinary bladder\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:2529045	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
Leuprolide\|\|INHIBITS\|\|Androgens:2810894	9/138,393	12/26,262,527	142.33	8.30e-16	8.48e-14
Estradiol\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:11160630	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
soy protein isolate\|\|TREATS\|\|Malignant neoplasm of prostate:10469537	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
Prostate\|\|ASSOCIATED_WITH\|\|Prostatic Neoplasms:5432910	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Breast\|\|LOCATION_OF\|\|Tumor cells, malignant:2665286	6/138,393	23/26,262,527	49.51	8.89e-09	4.20e-07
cancer regression\|\|PART_OF\|\|Prostate:8410297	7/138,393	6/26,262,527	221.41	1.82e-13	1.56e-11
FAVOR\|\|higher_than\|\|Tetradecapeptide:17287270	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Lymphography\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:821546	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Lobe\|\|LOCATION_OF\|\|Biopsy:927138	31/138,393	129/26,262,527	45.61	1.20e-38	3.89e-36
Anti-Inflammatory Agents, Non-Steroidal\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:9549346	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
Membrane Proteins\|\|PART_OF\|\|Prostate:2142916	5/138,393	8/26,262,527	118.61	4.92e-09	2.37e-07
HSPA5\|\|PART_OF\|\|Cell surface:11339573	21/138,393	85/26,262,527	46.89	6.68e-27	1.34e-24
MYC gene\|MYC\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:4917125	16/138,393	17/26,262,527	178.63	3.48e-28	7.27e-26
CATHEPSIN D\|CTSD\|\|ASSOCIATED_WITH\|\|Prostate carcinoma:5927826	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
High-Risk Cancer\|\|PROCESS_OF\|\|cohort:8955108	5/138,393	10/26,262,527	94.89	1.14e-08	5.31e-07
Gonadorelin\|\|DISRUPTS\|\|Malignant neoplasm of prostate:4683528	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Prostate\|\|LOCATION_OF\|\|Pelvis:4418533	7/138,393	10/26,262,527	132.84	2.02e-12	1.52e-10
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Cancer Patient:3040087	19/138,393	17/26,262,527	212.12	3.69e-34	1.01e-31
Procedures\|\|METHOD_OF\|\|Radical prostatectomy:924213	5/138,393	9/26,262,527	105.43	7.62e-09	3.62e-07
Epithelial Cells\|\|PART_OF\|\|Prostate carcinoma:5163093	10/138,393	11/26,262,527	172.53	5.24e-18	6.40e-16
Flutamide\|\|TREATS\|\|Malignant neoplasm of prostate:1640222	77/138,393	85/26,262,527	172.00	4.77e-129	6.61e-126
Tumor Markers\|\|PART_OF\|\|Prostate:2969616	21/138,393	23/26,262,527	173.29	2.30e-36	6.86e-34
KLK3\|PLAG1\|PROS1\|NPEPPS\|PSAT1\|\|COEXISTS_WITH\|\|KLK3 gene\|KLK3:8800689	5/138,393	11/26,262,527	86.26	1.65e-08	7.59e-07
External radiotherapy NOS\|\|TREATS\|\|Adenocarcinoma:1455332	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Diet\|\|AFFECTS\|\|Carcinogenesis:1462692	8/138,393	76/26,262,527	19.98	1.74e-08	8.02e-07
Malignant neoplasm of prostate\|\|OCCURS_IN\|\|Caucasoid Race:747579	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Prostate-Specific Antigen\|\|DISRUPTS\|\|Angiogenesis:10139934	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Prostatectomy, Retropubic\|\|PRECEDES\|\|Radical prostatectomy:11145405	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
KLK3 gene\|KLK3\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:14684388	4/138,393	1/26,262,527	759.09	3.76e-09	1.84e-07
Ablation\|\|TREATS\|\|Advanced cancer:1065969	5/138,393	8/26,262,527	118.61	4.92e-09	2.37e-07
Androgens\|\|ASSOCIATED_WITH\|\|Prostatic Diseases:1533827	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Immunotherapy\|\|TREATS\|\|Malignant neoplasm of prostate:999802	194/138,393	225/26,262,527	163.85	1.73e-319	6.91e-316
Benign prostatic hypertrophy\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:2270132	23/138,393	25/26,262,527	174.62	9.63e-40	3.20e-37
Androgen Antagonists\|\|ISA\|\|Steroids:451681	161/138,393	322/26,262,527	94.99	1.49e-236	3.88e-233
Imaging Device\|\|TREATS\|\|Malignant neoplasm of prostate:8072296	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
ELAC2\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9248671	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
Nodule\|\|PART_OF\|\|Benign prostatic hypertrophy:1387582	21/138,393	69/26,262,527	57.76	1.54e-28	3.32e-26
Stanolone\|\|CAUSES\|\|Down-Regulation:8527625	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Stanolone\|\|INTERACTS_WITH\|\|TGFB1 protein, human\|TGFB1:6648509	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Brachytherapy\|\|PRECEDES\|\|Implantation procedure:10801441	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Surgical margins\|\|PART_OF\|\|Prostate:3529249	16/138,393	16/26,262,527	189.79	1.80e-28	3.82e-26
instruments\|\|USES\|\|Robot:5832099	10/138,393	136/26,262,527	13.95	7.25e-09	3.47e-07
adjuvant therapy\|\|USES\|\|Gonadotropin-Releasing Hormone Analog:7998097	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Digital Rectal Examination\|\|ISA\|\|Procedures:2390640	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Cystectomy\|\|TREATS\|\|Bladder Neoplasm:2213353	6/138,393	31/26,262,527	36.73	4.20e-08	1.87e-06
8q24\|\|PART_OF\|\|Chromosomes, Human:3516100	6/138,393	22/26,262,527	51.76	7.08e-09	3.39e-07
Colon\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:1973243	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Mouse epithelium\|\|PART_OF\|\|Prostate:1600026	17/138,393	18/26,262,527	179.25	7.06e-30	1.59e-27
Meat\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:5663601	9/138,393	12/26,262,527	142.33	8.30e-16	8.48e-14
Osteoblasts\|\|LOCATION_OF\|\|Secondary malignant neoplasm of bone:296487	88/138,393	176/26,262,527	94.94	4.00e-130	5.61e-127
15-Hydroxyprostaglandin dehydrogenase (NAD+)\|HPGD\|PHGDH\|\|ISA\|\|Oxidoreductase:2029785	6/138,393	37/26,262,527	30.77	1.07e-07	3.92e-06
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|White American:8777100	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Tumor Suppressor Genes\|\|DISRUPTS\|\|Malignant neoplasm of prostate:5618268	15/138,393	14/26,262,527	203.34	4.49e-27	9.03e-25
Transglutaminases\|\|PART_OF\|\|Prostate:5172100	7/138,393	27/26,262,527	49.20	5.17e-10	3.02e-08
FRA16D\|\|PART_OF\|\|Chromosome Fragile Sites:8562661	7/138,393	42/26,262,527	31.63	7.70e-09	3.65e-07
Radical prostatectomy\|\|PRECEDES\|\|Radiotherapy, Adjuvant:3566681	55/138,393	75/26,262,527	139.22	5.15e-89	4.52e-86
Epithelial Cells\|\|PART_OF\|\|Seminal Vesicles:391716	11/138,393	140/26,262,527	14.91	6.73e-10	3.91e-08
Ablation\|\|TREATS\|\|Prostate cancer metastatic:4501387	24/138,393	24/26,262,527	189.80	5.28e-42	1.91e-39
Prostate-Specific Antigen\|\|STIMULATES\|\|Androgen Receptor\|AR:11721949	8/138,393	12/26,262,527	126.52	6.79e-14	6.00e-12
Prostate\|\|PART_OF\|\|Prostate carcinoma:1287617	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Prostate\|\|LOCATION_OF\|\|Biopsy sampling:8557172	9/138,393	11/26,262,527	155.27	4.76e-16	4.94e-14
Biopsy of prostate\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:537746	21/138,393	23/26,262,527	173.29	2.30e-36	6.86e-34
Androgens\|\|INHIBITS\|\|Androgens:702956	24/138,393	52/26,262,527	87.60	5.36e-36	1.57e-33
hepsin\|HPN\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:10030253	10/138,393	11/26,262,527	172.53	5.24e-18	6.40e-16
Luteinizing Hormone\|\|INHIBITS\|\|Testosterone:879553	6/138,393	23/26,262,527	49.51	8.89e-09	4.20e-07
Biopsy\|\|USES\|\|Reagents, Immunoassay, Tumor Marker, Enzyme, Prostate Specific Antigen:5156285	33/138,393	38/26,262,527	164.84	8.51e-56	4.21e-53
Neck\|\|LOCATION_OF\|\|Surgical margins:7917065	11/138,393	19/26,262,527	109.87	4.09e-18	5.11e-16
Non-Aspirin\|\|ISA\|\|Anti-Inflammatory Agents, Non-Steroidal:3382845	14/138,393	394/26,262,527	6.74	5.60e-08	2.18e-06
Prostate\|\|PART_OF\|\|Rats, Inbred F344:3401664	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Carcinoma, Neuroendocrine\|\|PART_OF\|\|Prostate:5723490	17/138,393	21/26,262,527	153.64	4.41e-29	9.64e-27
Flutamide\|\|TREATS\|\|Prostate carcinoma:1084590	13/138,393	15/26,262,527	164.48	7.85e-23	1.31e-20
capecitabine\|\|TREATS\|\|Malignant neoplasm of prostate:10008580	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Radical prostatectomy\|\|TREATS\|\|High-Risk Cancer:9330000	152/138,393	234/26,262,527	123.40	6.33e-237	1.70e-233
Proton therapy\|\|TREATS\|\|Toxic effect:14283801	5/138,393	10/26,262,527	94.89	1.14e-08	5.31e-07
Malignant neoplasm of prostate\|\|AFFECTS\|\|Cell Cycle:8012400	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
estramustine-binding protein\|\|ASSOCIATED_WITH\|\|Prostate:1504879	11/138,393	20/26,262,527	104.38	6.31e-18	7.68e-16
Antineoplastic Agents\|\|TREATS\|\|Hormone-refractory prostate cancer:5651445	17/138,393	16/26,262,527	201.65	1.83e-30	4.28e-28
docetaxel\|\|TREATS\|\|Cancer Model:11088770	6/138,393	14/26,262,527	81.33	7.55e-10	4.37e-08
Magnetic Resonance Imaging\|\|DIAGNOSES\|\|stage, prostate cancer:8408785	5/138,393	4/26,262,527	237.22	4.90e-10	2.87e-08
Interstitial brachytherapy\|\|TREATS\|\|Carcinoma:2680490	6/138,393	28/26,262,527	40.67	2.46e-08	1.12e-06
BIRC5 gene\|BIRC5\|\|PART_OF\|\|Malignant neoplasm of prostate:10623118	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
[M]Adenocarcinoma, metastatic, NOS\|\|PART_OF\|\|Prostate:970929	99/138,393	111/26,262,527	169.37	5.92e-165	1.01e-161
docetaxel\|\|NEG_TREATS\|\|Malignant neoplasm of prostate:9654275	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Virus Diseases\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:14012757	4/138,393	3/26,262,527	253.03	2.61e-08	1.17e-06
Estrogens\|\|INHIBITS\|\|Androgens:866532	13/138,393	37/26,262,527	66.68	6.68e-19	8.82e-17
Malignant transformation\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:7711942	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Neoplasm progression\|\|AFFECTS\|\|Malignant neoplasm of prostate:10773899	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
TP53 gene\|TP53\|\|PART_OF\|\|Malignant neoplasm of prostate:5516749	13/138,393	15/26,262,527	164.48	7.85e-23	1.31e-20
Radical prostatectomy\|\|PRECEDES\|\|Brachytherapy:8135049	9/138,393	11/26,262,527	155.27	4.76e-16	4.94e-14
Management procedure\|\|TREATS\|\|AIDS related complex:14459606	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Lymph Node Dissection\|\|AFFECTS\|\|Malignant neoplasm of prostate:12957019	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
invasive treatment\|\|TREATS\|\|Benign prostatic hypertrophy:6084030	10/138,393	62/26,262,527	30.61	6.25e-12	4.56e-10
Prostate\|\|LOCATION_OF\|\|Fever:1652292	8/138,393	25/26,262,527	60.73	7.04e-12	5.13e-10
Doxazosin\|\|TREATS\|\|Benign prostatic hypertrophy:5728900	12/138,393	142/26,262,527	16.04	5.18e-11	3.30e-09
Fiber\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:14462099	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Fibroblasts\|\|PART_OF\|\|Entire interstitial tissue of prostate:8420640	20/138,393	31/26,262,527	122.45	1.63e-32	4.16e-30
Radiopharmaceuticals\|\|TREATS\|\|Secondary malignant neoplasm of bone:5134645	21/138,393	34/26,262,527	117.23	9.12e-34	2.44e-31
Seminal Vesicles\|\|LOCATION_OF\|\|Amyloidosis:367816	10/138,393	40/26,262,527	47.45	1.33e-13	1.16e-11
Pads\|\|TREATS\|\|[D]Extravasation of urine:6328043	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Prostate\|\|LOCATION_OF\|\|catheter device:6998151	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Antiandrogen therapy\|\|TREATS\|\|Prostate cancer metastatic:8907523	5/138,393	3/26,262,527	316.29	2.19e-10	1.31e-08
Prostatic Intraepithelial Neoplasias\|\|COEXISTS_WITH\|\|Carcinoma:5917980	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostate-Specific Antigen\|\|ASSOCIATED_WITH\|\|High-Grade Prostatic Intraepithelial Neoplasia:6725634	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Androgens\|\|USES\|\|Androgens:45343	115/138,393	949/26,262,527	23.01	2.70e-108	2.99e-105
Protein Kinase C\|SPANXC\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:3879241	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Prostate\|\|LOCATION_OF\|\|Ultrasonography, Doppler, Color:6259120	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
Diethylstilbestrol\|\|TREATS\|\|Advanced cancer:2414079	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Prostate\|\|LOCATION_OF\|\|Weighing patient:10669381	7/138,393	9/26,262,527	147.60	1.19e-12	9.12e-11
Relapse\|\|ISA\|\|Recurrence:413034	15/138,393	336/26,262,527	8.47	1.02e-09	5.38e-08
Carcinoma, Transitional Cell\|\|ASSOCIATED_WITH\|\|Bladder:201974	16/138,393	247/26,262,527	12.29	1.51e-12	1.15e-10
Prostate-Specific Antigen\|\|DISRUPTS\|\|Cell Growth:8705220	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Health care facility\|\|USES\|\|urology:3618895	5/138,393	17/26,262,527	55.82	9.68e-08	3.54e-06
Transcription factor genes\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:11474226	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Epithelium\|\|PART_OF\|\|Malignant neoplasm of prostate:9017791	28/138,393	28/26,262,527	189.81	9.26e-49	3.99e-46
Leuprolide Acetate\|\|ISA\|\|Gonadotropin-Releasing Hormone Analog:3672013	16/138,393	64/26,262,527	47.45	6.38e-21	9.61e-19
Specimen from prostate\|\|PART_OF\|\|Carcinoma:3003723	29/138,393	34/26,262,527	161.89	4.67e-49	2.05e-46
Open approach\|\|METHOD_OF\|\|Radical prostatectomy:11791685	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Mitoxantrone\|\|TREATS\|\|Hormone-refractory prostate cancer:7093086	25/138,393	30/26,262,527	158.17	2.57e-42	9.41e-40
Finasteride\|\|PREVENTS\|\|Malignant neoplasm of prostate:5882004	57/138,393	65/26,262,527	166.48	2.14e-95	2.07e-92
Prostatic Tissue\|\|LOCATION_OF\|\|Malignant neoplasm of prostate:7564979	32/138,393	35/26,262,527	173.54	1.18e-54	5.67e-52
Stanolone\|\|PART_OF\|\|Protoplasm:867743	6/138,393	10/26,262,527	113.87	1.59e-10	9.61e-09
Neuroendocrine Tumors\|\|PART_OF\|\|Prostate:5723489	17/138,393	25/26,262,527	129.06	3.83e-28	7.98e-26
Biopsy\|\|ADMINISTERED_TO\|\|Participant:5450184	7/138,393	48/26,262,527	27.68	1.77e-08	8.13e-07
Radionuclide Imaging\|\|DIAGNOSES\|\|Secondary malignant neoplasm of bone:486917	65/138,393	312/26,262,527	39.55	1.15e-75	8.34e-73
Radical prostatectomy\|\|TREATS\|\|Hemorrhage:1265753	7/138,393	9/26,262,527	147.60	1.19e-12	9.12e-11
Carcinoma, Transitional Cell\|\|PART_OF\|\|Prostate:564980	120/138,393	182/26,262,527	125.23	5.06e-188	9.44e-185
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|member:5435259	12/138,393	12/26,262,527	189.78	1.10e-21	1.72e-19
Alternative Therapies\|\|TREATS\|\|Malignant neoplasm of prostate:7124634	27/138,393	29/26,262,527	176.71	1.70e-46	6.90e-44
Patient Selection\|\|METHOD_OF\|\|Brachytherapy:9433320	6/138,393	8/26,262,527	142.33	6.01e-11	3.76e-09
Androgen Antagonists\|\|USES\|\|Androgen Antagonists:523463	5/138,393	12/26,262,527	79.07	2.32e-08	1.06e-06
Disease Progression\|\|ASSOCIATED_WITH\|\|Prostate-Specific Antigen:5854168	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Hemibody Irradiation\|\|TREATS\|\|Neoplasm Metastasis:2264142	5/138,393	12/26,262,527	79.07	2.32e-08	1.06e-06
Chronic Fatigue Syndrome\|\|AFFECTS\|\|Retroviridae:14043994	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostate-Specific Antigen\|\|ASSOCIATED_WITH\|\|High-Risk Cancer:12998215	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Prostate\|\|LOCATION_OF\|\|Magnetic Resonance Imaging:2260248	384/138,393	515/26,262,527	141.89	0.00e+00	0.00e+00
Cyproterone Acetate\|\|TREATS\|\|Prostate carcinoma:758880	15/138,393	16/26,262,527	177.93	1.72e-26	3.38e-24
docetaxel\|\|TREATS\|\|Advanced cancer:6081874	16/138,393	102/26,262,527	29.77	4.57e-18	5.70e-16
atrial natriuretic factor precursor (79-98)\|\|AFFECTS\|\|Adenocarcinoma:12017565	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Fatty Acids\|\|ASSOCIATED_WITH\|\|Carcinogenesis:309135	5/138,393	15/26,262,527	63.26	5.75e-08	2.23e-06
Germ-Line Mutation\|\|ASSOCIATED_WITH\|\|BRCA1 gene\|BRCA1:5489395	18/138,393	447/26,262,527	7.64	1.12e-10	6.89e-09
Prostate\|\|LOCATION_OF\|\|Cell Line, Tumor:2493220	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Androgen Receptor\|AR\|\|AFFECTS\|\|Prostate:5112772	7/138,393	10/26,262,527	132.84	2.02e-12	1.52e-10
Prostatic Tissue\|\|PART_OF\|\|Prostatic Tissue:6615536	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Antigen assay\|\|METHOD_OF\|\|Scanning:7223411	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Disease Progression\|\|PROCESS_OF\|\|Transgenic Model:8250162	5/138,393	21/26,262,527	45.18	2.37e-07	8.32e-06
Prostate\|\|LOCATION_OF\|\|Rectal examination:1047489	13/138,393	17/26,262,527	145.13	2.49e-22	4.06e-20
Prostate\|\|PART_OF\|\|Rats, Wistar:1401004	11/138,393	36/26,262,527	57.99	1.20e-15	1.22e-13
Prostate\|\|LOCATION_OF\|\|Electroporation:16638240	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Prostate-Specific Antigen\|\|STIMULATES\|\|Androgens:7151961	8/138,393	10/26,262,527	151.82	2.38e-14	2.15e-12
agonists\|\|TREATS\|\|Malignant neoplasm of prostate:2523850	128/138,393	138/26,262,527	176.18	2.75e-214	6.43e-211
Pancreatic carcinoma\|\|ASSOCIATED_WITH\|\|Prostate:13345141	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Magnetic Resonance Imaging\|\|DIAGNOSES\|\|Prostatic Diseases:3097314	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Malignant neoplasm of prostate\|\|OCCURS_IN\|\|African race:8075389	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Taxotere\|\|TREATS\|\|Malignant neoplasm of prostate:9287531	8/138,393	10/26,262,527	151.82	2.38e-14	2.15e-12
Malignant neoplasm of prostate\|\|CAUSES\|\|Cessation of life:6444153	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
BIRC5 gene\|BIRC5\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:10467440	11/138,393	17/26,262,527	122.80	1.62e-18	2.10e-16
Tomography, Emission-Computed\|\|DIAGNOSES\|\|Secondary malignant neoplasm of lymph node:11650951	7/138,393	39/26,262,527	34.06	4.87e-09	2.37e-07
Castration Cell\|\|PART_OF\|\|Malignant neoplasm of prostate:13104439	128/138,393	172/26,262,527	141.35	1.78e-205	4.03e-202
Endocrine therapy\|\|METHOD_OF\|\|Radical prostatectomy:10640525	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Hand\|\|PART_OF\|\|Surgeon:4641	20/138,393	773/26,262,527	4.91	1.63e-08	7.54e-07
Tumor Suppressor Genes\|\|ASSOCIATED_WITH\|\|Carcinogenesis:3757208	25/138,393	402/26,262,527	11.80	2.32e-18	2.98e-16
Carcinoma\|\|PART_OF\|\|Colon:8275	72/138,393	2,303/26,262,527	5.94	2.56e-31	6.22e-29
External Beam Radiation Therapy\|\|compared_with\|\|Brachytherapy:6409065	7/138,393	14/26,262,527	94.89	1.19e-11	8.48e-10
HOXB13\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:11087308	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
Radical prostatectomy\|\|PRECEDES\|\|Urethral anastomosis:6161439	6/138,393	10/26,262,527	113.87	1.59e-10	9.61e-09
Androgen Receptor\|AR\|\|AFFECTS\|\|Trans-Activation (Genetics):6266105	7/138,393	22/26,262,527	60.38	1.53e-10	9.36e-09
Mitoxantrone\|\|USES\|\|Mitoxantrone:1857965	12/138,393	285/26,262,527	7.99	8.53e-08	3.30e-06
Diethylstilbestrol\|\|INHIBITS\|\|Testosterone:940365	7/138,393	12/26,262,527	110.70	5.19e-12	3.80e-10
Large cell neuroendocrine carcinoma\|\|PART_OF\|\|Prostate:11807612	5/138,393	9/26,262,527	105.43	7.62e-09	3.62e-07
Proto-Oncogene Proteins c-ets\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:11474231	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
Endocrine therapy\|\|compared_with\|\|Endocrine therapy:1673171	20/138,393	85/26,262,527	44.66	2.53e-25	4.78e-23
Gold\|\|TREATS\|\|Malignant neoplasm of prostate:3700849	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Leukemic Infiltration\|\|PART_OF\|\|Prostate:68717	10/138,393	24/26,262,527	79.08	1.83e-15	1.84e-13
Prostate-Specific Antigen\|\|COEXISTS_WITH\|\|C-reactive protein:11187479	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Cancer Detection\|\|TREATS\|\|Raised prostate specific antigen:5935328	14/138,393	13/26,262,527	204.39	2.22e-25	4.21e-23
Prostatic Intraepithelial Neoplasias\|\|COEXISTS_WITH\|\|Benign prostatic hypertrophy:5773518	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Chemotherapy-Oncologic Procedure\|\|TREATS\|\|Prostate cancer metastatic:2087154	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Screening procedure\|\|AFFECTS\|\|overdiagnosis:6335905	9/138,393	23/26,262,527	74.26	7.52e-14	6.62e-12
Fibroblasts\|\|PRODUCES\|\|Glycoproteins:901143	8/138,393	70/26,262,527	21.69	9.64e-09	4.55e-07
Basal Cell\|\|LOCATION_OF\|\|Compartments:1298017	10/138,393	72/26,262,527	26.36	2.38e-11	1.58e-09
Cell membrane\|\|PART_OF\|\|Malignant neoplasm of prostate:5321159	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
GRP gene\|GRP\|\|PART_OF\|\|Breast:17235093	11/138,393	18/26,262,527	115.98	2.60e-18	3.34e-16
Implantation procedure\|\|USES\|\|IODINE,I-125:888262	6/138,393	10/26,262,527	113.87	1.59e-10	9.61e-09
Benign prostatic hypertrophy\|\|ISA\|\|Prostatic Neoplasms:12228302	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Fluorescent in Situ Hybridization\|\|USES\|\|Probes:4142988	32/138,393	1,882/26,262,527	3.23	2.34e-08	1.07e-06
Stromal sarcoma\|\|PART_OF\|\|Prostate:8539089	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Recurrent disease\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:5148255	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
KLK3 gene\|KLK3\|\|ASSOCIATED_WITH\|\|Prostatic Diseases:6287330	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Solid tumor\|\|PART_OF\|\|Colon:1643750	6/138,393	21/26,262,527	54.22	5.59e-09	2.69e-07
Able\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:8744061	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Tumor Angiogenesis\|\|COEXISTS_WITH\|\|Prostate carcinoma:5359690	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Malignant neoplasm of prostate\|\|PRODUCES\|\|Androgen Receptor\|AR:11490893	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Androgens\|\|PART_OF\|\|Prostate:1125271	23/138,393	57/26,262,527	76.59	1.81e-33	4.82e-31
Stimulation procedure\|\|USES\|\|Androgens:85392	204/138,393	553/26,262,527	70.11	3.60e-277	1.22e-273
Malignant neoplasm of brain\|\|PART_OF\|\|Outpatients:15096280	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Strontium-89\|\|TREATS\|\|Neoplasm Metastasis:3833404	5/138,393	9/26,262,527	105.43	7.62e-09	3.62e-07
Galectin 3\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8016440	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Adverse effects\|\|AFFECTS\|\|Malignant neoplasm of prostate:10150100	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Squamous cell carcinoma\|\|PART_OF\|\|Bladder:120473	17/138,393	419/26,262,527	7.70	3.27e-10	1.94e-08
fibroblast cell line\|\|PART_OF\|\|Prostate:5085613	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Squamous cell carcinoma\|\|PART_OF\|\|Prostate:55409	51/138,393	100/26,262,527	96.82	1.74e-76	1.29e-73
Radioisotopes\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:5777517	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Teleradiotherapy procedure\|\|TREATS\|\|Carcinoma:276896	11/138,393	58/26,262,527	35.99	1.13e-13	9.90e-12
Pelvis\|\|LOCATION_OF\|\|NODE:118173	109/138,393	775/26,262,527	26.71	4.38e-109	4.90e-106
Radioimmunoassay\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:1344297	13/138,393	13/26,262,527	189.79	2.20e-23	3.82e-21
Telomerase\|\|ASSOCIATED_WITH\|\|Prostate:7447707	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
IFI27\|PSMD9\|SSSCA1\|DCTN6\|TMED7\|\|ASSOCIATED_WITH\|\|Prostate carcinoma:8361973	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Analgesics\|\|TREATS\|\|Secondary malignant neoplasm of bone:1840943	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Benign Neoplasm\|\|ASSOCIATED_WITH\|\|Breast:104619	16/138,393	15/26,262,527	202.44	9.06e-29	1.96e-26
Androgen Receptor\|AR\|\|INHIBITS\|\|Prostate-Specific Antigen:10056373	10/138,393	11/26,262,527	172.53	5.24e-18	6.40e-16
CD44 gene\|CD44\|\|PART_OF\|\|Malignant neoplasm of prostate:6732668	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
CRK protein, human\|CRK\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9573490	4/138,393	3/26,262,527	253.03	2.61e-08	1.17e-06
BRCA1 gene\|BRCA1\|\|ASSOCIATED_WITH\|\|Prostate:8756422	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostatic Tissue\|\|LOCATION_OF\|\|Polymerase Chain Reaction:5573810	13/138,393	14/26,262,527	176.23	4.22e-23	7.15e-21
Fine needle aspiration biopsy\|\|DIAGNOSES\|\|Prostate cancer metastatic:8784415	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Androgen Receptor\|AR\|\|INTERACTS_WITH\|\|AR gene\|AR:9877707	12/138,393	14/26,262,527	162.67	3.88e-21	5.87e-19
Androgen Receptor\|AR\|\|AFFECTS\|\|Gene Expression:8310512	6/138,393	14/26,262,527	81.33	7.55e-10	4.37e-08
Cancer Promoting Genes\|\|PART_OF\|\|Prostate:6641080	66/138,393	83/26,262,527	150.97	3.49e-108	3.83e-105
Transrectal Ultrasound\|\|METHOD_OF\|\|Digital Rectal Examination:3822786	9/138,393	13/26,262,527	131.39	1.40e-15	1.41e-13
Therapeutic agent (substance)\|\|TREATS\|\|Malignant neoplasm of prostate:7260164	50/138,393	47/26,262,527	201.95	8.98e-87	7.52e-84
Gonadal Steroid Hormones\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9107739	4/138,393	3/26,262,527	253.03	2.61e-08	1.17e-06
Rhabdomyosarcoma, Embryonal\|\|PART_OF\|\|Prostate:561372	25/138,393	37/26,262,527	128.24	1.19e-40	4.12e-38
Biopsy\|\|DIAGNOSES\|\|Large prostate:7748009	8/138,393	10/26,262,527	151.82	2.38e-14	2.15e-12
Carcinoma, Signet Ring Cell\|\|PART_OF\|\|Prostate:2861005	33/138,393	67/26,262,527	93.49	1.16e-49	5.09e-47
Combined Modality Therapy\|\|USES\|\|Estramustine:2152470	8/138,393	10/26,262,527	151.82	2.38e-14	2.15e-12
Neurovascular bundle\|\|LOCATION_OF\|\|Preservation, Biological:1972460	111/138,393	230/26,262,527	91.66	2.69e-162	4.56e-159
cyclooxygenase 2\|\|ASSOCIATED_WITH\|\|Carcinogenesis:7821391	13/138,393	251/26,262,527	9.83	2.39e-09	1.21e-07
zoledronic acid\|\|TREATS\|\|Malignant neoplasm of prostate:9789977	67/138,393	79/26,262,527	161.02	3.79e-111	4.35e-108
matriptase\|\|ISA\|\|Serine Protease:8224097	11/138,393	132/26,262,527	15.82	3.76e-10	2.23e-08
SRC gene\|SRC\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:10539909	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Testosterone\|\|STIMULATES\|\|Prostate-Specific Antigen:4539604	7/138,393	13/26,262,527	102.19	7.94e-12	5.78e-10
Nephrogenic adenoma\|\|PART_OF\|\|Prostatic Urethra:5879277	6/138,393	8/26,262,527	142.33	6.01e-11	3.76e-09
Prostatic Diseases\|\|PROCESS_OF\|\|cohort:3523523	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Stereotactic radiotherapy\|\|TREATS\|\|Malignant neoplasm of prostate:12251975	54/138,393	74/26,262,527	138.53	2.43e-87	2.06e-84
Bombesin\|\|PART_OF\|\|Amphibia:16484371	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
PCNA gene\|PCNA\|\|ASSOCIATED_WITH\|\|Prostate carcinoma:5114446	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
KLK3 gene\|KLK3\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:4260963	157/138,393	177/26,262,527	168.52	2.79e-260	8.35e-257
Local Therapy\|\|TREATS\|\|Prostate cancer metastatic:13528629	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Synovial sarcoma non-metastatic\|\|PART_OF\|\|Prostate:11628662	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Prostate\|\|LOCATION_OF\|\|Polyamines:620820	9/138,393	26/26,262,527	65.69	1.87e-13	1.60e-11
Core needle biopsy\|\|DIAGNOSES\|\|Adenocarcinoma:10565940	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Seminal Vesicles\|\|LOCATION_OF\|\|Localized amyloidosis:4210335	7/138,393	17/26,262,527	78.14	3.48e-11	2.23e-09
Percent Free Prostate-Specific Antigen\|\|METHOD_OF\|\|Percent Free Prostate-Specific Antigen:7095151	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Malignant neoplasm of prostate\|\|ASSOCIATED_WITH\|\|Gland structure:7064328	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
AKR1C2\|\|INHIBITS\|\|Stanolone:9972788	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Endocrine therapy\|\|TREATS\|\|Prostate cancer metastatic:2618518	76/138,393	82/26,262,527	175.98	6.36e-128	8.57e-125
Immunohistochemistry\|\|DIAGNOSES\|\|Prostate carcinoma:1596627	19/138,393	20/26,262,527	180.30	2.92e-33	7.71e-31
Biopsy of prostate\|\|ISA\|\|Diagnosis:3324393	5/138,393	4/26,262,527	237.22	4.90e-10	2.87e-08
Magnetic Resonance Spectroscopy\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:8671528	40/138,393	47/26,262,527	161.55	4.70e-67	2.88e-64
Endothelial Cells\|\|PART_OF\|\|Malignant neoplasm of prostate:10700922	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
nucleocapsid location\|\|LOCATION_OF\|\|Biopsy:9223630	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
Testosterone 5-alpha-Reductase\|\|ASSOCIATED_WITH\|\|Benign prostatic hypertrophy:2423902	5/138,393	11/26,262,527	86.26	1.65e-08	7.59e-07
Blood Coagulation Disorders\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:1492695	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Human Cell Line\|\|LOCATION_OF\|\|Cell Death:4813198	13/138,393	219/26,262,527	11.27	5.00e-10	2.93e-08
Prostate\|\|LOCATION_OF\|\|Virus:1114778	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Urethra\|\|LOCATION_OF\|\|Preservation, Biological:4423941	7/138,393	15/26,262,527	88.56	1.73e-11	1.23e-09
Transrectal Ultrasound\|\|USES\|\|Weight measurement scales:7473678	13/138,393	20/26,262,527	123.36	1.17e-21	1.83e-19
HT29 Cells\|\|PART_OF\|\|Malignant tumor of colon:3108455	24/138,393	967/26,262,527	4.71	1.41e-09	7.43e-08
Estrogens\|\|ASSOCIATED_WITH\|\|Carcinoma:277701	9/138,393	33/26,262,527	51.76	1.14e-12	8.83e-11
AR gene\|AR\|\|ASSOCIATED_WITH\|\|Prostate cancer recurrent:9847938	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Tissue Extracts\|\|PART_OF\|\|Prostate:3569820	7/138,393	20/26,262,527	66.42	8.81e-11	5.47e-09
Observation parameter\|\|PROCESS_OF\|\|cohort:1752595	15/138,393	490/26,262,527	5.81	1.23e-07	4.49e-06
Prostate\|\|LOCATION_OF\|\|Tumor Cell Invasion:4850797	30/138,393	40/26,262,527	142.36	1.73e-49	7.61e-47
Agent Orange\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:10621214	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Neoplasm progression\|\|COEXISTS_WITH\|\|Chromosome abnormality:6110323	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
maspin\|SERPINB5\|\|INHIBITS\|\|Tumor Cell Invasion:7135192	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Scanning\|\|DIAGNOSES\|\|Neoplasm Metastasis:411913	27/138,393	186/26,262,527	27.55	1.25e-28	2.71e-26
Zonal\|\|compared_with\|\|Zonal:380803	17/138,393	477/26,262,527	6.76	2.13e-09	1.08e-07
maspin\|SERPINB5\|\|ASSOCIATED_WITH\|\|Breast:7559255	10/138,393	14/26,262,527	135.56	2.87e-17	3.37e-15
Androgen therapy\|\|USES\|\|Flutamide:4966177	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Inferior Colliculus\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:831570	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Prostate\|\|LOCATION_OF\|\|Antimicrobial susceptibility:1452632	14/138,393	29/26,262,527	91.62	8.04e-22	1.29e-19
Breast\|\|PART_OF\|\|Cancer Survivor:13823460	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Suramin\|\|USES\|\|Suramin:77248	31/138,393	205/26,262,527	28.70	3.98e-33	1.05e-30
Radical prostatectomy\|\|TREATS\|\|African American:6904622	17/138,393	22/26,262,527	146.66	7.79e-29	1.69e-26
Estramustine\|\|DISRUPTS\|\|Microtubules:3677209	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Immunohistochemistry\|\|DIAGNOSES\|\|Prostate cancer metastatic:4325595	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
Head\|\|LOCATION_OF\|\|Malignant neoplasm of prostate:7022294	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Magnetic Resonance Imaging\|\|DIAGNOSES\|\|Prostate cancer metastatic:3289068	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Clusterin\|CLU\|\|ISA\|\|Molecular Chaperones:8182476	13/138,393	61/26,262,527	40.45	1.75e-16	1.91e-14
Androgen Receptor\|AR\|\|AUGMENTS\|\|androgen receptor activity:8361421	9/138,393	11/26,262,527	155.27	4.76e-16	4.94e-14
G-Protein-Coupled Receptors\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9302560	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
Prostatectomy, Retropubic\|\|TREATS\|\|Localized Carcinoma:6925284	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostate-Specific Antigen\|\|ASSOCIATED_WITH\|\|Prostate carcinoma:2243531	43/138,393	46/26,262,527	177.45	3.38e-73	2.35e-70
Biopsy\|\|DIAGNOSES\|\|Adenocarcinoma of prostate:6310808	18/138,393	20/26,262,527	170.81	2.71e-31	6.53e-29
Transurethral Resection\|\|TREATS\|\|Prostate carcinoma:204123	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Atypical proliferation\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:11917782	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostate\|\|LOCATION_OF\|\|Medical Imaging:1375010	151/138,393	245/26,262,527	117.09	9.66e-233	2.43e-229
Testing\|\|USES\|\|Reagents, Immunoassay, Tumor Marker, Enzyme, Prostate Specific Antigen:6232917	50/138,393	55/26,262,527	172.58	1.97e-84	1.59e-81
Hemangiosarcoma\|\|PART_OF\|\|Prostate:355545	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
Stimulation procedure\|\|USES\|\|R-1881:10093436	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
PCA3\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:11964668	16/138,393	21/26,262,527	144.60	3.77e-27	7.61e-25
Prostate-Specific Antigen\|\|ISA\|\|Local Therapy:8987848	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Malignant neoplasm of prostate\|\|ISA\|\|Solid tumor:6742487	69/138,393	70/26,262,527	187.15	1.42e-117	1.74e-114
Vaccination\|\|TREATS\|\|Malignant neoplasm of prostate:7958001	24/138,393	29/26,262,527	157.08	1.25e-40	4.31e-38
Malignant neoplasm of prostate\|\|ASSOCIATED_WITH\|\|Ovaro-:8166671	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Radical retropubic prostatectomy\|\|TREATS\|\|Age:3986992	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Adenocarcinoma\|\|PART_OF\|\|Breast:4548	22/138,393	459/26,262,527	9.10	3.74e-14	3.36e-12
Prostate\|\|LOCATION_OF\|\|Acid Phosphatase:147518	10/138,393	26/26,262,527	72.99	3.52e-15	3.52e-13
Cell of bone\|\|PART_OF\|\|Prostate cancer metastatic:9537291	18/138,393	19/26,262,527	179.80	1.43e-31	3.50e-29
Markers, Bone\|\|TREATS\|\|Malignant neoplasm of prostate:7374998	18/138,393	20/26,262,527	170.81	2.71e-31	6.53e-29
Thalidomide\|\|TREATS\|\|Malignant neoplasm of prostate:8912577	14/138,393	15/26,262,527	177.13	8.52e-25	1.56e-22
Epithelial Cells\|\|LOCATION_OF\|\|AR gene\|AR:12681126	6/138,393	8/26,262,527	142.33	6.01e-11	3.76e-09
nilutamide\|\|INHIBITS\|\|Androgens:6392008	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
Radical prostatectomy\|\|PRECEDES\|\|Prophylactic treatment:4181719	13/138,393	21/26,262,527	117.49	1.89e-21	2.94e-19
Gastrin releasing peptide\|\|INTERACTS_WITH\|\|Bombesin Receptor:4040125	9/138,393	20/26,262,527	85.40	2.72e-14	2.45e-12
BTG1 gene\|BTG1\|PPBP\|\|PART_OF\|\|Human Cell Line:4128499	27/138,393	28/26,262,527	183.03	8.84e-47	3.62e-44
TNF-related apoptosis-inducing ligand\|TNFSF10\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:11945794	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostate\|\|LOCATION_OF\|\|Vitamin D:8147213	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Radical prostatectomy\|\|TREATS\|\|High Risk Populations:11512582	4/138,393	3/26,262,527	253.03	2.61e-08	1.17e-06
Open prostatectomy\|\|ISA\|\|Prostatectomy:4009367	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
TP53 gene\|TP53\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:5197755	91/138,393	103/26,262,527	167.77	1.68e-151	2.74e-148
Urine\|\|LOCATION_OF\|\|alpha-methylacyl-CoA racemase:13472763	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Urokinase\|\|TREATS\|\|CAP - NOS:9322879	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Biopsy sample\|\|PART_OF\|\|Malignant neoplasm of prostate:1262402	25/138,393	24/26,262,527	197.71	5.43e-44	2.09e-41
Prostate\|\|LOCATION_OF\|\|Face:1982830	4/138,393	3/26,262,527	253.03	2.61e-08	1.17e-06
Proteasome inhibitor\|\|TREATS\|\|Malignant neoplasm of prostate:11859232	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Hormone manipulation\|\|TREATS\|\|Neoplasm Metastasis:1512030	7/138,393	10/26,262,527	132.84	2.02e-12	1.52e-10
CpG Islands\|\|COEXISTS_WITH\|\|Promoter Regions (Genetics):3707574	11/138,393	182/26,262,527	11.47	8.89e-09	4.20e-07
Zoladex\|\|TREATS\|\|Prostate cancer metastatic:3712435	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Neoplastic Cell\|\|PART_OF\|\|Prostate:3744160	40/138,393	42/26,262,527	180.78	2.00e-68	1.27e-65
Brachytherapy\|\|USES\|\|Iodine:6606049	7/138,393	46/26,262,527	28.88	1.36e-08	6.30e-07
Operation on prostate\|\|PRECEDES\|\|Radical prostatectomy:117487	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Antioxidants\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:11143808	5/138,393	8/26,262,527	118.61	4.92e-09	2.37e-07
Induction\|\|TREATS\|\|Malignant neoplasm of prostate:3516252	36/138,393	38/26,262,527	179.83	1.11e-61	6.10e-59
hyperbaric oxygen\|\|TREATS\|\|Irradiation cystitis:2920582	10/138,393	33/26,262,527	57.51	2.57e-14	2.31e-12
Quercetin\|\|AFFECTS\|\|Malignant neoplasm of prostate:16406569	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Aptamer\|\|INTERACTS_WITH\|\|Glutamate Carboxypeptidase II:10919165	7/138,393	9/26,262,527	147.60	1.19e-12	9.12e-11
Differential Diagnosis\|\|USES\|\|Choline:10875726	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
taxane\|\|TREATS\|\|Malignant neoplasm of prostate:9251338	24/138,393	24/26,262,527	189.80	5.28e-42	1.91e-39
Prostate\|\|LOCATION_OF\|\|magnetic resonance spectroscopic imaging:5114416	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
hepsin\|HPN\|\|PART_OF\|\|Cell surface:10817662	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Neoadjuvant Therapy\|\|PRECEDES\|\|Radical prostatectomy:5556699	16/138,393	19/26,262,527	159.82	1.20e-27	2.46e-25
Endocrine therapy\|\|TREATS\|\|Local disease:4715039	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Malignant neoplasm of prostate\|\|ASSOCIATED_WITH\|\|Bone Marrow:1149479	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Glutamate Carboxypeptidase II\|\|PART_OF\|\|Dendritic Cells:8293429	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Stanolone\|\|INHIBITS\|\|Oxidoreductase:3628922	9/138,393	28/26,262,527	61.00	3.26e-13	2.78e-11
Dose-Rate\|\|ISA\|\|Techniques:1038275	10/138,393	77/26,262,527	24.65	4.34e-11	2.77e-09
DNA, Mitochondrial\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:11773780	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
ETV1 gene\|ETV1\|\|PART_OF\|\|Malignant neoplasm of prostate:12475785	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Neoplasm Metastasis\|\|PROCESS_OF\|\|Cancer Patient:117122	24/138,393	227/26,262,527	20.07	1.19e-22	1.98e-20
ACPP gene\|ACPP\|\|ASSOCIATED_WITH\|\|Adenocarcinoma:2590421	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Malignant neoplasm of prostate\|\|AFFECTS\|\|Cessation of life:6381288	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Radical prostatectomy\|\|TREATS\|\|cohort:6323616	57/138,393	55/26,262,527	196.75	2.93e-98	2.92e-95
TLR4 gene\|TLR4\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:12226296	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
PRCA1 gene\|RNASEL\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:12618515	7/138,393	6/26,262,527	221.41	1.82e-13	1.56e-11
Androgens\|\|compared_with\|\|Androgens:1583014	5/138,393	13/26,262,527	72.99	3.20e-08	1.43e-06
Clodronate\|\|TREATS\|\|Malignant neoplasm of prostate:6935488	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Transrectal Ultrasound\|\|DIAGNOSES\|\|Carcinoma:3819632	6/138,393	8/26,262,527	142.33	6.01e-11	3.76e-09
Aspirin\|\|TREATS\|\|Malignant neoplasm of prostate:8251884	12/138,393	15/26,262,527	151.83	6.95e-21	1.04e-18
Endocrine therapy\|\|TREATS\|\|Prostate cancer recurrent:4181718	10/138,393	10/26,262,527	189.78	2.76e-18	3.46e-16
Antioxidants\|\|TREATS\|\|Malignant neoplasm of prostate:9060944	14/138,393	14/26,262,527	189.79	4.43e-25	8.24e-23
Serum specimen\|\|LOCATION_OF\|\|Acid Phosphatase:1497637	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Advance\|\|TREATS\|\|Malignant neoplasm of prostate:13542683	14/138,393	4/26,262,527	664.25	3.55e-29	7.78e-27
Leptin\|LEP\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9002516	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Radical prostatectomy\|\|TREATS\|\|Neoplasm Metastasis:2237160	21/138,393	22/26,262,527	181.17	1.21e-36	3.64e-34
Apigenin\|\|ISA\|\|Flavones:585203	9/138,393	156/26,262,527	10.95	2.87e-07	9.92e-06
Immunofluorescence\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:1691755	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostatic epithelium\|\|LOCATION_OF\|\|Compartments:6679623	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Epidermal Growth Factor Receptor\|EGFR\|\|ASSOCIATED_WITH\|\|Neoplasm progression:3628864	12/138,393	70/26,262,527	32.53	2.54e-14	2.29e-12
Small cell carcinoma of lung\|\|PART_OF\|\|Prostate:2590419	161/138,393	324/26,262,527	94.41	3.30e-236	8.50e-233
Estramustine phosphate\|\|compared_with\|\|Diethylstilbestrol:2434169	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Malignant neoplasm of prostate\|\|PRECEDES\|\|Malignant neoplasm of prostate:11703975	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Radium therapy\|\|TREATS\|\|Prostate cancer metastatic:16536183	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Flutamide\|\|TREATS\|\|Hormone-refractory prostate cancer:5718515	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Biopsy of prostate\|\|ISA\|\|Biopsy:7351376	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Interleukin-6\|\|ASSOCIATED_WITH\|\|Neoplasm progression:8049963	13/138,393	31/26,262,527	79.59	1.01e-19	1.42e-17
Implantation procedure\|\|TREATS\|\|Prostate carcinoma:1541692	19/138,393	17/26,262,527	212.12	3.69e-34	1.01e-31
Neoplasm Metastasis\|\|ASSOCIATED_WITH\|\|Skeletal bone:20823	11/138,393	100/26,262,527	20.88	2.40e-11	1.60e-09
Validation\|\|USES\|\|Health care facility:7706483	7/138,393	39/26,262,527	34.06	4.87e-09	2.37e-07
prednisolone\|\|TREATS\|\|Hormone-refractory prostate cancer:11588001	10/138,393	17/26,262,527	111.64	1.22e-16	1.38e-14
Receptors, Progesterone\|\|ASSOCIATED_WITH\|\|Prostate carcinoma:1407979	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Androgens\|\|STIMULATES\|\|Cyclic AMP-Dependent Protein Kinases:4993457	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Psychotherapy, Multiple\|\|USES\|\|Androgen Antagonists:1277114	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Pelvis\|\|LOCATION_OF\|\|Secondary malignant neoplasm of lymph node:177328	182/138,393	1,320/26,262,527	26.20	1.87e-179	3.39e-176
Angiogenesis Inhibitors\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:5757551	16/138,393	17/26,262,527	178.63	3.48e-28	7.27e-26
Patient observation\|\|TREATS\|\|Prostate carcinoma:8359327	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Transplantation\|\|TREATS\|\|Malignant neoplasm of prostate:7332199	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Radical retropubic prostatectomy\|\|TREATS\|\|CAP - NOS:6014673	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Prostate-Specific Antigen\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:11220449	8/138,393	4/26,262,527	379.56	2.77e-16	2.93e-14
Testosterone\|\|TREATS\|\|Benign prostatic hypertrophy:1629521	5/138,393	11/26,262,527	86.26	1.65e-08	7.59e-07
Replacement therapy\|\|USES\|\|Testosterone:977528	147/138,393	1,670/26,262,527	16.72	1.59e-119	1.98e-116
Biopsy\|\|USES\|\|Tool:910941	8/138,393	60/26,262,527	25.30	3.19e-09	1.57e-07
docetaxel\|\|compared_with\|\|Androgen therapy:17430112	5/138,393	4/26,262,527	237.22	4.90e-10	2.87e-08
Estrogen Receptor beta\|\|ASSOCIATED_WITH\|\|Prostate carcinoma:8860706	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Prostate carcinoma\|\|LOCATION_OF\|\|Acid Phosphatase:1533759	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Perineal approach\|\|ISA\|\|Route:1037836	11/138,393	22/26,262,527	94.89	1.43e-17	1.71e-15
TMPRSS2 gene\|TMPRSS2\|\|AFFECTS\|\|Malignant neoplasm of prostate:13958268	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Epithelial Cells\|\|PART_OF\|\|High-Grade Prostatic Intraepithelial Neoplasia:6952811	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Cell marker\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:9756807	12/138,393	15/26,262,527	151.83	6.95e-21	1.04e-18
RNA, Messenger\|\|ASSOCIATED_WITH\|\|Benign prostatic hypertrophy:6078734	8/138,393	12/26,262,527	126.52	6.79e-14	6.00e-12
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Hospital specialist:8755773	11/138,393	14/26,262,527	149.11	3.42e-19	4.56e-17
Testosterone 5-alpha-Reductase\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:3000504	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Toll-like receptors\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:11166837	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
prednisolone\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:2850274	5/138,393	10/26,262,527	94.89	1.14e-08	5.31e-07
CyberKnife\|\|TREATS\|\|Malignant neoplasm of prostate:12680256	18/138,393	20/26,262,527	170.81	2.71e-31	6.53e-29
Medical Imaging\|\|USES\|\|Tissue Microarray:11041732	7/138,393	27/26,262,527	49.20	5.17e-10	3.02e-08
Prostatectomy\|\|compared_with\|\|Radical prostatectomy:10344252	11/138,393	12/26,262,527	173.97	1.05e-19	1.44e-17
Tumorigenesis\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:5001296	15/138,393	16/26,262,527	177.93	1.72e-26	3.38e-24
High-Risk Cancer\|\|PART_OF\|\|Bladder:3783188	13/138,393	125/26,262,527	19.74	7.24e-13	5.66e-11
Transducers\|\|TREATS\|\|Malignant neoplasm of prostate:8497533	10/138,393	10/26,262,527	189.78	2.76e-18	3.46e-16
Prostate-Specific Antigen\|\|PREDISPOSES\|\|Disease Progression:4195791	11/138,393	11/26,262,527	189.78	5.49e-20	7.78e-18
Drainage procedure\|\|USES\|\|Urethral catheter:105192	9/138,393	61/26,262,527	28.00	1.46e-10	8.91e-09
PTEN gene\|PTEN\|\|PREDISPOSES\|\|Neoplasm progression:11264759	5/138,393	8/26,262,527	118.61	4.92e-09	2.37e-07
Consumption-archaic term for TB\|\|OCCURS_IN\|\|Malignant neoplasm of prostate:8075391	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Scanning\|\|DIAGNOSES\|\|Prostate carcinoma:1296542	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Eulexin\|\|ISA\|\|Flutamide:3147379	19/138,393	25/26,262,527	144.24	5.81e-32	1.46e-29
Cold Therapy\|\|TREATS\|\|Prostate cancer recurrent:6898608	25/138,393	37/26,262,527	128.24	1.19e-40	4.12e-38
Author\|\|DIAGNOSES\|\|Prostate carcinoma:1797404	17/138,393	17/26,262,527	189.79	3.65e-30	8.38e-28
[M]Unspecified tumor cell NOS\|\|PRODUCES\|\|AR gene\|AR:7483597	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Radical prostatectomy\|\|TREATS\|\|Adenocarcinoma, Mucinous:8344200	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Secondary malignant neoplasm of bone\|\|PROCESS_OF\|\|Cancer Model:12915250	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Malignant neoplasm of prostate\|\|MANIFESTATION_OF\|\|Pathogenesis:5718193	5/138,393	4/26,262,527	237.22	4.90e-10	2.87e-08
Prostate\|\|LOCATION_OF\|\|Cadmium:1113277	13/138,393	27/26,262,527	91.38	2.38e-20	3.50e-18
Single Nucleotide Polymorphism\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9752488	103/138,393	120/26,262,527	163.00	2.50e-170	4.34e-167
Caenorhabditis elegans\|\|ISA\|\|Nematoda:380933	1/138,393	3,954/26,262,527	0.05	3.37e-08	1.50e-06
Receptor Gene\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:5782817	31/138,393	33/26,262,527	178.31	3.02e-53	1.41e-50
Endocrine therapy\|\|TREATS\|\|Carcinoma:45556	17/138,393	37/26,262,527	87.20	6.68e-26	1.28e-23
Prostate\|\|LOCATION_OF\|\|Cystic Lesion:201977	5/138,393	16/26,262,527	59.30	7.51e-08	2.91e-06
KLK3 gene\|KLK3\|\|PART_OF\|\|Benign prostatic hypertrophy:5739361	8/138,393	10/26,262,527	151.82	2.38e-14	2.15e-12
Participant\|\|LOCATION_OF\|\|Prostate-Specific Antigen:4926611	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Prostate\|\|PRODUCES\|\|Human Glandular Kallikrein 2\|HK2:7364270	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
dehydroepiandrosterone\|\|INTERACTS_WITH\|\|Stanolone:2825458	5/138,393	13/26,262,527	72.99	3.20e-08	1.43e-06
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Middle Aged:5286976	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
AR gene\|AR\|\|STIMULATES\|\|AR gene\|AR:11459752	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Seminal Vesicles\|\|LOCATION_OF\|\|Ultrasonography:1728883	7/138,393	21/26,262,527	63.26	1.17e-10	7.17e-09
Prostate\|\|LOCATION_OF\|\|Spectrum Analysis:5013029	13/138,393	16/26,262,527	154.20	1.42e-22	2.34e-20
Prostate specific antigen measurement\|\|USES\|\|Digital Rectal Examination:6545693	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
tumor growth\|\|PROCESS_OF\|\|SCID Mice:5245109	17/138,393	157/26,262,527	20.55	1.20e-16	1.37e-14
Malignant neoplasm of prostate\|\|AFFECTS\|\|Family member:7277891	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Tumor stage\|\|PROCESS_OF\|\|Biopsy sample:6797633	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Androgen therapy\|\|TREATS\|\|Malignant neoplasm of prostate:767785	981/138,393	1,295/26,262,527	144.77	0.00e+00	0.00e+00
Combined Modality Therapy\|\|USES\|\|docetaxel:7504258	18/138,393	111/26,262,527	30.78	2.26e-20	3.34e-18
Receptors, Calcium-Sensing\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:15936586	4/138,393	2/26,262,527	379.55	1.12e-08	5.27e-07
Tumor Promoters\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:11079957	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Androgen Response Element\|\|COEXISTS_WITH\|\|Promoter Regions (Genetics):5559816	8/138,393	12/26,262,527	126.52	6.79e-14	6.00e-12
TMPRSS2 gene\|TMPRSS2\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:12782763	6/138,393	4/26,262,527	284.66	4.28e-12	3.15e-10
[M]Unspecified tumor cell NOS\|\|LOCATION_OF\|\|Proto-Oncogene Proteins c-akt\|AKT1:8562601	7/138,393	63/26,262,527	21.09	9.76e-08	3.58e-06
Immunohistochemistry\|\|DIAGNOSES\|\|Prostatic Neoplasms:10119663	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Estramustine\|\|ASSOCIATED_WITH\|\|Prostate cancer metastatic:6984342	7/138,393	9/26,262,527	147.60	1.19e-12	9.12e-11
Neoplastic Cell\|\|LOCATION_OF\|\|Aggressive behavior:2842755	7/138,393	56/26,262,527	23.72	4.65e-08	2.03e-06
BSG\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:13801722	7/138,393	10/26,262,527	132.84	2.02e-12	1.52e-10
Ribosomal RNA\|\|PART_OF\|\|16s:460666	4/138,393	7,888/26,262,527	0.10	2.36e-13	2.02e-11
Urine\|\|LOCATION_OF\|\|Sarcosine:416397	19/138,393	37/26,262,527	97.46	1.65e-29	3.66e-27
prostate cancer screening\|\|TREATS\|\|Male gender:7443889	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Androgen Receptor\|AR\|\|AFFECTS\|\|Sexual Development:10386922	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Nerve graft\|\|USES\|\|sural:1383627	11/138,393	136/26,262,527	15.35	5.05e-10	2.96e-08
Testicular ablation\|\|USES\|\|Androgens:4094562	9/138,393	12/26,262,527	142.33	8.30e-16	8.48e-14
Stanolone\|\|TREATS\|\|Malignant neoplasm of prostate:1826892	6/138,393	5/26,262,527	227.73	9.37e-12	6.74e-10
Cancer of Rectum\|\|ASSOCIATED_WITH\|\|Prostate:3376103	6/138,393	9/26,262,527	126.52	9.97e-11	6.13e-09
AR gene\|AR\|\|STIMULATES\|\|Androgens:8001385	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Leuprolide Acetate\|\|ISA\|\|Gonadorelin:3672016	6/138,393	8/26,262,527	142.33	6.01e-11	3.76e-09
Prednisone\|\|COEXISTS_WITH\|\|docetaxel:6234866	9/138,393	11/26,262,527	155.27	4.76e-16	4.94e-14
Testosterone\|\|CONVERTS_TO\|\|Stanolone:676942	14/138,393	64/26,262,527	41.52	8.84e-18	1.08e-15
Medical Castration\|\|TREATS\|\|Malignant neoplasm of prostate:5168968	23/138,393	23/26,262,527	189.80	2.59e-40	8.82e-38
Fibroblasts\|\|PART_OF\|\|Stroma:908927	43/138,393	1,836/26,262,527	4.45	4.37e-15	4.31e-13
Application procedure\|\|METHOD_OF\|\|Cancer Treatment:469603	17/138,393	285/26,262,527	11.32	1.07e-12	8.28e-11
Estrogens\|\|AFFECTS\|\|Carcinogenesis:5658720	7/138,393	33/26,262,527	40.26	1.74e-09	9.03e-08
Gonadotropin-Releasing Hormone Analog\|\|PART_OF\|\|Malignant neoplasm of prostate:2526069	11/138,393	10/26,262,527	208.76	2.76e-20	4.03e-18
Cytotoxic agent\|\|TREATS\|\|Hormone-refractory prostate cancer:11119070	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Antineoplastic Agents\|\|TREATS\|\|Malignant neoplasm of prostate:953857	76/138,393	77/26,262,527	187.41	2.31e-129	3.23e-126
Prostate-Specific Antigen\|\|COEXISTS_WITH\|\|Buffers:8090983	5/138,393	9/26,262,527	105.43	7.62e-09	3.62e-07
Flutamide\|\|TREATS\|\|Carcinoma:1433822	7/138,393	10/26,262,527	132.84	2.02e-12	1.52e-10
Prostatic Tissue\|\|LOCATION_OF\|\|Biopsy:2468629	11/138,393	12/26,262,527	173.97	1.05e-19	1.44e-17
Ablation\|\|TREATS\|\|Adenocarcinoma:4683721	9/138,393	13/26,262,527	131.39	1.40e-15	1.41e-13
Tumor Suppressor Genes\|\|ASSOCIATED_WITH\|\|Breast:5393918	23/138,393	91/26,262,527	47.97	1.62e-29	3.61e-27
Stem cells\|\|LOCATION_OF\|\|Malignant neoplasm of prostate:6679624	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
amidronate\|\|PREVENTS\|\|loss; bone:3656046	6/138,393	37/26,262,527	30.77	1.07e-07	3.92e-06
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Urologist:6224975	16/138,393	16/26,262,527	189.79	1.80e-28	3.82e-26
activated p21cdc42Hs kinase\|TNK2\|\|ISA\|\|Phosphotransferases:8491119	6/138,393	36/26,262,527	31.63	9.26e-08	3.42e-06
Cadherins\|\|ASSOCIATED_WITH\|\|Neoplasm progression:6635899	5/138,393	20/26,262,527	47.44	1.93e-07	6.79e-06
Secondary malignant neoplasm of bone\|\|PART_OF\|\|Prostate:28225	38/138,393	41/26,262,527	175.93	9.04e-65	5.33e-62
Bone Marrow\|\|LOCATION_OF\|\|Epithelial Cells:188442	15/138,393	85/26,262,527	33.49	1.03e-17	1.24e-15
KLK3 gene\|KLK3\|\|ASSOCIATED_WITH\|\|prostatitis:5983934	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Prostate-Specific Antigen\|\|COEXISTS_WITH\|\|Zonal:6385801	16/138,393	20/26,262,527	151.83	2.15e-27	4.37e-25
Interleukin-6\|\|AUGMENTS\|\|Malignant neoplasm of prostate:12347012	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Linomide\|\|USES\|\|Linomide:4145955	8/138,393	50/26,262,527	30.36	8.65e-10	5.00e-08
Ultrasonography\|\|METHOD_OF\|\|Biopsy:2053864	26/138,393	130/26,262,527	37.96	7.54e-31	1.79e-28
diagnostic procedure\|\|DIAGNOSES\|\|Prostate carcinoma:1607942	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
APC\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:6661937	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Toxic effect\|\|COEXISTS_WITH\|\|Hormone-refractory prostate cancer:5276092	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
KLK3\|PLAG1\|PROS1\|NPEPPS\|PSAT1\|\|compared_with\|\|KLK3\|PLAG1\|PROS1\|NPEPPS\|PSAT1:7568565	15/138,393	18/26,262,527	158.16	5.88e-26	1.13e-23
Phytotherapy\|\|TREATS\|\|Malignant neoplasm of prostate:9669909	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Prednisone\|\|TREATS\|\|Malignant neoplasm of prostate:8961248	20/138,393	23/26,262,527	165.04	2.10e-34	5.75e-32
Genes, Suppressor\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:5027147	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Endocrine therapy\|\|TREATS\|\|Neoplasm Metastasis:2034539	24/138,393	59/26,262,527	77.21	6.30e-35	1.76e-32
External Beam Radiation Therapy\|\|PRECEDES\|\|Radical prostatectomy:4697064	8/138,393	10/26,262,527	151.82	2.38e-14	2.15e-12
AR gene\|AR\|\|ASSOCIATED_WITH\|\|Neoplasm Metastasis:6365779	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Castration, Male\|\|METHOD_OF\|\|Androgen therapy:9976610	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Adenocarcinoma\|\|ASSOCIATED_WITH\|\|Lobe:1159835	7/138,393	74/26,262,527	17.95	2.69e-07	9.33e-06
Ganciclovir\|\|TREATS\|\|Malignant neoplasm of prostate:8063494	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
bicalutamide\|\|TREATS\|\|Locally Advanced Malignant Neoplasm:7548033	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Diphosphonates\|\|PREVENTS\|\|loss; bone:4493696	28/138,393	131/26,262,527	40.57	8.19e-34	2.20e-31
Ultrasonography\|\|DIAGNOSES\|\|Prostatic Diseases:798751	6/138,393	9/26,262,527	126.52	9.97e-11	6.13e-09
Prostate\|\|LOCATION_OF\|\|Zonal:1355574	204/138,393	374/26,262,527	103.66	2.40e-305	9.05e-302
MME gene\|MME\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:10038111	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Human Cell Line\|\|PART_OF\|\|Prostate:1665031	120/138,393	131/26,262,527	173.98	1.50e-200	3.25e-197
Prostate-Specific Antigen\|\|ASSOCIATED_WITH\|\|Aggressive behavior:12184299	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Estrogens\|\|ASSOCIATED_WITH\|\|Prostatic Diseases:2580986	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Pelvis\|\|LOCATION_OF\|\|Lymphocele:286693	19/138,393	197/26,262,527	18.30	1.44e-17	1.73e-15
Endorectal\|\|LOCATION_OF\|\|Magnetic Resonance Imaging:4886454	229/138,393	590/26,262,527	73.78	4.08e-315	1.60e-311
Radionuclide therapy\|\|TREATS\|\|Secondary malignant neoplasm of bone:5424110	8/138,393	22/26,262,527	69.01	3.01e-12	2.24e-10
Prostate\|\|LOCATION_OF\|\|Posterior displacement:8298314	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostate\|\|ASSOCIATED_WITH\|\|Neoplasm progression:7205712	11/138,393	12/26,262,527	173.97	1.05e-19	1.44e-17
PTEN gene\|PTEN\|\|INHIBITS\|\|Proto-Oncogene Proteins c-akt\|AKT1:8838443	9/138,393	116/26,262,527	14.72	2.64e-08	1.19e-06
maspin\|SERPINB5\|\|ISA\|\|Serine Proteinase Inhibitors:6099893	22/138,393	72/26,262,527	57.99	7.41e-30	1.67e-27
10q\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:4562253	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Cytoplasmic\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:14281410	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Behavior Therapy\|\|TREATS\|\|Malignant neoplasm of prostate:15478657	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Androgen Antagonists\|\|TREATS\|\|Prostate cancer metastatic:5435252	21/138,393	25/26,262,527	159.43	7.87e-36	2.27e-33
Digital Rectal Examination\|\|ADMINISTERED_TO\|\|General Practitioners:4402409	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Malignant neoplasm of prostate\|\|AFFECTS\|\|Signal Pathways:13318369	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
Goserelin\|\|ISA\|\|Gonadotropin-Releasing Hormone Analog:3670565	19/138,393	61/26,262,527	59.12	4.00e-26	7.76e-24
Markers, Bone\|\|TREATS\|\|Secondary malignant neoplasm of bone:6604969	14/138,393	39/26,262,527	68.13	2.35e-20	3.46e-18
Prostate\|\|LOCATION_OF\|\|Cisplatin:10368640	7/138,393	6/26,262,527	221.41	1.82e-13	1.56e-11
Glutamate Carboxypeptidase II\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:7317229	17/138,393	16/26,262,527	201.65	1.83e-30	4.28e-28
Human Cell Line\|\|LOCATION_OF\|\|Cell Cycle Arrest:6211701	8/138,393	88/26,262,527	17.25	5.02e-08	2.03e-06
Oestrogen therapy\|\|compared_with\|\|Orchiectomy:2433934	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Asians:6289557	49/138,393	60/26,262,527	155.03	3.74e-81	2.88e-78
Pelvic lymph node group\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8393919	7/138,393	11/26,262,527	120.77	3.29e-12	2.43e-10
Second Primary Cancers\|\|PART_OF\|\|Bladder:1447652	7/138,393	21/26,262,527	63.26	1.17e-10	7.17e-09
Abdomen\|\|LOCATION_OF\|\|tomography:969723	30/138,393	1,558/26,262,527	3.65	4.39e-09	2.15e-07
AR gene\|AR\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:4700021	212/138,393	241/26,262,527	167.19	0.00e+00	0.00e+00
Interleukin-6\|\|AFFECTS\|\|Neoplasm progression:5903573	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
atrial natriuretic factor prohormone (1-30), human\|\|AFFECTS\|\|Adenocarcinoma:12017569	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Cystoprostatectomy\|\|TREATS\|\|Carcinoma:2038355	9/138,393	14/26,262,527	122.00	2.29e-15	2.30e-13
Drug Combinations\|\|TREATS\|\|Malignant neoplasm of prostate:10787985	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Chronic inflammation\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:10504263	13/138,393	11/26,262,527	224.29	5.34e-24	9.50e-22
Tumor cells, malignant\|\|LOCATION_OF\|\|Gonadotropin-Releasing Hormone Receptor:8730567	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Prostatic epithelium\|\|PART_OF\|\|Malignant neoplasm of prostate:8009271	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Tumor Suppressor Genes\|\|AFFECTS\|\|Cell Cycle:6607429	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
tumor growth\|\|PROCESS_OF\|\|Animal Model:903978	18/138,393	255/26,262,527	13.40	1.57e-14	1.44e-12
Proto-Oncogene Proteins c-akt\|AKT1\|\|INTERACTS_WITH\|\|Proto-Oncogene Proteins c-akt\|AKT1:6258642	21/138,393	435/26,262,527	9.16	1.23e-13	1.08e-11
Triptorelin\|\|USES\|\|Triptorelin:4065820	7/138,393	54/26,262,527	24.60	3.70e-08	1.65e-06
Zoladex\|\|compared_with\|\|Orchiectomy:3272653	8/138,393	10/26,262,527	151.82	2.38e-14	2.15e-12
CCND2 gene\|CCND2\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:12042370	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Ovaro-\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8160729	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Radical prostatectomy\|\|PRECEDES\|\|Slinging procedure:11270578	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Diagnosis\|\|TREATS\|\|African American:5467364	7/138,393	42/26,262,527	31.63	7.70e-09	3.65e-07
TP53 gene\|TP53\|\|STIMULATES\|\|CDKN1A\|TCEAL1\|NSG1\|H3F3AP6:6071310	16/138,393	361/26,262,527	8.41	3.16e-10	1.88e-08
Human tissue\|\|PART_OF\|\|Malignant neoplasm of prostate:1532498	223/138,393	228/26,262,527	185.90	0.00e+00	0.00e+00
Malignant neoplasm of prostate\|\|LOCATION_OF\|\|Stromal Cells:6628952	12/138,393	12/26,262,527	189.78	1.10e-21	1.72e-19
Prostate-Specific Antigen\|\|higher_than\|\|Acid Phosphatase:3289155	17/138,393	20/26,262,527	161.32	2.45e-29	5.41e-27
polyestradiol phosphate\|\|TREATS\|\|Prostate carcinoma:679165	4/138,393	1/26,262,527	759.09	3.76e-09	1.84e-07
Prostatectomy\|\|compared_with\|\|Radical retropubic prostatectomy:10240666	16/138,393	23/26,262,527	132.03	1.09e-26	2.16e-24
Testosterone\|\|ASSOCIATED_WITH\|\|Carcinoma:119170	5/138,393	8/26,262,527	118.61	4.92e-09	2.37e-07
Malignant neoplasm of prostate\|\|ASSOCIATED_WITH\|\|lymph nodes:6262887	12/138,393	12/26,262,527	189.78	1.10e-21	1.72e-19
Ultrasonic guidance procedure\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:4053860	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Donor person:8492580	5/138,393	4/26,262,527	237.22	4.90e-10	2.87e-08
MicroRNAs\|\|INTERACTS_WITH\|\|Androgen Receptor\|AR:14563881	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
cohort\|\|LOCATION_OF\|\|PCA3:12782762	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
HSV-Tk Gene\|\|PART_OF\|\|Adenoviruses:1789049	7/138,393	41/26,262,527	32.40	6.63e-09	3.19e-07
Acid Phosphatase\|\|PART_OF\|\|Malignant neoplasm of prostate:2018888	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
film (photographic)\|\|USES\|\|Harbor:1223523	17/138,393	140/26,262,527	23.05	2.08e-17	2.46e-15
Combined Modality Therapy\|\|TREATS\|\|Hormone-refractory prostate cancer:9220926	11/138,393	11/26,262,527	189.78	5.49e-20	7.78e-18
African American\|\|ISA\|\|Ethnic group:4779460	23/138,393	699/26,262,527	6.25	1.60e-11	1.14e-09
AUSTRALIAN\|\|PROCESS_OF\|\|cohort:3328463	12/138,393	305/26,262,527	7.47	1.72e-07	6.08e-06
PERINEURAL INVASION\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:8574778	15/138,393	18/26,262,527	158.16	5.88e-26	1.13e-23
Prostate-Specific Antigen\|\|COEXISTS_WITH\|\|Prostate-Specific Antigen:3580554	96/138,393	116/26,262,527	157.16	8.78e-158	1.47e-154
Androgen Receptor\|AR\|\|PART_OF\|\|Prostatic Neoplasms:8788030	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
zoledronic acid\|\|compared_with\|\|PAMIDRONIC ACID:9803180	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Prostate-Specific Antigen\|\|AFFECTS\|\|Prostate:8619714	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Prostate-Specific Antigen\|\|compared_with\|\|Acid Phosphatase:3289154	32/138,393	41/26,262,527	148.15	4.34e-53	2.02e-50
Bladder Neoplasm\|\|PART_OF\|\|Prostate:2797366	6/138,393	9/26,262,527	126.52	9.97e-11	6.13e-09
Paracrine Communication\|\|PROCESS_OF\|\|Erinaceidae:12224314	7/138,393	42/26,262,527	31.63	7.70e-09	3.65e-07
Radical prostatectomy\|\|TREATS\|\|Disease Progression:5435242	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Prostate-Specific Antigen\|\|NEG_INTERACTS_WITH\|\|Prostate-Specific Antigen:7186070	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Pads\|\|TREATS\|\|Incontinence:637247	7/138,393	30/26,262,527	44.28	9.75e-10	5.17e-08
Radical cystectomy\|\|TREATS\|\|Malignant neoplasm of urinary bladder:766213	60/138,393	1,074/26,262,527	10.61	2.65e-39	8.72e-37
Osteoporosis\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:14861945	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Tomography, Emission-Computed\|\|DIAGNOSES\|\|Neoplasm Metastasis:10915403	8/138,393	59/26,262,527	25.73	2.82e-09	1.42e-07
Prostate\|\|LOCATION_OF\|\|Cytoplasmic:1172203	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Treatment Protocols\|\|USES\|\|Estramustine:8987850	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Carcinoma, Transitional Cell\|\|PART_OF\|\|Prostatic duct:2842328	6/138,393	11/26,262,527	103.51	2.44e-10	1.46e-08
Left ventricular structure\|\|PART_OF\|\|Mice, Nude:6135335	6/138,393	30/26,262,527	37.96	3.53e-08	1.58e-06
Prostate specific antigen measurement\|\|METHOD_OF\|\|prostate cancer screening:7773827	20/138,393	20/26,262,527	189.80	3.06e-35	8.64e-33
Digital Rectal Examination\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:1929123	144/138,393	171/26,262,527	159.97	1.46e-236	3.85e-233
gene polymorphism\|\|AFFECTS\|\|Malignant neoplasm of prostate:6852191	12/138,393	12/26,262,527	189.78	1.10e-21	1.72e-19
bicalutamide\|\|ISA\|\|Androgen Antagonists:6557414	164/138,393	194/26,262,527	160.61	2.31e-269	7.47e-266
Prostatectomy, Retropubic\|\|TREATS\|\|Malignant neoplasm of prostate:3333413	70/138,393	76/26,262,527	174.87	7.99e-118	9.85e-115
Orchiectomy\|\|compared_with\|\|Gonadotropin-Releasing Hormone Analog:3702546	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Negative Staining\|\|METHOD_OF\|\|Cell marker:7971525	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Chromatin\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:10042620	7/138,393	6/26,262,527	221.41	1.82e-13	1.56e-11
Prostate-Specific Antigen\|\|PART_OF\|\|Prostatic Tissue:3003724	10/138,393	13/26,262,527	145.99	1.68e-17	1.99e-15
Aredia\|\|ISA\|\|amidronate:6170276	11/138,393	47/26,262,527	44.42	1.49e-14	1.37e-12
Exertion\|\|AFFECTS\|\|Malignant neoplasm of prostate:5887065	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Carcinogenesis\|\|ASSOCIATED_WITH\|\|Organ:395492	12/138,393	113/26,262,527	20.15	4.39e-12	3.23e-10
CDKN1A\|TCEAL1\|NSG1\|H3F3AP6\|\|INHIBITS\|\|CDK2 gene\|CDK2:6387871	7/138,393	72/26,262,527	18.45	2.27e-07	7.96e-06
Dysplasia\|\|PART_OF\|\|Prostate:2746912	18/138,393	24/26,262,527	142.34	2.80e-30	6.50e-28
Aggressive behavior\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:7087412	42/138,393	45/26,262,527	177.17	1.64e-71	1.09e-68
Prostate\|\|LOCATION_OF\|\|Prostate specific antigen measurement:3199711	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Los Angeles\|\|ISA\|\|California:17177	29/138,393	759/26,262,527	7.25	1.05e-15	1.07e-13
VIABLE CELLS\|\|PART_OF\|\|Prostate carcinoma:3465893	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
13q14\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8273014	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Prostate-Specific Antigen\|\|PART_OF\|\|Benign prostatic hypertrophy:5114417	7/138,393	9/26,262,527	147.60	1.19e-12	9.12e-11
Prostatic Tissue\|\|LOCATION_OF\|\|Adenocarcinoma:3137080	10/138,393	11/26,262,527	172.53	5.24e-18	6.40e-16
branching morphogenesis\|\|PROCESS_OF\|\|Prostate:3740308	7/138,393	34/26,262,527	39.07	2.09e-09	1.06e-07
Testosterone\|\|ISA\|\|Hormones:1058967	10/138,393	142/26,262,527	13.36	1.07e-08	5.03e-07
Prostate specific antigen measurement\|\|METHOD_OF\|\|Biopsy:9473651	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Microsatellite Instability\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:6262861	14/138,393	18/26,262,527	147.61	5.10e-24	9.12e-22
calcification\|\|PROCESS_OF\|\|Bull:217551	11/138,393	2/26,262,527	1043.81	6.34e-24	1.13e-21
Magnetic Resonance Spectroscopy\|\|DIAGNOSES\|\|Prostate carcinoma:3444802	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Suramin\|\|TREATS\|\|Prostate carcinoma:4668438	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Prostate-Specific Antigen\|\|PART_OF\|\|Cytoplasmic:4212041	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
degarelix\|\|INHIBITS\|\|Gonadorelin:11976022	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
Malignant neoplasm of prostate\|\|AFFECTS\|\|Animal Model:6536261	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
docetaxel\|\|TREATS\|\|Hormone-refractory prostate cancer:9330001	12/138,393	12/26,262,527	189.78	1.10e-21	1.72e-19
Prostate\|\|LOCATION_OF\|\|Fibroblasts:1833554	9/138,393	22/26,262,527	77.64	5.43e-14	4.83e-12
AKT1 gene\|AKT1\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:13156122	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Androgen therapy\|\|PRECEDES\|\|Androgen therapy:13683804	11/138,393	14/26,262,527	149.11	3.42e-19	4.56e-17
Prostate\|\|LOCATION_OF\|\|APEX1 protein, human\|APEX1:6505771	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
MIRN145 gene\|MIR145\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:14168321	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
cancer prevention\|\|USES\|\|Beta Carotene:5697125	18/138,393	78/26,262,527	43.80	8.28e-23	1.38e-20
bicalutamide\|\|TREATS\|\|Malignant neoplasm of prostate:6651325	10/138,393	7/26,262,527	271.12	2.95e-19	3.96e-17
Organochlorine pesticide\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:10203510	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Pelvis\|\|LOCATION_OF\|\|Rhabdomyosarcoma:713176	14/138,393	92/26,262,527	28.88	7.96e-16	8.22e-14
PTEN gene\|PTEN\|\|DISRUPTS\|\|tumor growth:7155358	5/138,393	12/26,262,527	79.07	2.32e-08	1.06e-06
Biopsy of prostate\|\|DIAGNOSES\|\|Adenocarcinoma:3068942	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
multicatalytic endopeptidase complex\|\|PART_OF\|\|Neoplastic Cell:9297368	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Prostate carcinoma\|\|ASSOCIATED_WITH\|\|Prostate:314504	16/138,393	20/26,262,527	151.83	2.15e-27	4.37e-25
Angiostatins\|\|INHIBITS\|\|Angiogenesis:6475060	7/138,393	72/26,262,527	18.45	2.27e-07	7.96e-06
General Practitioners\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:6047396	9/138,393	11/26,262,527	155.27	4.76e-16	4.94e-14
lycopene\|\|ASSOCIATED_WITH\|\|Prostate:6950114	11/138,393	12/26,262,527	173.97	1.05e-19	1.44e-17
Precancerous lesions\|\|ASSOCIATED_WITH\|\|Prostate:2583844	8/138,393	10/26,262,527	151.82	2.38e-14	2.15e-12
Dutasteride\|\|TREATS\|\|Malignant neoplasm of prostate:10806731	21/138,393	24/26,262,527	166.07	4.30e-36	1.26e-33
Goserelin\|\|TREATS\|\|Malignant neoplasm of prostate:3920541	16/138,393	19/26,262,527	159.82	1.20e-27	2.46e-25
Open prostatectomy\|\|TREATS\|\|Benign prostatic hypertrophy:3884751	15/138,393	62/26,262,527	45.92	1.61e-19	2.20e-17
MicroRNAs\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:12445641	161/138,393	205/26,262,527	149.21	9.61e-261	2.96e-257
PTEN gene\|PTEN\|\|ASSOCIATED_WITH\|\|Breast:7570523	7/138,393	16/26,262,527	83.03	2.48e-11	1.64e-09
Ultrasound examination\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:6007003	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
GSTP1 gene\|GSTP1\|\|ASSOCIATED_WITH\|\|Carcinogenesis:7756678	5/138,393	14/26,262,527	67.78	4.33e-08	1.92e-06
Prostate-Specific Antigen\|\|INHIBITS\|\|Prostate-Specific Antigen:4543157	54/138,393	60/26,262,527	170.86	6.85e-91	6.20e-88
Combined Modality Therapy\|\|USES\|\|Gonadotropin-Releasing Hormone Analog:2474622	9/138,393	37/26,262,527	46.16	2.76e-12	2.06e-10
High-Grade Prostatic Intraepithelial Neoplasia\|\|COEXISTS_WITH\|\|Prostate carcinoma:8477867	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
vinorelbine\|\|TREATS\|\|Malignant neoplasm of prostate:9216543	6/138,393	12/26,262,527	94.89	3.65e-10	2.16e-08
Provenge\|\|TREATS\|\|Malignant neoplasm of prostate:9387428	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Hydroxymethylglutaryl-CoA Reductase Inhibitors\|\|ISA\|\|Anticholesteremic Agents:6363792	10/138,393	156/26,262,527	12.17	2.47e-08	1.13e-06
Hormones\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:192017	15/138,393	15/26,262,527	189.79	8.93e-27	1.77e-24
Ablation\|\|TREATS\|\|Locally Advanced Malignant Neoplasm:9689948	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Biopsy\|\|USES\|\|Periodicals:46821	33/138,393	551/26,262,527	11.37	2.99e-23	5.15e-21
Cathepsins B\|CTSB\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:6278577	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Radical prostatectomy\|\|compared_with\|\|Prostatectomy:10240663	11/138,393	14/26,262,527	149.11	3.42e-19	4.56e-17
AMACR protein, human\|AMACR\|\|INTERACTS_WITH\|\|branched chain fatty acid:10319842	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Cytokeratin\|\|ASSOCIATED_WITH\|\|Prostate:221238	5/138,393	10/26,262,527	94.89	1.14e-08	5.31e-07
Biopsy\|\|USES\|\|FAVOR:3570717	8/138,393	20/26,262,527	75.91	1.61e-12	1.23e-10
Zonal\|\|TREATS\|\|Malignant neoplasm of prostate:4939304	12/138,393	14/26,262,527	162.67	3.88e-21	5.87e-19
Human Glandular Kallikrein 2\|HK2\|\|PART_OF\|\|Recombinants:6416821	7/138,393	11/26,262,527	120.77	3.29e-12	2.43e-10
Neuroendocrine Cell\|\|PRODUCES\|\|Neuropeptides:4375897	9/138,393	20/26,262,527	85.40	2.72e-14	2.45e-12
Diet\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:2667531	31/138,393	36/26,262,527	163.45	1.99e-52	9.16e-50
PIM-1 Serine/Threonine Kinase\|PIM1\|\|ISA\|\|Phosphotransferases:5200463	9/138,393	61/26,262,527	28.00	1.46e-10	8.91e-09
Biopsy\|\|DIAGNOSES\|\|CAP - NOS:9983692	11/138,393	14/26,262,527	149.11	3.42e-19	4.56e-17
Paneth Cells\|\|PART_OF\|\|Adenocarcinoma:3508251	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Specific antibody\|\|PART_OF\|\|Prostate:7338027	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Diethylstilbestrol\|\|TREATS\|\|Prostate carcinoma:43258	18/138,393	21/26,262,527	162.68	5.01e-31	1.19e-28
Endopeptidases\|\|PART_OF\|\|integral to membrane:7867459	27/138,393	96/26,262,527	53.38	1.84e-35	5.27e-33
Sex Behavior\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:6827032	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Prostate\|\|LOCATION_OF\|\|Applicator - device:10628055	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Blood specimen\|\|LOCATION_OF\|\|Glutamate Carboxypeptidase II:6277880	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Malignant neoplasm of prostate\|\|OCCURS_IN\|\|Asians:8075388	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Combination Drug Therapy\|\|TREATS\|\|Malignant neoplasm of prostate:803721	10/138,393	11/26,262,527	172.53	5.24e-18	6.40e-16
Proto-Oncogene Proteins c-akt\|AKT1\|\|ISA\|\|Phosphotransferases:6258645	48/138,393	1,582/26,262,527	5.76	6.17e-21	9.31e-19
Breast\|\|LOCATION_OF\|\|Doxorubicin:3578715	5/138,393	13/26,262,527	72.99	3.20e-08	1.43e-06
Calmodulin\|\|INTERACTS_WITH\|\|Androgen Receptor\|AR:10508921	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Genistein\|\|TREATS\|\|Malignant neoplasm of prostate:7267604	15/138,393	17/26,262,527	167.46	3.22e-26	6.27e-24
zoledronic acid\|\|TREATS\|\|Secondary malignant neoplasm of bone:9058191	93/138,393	245/26,262,527	72.08	2.47e-128	3.37e-125
Malignant neoplasm of prostate\|\|AFFECTS\|\|Cell Proliferation:8829474	17/138,393	17/26,262,527	189.79	3.65e-30	8.38e-28
TSPY1 gene\|TSPY1\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9438093	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Bilateral adrenalectomy\|\|TREATS\|\|Carcinoma:123169	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Cell surface\|\|LOCATION_OF\|\|Glutamate Carboxypeptidase II:9683779	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Acetate\|\|INHIBITS\|\|Steroid 17-alpha-monooxygenase\|CYP17A1:13370278	22/138,393	24/26,262,527	173.98	4.71e-38	1.49e-35
Malignant neoplasm of prostate\|\|AFFECTS\|\|Retroviridae:12206764	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Ablation\|\|TREATS\|\|Malignant neoplasm of prostate:949403	153/138,393	171/26,262,527	169.98	4.19e-254	1.22e-250
Prostate\|\|LOCATION_OF\|\|Hyperplasia:69692	88/138,393	222/26,262,527	75.27	6.62e-123	8.53e-120
Prostate\|\|LOCATION_OF\|\|Benign prostatic hypertrophy:4718026	17/138,393	29/26,262,527	111.26	2.58e-27	5.22e-25
Prostate carcinoma\|\|ISA\|\|Prostatic Diseases:3579369	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Flutamide\|\|CAUSES\|\|Hepatotoxicity:5511925	6/138,393	8/26,262,527	142.33	6.01e-11	3.76e-09
Castration\|\|USES\|\|Gonadotropin-Releasing Hormone Analog:2622299	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Tumor Suppressor Genes\|\|ASSOCIATED_WITH\|\|Neoplasm progression:4079478	10/138,393	99/26,262,527	19.17	4.16e-10	2.47e-08
Diphosphonates\|\|TREATS\|\|Solid tumor:11099826	5/138,393	9/26,262,527	105.43	7.62e-09	3.62e-07
Malignant neoplasm of prostate\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:11298688	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Radical prostatectomy\|\|compared_with\|\|Patient observation:6209934	54/138,393	75/26,262,527	136.69	4.16e-87	3.51e-84
DNA Sequence\|\|PART_OF\|\|Chromosomes, Human, Pair 8:3060227	5/138,393	13/26,262,527	72.99	3.20e-08	1.43e-06
Early Diagnosis\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:831420	36/138,393	38/26,262,527	179.83	1.11e-61	6.10e-59
Mitogen-Activated Protein Kinases\|\|ASSOCIATED_WITH\|\|Prostate:6857286	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
alpha-methylacyl-CoA racemase\|\|INTERACTS_WITH\|\|alpha-methylacyl-CoA racemase:9753152	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
5-aza-2'-deoxycytidine\|\|ISA\|\|Azacitidine:3022419	8/138,393	95/26,262,527	15.98	8.71e-08	3.36e-06
Magnetic Resonance Imaging\|\|DIAGNOSES\|\|CAP - NOS:8398544	7/138,393	19/26,262,527	69.92	6.56e-11	4.09e-09
Stanolone\|\|AFFECTS\|\|Malignant neoplasm of prostate:7329325	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
HK2 gene\|HK2\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:7809958	6/138,393	14/26,262,527	81.33	7.55e-10	4.37e-08
Gland structure\|\|PART_OF\|\|Adenocarcinoma:3885768	9/138,393	26/26,262,527	65.69	1.87e-13	1.60e-11
Primary Neoplasm\|\|LOCATION_OF\|\|Tumor cells, malignant:2260629	22/138,393	196/26,262,527	21.30	2.09e-21	3.22e-19
Gonadal Steroid Hormones\|\|CAUSES\|\|Malignant neoplasm of prostate:6567384	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Acetylcysteine\|\|INHIBITS\|\|Reactive Oxygen Species:6807835	13/138,393	278/26,262,527	8.87	7.66e-09	3.64e-07
TNF gene\|TNF\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:10770635	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
GRPR gene\|GRPR\|\|PART_OF\|\|Malignant neoplasm of prostate:14710882	10/138,393	10/26,262,527	189.78	2.76e-18	3.46e-16
Mitoxantrone\|\|TREATS\|\|Prostate cancer metastatic:8025983	12/138,393	13/26,262,527	175.19	2.10e-21	3.22e-19
Prostate-Specific Antigen\|\|ISA\|\|Serine Protease:3580552	64/138,393	85/26,262,527	142.95	7.55e-104	8.05e-101
dehydroepiandrosterone\|\|ISA\|\|Androgens:317730	19/138,393	236/26,262,527	15.28	3.16e-16	3.33e-14
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Couples:8972334	17/138,393	19/26,262,527	169.81	1.33e-29	2.97e-27
Acid Phosphatase\|\|PART_OF\|\|Prostate:73736	105/138,393	369/26,262,527	54.04	1.59e-133	2.27e-130
NF-kappa B\|\|ASSOCIATED_WITH\|\|Prostate:9449494	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Genetic Markers:13787946	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Carcinoma, Transitional Cell\|\|PART_OF\|\|Urethra:772662	12/138,393	62/26,262,527	36.73	6.99e-15	6.71e-13
PTEN gene\|PTEN\|\|INHIBITS\|\|PTEN gene\|PTEN:7774169	10/138,393	90/26,262,527	21.09	1.77e-10	1.07e-08
silybin\|\|ISA\|\|Flavonoids:2816914	9/138,393	90/26,262,527	18.98	3.38e-09	1.66e-07
Pelvis\|\|LOCATION_OF\|\|lymph nodes:122876	10/138,393	86/26,262,527	22.07	1.17e-10	7.18e-09
Androgens\|\|AFFECTS\|\|receptor expression:5531250	6/138,393	26/26,262,527	43.79	1.67e-08	7.69e-07
Prostate-Specific Antigen\|\|PART_OF\|\|Racial group:6725130	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Citrate\|\|TREATS\|\|Malignant neoplasm of prostate:4840747	8/138,393	11/26,262,527	138.02	4.09e-14	3.65e-12
PCGEM1\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:16471034	4/138,393	3/26,262,527	253.03	2.61e-08	1.17e-06
Biopsy sample\|\|LOCATION_OF\|\|High-Grade Prostatic Intraepithelial Neoplasia:7153305	9/138,393	11/26,262,527	155.27	4.76e-16	4.94e-14
gene therapy\|\|TREATS\|\|Hormone-refractory prostate cancer:12394772	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Castration\|\|TREATS\|\|Prostatic Tissue:3265247	6/138,393	10/26,262,527	113.87	1.59e-10	9.61e-09
Neoplasm progression\|\|PART_OF\|\|Prostate:2822544	2,300/138,393	2,836/26,262,527	156.49	0.00e+00	0.00e+00
Sentinel Lymph Node\|\|PART_OF\|\|Prostate:9581940	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
E-Cadherin\|\|ASSOCIATED_WITH\|\|Prostate carcinoma:5744152	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Medical Imaging\|\|DIAGNOSES\|\|Prostate carcinoma:3321781	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Genistein\|\|ISA\|\|Isoflavones:1838774	57/138,393	628/26,262,527	17.23	3.84e-48	1.63e-45
Estrogen Receptor beta\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9176737	18/138,393	19/26,262,527	179.80	1.43e-31	3.50e-29
Estramustine\|\|TREATS\|\|High-Risk Cancer:10062847	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Recombination, Genetic\|\|PROCESS_OF\|\|Tissue Model:7776294	11/138,393	18/26,262,527	115.98	2.60e-18	3.34e-16
Androgens\|\|ASSOCIATED_WITH\|\|Prostate carcinoma:1513729	10/138,393	12/26,262,527	158.15	9.56e-18	1.15e-15
ORALIT\|\|TREATS\|\|Malignant neoplasm of prostate:8831577	5/138,393	4/26,262,527	237.22	4.90e-10	2.87e-08
Hyperplasia\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:4681110	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Carcinoma\|\|ASSOCIATED_WITH\|\|Gland structure:1204271	6/138,393	15/26,262,527	75.91	1.05e-09	5.56e-08
Digital Rectal Examination\|\|METHOD_OF\|\|Early Diagnosis:1396688	25/138,393	27/26,262,527	175.74	4.04e-43	1.52e-40
Radioimmunodetection\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:4049346	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Transrectal Ultrasound\|\|METHOD_OF\|\|Biopsy:1688316	36/138,393	41/26,262,527	166.67	7.51e-61	4.02e-58
celecoxib\|\|TREATS\|\|Malignant neoplasm of prostate:11844181	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Prostate-Specific Antigen\|\|ISA\|\|Analyte:5840197	6/138,393	12/26,262,527	94.89	3.65e-10	2.16e-08
AR gene\|AR\|\|PREDISPOSES\|\|Neoplasm progression:12280230	8/138,393	7/26,262,527	216.89	3.55e-15	3.52e-13
R-1881\|\|STIMULATES\|\|Androgen Receptor\|AR:4092106	6/138,393	9/26,262,527	126.52	9.97e-11	6.13e-09
Iodine\|\|TREATS\|\|Malignant neoplasm of prostate:8640756	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Second Degree Relative:4909811	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
Finasteride\|\|INHIBITS\|\|Oxidoreductase:4309804	31/138,393	176/26,262,527	33.43	5.84e-35	1.64e-32
Androgens\|\|STIMULATES\|\|Androgen Receptor:2917661	5/138,393	15/26,262,527	63.26	5.75e-08	2.23e-06
Chemopreventive Agent\|\|TREATS\|\|Malignant neoplasm of prostate:5391581	61/138,393	64/26,262,527	180.95	1.61e-103	1.69e-100
Ablation\|\|USES\|\|Androgens:2034338	841/138,393	1,456/26,262,527	110.28	0.00e+00	0.00e+00
Teleradiotherapy procedure\|\|TREATS\|\|Toxic effect:14219671	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Nerve-Sparing Prostatectomy\|\|TREATS\|\|Malignant neoplasm of prostate:6399352	24/138,393	25/26,262,527	182.21	1.03e-41	3.68e-39
bicalutamide\|\|STIMULATES\|\|Prostate-Specific Antigen:6651315	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Radiotherapy, Adjuvant\|\|TREATS\|\|High-Risk Cancer:5947239	5/138,393	11/26,262,527	86.26	1.65e-08	7.59e-07
adjuvant therapy\|\|TREATS\|\|Locally Advanced Malignant Neoplasm:4522596	5/138,393	21/26,262,527	45.18	2.37e-07	8.32e-06
Leuprolide Acetate\|\|USES\|\|Leuprolide Acetate:3952896	15/138,393	117/26,262,527	24.33	7.50e-16	7.75e-14
Tumor focality\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:6712202	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Radiotherapy, Conformal\|\|TREATS\|\|Adenocarcinoma:6676072	18/138,393	19/26,262,527	179.80	1.43e-31	3.50e-29
vitamin E succinate\|\|TREATS\|\|Malignant neoplasm of prostate:11685229	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Orchiectomy\|\|TREATS\|\|Malignant neoplasm of prostate:48918	123/138,393	154/26,262,527	151.70	2.75e-200	5.89e-197
Biopsy sample\|\|LOCATION_OF\|\|Malignant neoplasm of prostate:6101717	35/138,393	36/26,262,527	184.54	2.79e-60	1.48e-57
Mammary Neoplasms\|\|PROCESS_OF\|\|Mice, Nude:2018716	8/138,393	108/26,262,527	14.06	2.19e-07	7.70e-06
Prostatectomy, Retropubic\|\|METHOD_OF\|\|Radical prostatectomy:8308958	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
PTEN gene\|PTEN\|\|INTERACTS_WITH\|\|Proto-Oncogene Proteins c-akt\|AKT1:8015123	11/138,393	160/26,262,527	13.05	2.51e-09	1.27e-07
tumor growth\|\|PROCESS_OF\|\|Mice, Nude:1221937	115/138,393	1,170/26,262,527	18.67	7.08e-99	7.13e-96
Gossypol\|\|DISRUPTS\|\|Cancer Cell Growth:6968329	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Vitamin D3 Receptor\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:7363212	13/138,393	14/26,262,527	176.23	4.22e-23	7.15e-21
ZD1839\|\|ISA\|\|gefitinib:9807021	10/138,393	115/26,262,527	16.50	1.61e-09	8.44e-08
Dutasteride\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:10851741	14/138,393	15/26,262,527	177.13	8.52e-25	1.56e-22
docetaxel\|\|compared_with\|\|docetaxel:5903071	32/138,393	183/26,262,527	33.19	6.03e-36	1.77e-33
KLK3 gene\|KLK3\|\|COEXISTS_WITH\|\|KLK3 gene\|KLK3:4453101	47/138,393	78/26,262,527	114.39	2.80e-73	1.96e-70
Antiandrogen therapy\|\|USES\|\|bicalutamide:6651326	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Intraepithelial Neoplasia\|\|ASSOCIATED_WITH\|\|Prostate:10535504	6/138,393	9/26,262,527	126.52	9.97e-11	6.13e-09
Androgen Receptor\|AR\|\|INTERACTS_WITH\|\|Steroids:3070582	5/138,393	14/26,262,527	67.78	4.33e-08	1.92e-06
Malignant neoplasm of prostate\|\|LOCATION_OF\|\|Stem cells:7990816	33/138,393	34/26,262,527	184.23	6.60e-57	3.36e-54
Chromosome Pairing\|\|PROCESS_OF\|\|Plasticity:440850	1/138,393	19,775/26,262,527	0.01	1.65e-43	6.25e-41
Tamoxifen\|\|TREATS\|\|Malignant neoplasm of prostate:3712444	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Nested Case-Control Studies\|\|USES\|\|Longitudinal Studies:5401071	9/138,393	135/26,262,527	12.65	8.99e-08	3.42e-06
Gonadorelin\|\|USES\|\|Gonadorelin:836551	35/138,393	867/26,262,527	7.66	2.45e-19	3.29e-17
Malignant neoplasm of prostate\|\|AFFECTS\|\|Brothers:4567100	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Age\|\|PROCESS_OF\|\|cohort:804424	19/138,393	695/26,262,527	5.19	1.59e-08	7.35e-07
Composition\|\|PROCESS_OF\|\|Prostatic Tissue:5728918	7/138,393	16/26,262,527	83.03	2.48e-11	1.64e-09
Lymphoma, Large-Cell, Diffuse\|\|PART_OF\|\|Prostate:3723238	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Nerve bundle\|\|LOCATION_OF\|\|Preservation, Biological:6435671	7/138,393	10/26,262,527	132.84	2.02e-12	1.52e-10
Ductal Breast Carcinoma\|\|PART_OF\|\|Prostate:6344707	43/138,393	88/26,262,527	92.76	4.15e-64	2.42e-61
Diagnostic radiologic examination\|\|DIAGNOSES\|\|Secondary malignant neoplasm of bone:668164	7/138,393	37/26,262,527	35.90	3.52e-09	1.73e-07
Antigen assay\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:3306475	55/138,393	59/26,262,527	176.97	3.94e-93	3.64e-90
Malignant neoplasm of prostate\|\|ASSOCIATED_WITH\|\|Breast:6662020	18/138,393	23/26,262,527	148.53	1.61e-30	3.77e-28
Carcinoma of the Large Intestine\|\|ASSOCIATED_WITH\|\|Prostate:10852665	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Genistein\|\|ISA\|\|Phytoestrogens:4644108	21/138,393	554/26,262,527	7.19	9.77e-12	7.02e-10
Brachytherapy\|\|compared_with\|\|Teleradiotherapy procedure:8716698	13/138,393	28/26,262,527	88.11	3.47e-20	5.03e-18
Carcinoma\|\|PART_OF\|\|Organ:74829	13/138,393	121/26,262,527	20.39	4.95e-13	4.00e-11
circulating cancer cell\|\|PART_OF\|\|Prostate:7462065	27/138,393	38/26,262,527	134.86	3.18e-44	1.23e-41
^103^Palladium\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8135046	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Dietary Fats\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:7871464	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
Ketoconazole\|\|INHIBITS\|\|Testosterone:2227509	8/138,393	32/26,262,527	47.44	3.78e-11	2.41e-09
Cytoplasm\|\|PART_OF\|\|Tumor cells, malignant:406746	18/138,393	412/26,262,527	8.29	3.18e-11	2.10e-09
Prognostic Factor\|\|ASSOCIATED_WITH\|\|Adenocarcinoma of prostate:4872833	10/138,393	12/26,262,527	158.15	9.56e-18	1.15e-15
Inguinal part of abdomen\|\|LOCATION_OF\|\|Sentinel Lymph Node:13132582	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
AMACR protein, human\|AMACR\|\|ISA\|\|alpha-methylacyl-CoA racemase:9687609	20/138,393	29/26,262,527	130.89	5.99e-33	1.54e-30
Gelatinase A\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9791773	10/138,393	13/26,262,527	145.99	1.68e-17	1.99e-15
KLK3 gene\|KLK3\|\|compared_with\|\|KLK3 gene\|KLK3:1568377	73/138,393	113/26,262,527	122.66	1.40e-114	1.66e-111
Anandron\|\|ISA\|\|nilutamide:3761637	17/138,393	19/26,262,527	169.81	1.33e-29	2.97e-27
Polymorphism, Genetic\|\|AFFECTS\|\|Malignant neoplasm of prostate:9520972	15/138,393	15/26,262,527	189.79	8.93e-27	1.77e-24
Prostate\|\|LOCATION_OF\|\|Congenital Abnormality:5968371	6/138,393	19/26,262,527	59.93	3.37e-09	1.66e-07
Impotence\|\|PROCESS_OF\|\|Actuary:6718353	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Androgen Receptor\|AR\|\|ASSOCIATED_WITH\|\|Hormone-refractory prostate cancer:10299062	16/138,393	17/26,262,527	178.63	3.48e-28	7.27e-26
Radioimmunodetection\|\|ISA\|\|Scanning:2877395	5/138,393	17/26,262,527	55.82	9.68e-08	3.54e-06
Induction\|\|TREATS\|\|Prostatic Tissue:1259535	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Tumor cells, malignant\|\|LOCATION_OF\|\|Signal Transduction:4892395	9/138,393	135/26,262,527	12.65	8.99e-08	3.42e-06
Stromal Cells\|\|PART_OF\|\|Prostatic Tissue:2621772	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Specimen from prostate\|\|PART_OF\|\|Cancer Patient:6400103	24/138,393	24/26,262,527	189.80	5.28e-42	1.91e-39
KLK3 gene\|KLK3\|\|INTERACTS_WITH\|\|Androgens:4834726	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Catheterization\|\|TREATS\|\|[D]Acute retention of urine:1731389	5/138,393	20/26,262,527	47.44	1.93e-07	6.79e-06
Folate intake\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:11803164	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Endothelin-1\|\|PART_OF\|\|Malignant neoplasm of prostate:12583654	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Biopsy\|\|USES\|\|Robot:8311028	5/138,393	16/26,262,527	59.30	7.51e-08	2.91e-06
PTEN gene\|PTEN\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:11792285	7/138,393	3/26,262,527	442.81	1.29e-14	1.21e-12
Methotrexate\|\|TREATS\|\|Malignant neoplasm of prostate:1929510	6/138,393	5/26,262,527	227.73	9.37e-12	6.74e-10
Tissue, Fresh\|\|PART_OF\|\|Malignant neoplasm of prostate:5516112	8/138,393	10/26,262,527	151.82	2.38e-14	2.15e-12
Prostatic Tissue\|\|LOCATION_OF\|\|Cell Culture Techniques:1355577	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Proto-Oncogene Proteins c-akt\|AKT1\|\|AFFECTS\|\|Malignant neoplasm of prostate:9553473	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Suramin\|\|TREATS\|\|Malignant neoplasm of prostate:4425061	13/138,393	15/26,262,527	164.48	7.85e-23	1.31e-20
Androgens\|\|ISA\|\|Cancer Treatment:5435251	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Prostate\|\|LOCATION_OF\|\|Serum testosterone measurement:9868639	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Ablation\|\|TREATS\|\|Carcinoma:758776	5/138,393	15/26,262,527	63.26	5.75e-08	2.23e-06
Leptocyte\|\|PART_OF\|\|Malignant neoplasm of prostate:9009109	16/138,393	16/26,262,527	189.79	1.80e-28	3.82e-26
Prednisone\|\|ASSOCIATED_WITH\|\|Hormone-refractory prostate cancer:9858245	15/138,393	15/26,262,527	189.79	8.93e-27	1.77e-24
Up-Regulation (Physiology)\|\|AFFECTS\|\|Neoplasm progression:5989616	8/138,393	21/26,262,527	72.30	2.22e-12	1.66e-10
Estrogen Receptor beta\|\|ASSOCIATED_WITH\|\|Prostate:7380021	16/138,393	27/26,262,527	112.47	7.54e-26	1.45e-23
Proto-Oncogene Proteins c-akt\|AKT1\|\|ISA\|\|Protein-Serine-Threonine Kinases:4887041	23/138,393	801/26,262,527	5.45	2.10e-10	1.26e-08
intraoperative radiotherapy\|\|TREATS\|\|Malignant neoplasm of prostate:3858627	6/138,393	9/26,262,527	126.52	9.97e-11	6.13e-09
Body mass index procedure\|\|AFFECTS\|\|Malignant neoplasm of prostate:13674699	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
docetaxel\|\|NEG_TREATS\|\|Prostate cancer metastatic:12895199	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Prostate\|\|LOCATION_OF\|\|Malignant neoplasm of lung:11081849	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Antigen assay\|\|USES\|\|Body mass index procedure:13107484	6/138,393	8/26,262,527	142.33	6.01e-11	3.76e-09
Exercise\|\|TREATS\|\|Cancer Patient:4896997	7/138,393	45/26,262,527	29.52	1.18e-08	5.51e-07
Finasteride\|\|INHIBITS\|\|Prostate-Specific Antigen:4539600	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Lobe\|\|PART_OF\|\|Seminal Vesicles:903851	8/138,393	25/26,262,527	60.73	7.04e-12	5.13e-10
clinical aspects\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9269736	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Radical prostatectomy\|\|TREATS\|\|Tissue specimen:11219384	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Tumor Suppressor Genes\|\|PART_OF\|\|Malignant neoplasm of prostate:8066867	22/138,393	24/26,262,527	173.98	4.71e-38	1.49e-35
[M]Unspecified tumor cell NOS\|\|PART_OF\|\|Solid tumor:4754165	10/138,393	25/26,262,527	75.91	2.55e-15	2.56e-13
Polyunsaturated Fatty Acids\|\|AFFECTS\|\|Malignant neoplasm of prostate:10671636	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Digital palpation\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:2355902	10/138,393	12/26,262,527	158.15	9.56e-18	1.15e-15
Androgens\|\|ASSOCIATED_WITH\|\|Carcinogenesis:289993	23/138,393	42/26,262,527	103.94	6.49e-36	1.90e-33
Radical prostatectomy\|\|PRECEDES\|\|Androgen Suppression:10676232	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Cystoprostatectomy\|\|TREATS\|\|Carcinoma, Transitional Cell:3943895	7/138,393	17/26,262,527	78.14	3.48e-11	2.23e-09
Prostate\|\|LOCATION_OF\|\|Cell Culture Techniques:1280693	33/138,393	47/26,262,527	133.27	1.38e-53	6.53e-51
Radiotherapy, Intensity-Modulated\|\|ISA\|\|Radiotherapy, Conformal:9313349	7/138,393	30/26,262,527	44.28	9.75e-10	5.17e-08
Fatty Acids\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:4996175	9/138,393	11/26,262,527	155.27	4.76e-16	4.94e-14
Cystadenocarcinoma, Papillary\|\|PART_OF\|\|Prostate:2580549	10/138,393	15/26,262,527	126.52	4.77e-17	5.53e-15
Malignant neoplasm of prostate\|\|AFFECTS\|\|cell motility:12744645	8/138,393	7/26,262,527	216.89	3.55e-15	3.52e-13
Frozen Sections\|\|PART_OF\|\|Prostate:1117720	10/138,393	15/26,262,527	126.52	4.77e-17	5.53e-15
Growth Factor\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:3803872	40/138,393	42/26,262,527	180.78	2.00e-68	1.27e-65
Endopeptidases\|\|PART_OF\|\|Malignant neoplasm of prostate:10714044	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostatic Neoplasms\|\|PROCESS_OF\|\|Transgenic Model:9048787	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Unrelated\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:3166790	6/138,393	8/26,262,527	142.33	6.01e-11	3.76e-09
Epidermal Growth Factor Receptor\|\|PART_OF\|\|integral to membrane:4487836	5/138,393	15/26,262,527	63.26	5.75e-08	2.23e-06
Cell Nucleus\|\|LOCATION_OF\|\|Androgen Receptor\|AR:4361033	8/138,393	21/26,262,527	72.30	2.22e-12	1.66e-10
Combined Modality Therapy\|\|compared_with\|\|Castration:4475924	5/138,393	9/26,262,527	105.43	7.62e-09	3.62e-07
Stroma\|\|PART_OF\|\|Benign prostatic hypertrophy:1271269	10/138,393	86/26,262,527	22.07	1.17e-10	7.18e-09
Ultrasonography\|\|METHOD_OF\|\|Biopsy of prostate:3417145	5/138,393	9/26,262,527	105.43	7.62e-09	3.62e-07
A-23187\|\|ISA\|\|Ionophores:817043	2/138,393	4,290/26,262,527	0.09	1.11e-07	4.07e-06
Prostate\|\|LOCATION_OF\|\|protrusion:149685	9/138,393	31/26,262,527	55.10	7.06e-13	5.52e-11
Casodex\|\|TREATS\|\|Malignant neoplasm of prostate:5416676	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Autoantibodies\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:11547947	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Lymphoma\|\|PART_OF\|\|Prostate:1783495	40/138,393	77/26,262,527	98.61	1.35e-60	7.22e-58
Tumorigenesis\|\|PART_OF\|\|Prostate:4164712	455/138,393	586/26,262,527	147.83	0.00e+00	0.00e+00
Secondary malignant neoplasm of bone\|\|AFFECTS\|\|Malignant neoplasm of prostate:5385280	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Percent Free Prostate-Specific Antigen\|\|METHOD_OF\|\|Biopsy:7748010	6/138,393	8/26,262,527	142.33	6.01e-11	3.76e-09
Combined Modality Therapy\|\|USES\|\|Flutamide:3026310	30/138,393	59/26,262,527	96.51	1.27e-45	5.05e-43
Epirubicin\|\|TREATS\|\|Malignant neoplasm of prostate:5472408	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
tomography\|\|ISA\|\|Medical Imaging:176080	188/138,393	12,824/26,262,527	2.78	4.36e-33	1.15e-30
hydroxyflutamide\|\|ISA\|\|Nonsteroidal antiandrogen:5363055	6/138,393	11/26,262,527	103.51	2.44e-10	1.46e-08
Androgens\|\|AFFECTS\|\|Prostatic Tissue:4804398	7/138,393	10/26,262,527	132.84	2.02e-12	1.52e-10
Androgens\|\|INTERACTS_WITH\|\|AR gene\|AR:4092101	7/138,393	11/26,262,527	120.77	3.29e-12	2.43e-10
Carcinoma\|\|LOCATION_OF\|\|KLK3 gene\|KLK3:7386855	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Malignant neoplasm of prostate\|\|COEXISTS_WITH\|\|Primary Neoplasm:6522775	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Vitamin D\|\|AFFECTS\|\|Malignant neoplasm of prostate:9133948	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Lymphatic vessel\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:11333971	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
E-Cadherin\|\|ASSOCIATED_WITH\|\|Prostate:6696849	8/138,393	11/26,262,527	138.02	4.09e-14	3.65e-12
Bladder\|\|LOCATION_OF\|\|Neck:10043	412/138,393	4,138/26,262,527	18.95	0.00e+00	0.00e+00
nilutamide\|\|USES\|\|nilutamide:4309623	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Signal Transduction\|\|AFFECTS\|\|Malignant neoplasm of prostate:10598328	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Radical prostatectomy\|\|CAUSES\|\|Erectile dysfunction:7831363	8/138,393	15/26,262,527	101.22	2.61e-13	2.22e-11
Fenretinide\|\|ISA\|\|Retinoids:2822568	13/138,393	129/26,262,527	19.13	1.05e-12	8.13e-11
KLK3\|PLAG1\|PROS1\|NPEPPS\|PSAT1\|\|INTERACTS_WITH\|\|KLK3 gene\|KLK3:7000533	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Amphetamine\|\|TREATS\|\|AIDS related complex:13143641	8/138,393	31/26,262,527	48.98	3.03e-11	2.01e-09
Prostate\|\|LOCATION_OF\|\|Blood specimen:5908772	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Physical activity\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:5883563	19/138,393	27/26,262,527	133.56	1.70e-31	4.14e-29
Chronic Fatigue Syndrome\|\|AFFECTS\|\|Gammaretrovirus:14095902	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Malignant neoplasm of prostate\|\|PRECEDES\|\|Malignant neoplasm of urinary bladder:10889970	6/138,393	8/26,262,527	142.33	6.01e-11	3.76e-09
RNASEL\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:12454179	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Orchiectomy\|\|compared_with\|\|Orchiectomy:3427560	17/138,393	26/26,262,527	124.09	6.30e-28	1.31e-25
SDC1 gene\|SDC1\|\|PART_OF\|\|Malignant neoplasm of prostate:10038101	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
In Situ Hybridization\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:5870638	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Buserelin\|\|ISA\|\|Gonadotropin-Releasing Hormone Analog:1944013	20/138,393	169/26,262,527	22.46	5.16e-20	7.46e-18
Androgen Receptor\|AR\|\|DISRUPTS\|\|androgen receptor activity:9849827	7/138,393	10/26,262,527	132.84	2.02e-12	1.52e-10
Diphosphonates\|\|TREATS\|\|Secondary malignant neoplasm of bone:1382677	104/138,393	347/26,262,527	56.92	2.78e-134	4.07e-131
Cancer Vaccines\|\|TREATS\|\|Malignant neoplasm of prostate:6317166	21/138,393	21/26,262,527	189.80	6.22e-37	1.90e-34
resveratrol\|\|INHIBITS\|\|Androgen Receptor\|AR:10819972	8/138,393	10/26,262,527	151.82	2.38e-14	2.15e-12
Adrenalectomy\|\|TREATS\|\|Prostate carcinoma:164862	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
PREDICTED\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:3725292	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Prednisone\|\|INHIBITS\|\|Prostate-Specific Antigen:7774301	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
frontal sinus\|\|LOCATION_OF\|\|Diagnostic radiologic examination:152425	6/138,393	4/26,262,527	284.66	4.28e-12	3.15e-10
Estramustine phosphate\|\|ASSOCIATED_WITH\|\|Prostate carcinoma:1280731	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Signal Transduction Pathways\|\|AFFECTS\|\|Malignant neoplasm of prostate:8648636	9/138,393	8/26,262,527	213.50	6.99e-17	8.04e-15
extragonadal germ cell tumor\|\|PART_OF\|\|Prostate:3943860	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Replacement therapy\|\|TREATS\|\|Malignant neoplasm of prostate:11051319	18/138,393	21/26,262,527	162.68	5.01e-31	1.19e-28
brush border membrane\|\|LOCATION_OF\|\|Vesicle:421832	3/138,393	4,938/26,262,527	0.12	3.28e-08	1.46e-06
African American\|\|ISA\|\|Racial group:5393221	67/138,393	1,507/26,262,527	8.44	6.81e-38	2.14e-35
HISTORY OF SYMPTOMS & DISEASES:FINDING:POINT IN TIME:KIDNEY:NOMINAL\|\|PROCESS_OF\|\|Recipient, Transplant:548898	9/138,393	8,176/26,262,527	0.21	8.25e-10	4.77e-08
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Turkish population:10857636	13/138,393	15/26,262,527	164.48	7.85e-23	1.31e-20
Ibandronate\|\|TREATS\|\|Malignant neoplasm of prostate:9896988	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Glutamate Carboxypeptidase II\|\|PART_OF\|\|Prostate:6970554	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Basal Cell Neoplasm\|\|PART_OF\|\|Adenoidal structure:2688097	5/138,393	13/26,262,527	72.99	3.20e-08	1.43e-06
Pathologic Neovascularization\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:10203101	7/138,393	6/26,262,527	221.41	1.82e-13	1.56e-11
Androgen Suppression\|\|PREVENTS\|\|Adverse effects:8391427	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
agonists\|\|INTERACTS_WITH\|\|Androgen Antagonists:4010136	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Tumor cells, malignant\|\|LOCATION_OF\|\|Prostate-Specific Antigen:4209718	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
Glutamate Carboxypeptidase II\|\|AUGMENTS\|\|Malignant neoplasm of prostate:12011520	12/138,393	12/26,262,527	189.78	1.10e-21	1.72e-19
Prostate\|\|LOCATION_OF\|\|Sample weight:4722373	6/138,393	15/26,262,527	75.91	1.05e-09	5.56e-08
caveolin 1\|\|PART_OF\|\|Prostate cancer metastatic:7990831	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Tumor cells, malignant\|\|LOCATION_OF\|\|Silence:8606357	10/138,393	64/26,262,527	29.65	8.29e-12	6.03e-10
Fluorescence\|\|PROCESS_OF\|\|Malignant neoplasm of prostate:11691428	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
BIRC4 gene\|XIAP\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:10637270	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Prostate\|\|LOCATION_OF\|\|Tissue culture:188758	5/138,393	8/26,262,527	118.61	4.92e-09	2.37e-07
AR gene\|AR\|\|INTERACTS_WITH\|\|PTEN gene\|PTEN:10862246	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Rectum\|\|LOCATION_OF\|\|Observation parameter:8255028	6/138,393	8/26,262,527	142.33	6.01e-11	3.76e-09
VIABLE CELLS\|\|PART_OF\|\|Malignant neoplasm of prostate:8326103	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Androgen Receptor\|AR\|\|ISA\|\|Nuclear Hormone Receptors:8296402	5/138,393	12/26,262,527	79.07	2.32e-08	1.06e-06
Testosterone\|\|compared_with\|\|Stanolone:716104	8/138,393	48/26,262,527	31.63	6.47e-10	3.76e-08
CAP - NOS\|\|PROCESS_OF\|\|Caucasoid Race:6798266	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Metastatic Carcinoma\|\|ASSOCIATED_WITH\|\|Prostate:4500376	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
External Beam Radiation Therapy\|\|TREATS\|\|Malignant neoplasm of prostate:2651813	387/138,393	479/26,262,527	153.75	0.00e+00	0.00e+00
Medical center\|\|LOCATION_OF\|\|Biopsy:715441	14/138,393	54/26,262,527	49.20	1.12e-18	1.46e-16
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Control Groups:1642279	24/138,393	27/26,262,527	168.71	3.71e-41	1.30e-38
Genistein\|\|INHIBITS\|\|CYP24\|CYP24A1:9890382	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Malignant neoplasm of prostate\|\|COEXISTS_WITH\|\|Tumorigenesis:7705091	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Prostate\|\|ASSOCIATED_WITH\|\|Tumorigenesis:7028414	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
Polymorphism, Genetic\|\|PROCESS_OF\|\|Japanese Population:1318068	9/138,393	150/26,262,527	11.39	2.09e-07	7.38e-06
MicroRNAs\|\|ISA\|\|RNA, Untranslated:9540076	22/138,393	815/26,262,527	5.12	1.53e-09	8.06e-08
Human tissue\|\|PART_OF\|\|Prostate carcinoma:1084582	11/138,393	12/26,262,527	173.97	1.05e-19	1.44e-17
Antimicrobial susceptibility\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:5316581	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
Granulocyte-Macrophage Colony-Stimulating Factor\|\|PART_OF\|\|Malignant neoplasm of prostate:8359125	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Proto-Oncogene Proteins c-akt\|AKT1\|\|AUGMENTS\|\|Cell Growth:10819881	6/138,393	27/26,262,527	42.17	2.03e-08	9.33e-07
Prostate carcinoma\|\|PROCESS_OF\|\|Caucasoid Race:3722121	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
AR gene\|AR\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:8863214	12/138,393	11/26,262,527	207.04	5.52e-22	8.86e-20
Tomography, Emission-Computed, Single-Photon\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:10166614	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Prostate-Specific Antigen\|\|PREDISPOSES\|\|Carcinoma:3769775	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Epithelial Cells\|\|PART_OF\|\|Prostatic Tissue:1346582	6/138,393	10/26,262,527	113.87	1.59e-10	9.61e-09
phenethyl isothiocyanate\|\|USES\|\|phenethyl isothiocyanate:4857497	13/138,393	66/26,262,527	37.38	4.31e-16	4.53e-14
Prostatic Intraepithelial Neoplasias\|\|ASSOCIATED_WITH\|\|Gland structure:7385719	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Epithelium\|\|PART_OF\|\|Seminal Vesicles:159958	33/138,393	258/26,262,527	24.28	5.26e-33	1.38e-30
Promoter Regions (Genetics)\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9259806	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Androgens\|\|COEXISTS_WITH\|\|Androgen Receptor\|AR:2493219	11/138,393	25/26,262,527	83.50	4.37e-17	5.09e-15
Scanning\|\|USES\|\|Capromab Pendetide:7550651	17/138,393	32/26,262,527	100.83	9.44e-27	1.87e-24
Immunohistochemistry\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:3526516	52/138,393	54/26,262,527	182.81	1.20e-88	1.04e-85
MicroRNAs\|\|DISRUPTS\|\|Malignant neoplasm of prostate:15749678	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Androgen Antagonists\|\|AFFECTS\|\|Malignant neoplasm of prostate:4332224	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Surgical Procedures, Endoscopic\|\|TREATS\|\|Malignant neoplasm of prostate:6070781	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Antigen assay\|\|METHOD_OF\|\|Biopsy:5601046	23/138,393	25/26,262,527	174.62	9.63e-40	3.20e-37
Veins\|\|PART_OF\|\|Tail:183036	52/138,393	3,183/26,262,527	3.10	5.47e-12	4.00e-10
Androgens\|\|INHIBITS\|\|Androgen Receptor\|AR:4316430	6/138,393	24/26,262,527	47.44	1.11e-08	5.20e-07
Prostate\|\|LOCATION_OF\|\|Differential Diagnosis:4252360	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Radical cystectomy\|\|TREATS\|\|Carcinoma:160459	14/138,393	102/26,262,527	26.05	2.90e-15	2.91e-13
Male gender\|\|PROCESS_OF\|\|human old age (65+):96898	59/138,393	2,068/26,262,527	5.42	4.54e-24	8.13e-22
Androgen Antagonists\|\|DISRUPTS\|\|androgen receptor activity:9915783	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Adenocarcinoma of prostate\|\|LOCATION_OF\|\|Neuroendocrine Cell:5518506	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Gene Rearrangement\|\|PROCESS_OF\|\|cohort:9821419	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Gene Transduction Agent\|\|TREATS\|\|Malignant neoplasm of prostate:8867623	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Androgen Suppression\|\|TREATS\|\|Locally Advanced Malignant Neoplasm:6813106	17/138,393	20/26,262,527	161.32	2.45e-29	5.41e-27
Prostatic Urethra\|\|LOCATION_OF\|\|polyps:318952	22/138,393	31/26,262,527	134.70	2.66e-36	7.90e-34
Antigen assay\|\|METHOD_OF\|\|Therapeutic radiology procedure:10900191	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Microarray Analysis\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:9720155	16/138,393	16/26,262,527	189.79	1.80e-28	3.82e-26
Stanolone\|\|STIMULATES\|\|Acid Phosphatase:3017640	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Breast fluid\|\|LOCATION_OF\|\|Prostate-Specific Antigen:7648766	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Ablation\|\|NEG_TREATS\|\|Malignant neoplasm of prostate:7933946	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Radical prostatectomy\|\|TREATS\|\|advanced disease:7698018	13/138,393	11/26,262,527	224.29	5.34e-24	9.50e-22
Testosterone\|\|TREATS\|\|Malignant neoplasm of prostate:1431382	50/138,393	50/26,262,527	189.84	7.29e-86	6.03e-83
sarcoma\|\|PART_OF\|\|Prostate:1502	61/138,393	92/26,262,527	125.88	1.51e-96	1.48e-93
Hyperlipidemia\|\|COEXISTS_WITH\|\|Alcoholic Intoxication:121129	356/138,393	2/26,262,527	33865.77	0.00e+00	0.00e+00
Immunohistochemistry\|\|METHOD_OF\|\|Division (procedure):1562101	19/138,393	830/26,262,527	4.34	2.28e-07	7.99e-06
Intravenous therapy\|\|USES\|\|fosfestrol:1579171	5/138,393	4/26,262,527	237.22	4.90e-10	2.87e-08
Implants\|\|USES\|\|Iodine:8280466	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
docetaxel/estramustine\|\|compared_with\|\|Prednisone:10882547	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Androgens\|\|STIMULATES\|\|Androgens:790472	27/138,393	78/26,262,527	65.70	1.57e-37	4.90e-35
Cancer Prognosis\|\|PROCESS_OF\|\|cohort:13468756	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Acid Phosphatase\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:3289153	17/138,393	18/26,262,527	179.25	7.06e-30	1.59e-27
Quercetin\|\|TREATS\|\|Malignant neoplasm of prostate:10241314	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Radical prostatectomy\|\|TREATS\|\|Recipient, Transplant:8025378	12/138,393	20/26,262,527	113.87	8.82e-20	1.25e-17
Prostate cancer metastatic\|\|ISA\|\|Malignant neoplasm of prostate:5875265	22/138,393	22/26,262,527	189.80	1.27e-38	4.06e-36
External Beam Radiation Therapy\|\|NEG_TREATS\|\|Malignant neoplasm of prostate:7828797	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
Needle biopsy procedure\|\|DIAGNOSES\|\|Carcinoma:160901	10/138,393	30/26,262,527	63.26	1.15e-14	1.09e-12
PIK3CA\|PIK3CB\|PIK3CD\|PIK3CG\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:13318390	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Fluoroscopy\|\|ISA\|\|Medical Imaging:65537	28/138,393	1,199/26,262,527	4.43	2.41e-10	1.45e-08
Transurethral Resection\|\|TREATS\|\|Urinary tract obstruction:4963694	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
KLK3 gene\|KLK3\|\|PART_OF\|\|Voluntary Workers:7406032	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Androgen Suppression\|\|TREATS\|\|Adenocarcinoma:4167237	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Cyproterone Acetate\|\|TREATS\|\|Metastatic Carcinoma:3322549	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Insulin-Like Growth Factor I\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:7424913	44/138,393	54/26,262,527	154.67	5.26e-73	3.61e-70
Epitopes\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:5027154	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Participant:5432920	84/138,393	84/26,262,527	189.88	3.97e-143	6.12e-140
Estracyt\|\|USES\|\|Estracyt:1066464	10/138,393	13/26,262,527	145.99	1.68e-17	1.99e-15
Down-Regulation\|\|AFFECTS\|\|Cell Proliferation:5171714	7/138,393	65/26,262,527	20.44	1.19e-07	4.34e-06
Prostate-Specific Antigen\|\|PRODUCES\|\|Prostate-Specific Antigen:4363469	16/138,393	16/26,262,527	189.79	1.80e-28	3.82e-26
Malignant neoplasm of prostate\|\|PART_OF\|\|Urothelium:9357783	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
KLK3 gene\|KLK3\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:4135744	78/138,393	95/26,262,527	155.90	2.49e-128	3.38e-125
Fossa\|\|LOCATION_OF\|\|Biopsy of prostate:7862580	7/138,393	11/26,262,527	120.77	3.29e-12	2.43e-10
Estrogens\|\|INHIBITS\|\|Androgens:3272409	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Testosterone\|\|ASSOCIATED_WITH\|\|Benign prostatic hypertrophy:781733	8/138,393	20/26,262,527	75.91	1.61e-12	1.23e-10
Ketoconazole\|\|TREATS\|\|Malignant neoplasm of prostate:2383894	41/138,393	55/26,262,527	141.50	5.53e-67	3.37e-64
Organ\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:6691696	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Androgens\|\|AUGMENTS\|\|tumor growth:5833294	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Prostate specific antigen measurement\|\|ISA\|\|Diagnosis:3306477	13/138,393	13/26,262,527	189.79	2.20e-23	3.82e-21
Radical prostatectomy\|\|compared_with\|\|External Beam Radiation Therapy:4011391	18/138,393	21/26,262,527	162.68	5.01e-31	1.19e-28
Thalidomide\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9330008	12/138,393	15/26,262,527	151.83	6.95e-21	1.04e-18
Strontium-89\|\|TREATS\|\|Bone pain:3540349	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Radical prostatectomy\|\|compared_with\|\|Brachytherapy:8219407	16/138,393	18/26,262,527	168.70	6.55e-28	1.35e-25
Isoflavones\|\|AFFECTS\|\|Malignant neoplasm of prostate:9832597	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Therapeutic regimen\|\|TREATS\|\|Malignant neoplasm of prostate:4817105	10/138,393	10/26,262,527	189.78	2.76e-18	3.46e-16
Prostatic Neoplasms\|\|PROCESS_OF\|\|Rats, Wistar:2787039	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
cofactor\|\|AFFECTS\|\|androgen receptor activity:8801663	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Glutamate Carboxypeptidase II\|\|ISA\|\|Hydrolase:6651004	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
atrial natriuretic factor prohormone (31-67)\|\|ISA\|\|Atrial Natriuretic Factor:6283061	6/138,393	28/26,262,527	40.67	2.46e-08	1.12e-06
Cessation of life\|\|PROCESS_OF\|\|cohort:526160	18/138,393	737/26,262,527	4.64	1.88e-07	6.64e-06
Candidate Disease Gene\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:7358557	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Amino Acids\|\|TREATS\|\|Malignant neoplasm of prostate:7236756	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
terazosine\|\|DISRUPTS\|\|Cancer Cell Growth:8753301	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Neoplasm Metastasis\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:153221	68/138,393	73/26,262,527	176.86	9.73e-115	1.16e-111
Orchiectomy\|\|TREATS\|\|Neoplasm Metastasis:2972619	7/138,393	10/26,262,527	132.84	2.02e-12	1.52e-10
Androgen Receptor\|AR\|\|INTERACTS_WITH\|\|Chromatin:1572217	5/138,393	9/26,262,527	105.43	7.62e-09	3.62e-07
MicroRNAs\|\|INTERACTS_WITH\|\|Androgens:12445643	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Rat Cell Line\|\|PART_OF\|\|Prostate carcinoma:4424862	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Prostatectomy, Retropubic\|\|TREATS\|\|High-Risk Cancer:15140083	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Orchiectomy\|\|TREATS\|\|Prostate cancer stage IV:1740798	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Breast\|\|PART_OF\|\|Caucasoid Race:99188	6/138,393	18/26,262,527	63.26	2.58e-09	1.30e-07
Prognostic Factor\|\|PROCESS_OF\|\|Biopsy sample:2623877	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Outpatients:5589900	15/138,393	16/26,262,527	177.93	1.72e-26	3.38e-24
Radical prostatectomy\|\|TREATS\|\|Control Groups:6381266	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Endocrine therapy\|\|USES\|\|Flutamide:2846976	9/138,393	12/26,262,527	142.33	8.30e-16	8.48e-14
Validation\|\|USES\|\|Longitudinal Studies:887862	47/138,393	1,135/26,262,527	7.86	7.56e-26	1.45e-23
Lymphoma, Non-Hodgkin's\|\|ASSOCIATED_WITH\|\|Prostate:7121790	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Chemoprevention\|\|AFFECTS\|\|Malignant neoplasm of prostate:8843492	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Malignant neoplasm of urinary bladder\|\|ISA\|\|Cancer of Urinary Tract:2289329	8/138,393	14/26,262,527	108.44	1.71e-13	1.48e-11
S-Phase Fraction\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:4866437	12/138,393	13/26,262,527	175.19	2.10e-21	3.22e-19
Leuprolide Acetate\|\|ISA\|\|Leuprolide:4992707	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Entire small artery\|\|LOCATION_OF\|\|Systemic arterial pressure:139612	5/138,393	11/26,262,527	86.26	1.65e-08	7.59e-07
Prostate-Specific Antigen\|\|ISA\|\|Diagnosis:5610874	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Polymerase Chain Reaction\|\|DIAGNOSES\|\|Benign prostatic hypertrophy:9001663	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Blood Tests\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:88954	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Leuprolide\|\|ISA\|\|Gonadorelin\|GNRH1:2327756	5/138,393	17/26,262,527	55.82	9.68e-08	3.54e-06
paracrine\|\|PROCESS_OF\|\|Stroma:3137081	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Calcitonin\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:11404747	8/138,393	7/26,262,527	216.89	3.55e-15	3.52e-13
Androgens\|\|CAUSES\|\|Down-Regulation:6567950	5/138,393	8/26,262,527	118.61	4.92e-09	2.37e-07
Human tissue\|\|LOCATION_OF\|\|Integrins:5222872	5/138,393	11/26,262,527	86.26	1.65e-08	7.59e-07
Ileal conduit procedure\|\|ISA\|\|Urinary Diversion:323847	25/138,393	395/26,262,527	12.01	1.57e-18	2.03e-16
E2F3\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:11571526	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Cell Transformation, Neoplastic\|\|PART_OF\|\|Prostatic epithelium:632248	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Malignant neoplasm of prostate\|\|AFFECTS\|\|tumor growth:4610884	12/138,393	12/26,262,527	189.78	1.10e-21	1.72e-19
Application procedure\|\|TREATS\|\|AIDS related complex:2518943	6/138,393	20/26,262,527	56.93	4.37e-09	2.14e-07
Gonadorelin\|GNRH1\|\|TREATS\|\|Advanced cancer:3164537	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Acid Phosphatase\|\|ASSOCIATED_WITH\|\|Prostate:64323	10/138,393	51/26,262,527	37.21	1.11e-12	8.60e-11
Radical perineal prostatectomy\|\|compared_with\|\|Radical retropubic prostatectomy:5782953	5/138,393	10/26,262,527	94.89	1.14e-08	5.31e-07
Surgical margins\|\|LOCATION_OF\|\|Biopsy:3883826	5/138,393	11/26,262,527	86.26	1.65e-08	7.59e-07
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Western society:5861271	18/138,393	18/26,262,527	189.79	7.40e-32	1.83e-29
Metalloproteases\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:10465823	5/138,393	4/26,262,527	237.22	4.90e-10	2.87e-08
Toremifene\|\|PREDISPOSES\|\|Fracture:12728737	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
Glutamate Carboxypeptidase II\|\|ISA\|\|Carboxypeptidase:7077286	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Radiotherapy, Conformal\|\|TREATS\|\|Carcinoma:5709778	8/138,393	17/26,262,527	89.31	5.69e-13	4.59e-11
Polychlorinated Biphenyls\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:10203509	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
TRANSCRIPTION FACTOR\|\|PART_OF\|\|Malignant neoplasm of prostate:12973026	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Estramustine\|\|TREATS\|\|Malignant neoplasm of prostate:1533345	40/138,393	47/26,262,527	161.55	4.70e-67	2.88e-64
Calcitriol\|\|AFFECTS\|\|Malignant neoplasm of prostate:9876417	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Prostatic Tissue\|\|LOCATION_OF\|\|FLVCR1:11619575	5/138,393	2/26,262,527	474.44	8.24e-11	5.13e-09
Therapeutic Intervention\|\|TREATS\|\|Malignant neoplasm of prostate:3820634	22/138,393	22/26,262,527	189.80	1.27e-38	4.06e-36
Transurethral Resection of Prostate\|\|TREATS\|\|Large prostate:3338031	6/138,393	42/26,262,527	27.11	2.11e-07	7.41e-06
Rat Cell Line\|\|PART_OF\|\|Malignant neoplasm of prostate:3265254	44/138,393	51/26,262,527	163.77	8.71e-74	6.11e-71
Androgen Receptor\|AR\|\|INTERACTS_WITH\|\|Androgens:1153537	45/138,393	127/26,262,527	67.26	7.30e-62	4.05e-59
Cell Therapy\|\|TREATS\|\|Malignant neoplasm of prostate:8116445	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Gossypol\|\|CAUSES\|\|Hypoprothrombinemias:105553	20/138,393	1/26,262,527	3795.90	5.12e-45	2.01e-42
Dutasteride\|\|USES\|\|Dutasteride:10240690	22/138,393	78/26,262,527	53.53	3.34e-29	7.32e-27
Mitoxantrone\|\|TREATS\|\|High-Risk Cancer:11780565	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Pharmacological Treatment\|\|TREATS\|\|Malignant neoplasm of prostate:9871251	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Androgen therapy\|\|TREATS\|\|Body Composition:10615544	13/138,393	13/26,262,527	189.79	2.20e-23	3.82e-21
lycopene\|\|ISA\|\|Antioxidants:6638196	17/138,393	153/26,262,527	21.09	8.11e-17	9.28e-15
prognostic\|\|ISA\|\|Purpose:284554	18/138,393	670/26,262,527	5.10	4.81e-08	2.03e-06
docetaxel\|\|ISA\|\|Antineoplastic Agents:6240453	40/138,393	172/26,262,527	44.14	6.74e-49	2.93e-46
Dutasteride\|\|INHIBITS\|\|Oxidoreductase:7948224	20/138,393	46/26,262,527	82.52	7.92e-30	1.78e-27
Prostate\|\|PART_OF\|\|Mice, Transgenic:5553346	48/138,393	72/26,262,527	126.56	2.07e-76	1.52e-73
KLK3 gene\|KLK3\|\|COEXISTS_WITH\|\|Testosterone:8619718	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Radioimmunotherapy\|\|TREATS\|\|Prostate cancer metastatic:8003632	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
NODE\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:4079941	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Chromosome abnormality\|\|COEXISTS_WITH\|\|Prostatic Neoplasms:7087409	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Head\|\|LOCATION_OF\|\|Prostate:1413982	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Dendritic Cells\|\|PART_OF\|\|Malignant neoplasm of prostate:7544997	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Exploration procedure\|\|TREATS\|\|Malignant neoplasm of prostate:1746522	11/138,393	10/26,262,527	208.76	2.76e-20	4.03e-18
Adiponectin\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:13830788	8/138,393	13/26,262,527	116.79	1.09e-13	9.55e-12
Fatty Acids, Omega-3\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:11628160	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Transrectal Ultrasound\|\|USES\|\|Probes:3822787	5/138,393	10/26,262,527	94.89	1.14e-08	5.31e-07
Epidermal Growth Factor\|EGF\|\|ISA\|\|Growth Factor:906270	20/138,393	833/26,262,527	4.56	5.30e-08	2.07e-06
Assessment procedure\|\|USES\|\|Choline:3582528	5/138,393	12/26,262,527	79.07	2.32e-08	1.06e-06
Androgen Receptor\|AR\|\|PART_OF\|\|Stroma:8151860	12/138,393	33/26,262,527	69.01	1.05e-17	1.27e-15
Radiotherapy, Conformal\|\|TREATS\|\|Toxic effect:8298303	13/138,393	27/26,262,527	91.38	2.38e-20	3.50e-18
HK2 gene\|HK2\|\|compared_with\|\|Prostate-Specific Antigen:8244540	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Pathologic stage\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:6712201	19/138,393	21/26,262,527	171.72	5.53e-33	1.43e-30
Thalidomide\|\|ISA\|\|Angiogenesis Inhibitors:6475059	9/138,393	84/26,262,527	20.33	1.93e-09	9.80e-08
Lymph node excision\|\|TREATS\|\|Prostate carcinoma:1323216	11/138,393	10/26,262,527	208.76	2.76e-20	4.03e-18
Cell Transformation, Neoplastic\|\|PART_OF\|\|Prostate:3338620	12/138,393	14/26,262,527	162.67	3.88e-21	5.87e-19
E-Cadherin\|\|ISA\|\|Cell Adhesion Molecules:2792681	12/138,393	266/26,262,527	8.56	4.16e-08	1.85e-06
Stroma\|\|ASSOCIATED_WITH\|\|Neoplasm progression:6206113	8/138,393	57/26,262,527	26.64	2.21e-09	1.11e-07
Vaccines\|\|INTERACTS_WITH\|\|Prostate-Specific Antigen:9559656	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Supplementation\|\|USES\|\|Iron:173100	3/138,393	4,716/26,262,527	0.12	9.15e-08	3.42e-06
UVRAG\|TP63\|CKAP4\|\|ASSOCIATED_WITH\|\|Gland structure:9756808	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
CXCR4 gene\|CXCR4\|\|ASSOCIATED_WITH\|\|Prostate cancer metastatic:9530346	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Androgens\|\|ISA\|\|Gonadal Steroid Hormones:2763954	7/138,393	47/26,262,527	28.26	1.55e-08	7.19e-07
Prostate-Specific Antigen\|\|INTERACTS_WITH\|\|AR gene\|AR:10849037	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
KLK3 gene\|KLK3\|\|PART_OF\|\|Prostate carcinoma:5982187	5/138,393	9/26,262,527	105.43	7.62e-09	3.62e-07
Stanolone\|\|STIMULATES\|\|Luciferases:7112455	6/138,393	9/26,262,527	126.52	9.97e-11	6.13e-09
Prostate-Specific Antigen\|\|PART_OF\|\|Recombinants:6416818	10/138,393	19/26,262,527	99.88	2.86e-16	3.02e-14
Core needle biopsy\|\|ISA\|\|Biopsy:4981696	17/138,393	68/26,262,527	47.45	3.88e-22	6.31e-20
PTEN gene\|PTEN\|\|AFFECTS\|\|Malignant neoplasm of prostate:9421702	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
Prostatic Tissue\|\|LOCATION_OF\|\|Zonal:2858586	6/138,393	9/26,262,527	126.52	9.97e-11	6.13e-09
Left ventricular structure\|\|LOCATION_OF\|\|Contraction:286430	1/138,393	3,628/26,262,527	0.05	2.10e-07	7.39e-06
Carcinoma\|\|PART_OF\|\|Bladder:831	397/138,393	6,008/26,262,527	12.57	3.13e-275	1.04e-271
Magnetic Resonance Imaging\|\|PRECEDES\|\|Radical prostatectomy:7727207	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Food\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:10634241	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Androgens\|\|INTERACTS_WITH\|\|Growth Factor:703151	6/138,393	14/26,262,527	81.33	7.55e-10	4.37e-08
Teleradiotherapy procedure\|\|TREATS\|\|Locally Advanced Malignant Neoplasm:540817	24/138,393	31/26,262,527	146.94	3.94e-40	1.33e-37
Chemoprevention\|\|USES\|\|lycopene:11507638	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Biopsy\|\|METHOD_OF\|\|Transrectal Ultrasound:3863909	13/138,393	13/26,262,527	189.79	2.20e-23	3.82e-21
Proto-Oncogene Proteins c-akt\|AKT1\|\|STIMULATES\|\|Androgen Receptor\|AR:8898033	6/138,393	8/26,262,527	142.33	6.01e-11	3.76e-09
Disease Progression\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:4129805	46/138,393	45/26,262,527	194.05	2.02e-79	1.54e-76
Prostate-Specific Antigen\|\|ASSOCIATED_WITH\|\|Asthenia:6514163	6/138,393	8/26,262,527	142.33	6.01e-11	3.76e-09
Radical prostatectomy\|\|TREATS\|\|Positive Lymph Node:4968248	14/138,393	15/26,262,527	177.13	8.52e-25	1.56e-22
Single Nucleotide Polymorphism\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:9560706	54/138,393	56/26,262,527	183.06	5.11e-92	4.71e-89
Benign prostatic hypertrophy\|\|PROCESS_OF\|\|Control Groups:1771465	10/138,393	15/26,262,527	126.52	4.77e-17	5.53e-15
Carcinoma of the Large Intestine\|\|PROCESS_OF\|\|Survivors:3623558	23/138,393	722/26,262,527	6.05	2.97e-11	1.97e-09
TP53 gene\|TP53\|\|ASSOCIATED_WITH\|\|Prostate carcinoma:5064552	14/138,393	17/26,262,527	156.30	2.88e-24	5.18e-22
PIM1 gene\|PIM1\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:13253650	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
Vitamin E\|\|TREATS\|\|Malignant neoplasm of prostate:3199656	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
Goserelin\|\|TREATS\|\|Carcinoma:5177748	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostatic Tissue\|\|PART_OF\|\|Prostate:2478436	10/138,393	13/26,262,527	145.99	1.68e-17	1.99e-15
Colon\|\|LOCATION_OF\|\|Malignant neoplasm of prostate:4910419	4/138,393	3/26,262,527	253.03	2.61e-08	1.17e-06
Androgen Receptor\|\|AFFECTS\|\|Signal Transduction:12045549	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Secondary malignant neoplasm of lymph node\|\|PART_OF\|\|Prostate:4481720	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Vitamins\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:10504259	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Cholesterol\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:671822	11/138,393	13/26,262,527	160.59	1.92e-19	2.59e-17
radiologist\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:7090354	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Prostate\|\|LOCATION_OF\|\|Infiltration:140324	20/138,393	50/26,262,527	75.92	3.09e-29	6.80e-27
Epidermal Growth Factor Receptor\|EGFR\|\|ASSOCIATED_WITH\|\|Prostatic Neoplasms:6018086	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Castration\|\|AFFECTS\|\|tumor growth:1141130	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Lower urinary tract symptoms\|\|PREDISPOSES\|\|Erectile dysfunction:10708488	5/138,393	15/26,262,527	63.26	5.75e-08	2.23e-06
daidzein\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:13219931	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Exercise\|\|TREATS\|\|Cancer Survivor:9522817	7/138,393	72/26,262,527	18.45	2.27e-07	7.96e-06
Antioxidants\|\|PREVENTS\|\|Malignant neoplasm of prostate:10035645	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Polymorphism, Genetic\|\|ASSOCIATED_WITH\|\|Insulin-Like Growth Factor Binding Protein 3:10572436	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Gastrin releasing peptide\|\|INTERACTS_WITH\|\|Gastrin releasing peptide\|GRP:17235085	11/138,393	18/26,262,527	115.98	2.60e-18	3.34e-16
abiraterone\|\|INHIBITS\|\|Androgens:15936514	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Clinical Trials\|\|USES\|\|End Point:1836855	50/138,393	1,592/26,262,527	5.96	2.37e-22	3.89e-20
Prostate-Specific Antigen\|\|lower_than\|\|Prostate-Specific Antigen:4869480	5/138,393	8/26,262,527	118.61	4.92e-09	2.37e-07
Neoplasm progression\|\|PART_OF\|\|Breast:2673896	55/138,393	2,530/26,262,527	4.13	1.75e-17	2.07e-15
Seminal Vesicles\|\|LOCATION_OF\|\|Infiltration:1191283	44/138,393	54/26,262,527	154.67	5.26e-73	3.61e-70
gemcitabine\|\|TREATS\|\|Malignant neoplasm of prostate:11772775	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostate-Specific Antigen\|\|ASSOCIATED_WITH\|\|Breast:6726408	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Pelvic lymph node group\|\|LOCATION_OF\|\|Micrometastasis:6708087	9/138,393	23/26,262,527	74.26	7.52e-14	6.62e-12
Antineoplastic Agents\|\|TREATS\|\|Prostate cancer metastatic:1763031	10/138,393	8/26,262,527	237.23	6.60e-19	8.72e-17
Radiopharmaceuticals\|\|TREATS\|\|Prostate cancer metastatic:14124224	13/138,393	13/26,262,527	189.79	2.20e-23	3.82e-21
Functional RNA\|\|AFFECTS\|\|Gene Expression:10615559	22/138,393	1,002/26,262,527	4.17	5.37e-08	2.10e-06
Magnetic Resonance Imaging\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:3289067	289/138,393	330/26,262,527	166.54	0.00e+00	0.00e+00
GNRH1 gene\|GNRH1\|\|DISRUPTS\|\|tumor growth:2723454	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Pelvis\|\|LOCATION_OF\|\|Secondary malignant neoplasm of bone:2580440	12/138,393	65/26,262,527	35.04	1.15e-14	1.09e-12
Structure of great blood vessel (organ)\|\|LOCATION_OF\|\|Laceration:249577	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Epidermal growth factor receptor inhibitor\|\|TREATS\|\|Malignant neoplasm of prostate:12232146	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Aspirin\|\|ISA\|\|Anti-Inflammatory Agents, Non-Steroidal:531247	29/138,393	1,008/26,262,527	5.46	9.71e-13	7.55e-11
Transurethral Resection of Prostate\|\|PRECEDES\|\|Radical prostatectomy:1216759	14/138,393	20/26,262,527	132.85	1.49e-23	2.62e-21
ETS1 gene\|ETS1\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8886049	24/138,393	31/26,262,527	146.94	3.94e-40	1.33e-37
Digital Rectal Examination\|\|DIAGNOSES\|\|Benign prostatic hypertrophy:5586739	5/138,393	12/26,262,527	79.07	2.32e-08	1.06e-06
Breast\|\|LOCATION_OF\|\|loss; bone:11263864	9/138,393	12/26,262,527	142.33	8.30e-16	8.48e-14
Risk Reduction\|\|USES\|\|Dutasteride:13599958	11/138,393	11/26,262,527	189.78	5.49e-20	7.78e-18
Orchiectomy\|\|TREATS\|\|Prostate carcinoma:468011	34/138,393	44/26,262,527	146.67	3.33e-56	1.67e-53
ERBB2 gene\|ERBB2\|\|PART_OF\|\|Malignant neoplasm of prostate:5721795	12/138,393	15/26,262,527	151.83	6.95e-21	1.04e-18
Castration, Male\|\|TREATS\|\|Carcinoma:38047	7/138,393	5/26,262,527	265.69	8.42e-14	7.41e-12
Phytoestrogens\|\|TREATS\|\|Malignant neoplasm of prostate:9975383	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Prednisone\|\|compared_with\|\|Mitoxantrone:11143631	10/138,393	11/26,262,527	172.53	5.24e-18	6.40e-16
E-Cadherin\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:5124241	28/138,393	38/26,262,527	139.86	3.93e-46	1.58e-43
Seed Implantation\|\|METHOD_OF\|\|Brachytherapy:6834341	6/138,393	10/26,262,527	113.87	1.59e-10	9.61e-09
Androgen therapy\|\|TREATS\|\|Neoplasm Metastasis:5391592	17/138,393	17/26,262,527	189.79	3.65e-30	8.38e-28
Chromosomes, Human, Pair 2\|\|LOCATION_OF\|\|Malignant neoplasm of prostate:4789025	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Glutathione S-Transferase\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8087359	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
Proto-Oncogene Proteins c-akt\|AKT1\|\|INHIBITS\|\|1-Phosphatidylinositol 3-Kinase:8518019	8/138,393	98/26,262,527	15.49	1.09e-07	3.98e-06
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Black race:1413216	47/138,393	59/26,262,527	151.22	1.53e-77	1.15e-74
Breast\|\|LOCATION_OF\|\|Carcinoma of the Large Intestine:10459606	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Induction\|\|USES\|\|Androgens:565783	55/138,393	183/26,262,527	57.06	6.63e-72	4.48e-69
degarelix\|\|INHIBITS\|\|Testosterone:13518948	12/138,393	13/26,262,527	175.19	2.10e-21	3.22e-19
Malignant neoplasm of prostate\|\|COEXISTS_WITH\|\|Prostatic Intraepithelial Neoplasias:5478295	11/138,393	13/26,262,527	160.59	1.92e-19	2.59e-17
Adenocarcinoma\|\|ISA\|\|Carcinoma:27087	21/138,393	262/26,262,527	15.21	9.72e-18	1.17e-15
Flutamide\|\|DISRUPTS\|\|tumor growth:3756977	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
AMACR protein, human\|AMACR\|\|PART_OF\|\|Malignant neoplasm of prostate:10134190	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Brachytherapy\|\|TREATS\|\|Malignant neoplasm of prostate:2006364	743/138,393	964/26,262,527	147.05	0.00e+00	0.00e+00
Teleradiotherapy procedure\|\|TREATS\|\|cohort:10008557	6/138,393	8/26,262,527	142.33	6.01e-11	3.76e-09
dehydroepiandrosterone\|\|ISA\|\|Steroids:632420	12/138,393	290/26,262,527	7.85	1.02e-07	3.74e-06
Neoplasm progression\|\|ASSOCIATED_WITH\|\|Prostate:5262993	19/138,393	19/26,262,527	189.79	1.50e-33	4.01e-31
Goserelin\|\|USES\|\|Goserelin:3353808	17/138,393	69/26,262,527	46.76	4.81e-22	7.78e-20
Flutamide\|\|TREATS\|\|Metastatic Carcinoma:1942308	5/138,393	4/26,262,527	237.22	4.90e-10	2.87e-08
Glycoproteins\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8735675	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
Brachytherapy\|\|USES\|\|IODINE,I-125:2618555	21/138,393	47/26,262,527	84.80	1.90e-31	4.63e-29
Radical prostatectomy\|\|TREATS\|\|Localized Carcinoma:1236580	21/138,393	24/26,262,527	166.07	4.30e-36	1.26e-33
Prostatectomy\|\|TREATS\|\|Carcinoma:23639	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
Interstitial brachytherapy\|\|USES\|\|IODINE,I-125:5988154	7/138,393	15/26,262,527	88.56	1.73e-11	1.23e-09
Prostate\|\|LOCATION_OF\|\|Abnormal shape:11562661	5/138,393	8/26,262,527	118.61	4.92e-09	2.37e-07
Estradiol\|\|DISRUPTS\|\|tumor growth:2194571	7/138,393	17/26,262,527	78.14	3.48e-11	2.23e-09
Prostatectomy\|\|PRECEDES\|\|Endocrine therapy:9338699	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Mucins\|\|CAUSES\|\|Adenocarcinoma:1329672	6/138,393	18/26,262,527	63.26	2.58e-09	1.30e-07
Proto-Oncogene Proteins c-akt\|AKT1\|\|AFFECTS\|\|androgen receptor activity:10434478	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prognosis bad\|\|PROCESS_OF\|\|Cancer Patient:2191337	9/138,393	153/26,262,527	11.16	2.45e-07	8.50e-06
Chlormadinone Acetate\|\|TREATS\|\|Malignant neoplasm of prostate:860098	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Malignant neoplasm of prostate\|\|AFFECTS\|\|Aggressive behavior:10794556	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Prednisone\|\|compared_with\|\|docetaxel:11143630	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Induction\|\|AFFECTS\|\|Malignant neoplasm of prostate:5391606	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Calcitriol\|\|ISA\|\|Dihydroxycholecalciferols:1638005	9/138,393	79/26,262,527	21.62	1.18e-09	6.21e-08
Prostate-Specific Antigen\|\|NEG_ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8244550	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Gonadorelin\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:3657505	12/138,393	14/26,262,527	162.67	3.88e-21	5.87e-19
AR gene\|AR\|\|PART_OF\|\|Prostate carcinoma:4428213	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
PSCA gene\|PSCA\|\|ASSOCIATED_WITH\|\|Pancreatic carcinoma:11319922	5/138,393	10/26,262,527	94.89	1.14e-08	5.31e-07
Teleradiotherapy procedure\|\|TREATS\|\|Adenocarcinoma of prostate:3157582	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
maspin\|SERPINB5\|\|ISA\|\|Tumor Suppressor Genes:6354460	11/138,393	33/26,262,527	63.26	5.37e-16	5.56e-14
Hypophysectomy\|\|TREATS\|\|Malignant neoplasm of prostate:446373	5/138,393	3/26,262,527	316.29	2.19e-10	1.31e-08
Androgens, Synthetic\|\|STIMULATES\|\|Androgen Receptor\|AR:4802895	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Free prostate-specific antigen\|\|USES\|\|Digital Rectal Examination:8544380	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Mass Screening\|\|USES\|\|Reagents, Immunoassay, Tumor Marker, Enzyme, Prostate Specific Antigen:5671551	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Residual Cancer\|\|ASSOCIATED_WITH\|\|Prostate:4079937	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Psychotherapy, Multiple\|\|TREATS\|\|Malignant neoplasm of prostate:4167238	24/138,393	26/26,262,527	175.20	1.97e-41	6.98e-39
Single Nucleotide Polymorphism\|\|COEXISTS_WITH\|\|Prostate-Specific Antigen:12599489	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
established cell line\|\|PART_OF\|\|Prostate carcinoma:7088243	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Aspirin\|\|PREVENTS\|\|Malignant neoplasm of prostate:10195160	11/138,393	12/26,262,527	173.97	1.05e-19	1.44e-17
Androgen therapy\|\|TREATS\|\|Age:11433478	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Hydroxymethylglutaryl-CoA Reductase Inhibitors\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:13160095	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Prostate cancer metastatic\|\|PROCESS_OF\|\|Mice, Nude:10216862	7/138,393	6/26,262,527	221.41	1.82e-13	1.56e-11
Zonal\|\|COEXISTS_WITH\|\|Zonal:319241	60/138,393	2,354/26,262,527	4.84	4.11e-22	6.69e-20
Early Diagnosis\|\|METHOD_OF\|\|Biopsy:2428268	12/138,393	28/26,262,527	81.34	2.10e-18	2.71e-16
AR gene\|AR\|\|INTERACTS_WITH\|\|AR gene\|AR:9131624	14/138,393	21/26,262,527	126.52	2.47e-23	4.27e-21
Prostate\|\|LOCATION_OF\|\|Tumor cells, malignant:5980163	22/138,393	22/26,262,527	189.80	1.27e-38	4.06e-36
Radical prostatectomy\|\|TREATS\|\|Curative treatment:4162332	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Carcinoma\|\|AFFECTS\|\|Liver function:144700	6/138,393	1/26,262,527	1138.66	1.45e-13	1.26e-11
Prostate implantation\|\|TREATS\|\|Malignant neoplasm of prostate:2344777	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Androgen therapy\|\|PREDISPOSES\|\|Cardiovascular Diseases:12653371	11/138,393	13/26,262,527	160.59	1.92e-19	2.59e-17
taxane\|\|TREATS\|\|Malignant neoplasm of prostate:16767836	4/138,393	3/26,262,527	253.03	2.61e-08	1.17e-06
T-Lymphocyte\|\|PART_OF\|\|Malignant neoplasm of prostate:10564114	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Androgen Receptor\|\|PART_OF\|\|Malignant neoplasm of prostate:5801640	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Aspirin\|\|AFFECTS\|\|Malignant neoplasm of prostate:8490489	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Castration Cell\|\|LOCATION_OF\|\|docetaxel:15898166	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Division (procedure)\|\|USES\|\|Paraffin:606	104/138,393	7,496/26,262,527	2.63	2.03e-17	2.40e-15
Human Glandular Kallikrein 2\|HK2\|\|ISA\|\|Tissue Kallikrein:6307085	44/138,393	60/26,262,527	139.21	1.55e-71	1.03e-68
deoxypyridinoline\|\|PREDISPOSES\|\|Secondary malignant neoplasm of bone:6505561	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Oncogenes\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:4606718	15/138,393	13/26,262,527	218.99	2.18e-27	4.41e-25
Prostate\|\|LOCATION_OF\|\|AR gene\|AR:2375652	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Bladder\|\|LOCATION_OF\|\|Adverse effects:1177918	10/138,393	44/26,262,527	43.13	3.04e-13	2.59e-11
Androgen Suppression\|\|NEG_TREATS\|\|Malignant neoplasm of prostate:8767555	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Bombesin Receptor\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:14739303	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Tertiary referral hospital\|\|LOCATION_OF\|\|Biopsy:7663632	7/138,393	31/26,262,527	42.85	1.19e-09	6.28e-08
Casodex\|\|compared_with\|\|Castration:4643513	8/138,393	14/26,262,527	108.44	1.71e-13	1.48e-11
Endocrine therapy\|\|TREATS\|\|[M]Adenocarcinoma, metastatic, NOS:2761882	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Probes\|\|TREATS\|\|Malignant neoplasm of prostate:3526521	18/138,393	20/26,262,527	170.81	2.71e-31	6.53e-29
Prostatectomy\|\|TREATS\|\|Prostate carcinoma:4480253	14/138,393	17/26,262,527	156.30	2.88e-24	5.18e-22
Paclitaxel\|\|TREATS\|\|Cancer Model:7684432	6/138,393	18/26,262,527	63.26	2.58e-09	1.30e-07
adjuvant therapy\|\|TREATS\|\|Malignant neoplasm of prostate:3134322	45/138,393	51/26,262,527	167.50	9.73e-76	7.10e-73
Estradiol\|\|AUGMENTS\|\|Prostate:1932138	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
High-Grade Prostatic Intraepithelial Neoplasia\|\|COEXISTS_WITH\|\|High-Grade Prostatic Intraepithelial Neoplasia:6695291	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Operation on prostate\|\|TREATS\|\|Benign prostatic hypertrophy:2388320	8/138,393	21/26,262,527	72.30	2.22e-12	1.66e-10
Prostate\|\|LOCATION_OF\|\|Glandular proliferation:5879278	5/138,393	10/26,262,527	94.89	1.14e-08	5.31e-07
Goserelin Acetate\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:5718511	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Nerve\|\|LOCATION_OF\|\|Preservation, Biological:131118	17/138,393	121/26,262,527	26.66	2.24e-18	2.89e-16
Multiple malignancy\|\|PART_OF\|\|Prostate:85518	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Estrogen Receptor beta\|ESR2\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:10078336	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Tumor Immunity\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:1518261	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Malignant neoplasm of prostate\|\|LOCATION_OF\|\|TP53 gene\|TP53:6076323	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Radical retropubic prostatectomy\|\|PRECEDES\|\|Radical prostatectomy:9307543	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Carcinoma, Transitional Cell\|\|ASSOCIATED_WITH\|\|Prostatic Urethra:2761877	9/138,393	16/26,262,527	106.75	5.66e-15	5.57e-13
Health Personnel\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:10142348	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Health care facility\|\|LOCATION_OF\|\|Magnetic Resonance Imaging:2578426	11/138,393	202/26,262,527	10.33	2.46e-08	1.12e-06
Intestines\|\|LOCATION_OF\|\|Adverse effects:169852	12/138,393	130/26,262,527	17.52	2.00e-11	1.33e-09
Tumor cells, malignant\|\|PART_OF\|\|Prostate:2582995	376/138,393	402/26,262,527	177.98	0.00e+00	0.00e+00
GSTM1 gene\|GSTM1\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:11045623	10/138,393	11/26,262,527	172.53	5.24e-18	6.40e-16
TRANCE protein\|\|compared_with\|\|zoledronic acid:14573367	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|sibling:6107159	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Human Age Group\|\|LOCATION_OF\|\|KLK3 gene\|KLK3:6122599	6/138,393	10/26,262,527	113.87	1.59e-10	9.61e-09
Radical prostatectomy\|\|METHOD_OF\|\|Salvage Therapy:7975033	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Osteoporosis\|\|PROCESS_OF\|\|Cancer Patient:6505559	8/138,393	19/26,262,527	79.91	1.16e-12	8.96e-11
Cruciferous Vegetable\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:8460995	8/138,393	7/26,262,527	216.89	3.55e-15	3.52e-13
Dendritic Cell Vaccine\|\|TREATS\|\|Malignant neoplasm of prostate:12825593	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
adjuvant therapy\|\|TREATS\|\|Prostate carcinoma:2307804	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Japanese Americans:7296948	6/138,393	9/26,262,527	126.52	9.97e-11	6.13e-09
Tissue specimen\|\|PART_OF\|\|Prostate:910138	85/138,393	96/26,262,527	168.13	1.11e-141	1.69e-138
Iressa\|\|ISA\|\|gefitinib:9746946	17/138,393	438/26,262,527	7.37	6.23e-10	3.63e-08
Complement System Proteins\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:3781939	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Hereditary Malignant Neoplasm\|\|PART_OF\|\|Prostate:10168851	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Tumor Suppressor Genes\|\|PART_OF\|\|Prostate:6486467	33/138,393	40/26,262,527	156.60	2.84e-55	1.39e-52
Androgens\|\|ASSOCIATED_WITH\|\|Tumorigenesis:1339137	8/138,393	12/26,262,527	126.52	6.79e-14	6.00e-12
immortalized cell\|\|PART_OF\|\|Prostate:11027135	10/138,393	12/26,262,527	158.15	9.56e-18	1.15e-15
Secondary malignant neoplasm of bone\|\|PROCESS_OF\|\|SCID Mice:6149833	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Medical Imaging\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:1204013	20/138,393	21/26,262,527	180.76	5.94e-35	1.66e-32
Androgen Receptor\|AR\|\|AFFECTS\|\|Cell Survival:11806458	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Microsomes\|\|PART_OF\|\|Prostate:711095	11/138,393	51/26,262,527	40.93	3.26e-14	2.93e-12
Androgen Antagonists\|\|TREATS\|\|Prostate carcinoma:927450	13/138,393	17/26,262,527	145.13	2.49e-22	4.06e-20
Granulocyte-Macrophage Colony-Stimulating Factor\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8172154	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
Genome\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:7380597	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Prostate\|\|LOCATION_OF\|\|[M]Unspecified tumor cell NOS:3371377	22/138,393	25/26,262,527	167.02	8.81e-38	2.76e-35
Epithelium\|\|LOCATION_OF\|\|Prostatic Intraepithelial Neoplasias:6904842	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
melanoma\|\|PART_OF\|\|Ovary:268916	8/138,393	39/26,262,527	38.93	1.49e-10	9.13e-09
Organ\|\|PART_OF\|\|Prostate:1127537	10/138,393	18/26,262,527	105.43	1.89e-16	2.06e-14
Pain management\|\|TREATS\|\|Secondary malignant neoplasm of bone:2550267	8/138,393	17/26,262,527	89.31	5.69e-13	4.59e-11
Bone Marrow\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:1781424	31/138,393	34/26,262,527	173.06	5.74e-53	2.67e-50
Buserelin\|\|TREATS\|\|Malignant neoplasm of prostate:2465816	17/138,393	20/26,262,527	161.32	2.45e-29	5.41e-27
Orchiectomy\|\|compared_with\|\|Estrogens:3210605	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
TMPRSS2 gene\|TMPRSS2\|\|PART_OF\|\|Malignant neoplasm of prostate:13719473	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Secondary malignant neoplasm of bone\|\|LOCATION_OF\|\|Prostate-Specific Antigen:6909966	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Carcinoma\|\|PART_OF\|\|Breast:435	177/138,393	3,948/26,262,527	8.52	1.19e-97	1.17e-94
Protein-tyrosine kinase inhibitor\|\|TREATS\|\|Malignant neoplasm of prostate:7331676	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
Androgen Antagonists\|\|TREATS\|\|Malignant neoplasm of prostate:1375506	203/138,393	219/26,262,527	176.16	0.00e+00	0.00e+00
Leuprolide Acetate\|\|TREATS\|\|Malignant neoplasm of prostate:3066796	28/138,393	34/26,262,527	156.31	4.11e-47	1.69e-44
Testosterone\|\|CAUSES\|\|Malignant neoplasm of prostate:3065602	19/138,393	20/26,262,527	180.30	2.92e-33	7.71e-31
Prostate-Specific Antigen\|\|ASSOCIATED_WITH\|\|Carcinoma:3627166	12/138,393	13/26,262,527	175.19	2.10e-21	3.22e-19
Slinging procedure\|\|TREATS\|\|Incontinence:204153	8/138,393	83/26,262,527	18.29	3.29e-08	1.47e-06
Estrogens\|\|ASSOCIATED_WITH\|\|Neoplasm progression:10726359	6/138,393	25/26,262,527	45.55	1.36e-08	6.33e-07
Androgen Receptor\|AR\|\|COEXISTS_WITH\|\|FLVCR1:14780287	4/138,393	1/26,262,527	759.09	3.76e-09	1.84e-07
Biopsy sample\|\|PART_OF\|\|Prostatic Tissue:1013999	6/138,393	8/26,262,527	142.33	6.01e-11	3.76e-09
Tumor Burden\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:2026986	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Estramustine\|\|ASSOCIATED_WITH\|\|Prostate carcinoma:1236594	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Adverse effects\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:8150090	23/138,393	23/26,262,527	189.80	2.59e-40	8.82e-38
Testosterone\|\|ASSOCIATED_WITH\|\|Carcinogenesis:2728062	5/138,393	9/26,262,527	105.43	7.62e-09	3.62e-07
Silence\|\|PROCESS_OF\|\|Transcription, Genetic:4189162	45/138,393	2,346/26,262,527	3.64	8.57e-13	6.67e-11
Active monitoring\|\|TREATS\|\|Malignant neoplasm of prostate:9382249	10/138,393	12/26,262,527	158.15	9.56e-18	1.15e-15
TP53 gene\|TP53\|\|AFFECTS\|\|Malignant neoplasm of prostate:6402909	8/138,393	10/26,262,527	151.82	2.38e-14	2.15e-12
Vasectomy\|\|METHOD_OF\|\|Contraceptive methods:345818	7/138,393	61/26,262,527	21.78	7.97e-08	3.08e-06
Peptide Hydrolases\|\|ASSOCIATED_WITH\|\|Prostate:599125	5/138,393	14/26,262,527	67.78	4.33e-08	1.92e-06
Prostatic Tissue\|\|LOCATION_OF\|\|Dihydrotestosterone Assay:1473763	9/138,393	17/26,262,527	100.47	8.61e-15	8.17e-13
Finasteride\|\|INHIBITS\|\|Prostate size:4966176	5/138,393	17/26,262,527	55.82	9.68e-08	3.54e-06
VAV3 gene\|VAV3\|\|STIMULATES\|\|Androgen Receptor\|AR:11771781	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostatic Neoplasms\|\|PART_OF\|\|Prostate:1577307	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Mass Screening\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:3724286	7/138,393	11/26,262,527	120.77	3.29e-12	2.43e-10
Radiotherapy, Intensity-Modulated\|\|compared_with\|\|Radiotherapy, Conformal:8879243	16/138,393	92/26,262,527	33.01	1.05e-18	1.37e-16
Zinc\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:7508541	12/138,393	13/26,262,527	175.19	2.10e-21	3.22e-19
Prostatectomy\|\|TREATS\|\|Male gender:1720481	9/138,393	11/26,262,527	155.27	4.76e-16	4.94e-14
Glutamate Carboxypeptidase II\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:6555959	34/138,393	41/26,262,527	157.41	5.89e-57	3.00e-54
Single Nucleotide Polymorphism\|\|COEXISTS_WITH\|\|8q24:13099906	5/138,393	11/26,262,527	86.26	1.65e-08	7.59e-07
Diethylstilbestrol\|\|TREATS\|\|Carcinoma:42962	13/138,393	15/26,262,527	164.48	7.85e-23	1.31e-20
Brachytherapy\|\|PRECEDES\|\|Brachytherapy:3565355	21/138,393	42/26,262,527	94.90	2.87e-32	7.29e-30
Peptides\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:2848862	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Cell Adhesion Molecules\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:6723619	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Tumor Initiation\|\|PART_OF\|\|Prostate:7242887	11/138,393	11/26,262,527	189.78	5.49e-20	7.78e-18
Pelvis\|\|LOCATION_OF\|\|Malignant neoplasm of prostate:2264137	11/138,393	11/26,262,527	189.78	5.49e-20	7.78e-18
Lipids\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:7531117	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Lobe\|\|LOCATION_OF\|\|SULFUR,COLLOIDAL:11480916	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Tumor Markers\|\|ASSOCIATED_WITH\|\|Prostate:7520483	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Androgens\|\|AFFECTS\|\|Malignant neoplasm of prostate:4235549	31/138,393	30/26,262,527	196.14	4.01e-54	1.90e-51
zoledronic acid\|\|TREATS\|\|loss; bone:10114216	6/138,393	28/26,262,527	40.67	2.46e-08	1.12e-06
Acid Phosphatase\|\|compared_with\|\|Acid Phosphatase:1226402	6/138,393	22/26,262,527	51.76	7.08e-09	3.39e-07
Adverse effects\|\|CAUSES\|\|Immune response:8735709	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Telomerase\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8012450	8/138,393	10/26,262,527	151.82	2.38e-14	2.15e-12
Systemic Therapy\|\|TREATS\|\|Prostate cancer metastatic:5134647	23/138,393	23/26,262,527	189.80	2.59e-40	8.82e-38
Aggressive behavior\|\|MANIFESTATION_OF\|\|Malignant neoplasm of prostate:10623119	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
KLK3 gene\|KLK3\|\|PART_OF\|\|Adenocarcinoma of prostate:9132052	5/138,393	4/26,262,527	237.22	4.90e-10	2.87e-08
Gonadorelin\|GNRH1\|\|TREATS\|\|Malignant neoplasm of prostate:2743988	44/138,393	49/26,262,527	170.46	2.51e-74	1.79e-71
Stanolone\|\|INTERACTS_WITH\|\|Prostate-Specific Antigen:5821100	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostate\|\|LOCATION_OF\|\|Malignant neoplasm of prostate:2889187	49/138,393	47/26,262,527	197.91	8.83e-85	7.19e-82
Proteome\|\|PART_OF\|\|Prostate:10939965	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Meetings\|\|METHOD_OF\|\|Therapeutic radiology procedure:7305736	13/138,393	25/26,262,527	98.69	1.08e-20	1.61e-18
[M]Unspecified tumor cell NOS\|\|LOCATION_OF\|\|Glutamate Carboxypeptidase II:9789334	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
Prostate-Specific Antigen\|\|INTERACTS_WITH\|\|Finasteride:6251328	7/138,393	14/26,262,527	94.89	1.19e-11	8.48e-10
NME1 gene\|NME1\|\|ASSOCIATED_WITH\|\|Prostate carcinoma:5686999	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
interstitial\|\|LOCATION_OF\|\|Fever:2006419	17/138,393	304/26,262,527	10.61	2.82e-12	2.10e-10
Growth Factor\|\|STIMULATES\|\|Androgen Receptor\|AR:6033060	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
Reactive Oxygen Species\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:12351007	8/138,393	10/26,262,527	151.82	2.38e-14	2.15e-12
Androgens\|\|INTERACTS_WITH\|\|Prostate-Specific Antigen:4704714	22/138,393	31/26,262,527	134.70	2.66e-36	7.90e-34
Ablation\|\|TREATS\|\|Prostate carcinoma:1343442	17/138,393	19/26,262,527	169.81	1.33e-29	2.97e-27
Breast\|\|LOCATION_OF\|\|Carcinoma:96222	13/138,393	76/26,262,527	32.46	2.19e-15	2.20e-13
Screening procedure\|\|TREATS\|\|cohort:2870169	15/138,393	265/26,262,527	10.74	4.49e-11	2.86e-09
Teleradiotherapy procedure\|\|TREATS\|\|Adenocarcinoma:1837790	29/138,393	38/26,262,527	144.85	4.76e-48	2.00e-45
Disseminated Intravascular Coagulation\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:9058563	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Research Personnel:9421682	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Not significant\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:4072035	10/138,393	9/26,262,527	210.87	1.39e-18	1.80e-16
Neoplasm Metastasis\|\|ASSOCIATED_WITH\|\|lymph nodes:47018	39/138,393	980/26,262,527	7.55	3.72e-21	5.68e-19
Cell marker\|\|DIAGNOSES\|\|Prostate carcinoma:11565079	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
HDAC1 gene\|HDAC1\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9277702	5/138,393	9/26,262,527	105.43	7.62e-09	3.62e-07
Multiple Myeloma\|\|PART_OF\|\|Prostate:4508315	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
Androgen Antagonists\|\|INHIBITS\|\|Androgen Receptor\|AR:5620478	13/138,393	25/26,262,527	98.69	1.08e-20	1.61e-18
Screening procedure\|\|ISA\|\|Diagnosis:444889	42/138,393	855/26,262,527	9.32	5.74e-26	1.11e-23
Malignant neoplasm of prostate\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:2006383	211/138,393	219/26,262,527	183.11	0.00e+00	0.00e+00
Prostatic Neoplasms\|\|ASSOCIATED_WITH\|\|Prostate:6286553	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Nonsteroidal antiandrogen\|\|INHIBITS\|\|Androgens:7027940	11/138,393	15/26,262,527	139.17	5.90e-19	7.80e-17
Digital Rectal Examination\|\|METHOD_OF\|\|Ultrasonography:4502032	9/138,393	17/26,262,527	100.47	8.61e-15	8.17e-13
Prostate\|\|LOCATION_OF\|\|Body mass index procedure:14398427	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
long-term care\|\|USES\|\|Gonadotropin-Releasing Hormone Analog:1570212	7/138,393	22/26,262,527	60.38	1.53e-10	9.36e-09
Xenograft procedure\|\|USES\|\|Paclitaxel:8701709	5/138,393	19/26,262,527	49.94	1.55e-07	5.48e-06
Integrins\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:6489540	13/138,393	15/26,262,527	164.48	7.85e-23	1.31e-20
Transfection\|\|USES\|\|DNA, Complementary:2399230	26/138,393	1,258/26,262,527	3.92	1.15e-08	5.38e-07
PTEN gene\|PTEN\|\|ASSOCIATED_WITH\|\|Prostate:7570525	18/138,393	23/26,262,527	148.53	1.61e-30	3.77e-28
docetaxel\|\|DISRUPTS\|\|Cell Growth:10069280	7/138,393	13/26,262,527	102.19	7.94e-12	5.78e-10
Malignant neoplasm of prostate\|\|OCCURS_IN\|\|General Population:5916823	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Estramustine phosphate\|\|TREATS\|\|Malignant neoplasm of prostate:728715	31/138,393	36/26,262,527	163.45	1.99e-52	9.16e-50
prostatitis\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:11264194	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Chronic inflammation\|\|COEXISTS_WITH\|\|Benign prostatic hypertrophy:9608817	5/138,393	13/26,262,527	72.99	3.20e-08	1.43e-06
Prostate\|\|ASSOCIATED_WITH\|\|Prostate cancer metastatic:12621083	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Digital Rectal Examination\|\|DIAGNOSES\|\|Carcinoma:3375186	9/138,393	12/26,262,527	142.33	8.30e-16	8.48e-14
Adenoma of large intestine\|\|ASSOCIATED_WITH\|\|Prostate:11450239	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
GTP-Binding Proteins\|MTG1\|\|PART_OF\|\|Cytoskeleton:11625674	6/138,393	13/26,262,527	87.59	5.31e-10	3.10e-08
[M]Unspecified tumor cell NOS\|\|LOCATION_OF\|\|AR gene\|AR:7331756	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Immigrants:7896792	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Lower urinary tract symptoms\|\|PROCESS_OF\|\|Middle Aged:7448166	5/138,393	18/26,262,527	52.72	1.23e-07	4.49e-06
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|descent:12821601	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Screening procedure\|\|TREATS\|\|Asymptomatic:878801	17/138,393	264/26,262,527	12.22	3.36e-13	2.86e-11
Radical prostatectomy\|\|TREATS\|\|Localized Malignant Neoplasm:3326739	36/138,393	36/26,262,527	189.82	2.92e-62	1.64e-59
OR51E2\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8883880	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Magnetic Resonance Imaging\|\|DIAGNOSES\|\|Prostate cancer recurrent:6936740	15/138,393	18/26,262,527	158.16	5.88e-26	1.13e-23
Prostate-Specific Antigen\|\|ASSOCIATED_WITH\|\|Prostate:1280684	42/138,393	56/26,262,527	142.37	1.16e-68	7.41e-66
bicalutamide\|\|USES\|\|bicalutamide:6828522	54/138,393	82/26,262,527	125.02	1.54e-85	1.27e-82
Chemoprevention\|\|USES\|\|Cyclooxygenase 2 Inhibitors:7927541	7/138,393	70/26,262,527	18.98	1.90e-07	6.70e-06
Magnetic Resonance Imaging\|\|METHOD_OF\|\|Cancer Diagnosis:9319661	12/138,393	21/26,262,527	108.45	1.38e-19	1.88e-17
CD82 gene\|CD82\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:7317495	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
Free testosterone\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:11414572	7/138,393	6/26,262,527	221.41	1.82e-13	1.56e-11
Mesenchyma\|\|PART_OF\|\|Epithelial Cells:3451282	5/138,393	14/26,262,527	67.78	4.33e-08	1.92e-06
Malignant neoplasm of prostate\|\|AFFECTS\|\|Cancer Cell Growth:9407778	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Adenocarcinoma of prostate\|\|ISA\|\|Adenocarcinoma:7722977	6/138,393	5/26,262,527	227.73	9.37e-12	6.74e-10
Androgen Suppression\|\|TREATS\|\|Prostate cancer recurrent:9668476	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Monoamine Oxidase A\|MAOA\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:13099628	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Malignant neoplasm of prostate\|\|AFFECTS\|\|Consumption-archaic term for TB:10212211	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
radiotracer\|\|INTERACTS_WITH\|\|Amino Acid Transporter:17277500	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Cancer Treatment\|\|TREATS\|\|Malignant neoplasm of prostate:7229180	28/138,393	29/26,262,527	183.26	1.81e-48	7.76e-46
Androgen Receptor\|AR\|\|STIMULATES\|\|Stanolone:2424063	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Leuprolide\|\|compared_with\|\|Diethylstilbestrol:2722225	7/138,393	9/26,262,527	147.60	1.19e-12	9.12e-11
Biopsy\|\|METHOD_OF\|\|Core needle biopsy:3074876	7/138,393	28/26,262,527	47.44	6.43e-10	3.75e-08
Insulin-Like-Growth Factor I Receptor\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9234557	11/138,393	12/26,262,527	173.97	1.05e-19	1.44e-17
Bombesin\|\|PART_OF\|\|Amphibia:1487489	13/138,393	77/26,262,527	32.04	2.55e-15	2.56e-13
Mitogen-Activated Protein Kinases\|\|STIMULATES\|\|Androgen Receptor\|AR:9795309	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Doxazosin\|\|USES\|\|Doxazosin:3144553	12/138,393	246/26,262,527	9.26	1.84e-08	8.43e-07
Human Glandular Kallikrein 2\|HK2\|\|compared_with\|\|Prostate-Specific Antigen:7244189	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
RNA, Small Interfering\|\|DISRUPTS\|\|Cell Proliferation:10404990	15/138,393	201/26,262,527	14.16	1.11e-12	8.65e-11
Prostate\|\|PART_OF\|\|Cancer Patient:9839018	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
ADAM9\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:11456739	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Immunohistochemistry\|\|DIAGNOSES\|\|Benign prostatic hypertrophy:5158759	7/138,393	9/26,262,527	147.60	1.19e-12	9.12e-11
Minor pelvis\|\|LOCATION_OF\|\|tomography:1919684	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Digital Rectal Examination\|\|METHOD_OF\|\|Antigen assay:7192956	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Upper Extremity\|\|PART_OF\|\|Ovaro-:11843052	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Androgen Receptor\|AR\|\|PART_OF\|\|[M]Unspecified tumor cell NOS:5067329	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Magnetic Resonance Imaging\|\|DIAGNOSES\|\|Neoplasm Metastasis:3026752	16/138,393	203/26,262,527	14.96	9.10e-14	8.00e-12
Neuroendocrine Cell\|\|PRODUCES\|\|Hormones:2463346	5/138,393	17/26,262,527	55.82	9.68e-08	3.54e-06
Androgens\|\|INTERACTS_WITH\|\|Acid Phosphatase:1466897	6/138,393	13/26,262,527	87.59	5.31e-10	3.10e-08
lymph nodes\|\|PART_OF\|\|Prostate carcinoma:1804530	4/138,393	3/26,262,527	253.03	2.61e-08	1.17e-06
PTEN gene\|PTEN\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:8319910	11/138,393	13/26,262,527	160.59	1.92e-19	2.59e-17
proteomic profiling\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:11167959	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Estramustine\|\|NEG_TREATS\|\|Malignant neoplasm of prostate:9654274	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
TP53 gene\|TP53\|\|ASSOCIATED_WITH\|\|Carcinogenesis:4691319	15/138,393	398/26,262,527	7.15	9.02e-09	4.26e-07
Strontium-89\|\|TREATS\|\|Malignant neoplasm of prostate:4866110	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Prostatic Tissue\|\|LOCATION_OF\|\|Carcinoma:1362608	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Toremifene\|\|PREVENTS\|\|Malignant neoplasm of prostate:9514652	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
athymia\|\|PROCESS_OF\|\|Mice, Nude:1009079	10/138,393	168/26,262,527	11.30	4.79e-08	2.03e-06
prostate stem cell antigen\|\|PART_OF\|\|Prostate:8538833	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Tumor Suppressor Genes\|\|ASSOCIATED_WITH\|\|Tumorigenesis:3694969	16/138,393	349/26,262,527	8.70	1.98e-10	1.19e-08
Local anesthesia\|\|METHOD_OF\|\|Brachytherapy:8416777	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Oestrogen therapy\|\|TREATS\|\|Carcinoma:138341	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Stromal Cells\|\|PART_OF\|\|Smooth muscle (tissue):5320642	10/138,393	29/26,262,527	65.44	8.67e-15	8.22e-13
agonists\|\|INHIBITS\|\|Testosterone:2089191	13/138,393	32/26,262,527	77.10	1.41e-19	1.92e-17
NCOR2 gene\|NCOR2\|\|STIMULATES\|\|Androgen Receptor\|AR:9992859	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Papilloma, Inverted\|\|PART_OF\|\|Bladder:374399	10/138,393	151/26,262,527	12.57	1.85e-08	8.49e-07
Radical prostatectomy\|\|TREATS\|\|Cancer Patient:4543159	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Spheroids, Cellular\|\|PART_OF\|\|Malignant neoplasm of prostate:7230589	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Hormones\|\|PART_OF\|\|Prostate:229210	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Androgen Antagonists\|\|TREATS\|\|Benign prostatic hypertrophy:2505284	6/138,393	17/26,262,527	66.98	1.94e-09	9.82e-08
tumor growth\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:7981035	28/138,393	27/26,262,527	196.84	4.65e-49	2.04e-46
TRANSCRIPTION FACTOR\|\|AFFECTS\|\|Cell Proliferation:3697160	15/138,393	335/26,262,527	8.50	9.78e-10	5.18e-08
Prostate\|\|LOCATION_OF\|\|Magnetic resonance imaging guided biopsy:9167205	22/138,393	29/26,262,527	143.98	9.08e-37	2.76e-34
Aptosyn\|\|ISA\|\|sulindac sulfone:8924037	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Implantation procedure\|\|TREATS\|\|Carcinoma:128581	16/138,393	49/26,262,527	61.97	1.65e-22	2.72e-20
High-Grade Prostatic Intraepithelial Neoplasia\|\|PART_OF\|\|Prostate:7387517	11/138,393	12/26,262,527	173.97	1.05e-19	1.44e-17
Prognostic Factor\|\|ASSOCIATED_WITH\|\|Prostate cancer metastatic:5718501	13/138,393	15/26,262,527	164.48	7.85e-23	1.31e-20
Fibroblast Growth Factor 8\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8279954	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Protease Inhibitor\|\|PART_OF\|\|Extracellular:3556515	5/138,393	21/26,262,527	45.18	2.37e-07	8.32e-06
Rectum\|\|LOCATION_OF\|\|Probes:1012111	8/138,393	27/26,262,527	56.23	1.18e-11	8.48e-10
Percent Free Prostate-Specific Antigen\|\|DIAGNOSES\|\|CAP - NOS:7918013	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Tumor cells, malignant\|\|LOCATION_OF\|\|PTEN gene\|PTEN:7648009	7/138,393	23/26,262,527	57.76	1.99e-10	1.20e-08
Proto-Oncogenes\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:5914813	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Cultured Cells\|\|PART_OF\|\|Malignant neoplasm of prostate:6569127	35/138,393	37/26,262,527	179.56	5.40e-60	2.86e-57
uptake\|\|PROCESS_OF\|\|Prostate:329954	7/138,393	14/26,262,527	94.89	1.19e-11	8.48e-10
Pes\|\|LOCATION_OF\|\|Lymphography:606025	8/138,393	56/26,262,527	27.11	1.94e-09	9.82e-08
Supplementation\|\|AFFECTS\|\|Malignant neoplasm of prostate:11247159	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Radical prostatectomy\|\|ISA\|\|Prostatectomy:6219379	13/138,393	14/26,262,527	176.23	4.22e-23	7.15e-21
ixabepilone\|\|ISA\|\|epothilone B lactam:10889967	6/138,393	35/26,262,527	32.53	7.97e-08	3.08e-06
Immunotherapy\|\|AFFECTS\|\|Malignant neoplasm of prostate:13447525	10/138,393	9/26,262,527	210.87	1.39e-18	1.80e-16
Selenium\|\|NEG_ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:10669380	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Health care facility\|\|LOCATION_OF\|\|Core needle biopsy:7137579	9/138,393	48/26,262,527	35.58	2.14e-11	1.43e-09
Finasteride\|\|TREATS\|\|Benign prostatic hypertrophy:4457062	58/138,393	259/26,262,527	42.51	2.63e-69	1.68e-66
Teleradiotherapy procedure\|\|METHOD_OF\|\|Radical prostatectomy:11091744	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Medical Imaging\|\|USES\|\|Prostascint:8797656	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Neoplasm Metastasis\|\|LOCATION_OF\|\|Prostate-Specific Antigen:3851553	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Castration\|\|TREATS\|\|Neoplasm Metastasis:289557	13/138,393	13/26,262,527	189.79	2.20e-23	3.82e-21
Radical prostatectomy\|\|PREDISPOSES\|\|Urinary Incontinence:7975036	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
radiosensitization\|\|TREATS\|\|Malignant neoplasm of prostate:10487238	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Peptides\|\|ASSOCIATED_WITH\|\|Prostate:2524213	6/138,393	24/26,262,527	47.44	1.11e-08	5.20e-07
Prostate\|\|LOCATION_OF\|\|Tissue damage:7386275	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Prostatectomy\|\|TREATS\|\|Malignant neoplasm of prostate:2605017	253/138,393	265/26,262,527	181.50	0.00e+00	0.00e+00
IODINE,I-125\|\|TREATS\|\|Malignant neoplasm of prostate:738806	15/138,393	15/26,262,527	189.79	8.93e-27	1.77e-24
Small cell carcinoma of lung\|\|ASSOCIATED_WITH\|\|Prostate:3950529	6/138,393	11/26,262,527	103.51	2.44e-10	1.46e-08
Malignant neoplasm of prostate\|\|AFFECTS\|\|Ethnic group:7791127	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Antineoplastic Agents\|\|AFFECTS\|\|Malignant neoplasm of prostate:2703099	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Androgen therapy\|\|CAUSES\|\|Osteoporosis:9231548	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Radical prostatectomy\|\|TREATS\|\|Benign prostatic hypertrophy:1806707	9/138,393	12/26,262,527	142.33	8.30e-16	8.48e-14
Etoposide\|\|ASSOCIATED_WITH\|\|Hormone-refractory prostate cancer:6807439	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Transurethral Resection of Prostate\|\|TREATS\|\|Prostate carcinoma:3540406	7/138,393	9/26,262,527	147.60	1.19e-12	9.12e-11
Hypoxia\|\|COEXISTS_WITH\|\|Prostatic Neoplasms:5457835	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Epitopes\|\|PART_OF\|\|Protoplasm:1826047	8/138,393	104/26,262,527	14.60	1.67e-07	5.91e-06
SLC5A5 protein, human\|SLC5A5\|\|ISA\|\|sodium-iodide symporter:7454131	22/138,393	424/26,262,527	9.85	8.14e-15	7.73e-13
Rat Cell Line\|\|PART_OF\|\|Prostate:3849551	5/138,393	8/26,262,527	118.61	4.92e-09	2.37e-07
Prostatic Tissue\|\|PART_OF\|\|Carcinoma:1250223	44/138,393	50/26,262,527	167.05	4.70e-74	3.32e-71
Testosterone\|\|TREATS\|\|Hypogonadism:54108	11/138,393	71/26,262,527	29.40	8.17e-13	6.38e-11
Benign prostatic hypertrophy\|\|ASSOCIATED_WITH\|\|Prostate:1018114	19/138,393	65/26,262,527	55.48	1.12e-25	2.13e-23
c-myc Genes\|MYC\|\|PART_OF\|\|Malignant neoplasm of prostate:3569814	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostate\|\|LOCATION_OF\|\|Flexible fiberoptic sigmoidoscopy:9721835	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Performance\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:10497249	16/138,393	17/26,262,527	178.63	3.48e-28	7.27e-26
PTEN gene\|PTEN\|\|CAUSES\|\|Malignant neoplasm of prostate:7736673	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
Paraneoplastic Syndromes\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:12778649	8/138,393	10/26,262,527	151.82	2.38e-14	2.15e-12
Prostate\|\|LOCATION_OF\|\|estramustine-binding protein:3725294	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Management procedure\|\|USES\|\|Diphosphonates:5190851	8/138,393	32/26,262,527	47.44	3.78e-11	2.41e-09
Percent Free Prostate-Specific Antigen\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:7025161	27/138,393	34/26,262,527	150.73	3.54e-45	1.39e-42
Oligonucleotides, Antisense\|\|INTERACTS_WITH\|\|Codon Nucleotides:9711575	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Estradurin\|\|ISA\|\|polyestradiol phosphate:239838	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Cryosurgery\|\|TREATS\|\|Local disease:850483	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
DNA Methylation\|\|ISA\|\|Gene Expression Regulation:7990817	8/138,393	70/26,262,527	21.69	9.64e-09	4.55e-07
AR gene\|AR\|\|AFFECTS\|\|Gene Expression:9915782	8/138,393	10/26,262,527	151.82	2.38e-14	2.15e-12
Radical prostatectomy\|\|PRECEDES\|\|Teleradiotherapy procedure:9175464	16/138,393	21/26,262,527	144.60	3.77e-27	7.61e-25
TP53 gene\|TP53\|\|ASSOCIATED_WITH\|\|Prostatic Intraepithelial Neoplasias:6594499	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Fluorouracil\|\|TREATS\|\|Hormone-refractory prostate cancer:5626303	10/138,393	14/26,262,527	135.56	2.87e-17	3.37e-15
Teleradiotherapy procedure\|\|TREATS\|\|Secondary malignant neoplasm of bone:5540170	6/138,393	29/26,262,527	39.26	2.96e-08	1.33e-06
GRP gene\|GRP\|\|PART_OF\|\|Ovaro-:17235088	11/138,393	18/26,262,527	115.98	2.60e-18	3.34e-16
Open prostatectomy\|\|TREATS\|\|Malignant neoplasm of prostate:3910186	11/138,393	13/26,262,527	160.59	1.92e-19	2.59e-17
Steroids\|\|AFFECTS\|\|Anabolism:471347	5/138,393	12/26,262,527	79.07	2.32e-08	1.06e-06
Androgen Antagonists\|\|higher_than\|\|Castration:2999677	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Chemoprevention\|\|USES\|\|5-Alpha reductase inhibitor:12626523	10/138,393	11/26,262,527	172.53	5.24e-18	6.40e-16
Surgical margins\|\|PART_OF\|\|Surgical margins:4079485	6/138,393	38/26,262,527	29.96	1.23e-07	4.49e-06
Diphosphonates\|\|DISRUPTS\|\|Osteoclasts:1813071	22/138,393	165/26,262,527	25.31	6.91e-23	1.17e-20
Radiotherapy, Conformal\|\|TREATS\|\|Locally Advanced Malignant Neoplasm:5669005	5/138,393	9/26,262,527	105.43	7.62e-09	3.62e-07
Transurethral Resection of Prostate\|\|TREATS\|\|Malignant neoplasm of prostate:3708313	51/138,393	61/26,262,527	158.72	8.98e-85	7.28e-82
Gastrin releasing peptide\|\|ISA\|\|Bombesin:2037216	7/138,393	66/26,262,527	20.13	1.31e-07	4.76e-06
Prostatectomy, Suprapubic\|\|TREATS\|\|Benign prostatic hypertrophy:2994333	9/138,393	43/26,262,527	39.72	8.97e-12	6.51e-10
Estrogen Receptors\|\|ASSOCIATED_WITH\|\|Prostate:1022710	9/138,393	26/26,262,527	65.69	1.87e-13	1.60e-11
Seminal Vesicles\|\|LOCATION_OF\|\|Preservation, Biological:8269977	11/138,393	18/26,262,527	115.98	2.60e-18	3.34e-16
Radical prostatectomy\|\|PRECEDES\|\|Division (procedure):4558193	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
Cell of bone\|\|PART_OF\|\|Neoplasm Metastasis:7530010	6/138,393	18/26,262,527	63.26	2.58e-09	1.30e-07
Microsatellite Repeats\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8026659	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Binding Protein\|\|ASSOCIATED_WITH\|\|Prostate:861353	7/138,393	26/26,262,527	51.09	4.12e-10	2.44e-08
Division (procedure)\|\|USES\|\|Tissue Microarray:8169394	20/138,393	231/26,262,527	16.43	1.44e-17	1.72e-15
Serum specimen\|\|LOCATION_OF\|\|KLK3 gene\|KLK3:7025158	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
FLVCR1\|\|ASSOCIATED_WITH\|\|Benign prostatic hypertrophy:5873479	11/138,393	10/26,262,527	208.76	2.76e-20	4.03e-18
Malignant neoplasm of prostate\|\|PART_OF\|\|Biopsy sample:11014777	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
Prostate\|\|LOCATION_OF\|\|neoplasm/cancer invasiveness:5878578	14/138,393	14/26,262,527	189.79	4.43e-25	8.24e-23
Radical prostatectomy\|\|compared_with\|\|Open approach:10074208	8/138,393	10/26,262,527	151.82	2.38e-14	2.15e-12
Radioactive implant\|\|TREATS\|\|Malignant neoplasm of prostate:2050777	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Malignant neoplasm of prostate\|\|AFFECTS\|\|Couples:9876168	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Gonadal Steroid Hormones\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:12789194	6/138,393	8/26,262,527	142.33	6.01e-11	3.76e-09
ZD4054\|\|TREATS\|\|Malignant neoplasm of prostate:13025886	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Growth Factor\|\|STIMULATES\|\|Androgens:5740475	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Carboplatin\|\|TREATS\|\|Hormone-refractory prostate cancer:5758008	14/138,393	20/26,262,527	132.85	1.49e-23	2.62e-21
Radical prostatectomy\|\|PRECEDES\|\|Elevation procedure:5452687	22/138,393	27/26,262,527	154.65	2.92e-37	9.04e-35
Carcinoma\|\|PART_OF\|\|Colon and rectum:351254	7/138,393	56/26,262,527	23.72	4.65e-08	2.03e-06
Universities\|\|LOCATION_OF\|\|Transrectal Ultrasound:8190468	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Malignant neoplasm of prostate\|\|PRODUCES\|\|Androgens:8278911	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
AR\|\|INTERACTS_WITH\|\|Androgens:5997612	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Slide\|\|PART_OF\|\|Tissue Microarray:9181653	13/138,393	134/26,262,527	18.41	1.63e-12	1.24e-10
Extracellular Signal Regulated Kinases\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8421247	4/138,393	3/26,262,527	253.03	2.61e-08	1.17e-06
Androgen Receptor\|AR\|\|PREDISPOSES\|\|Cancer Cell Growth:10389100	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Androgen therapy\|\|TREATS\|\|Secondary malignant neoplasm of bone:462490	10/138,393	12/26,262,527	158.15	9.56e-18	1.15e-15
Orchiectomy\|\|compared_with\|\|Oestrogen therapy:3050673	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
invasive treatment\|\|TREATS\|\|Localized Malignant Neoplasm:8919843	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Acid Phosphatase\|\|ASSOCIATED_WITH\|\|Adenocarcinoma of prostate:1402047	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Androgens\|\|AFFECTS\|\|Cancer Cell Growth:5229897	5/138,393	8/26,262,527	118.61	4.92e-09	2.37e-07
Glutamate Carboxypeptidase II\|\|PART_OF\|\|Epithelium:8042164	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Prostate-Specific Antigen\|\|ASSOCIATED_WITH\|\|Adenocarcinoma:2675921	12/138,393	15/26,262,527	151.83	6.95e-21	1.04e-18
Somatotropin-Releasing Hormone\|\|DISRUPTS\|\|Malignant neoplasm of prostate:7247351	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Leuprolide\|\|ISA\|\|Gonadotropin-Releasing Hormone Analog:2265498	30/138,393	77/26,262,527	73.95	8.25e-43	3.06e-40
Benign prostatic hypertrophy\|\|ISA\|\|Hyperplasia:1256243	36/138,393	49/26,262,527	139.46	7.70e-59	4.03e-56
alpha-methylacyl-CoA racemase\|\|INTERACTS_WITH\|\|branched chain fatty acid:8830794	9/138,393	12/26,262,527	142.33	8.30e-16	8.48e-14
EZH2 gene\|EZH2\|\|PART_OF\|\|Malignant neoplasm of prostate:9865242	8/138,393	7/26,262,527	216.89	3.55e-15	3.52e-13
docetaxel\|\|COEXISTS_WITH\|\|docetaxel:7039849	12/138,393	39/26,262,527	58.40	5.65e-17	6.54e-15
Prostatic Tissue\|\|LOCATION_OF\|\|Benign prostatic hypertrophy:2346281	6/138,393	16/26,262,527	71.17	1.44e-09	7.58e-08
Prostate\|\|ASSOCIATED_WITH\|\|Neoplasm Metastasis:3627904	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Cessation of life\|\|PROCESS_OF\|\|Cancer Patient:573857	12/138,393	288/26,262,527	7.91	9.51e-08	3.49e-06
Bone Morphogenetic Proteins\|\|ASSOCIATED_WITH\|\|Prostate:6628963	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Radical retropubic prostatectomy\|\|TREATS\|\|Erectile dysfunction:8236122	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Sarcosine\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:14080634	16/138,393	16/26,262,527	189.79	1.80e-28	3.82e-26
Hepatocyte Growth Factor\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:7622257	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Radiotherapy, Intensity-Modulated\|\|PREVENTS\|\|Toxic effect:8287726	9/138,393	33/26,262,527	51.76	1.14e-12	8.83e-11
Prostate-Specific Antigen\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:2003060	403/138,393	483/26,262,527	158.80	0.00e+00	0.00e+00
Malignant neoplasm of prostate\|\|LOCATION_OF\|\|Endothelial Cells:13066381	10/138,393	13/26,262,527	145.99	1.68e-17	1.99e-15
Radical prostatectomy\|\|TREATS\|\|Raised prostate specific antigen:4500375	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Estradiol\|\|TREATS\|\|Prostate carcinoma:43257	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Areae\|\|LOCATION_OF\|\|Prostate-Specific Antigen:3412248	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Ketoconazole\|\|TREATS\|\|Hormone-refractory prostate cancer:3920540	10/138,393	14/26,262,527	135.56	2.87e-17	3.37e-15
PERINEURAL INVASION\|\|COEXISTS_WITH\|\|PERINEURAL INVASION:9154205	5/138,393	10/26,262,527	94.89	1.14e-08	5.31e-07
Estracyt\|\|TREATS\|\|Malignant neoplasm of prostate:658635	13/138,393	11/26,262,527	224.29	5.34e-24	9.50e-22
Gonadotropin-Releasing Hormone Analog\|\|TREATS\|\|Malignant neoplasm of prostate:4011395	20/138,393	17/26,262,527	223.29	3.58e-36	1.06e-33
Biopsy\|\|ISA\|\|Diagnosis:87843	106/138,393	2,746/26,262,527	7.33	2.38e-53	1.12e-50
lycopene\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9842122	16/138,393	16/26,262,527	189.79	1.80e-28	3.82e-26
KLK3 gene\|KLK3\|\|ASSOCIATED_WITH\|\|Prostate carcinoma:3746259	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
fosfestrol\|\|TREATS\|\|Malignant neoplasm of prostate:433452	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
tomography\|\|DIAGNOSES\|\|Secondary malignant neoplasm of lymph node:1493904	10/138,393	173/26,262,527	10.97	6.21e-08	2.41e-06
diagnostic use\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:5674113	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Biopsy\|\|NEG_DIAGNOSES\|\|Malignant neoplasm of prostate:7162597	18/138,393	19/26,262,527	179.80	1.43e-31	3.50e-29
Cell Adhesion Molecules\|\|PART_OF\|\|Extracellular Matrix:3583749	9/138,393	121/26,262,527	14.12	3.72e-08	1.66e-06
Epithelium\|\|LOCATION_OF\|\|Malignant neoplasm of prostate:7832483	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Clusterin\|CLU\|\|ISA\|\|Glycoproteins:3795666	10/138,393	125/26,262,527	15.18	3.40e-09	1.67e-07
Tumor cells, malignant\|\|LOCATION_OF\|\|amino acid transport:17277499	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Digital Rectal Examination\|\|USES\|\|Reagents, Immunoassay, Tumor Marker, Enzyme, Prostate Specific Antigen:5693543	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Antibiotic Prophylaxis\|\|USES\|\|Fluoroquinolones:10074228	5/138,393	19/26,262,527	49.94	1.55e-07	5.48e-06
Epithelial Cells\|\|LOCATION_OF\|\|PTEN gene\|PTEN:10125641	6/138,393	20/26,262,527	56.93	4.37e-09	2.14e-07
Tumor cells, malignant\|\|LOCATION_OF\|\|Zinc:9498062	5/138,393	10/26,262,527	94.89	1.14e-08	5.31e-07
Carotenoids\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:4398714	10/138,393	13/26,262,527	145.99	1.68e-17	1.99e-15
Angioendotheliomatosis\|\|PART_OF\|\|Prostate:3237405	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Brachytherapy\|\|TREATS\|\|Carcinoma:215420	14/138,393	135/26,262,527	19.68	9.91e-14	8.71e-12
PROSTVAC\|\|TREATS\|\|Malignant neoplasm of prostate:15850386	4/138,393	3/26,262,527	253.03	2.61e-08	1.17e-06
Stratum germinativum\|\|PART_OF\|\|Prostate:4669040	11/138,393	12/26,262,527	173.97	1.05e-19	1.44e-17
Biopsy sample\|\|PART_OF\|\|Prostate carcinoma:6071874	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Diagnosis\|\|TREATS\|\|Local disease:4889314	5/138,393	13/26,262,527	72.99	3.20e-08	1.43e-06
Gonadorelin\|GNRH1\|\|ASSOCIATED_WITH\|\|Prostate cancer metastatic:7002381	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Malignant neoplasm of prostate\|\|AFFECTS\|\|Secondary malignant neoplasm of bone:3933423	9/138,393	11/26,262,527	155.27	4.76e-16	4.94e-14
STAT5A gene\|STAT5A\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:10204926	7/138,393	11/26,262,527	120.77	3.29e-12	2.43e-10
Spectrum Analysis, Mass\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:11773155	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Cryosurgery\|\|TREATS\|\|Carcinoma:787221	6/138,393	35/26,262,527	32.53	7.97e-08	3.08e-06
Benign prostatic hypertrophy\|\|COEXISTS_WITH\|\|Prostatic Intraepithelial Neoplasias:6594511	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
bicalutamide\|\|compared_with\|\|Castration:6536263	11/138,393	16/26,262,527	130.48	9.91e-19	1.30e-16
Cancer Treatment\|\|USES\|\|Gonadotropin-Releasing Hormone Analog:3316533	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Cancer Control\|\|ISA\|\|Intervention regimes:3180540	12/138,393	89/26,262,527	25.59	3.33e-13	2.84e-11
Proprotein Convertase 1\|KRT6A\|PCSK1\|BTG2\|ACTR1B\|CBX8\|\|PART_OF\|\|Malignant neoplasm of prostate:10331566	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
Cancer-related morbidities\|\|MANIFESTATION_OF\|\|Malignant neoplasm of prostate:6413547	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
16q\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:5916827	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
Secondary malignant neoplasm of bone\|\|PART_OF\|\|Breast:88732	7/138,393	25/26,262,527	53.14	3.26e-10	1.94e-08
BRCA2 gene\|BRCA2\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:7823332	14/138,393	15/26,262,527	177.13	8.52e-25	1.56e-22
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|SCID Mice:7147533	12/138,393	13/26,262,527	175.19	2.10e-21	3.22e-19
Electroporation\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:15863327	5/138,393	4/26,262,527	237.22	4.90e-10	2.87e-08
Malignant transformation\|\|PART_OF\|\|Prostate:2934113	20/138,393	20/26,262,527	189.80	3.06e-35	8.64e-33
Androgen therapy\|\|TREATS\|\|Male gender:5120844	9/138,393	11/26,262,527	155.27	4.76e-16	4.94e-14
Estramustine phosphate\|\|TREATS\|\|Advanced cancer:2414078	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
tomography\|\|DIAGNOSES\|\|Secondary malignant neoplasm of bone:1789753	8/138,393	37/26,262,527	41.03	1.03e-10	6.35e-09
Salvage procedure\|\|TREATS\|\|Malignant neoplasm of prostate:8373135	31/138,393	30/26,262,527	196.14	4.01e-54	1.90e-51
Cancer Treatment\|\|TREATS\|\|Osteoporosis:10358158	4/138,393	3/26,262,527	253.03	2.61e-08	1.17e-06
RGN\|\|ASSOCIATED_WITH\|\|Prostate:12853309	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Medical Imaging\|\|USES\|\|Capromab Pendetide:6950140	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Radical prostatectomy\|\|TREATS\|\|Caucasoid Race:6675467	11/138,393	12/26,262,527	173.97	1.05e-19	1.44e-17
Somatotropin-Releasing Hormone\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9752326	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
virulizin\|\|ISA\|\|Biological Response Modifiers:9662666	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Magnetic Resonance Imaging\|\|DIAGNOSES\|\|Antimicrobial susceptibility:2678439	16/138,393	207/26,262,527	14.67	1.20e-13	1.05e-11
Malignant neoplasm of lung\|\|PRECEDES\|\|Malignant neoplasm of prostate:7752533	14/138,393	14/26,262,527	189.79	4.43e-25	8.24e-23
Diphosphonates\|\|DISRUPTS\|\|Osteolysis:2109184	5/138,393	21/26,262,527	45.18	2.37e-07	8.32e-06
Biopsy\|\|ADMINISTERED_TO\|\|Physicians:1119825	7/138,393	56/26,262,527	23.72	4.65e-08	2.03e-06
Tissue specimen\|\|PART_OF\|\|Prostatic Neoplasms:8329712	4/138,393	3/26,262,527	253.03	2.61e-08	1.17e-06
Phytoestrogens\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:8811241	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Early Diagnosis\|\|USES\|\|Reagents, Immunoassay, Tumor Marker, Enzyme, Prostate Specific Antigen:6598839	12/138,393	12/26,262,527	189.78	1.10e-21	1.72e-19
Prostatectomy, Retropubic\|\|TREATS\|\|Benign prostatic hypertrophy:386182	6/138,393	19/26,262,527	59.93	3.37e-09	1.66e-07
Aggressive behavior\|\|COEXISTS_WITH\|\|Prostate carcinoma:6444159	5/138,393	4/26,262,527	237.22	4.90e-10	2.87e-08
Osteoporosis\|\|AFFECTS\|\|Malignant neoplasm of prostate:9876418	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
AR gene\|AR\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:10716674	9/138,393	6/26,262,527	284.67	1.45e-17	1.74e-15
Cytotoxic Chemotherapy\|\|TREATS\|\|Malignant neoplasm of prostate:2212549	19/138,393	21/26,262,527	171.72	5.53e-33	1.43e-30
Fibroblast Growth Factor 8\|\|PART_OF\|\|Malignant neoplasm of prostate:6690848	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Androgen Receptor\|AR\|\|INTERACTS_WITH\|\|KLK3 gene\|KLK3:12287487	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Gland structure\|\|PART_OF\|\|Benign prostatic hypertrophy:2064165	8/138,393	15/26,262,527	101.22	2.61e-13	2.22e-11
Radical cystoprostatectomy\|\|TREATS\|\|Carcinoma, Transitional Cell:1764973	15/138,393	26/26,262,527	109.49	3.46e-24	6.21e-22
Prostate-Specific Antigen\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:10610769	10/138,393	2/26,262,527	948.91	1.02e-21	1.64e-19
Androgens\|\|AFFECTS\|\|tumor growth:2948236	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
bortezomib\|\|ISA\|\|Proteasome inhibitor:9699481	39/138,393	1,389/26,262,527	5.33	2.97e-16	3.13e-14
High-Grade Prostatic Intraepithelial Neoplasia\|\|AFFECTS\|\|Malignant neoplasm of prostate:9024073	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
FAVOR\|\|compared_with\|\|Tetradecapeptide:17287269	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Tumor Angiogenesis\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:5781232	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
Diphosphonates\|\|TREATS\|\|Prostate cancer metastatic:8959521	17/138,393	22/26,262,527	146.66	7.79e-29	1.69e-26
Malignant neoplasm of prostate\|\|COEXISTS_WITH\|\|Toxic effect:9587656	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Implantation procedure\|\|USES\|\|Urinary Sphincter, Artificial:2680674	19/138,393	324/26,262,527	11.13	6.82e-14	6.02e-12
docetaxel\|\|higher_than\|\|docetaxel:5903072	6/138,393	21/26,262,527	54.22	5.59e-09	2.69e-07
Histone Deacetylase\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9277693	6/138,393	8/26,262,527	142.33	6.01e-11	3.76e-09
Raised prostate specific antigen\|\|PROCESS_OF\|\|Voluntary Workers:6509000	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
mutation analysis\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:7763400	12/138,393	13/26,262,527	175.19	2.10e-21	3.22e-19
Lipids\|\|ASSOCIATED_WITH\|\|ovarian neoplasm:370394	6/138,393	1/26,262,527	1138.66	1.45e-13	1.26e-11
gefitinib\|\|TREATS\|\|Malignant neoplasm of prostate:10387314	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Castration, Male\|\|TREATS\|\|Malignant neoplasm of prostate:2426199	25/138,393	29/26,262,527	163.62	1.41e-42	5.19e-40
Entire tibia\|\|PART_OF\|\|Mice, Nude:7143766	7/138,393	23/26,262,527	57.76	1.99e-10	1.20e-08
MicroRNAs\|\|AFFECTS\|\|Gene Expression:13379587	6/138,393	1/26,262,527	1138.66	1.45e-13	1.26e-11
Estramustine phosphate\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:1247879	14/138,393	14/26,262,527	189.79	4.43e-25	8.24e-23
Malignant neoplasm of prostate\|\|PART_OF\|\|Participant:11303495	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Bone Marrow\|\|LOCATION_OF\|\|Acid Phosphatase:910164	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Androgen Receptor\|AR\|\|INHIBITS\|\|Androgen Receptor\|AR:4010149	21/138,393	38/26,262,527	104.89	5.51e-33	1.43e-30
Endocrine therapy\|\|TREATS\|\|Localized Malignant Neoplasm:9333830	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Neoplasm Metastasis\|\|PART_OF\|\|Prostate:55410	199/138,393	219/26,262,527	172.68	0.00e+00	0.00e+00
Carcinoma, Transitional Cell\|\|ASSOCIATED_WITH\|\|Prostate:1265755	34/138,393	55/26,262,527	117.34	9.62e-54	4.55e-51
bicalutamide\|\|ISA\|\|Nonsteroidal antiandrogen:6536262	20/138,393	23/26,262,527	165.04	2.10e-34	5.75e-32
Cystoprostatectomy\|\|TREATS\|\|Malignant neoplasm of urinary bladder:3204752	33/138,393	53/26,262,527	118.19	2.75e-52	1.26e-49
Radical prostatectomy\|\|USES\|\|FAVOR:10347648	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Treatment Protocols\|\|TREATS\|\|Prostate carcinoma:2468641	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Selenium\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:7797749	27/138,393	34/26,262,527	150.73	3.54e-45	1.39e-42
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Asian Americans:6273663	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
research study\|\|USES\|\|Phantoms, Imaging:346123	48/138,393	2,125/26,262,527	4.29	4.50e-16	4.72e-14
Adenocarcinoma\|\|ASSOCIATED_WITH\|\|Seminal Vesicles:5029017	7/138,393	9/26,262,527	147.60	1.19e-12	9.12e-11
Neuroendocrine Cell\|\|PART_OF\|\|Malignant neoplasm of prostate:5050978	19/138,393	21/26,262,527	171.72	5.53e-33	1.43e-30
Testosterone\|\|CAUSES\|\|Adverse effects:4045023	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Biopsy\|\|DIAGNOSES\|\|Benign prostatic hypertrophy:6494075	17/138,393	18/26,262,527	179.25	7.06e-30	1.59e-27
Testosterone\|\|INTERACTS_WITH\|\|Androgens:696851	19/138,393	172/26,262,527	20.97	1.41e-18	1.83e-16
KLK3\|PLAG1\|PROS1\|NPEPPS\|PSAT1\|\|PART_OF\|\|Malignant neoplasm of prostate:8601210	5/138,393	8/26,262,527	118.61	4.92e-09	2.37e-07
Neoadjuvant Therapy\|\|AFFECTS\|\|Malignant neoplasm of prostate:5556700	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Biopsy\|\|USES\|\|Zonal:6448485	44/138,393	79/26,262,527	105.73	1.54e-67	9.51e-65
Endocrine therapy\|\|USES\|\|Leuprolide:6043088	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Immunoassay\|\|METHOD_OF\|\|Free prostate-specific antigen:6648858	8/138,393	10/26,262,527	151.82	2.38e-14	2.15e-12
Bone specimen\|\|PART_OF\|\|Prostate cancer metastatic:12485813	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Ethnic group:8010174	32/138,393	34/26,262,527	178.65	6.20e-55	3.00e-52
Estramustine\|\|TREATS\|\|Hormone-refractory prostate cancer:5064578	42/138,393	57/26,262,527	139.87	2.01e-68	1.27e-65
Malignant neoplasm of prostate\|\|AFFECTS\|\|Cell physiology:8280537	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Tea\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:5745823	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Metformin\|\|AFFECTS\|\|Malignant neoplasm of prostate:15276122	5/138,393	8/26,262,527	118.61	4.92e-09	2.37e-07
Cyclophosphamide\|\|TREATS\|\|Hormone-refractory prostate cancer:5299937	9/138,393	13/26,262,527	131.39	1.40e-15	1.41e-13
Prophylactic treatment\|\|TREATS\|\|Prostate cancer metastatic:4108648	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Hepatic\|\|LOCATION_OF\|\|Medical Imaging:606466	121/138,393	1,145/26,262,527	20.07	2.29e-107	2.49e-104
External Beam Radiation Therapy\|\|TREATS\|\|Localized Carcinoma:4708073	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Dexamethasone\|\|TREATS\|\|Malignant neoplasm of prostate:3461787	12/138,393	16/26,262,527	142.34	1.21e-20	1.80e-18
Prostate carcinoma\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:8740281	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
HSPB1 gene\|HSPB1\|\|PART_OF\|\|Malignant neoplasm of prostate:11824406	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Kininogenase\|\|TREATS\|\|Raised prostate specific antigen:14081743	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Primary Neoplasm\|\|PART_OF\|\|Bladder:4947	16/138,393	164/26,262,527	18.52	4.22e-15	4.17e-13
Receptor Protein-Tyrosine Kinases\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9768743	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
TRANSCRIPTION FACTOR\|\|INTERACTS_WITH\|\|Androgen Receptor\|AR:12529313	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Locally Advanced Malignant Neoplasm\|\|PART_OF\|\|Bladder:1109508	12/138,393	300/26,262,527	7.59	1.45e-07	5.27e-06
Prostate carcinoma\|\|PROCESS_OF\|\|Rats, Inbred F344:3507227	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Surgical margins\|\|PART_OF\|\|Malignant neoplasm of prostate:5039690	19/138,393	21/26,262,527	171.72	5.53e-33	1.43e-30
Tumorigenesis\|\|PROCESS_OF\|\|Transgenic Model:6543082	7/138,393	29/26,262,527	45.81	7.95e-10	4.59e-08
zoledronic acid\|\|PREVENTS\|\|Bone pain:11142551	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
MicroRNAs\|\|ISA\|\|Functional RNA:10195109	61/138,393	2,651/26,262,527	4.37	2.37e-20	3.49e-18
Prostate\|\|PART_OF\|\|Mice, Nude:2671058	53/138,393	61/26,262,527	164.94	1.15e-88	1.00e-85
Induction\|\|AFFECTS\|\|Cell Cycle:1741062	7/138,393	67/26,262,527	19.83	1.44e-07	5.23e-06
Genistein\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8929059	15/138,393	17/26,262,527	167.46	3.22e-26	6.27e-24
Cottonseed\|\|LOCATION_OF\|\|Gossypol:62790	8/138,393	91/26,262,527	16.68	6.39e-08	2.48e-06
peripheral blood\|\|LOCATION_OF\|\|Prostate-Specific Antigen:4902996	35/138,393	51/26,262,527	130.27	1.77e-56	8.91e-54
Glutamate Carboxypeptidase II\|\|PART_OF\|\|Extracellular:7916915	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Malignant neoplasm of prostate\|\|PART_OF\|\|Prostatic epithelium:10830910	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostate\|\|PART_OF\|\|Bladder:69231	14/138,393	20/26,262,527	132.85	1.49e-23	2.62e-21
TGFB1 protein, human\|TGFB1\|\|ASSOCIATED_WITH\|\|Prostate:6365088	9/138,393	19/26,262,527	89.90	1.89e-14	1.73e-12
Adenocarcinoma\|\|PRODUCES\|\|Prostate-Specific Antigen:7132890	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Somatomedins\|\|ASSOCIATED_WITH\|\|Hypopituitarism:298255	9/138,393	1/26,262,527	1708.02	2.97e-20	4.33e-18
alpha-Linolenic Acid\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:5875194	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
Cancer of Urinary Tract\|\|PART_OF\|\|Prostate:4472790	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Free prostate-specific antigen\|\|METHOD_OF\|\|Early Diagnosis:7025162	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
leukemia\|\|PART_OF\|\|Bladder:627936	6/138,393	15/26,262,527	75.91	1.05e-09	5.56e-08
Breast\|\|PART_OF\|\|Outpatients:6030682	10/138,393	23/26,262,527	82.51	1.30e-15	1.32e-13
Combination Drug Therapy\|\|USES\|\|docetaxel:7476758	10/138,393	148/26,262,527	12.82	1.55e-08	7.17e-07
Polymorphism, Genetic\|\|ASSOCIATED_WITH\|\|ELAC2:9170762	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Androgens\|\|STIMULATES\|\|KLK3 gene\|KLK3:6173481	7/138,393	11/26,262,527	120.77	3.29e-12	2.43e-10
Castration\|\|PRECEDES\|\|Xenograft procedure:9608799	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Androgen therapy\|\|AFFECTS\|\|Malignant neoplasm of prostate:10704360	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Digital Rectal Examination\|\|DIAGNOSES\|\|Prostate carcinoma:5383026	13/138,393	18/26,262,527	137.07	4.26e-22	6.89e-20
Human tissue\|\|PART_OF\|\|Prostatic Neoplasms:2159855	18/138,393	18/26,262,527	189.79	7.40e-32	1.83e-29
Adenocarcinoma, Mucinous\|\|PART_OF\|\|Prostate:388708	72/138,393	131/26,262,527	104.35	3.97e-109	4.46e-106
Capromab Pendetide\|\|ISA\|\|Monoclonal Antibodies:7836825	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Glycoproteins\|\|PART_OF\|\|Malignant neoplasm of prostate:9882224	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Antibodies, Anti-Idiotypic\|\|PART_OF\|\|Malignant neoplasm of prostate:14055258	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
mutation analysis\|\|DIAGNOSES\|\|Prostate carcinoma:9260956	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Stimulation procedure\|\|TREATS\|\|Malignant neoplasm of prostate:2876137	10/138,393	9/26,262,527	210.87	1.39e-18	1.80e-16
Seminal fluid\|\|LOCATION_OF\|\|Glutamate Carboxypeptidase II:6676183	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|African race:5679265	19/138,393	24/26,262,527	150.25	3.32e-32	8.35e-30
Radical prostatectomy\|\|PRECEDES\|\|Intracavernous injection:3682471	5/138,393	10/26,262,527	94.89	1.14e-08	5.31e-07
docetaxel\|\|CAUSES\|\|Cell Death:8334774	8/138,393	16/26,262,527	94.89	3.89e-13	3.15e-11
Prostate\|\|LOCATION_OF\|\|Prolactin\|PRL:1599776	8/138,393	10/26,262,527	151.82	2.38e-14	2.15e-12
Prostatectomy\|\|PRECEDES\|\|Radiotherapy, Adjuvant:9054850	10/138,393	11/26,262,527	172.53	5.24e-18	6.40e-16
Oncogenes\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:15172995	4/138,393	3/26,262,527	253.03	2.61e-08	1.17e-06
Carcinoma, Spindle-Cell\|\|PART_OF\|\|Prostate:5111415	14/138,393	36/26,262,527	73.81	9.29e-21	1.39e-18
EGFR gene\|EGFR\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:7660576	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
Malignant neoplasm of prostate\|\|PART_OF\|\|Breast:4460597	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
HIGH SENSITIVITY\|\|DIAGNOSES\|\|Malignant neoplasm of urinary bladder:7943231	5/138,393	20/26,262,527	47.44	1.93e-07	6.79e-06
Estramustine\|\|TREATS\|\|Refractory Carcinoma:7712490	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Autopsy\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:1045838	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Microarray Analysis\|\|USES\|\|DNA, Complementary:7153467	71/138,393	1,805/26,262,527	7.47	8.07e-37	2.46e-34
Adenocarcinoma\|\|PROCESS_OF\|\|Rats, Wistar:788767	14/138,393	33/26,262,527	80.52	3.44e-21	5.25e-19
Chromosome abnormality\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:5100057	23/138,393	25/26,262,527	174.62	9.63e-40	3.20e-37
Interleukin-6\|\|AFFECTS\|\|androgen receptor activity:7866572	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Cold Therapy\|\|TREATS\|\|Prostate carcinoma:866475	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Alendronate\|\|TREATS\|\|Malignant neoplasm of prostate:11094577	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
DNA Adducts\|\|ASSOCIATED_WITH\|\|Prostate:6289846	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Androgen therapy\|\|TREATS\|\|High-Risk Cancer:11754472	44/138,393	47/26,262,527	177.71	6.98e-75	5.02e-72
Acinar Cell Carcinoma\|\|PART_OF\|\|Prostate:2858325	25/138,393	28/26,262,527	169.47	7.61e-43	2.83e-40
Androgen Receptor\|AR\|\|AFFECTS\|\|receptor function:7462855	6/138,393	8/26,262,527	142.33	6.01e-11	3.76e-09
Repositioning\|\|TREATS\|\|Malignant neoplasm of prostate:10676236	6/138,393	5/26,262,527	227.73	9.37e-12	6.74e-10
Silence\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:8735676	17/138,393	18/26,262,527	179.25	7.06e-30	1.59e-27
Prostate-Specific Antigen\|\|ASSOCIATED_WITH\|\|Hormone-refractory prostate cancer:5509535	11/138,393	13/26,262,527	160.59	1.92e-19	2.59e-17
IMMUNOHISTOCHEMICAL\|\|DIAGNOSES\|\|Prostate cancer metastatic:4270299	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Malignant neoplasm of prostate\|\|LOCATION_OF\|\|AR gene\|AR:8352644	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Teleradiotherapy procedure\|\|PRECEDES\|\|Radical prostatectomy:10367001	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Pelvis\|\|LOCATION_OF\|\|tomography:1362028	28/138,393	517/26,262,527	10.28	6.86e-19	9.04e-17
Tumor Suppressor Genes\|\|ASSOCIATED_WITH\|\|Prostate:7269249	31/138,393	33/26,262,527	178.31	3.02e-53	1.41e-50
maspin\|SERPINB5\|\|PART_OF\|\|Recombinants:6099896	7/138,393	22/26,262,527	60.38	1.53e-10	9.36e-09
Androgen therapy\|\|TREATS\|\|cohort:12018841	11/138,393	9/26,262,527	231.96	1.32e-20	1.96e-18
Intervention regimes\|\|TREATS\|\|Couples:1790632	16/138,393	151/26,262,527	20.11	1.28e-15	1.30e-13
satraplatin\|\|TREATS\|\|Malignant neoplasm of prostate:12459031	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Antioxidants\|\|AFFECTS\|\|Malignant neoplasm of prostate:10808042	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
Prostate\|\|LOCATION_OF\|\|Stromal Invasion:7586417	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
Androgen therapy\|\|USES\|\|Leuprolide:5971800	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Urine specimen\|\|LOCATION_OF\|\|Sarcosine:14263458	9/138,393	12/26,262,527	142.33	8.30e-16	8.48e-14
Ultrasonography\|\|METHOD_OF\|\|Digital Rectal Examination:4444996	11/138,393	19/26,262,527	109.87	4.09e-18	5.11e-16
Oligonucleotides, Antisense\|\|INTERACTS_WITH\|\|Clusterin\|CLU:9284480	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
[M]Unspecified tumor cell NOS\|\|LOCATION_OF\|\|Glycoproteins:1236498	11/138,393	47/26,262,527	44.42	1.49e-14	1.37e-12
Urinary Sphincter, Artificial\|\|TREATS\|\|Urinary Incontinence:986016	14/138,393	124/26,262,527	21.43	3.39e-14	3.05e-12
Paclitaxel\|\|ISA\|\|Antineoplastic Agents:5938619	19/138,393	482/26,262,527	7.48	4.90e-11	3.12e-09
Androgen Receptor\|AR\|\|ASSOCIATED_WITH\|\|Prostate:812546	45/138,393	127/26,262,527	67.26	7.30e-62	4.05e-59
Brachytherapy\|\|TREATS\|\|High-Risk Cancer:9503525	29/138,393	39/26,262,527	141.14	8.25e-48	3.45e-45
Needle biopsy procedure\|\|ISA\|\|Biopsy:1388887	14/138,393	44/26,262,527	60.39	9.66e-20	1.36e-17
Prostatic Neoplasms\|\|LOCATION_OF\|\|Stem cells:12979921	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Prostate cancer metastatic\|\|PART_OF\|\|lymph nodes:4707380	11/138,393	17/26,262,527	122.80	1.62e-18	2.10e-16
APEX1 protein, human\|APEX1\|\|ASSOCIATED_WITH\|\|Prostate:6279091	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Bladder\|\|LOCATION_OF\|\|tomography:326188	7/138,393	41/26,262,527	32.40	6.63e-09	3.19e-07
docetaxel\|\|COEXISTS_WITH\|\|Estramustine:8063051	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Glucocorticoid Receptor\|\|INTERACTS_WITH\|\|Androgen Receptor\|AR:8205944	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Interstitial brachytherapy\|\|TREATS\|\|Adenocarcinoma:2660837	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
targeting\|\|PROCESS_OF\|\|Angiogenesis:7257745	16/138,393	233/26,262,527	13.03	6.56e-13	5.28e-11
Stage A2\|\|ISA\|\|Stage:2548167	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Prostate-Specific Antigen\|\|AFFECTS\|\|Antimicrobial susceptibility:6067618	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Prostate\|\|LOCATION_OF\|\|Diastasis:985902	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
KLK3 gene\|KLK3\|\|PRODUCES\|\|Prostate-Specific Antigen:13786390	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Primary Gleason pattern\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9098054	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Gonadotropin-Releasing Hormone Analog\|\|INHIBITS\|\|Gonadorelin:3091436	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Lymphocyte antigen CD66A\|\|ISA\|\|Cell Adhesion Molecules:7201821	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Malignant neoplasm of prostate\|\|OCCURS_IN\|\|Malignant neoplasm of prostate:4145315	30/138,393	31/26,262,527	183.69	7.62e-52	3.48e-49
Endocrine therapy\|\|NEG_TREATS\|\|Malignant neoplasm of prostate:9306590	11/138,393	12/26,262,527	173.97	1.05e-19	1.44e-17
Primary Neoplasm\|\|PART_OF\|\|Prostate:312486	33/138,393	39/26,262,527	160.61	1.56e-55	7.70e-53
Brachytherapy\|\|compared_with\|\|External Beam Radiation Therapy:5658604	14/138,393	39/26,262,527	68.13	2.35e-20	3.46e-18
Abbott\|\|LOCATION_OF\|\|Prostate specific antigen measurement:6516371	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Nuclear Matrix-Associated Proteins\|\|PART_OF\|\|Malignant neoplasm of prostate:7435053	5/138,393	11/26,262,527	86.26	1.65e-08	7.59e-07
Radiotherapy, Conformal\|\|TREATS\|\|Malignant neoplasm of prostate:4685364	306/138,393	385/26,262,527	151.16	0.00e+00	0.00e+00
Prostate-Specific Antigen\|\|INTERACTS_WITH\|\|Androgen Receptor\|AR:9061504	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
STAT3 gene\|STAT3\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9676116	12/138,393	13/26,262,527	175.19	2.10e-21	3.22e-19
Core needle biopsy\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:4388179	62/138,393	71/26,262,527	165.79	1.54e-103	1.63e-100
Seminal Vesicles\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:1192298	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Rodent:1583750	15/138,393	14/26,262,527	203.34	4.49e-27	9.03e-25
Acid Phosphatase\|\|COEXISTS_WITH\|\|Prostate-Specific Antigen:4524326	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Animals, Laboratory:5349130	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Antiandrogen therapy\|\|TREATS\|\|Malignant neoplasm of prostate:785198	65/138,393	69/26,262,527	178.85	5.70e-110	6.47e-107
Reagents, Immunoassay, Tumor Marker, Enzyme, Prostate Specific Antigen\|\|AFFECTS\|\|Malignant neoplasm of prostate:4232435	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
amidronate\|\|ISA\|\|Diphosphonates:1788540	21/138,393	479/26,262,527	8.32	7.13e-13	5.58e-11
Prostate\|\|LOCATION_OF\|\|Infarction:43792	6/138,393	17/26,262,527	66.98	1.94e-09	9.82e-08
PTEN gene\|PTEN\|\|STIMULATES\|\|Proto-Oncogene Proteins c-akt\|AKT1:7881879	19/138,393	217/26,262,527	16.62	7.54e-17	8.64e-15
Prostate-Specific Antigen\|\|ISA\|\|Peptide Hydrolases:5165772	9/138,393	12/26,262,527	142.33	8.30e-16	8.48e-14
Transforming Growth Factor beta\|\|ASSOCIATED_WITH\|\|Prostate:3797905	10/138,393	22/26,262,527	86.26	9.10e-16	9.28e-14
Metabolites\|\|ASSOCIATED_WITH\|\|Prostate:680832	7/138,393	10/26,262,527	132.84	2.02e-12	1.52e-10
Tumor Suppressor Genes\|\|ASSOCIATED_WITH\|\|Prostatic Neoplasms:6365738	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Prostate-Specific Antigen\|\|ASSOCIATED_WITH\|\|Disease Progression:6598774	10/138,393	10/26,262,527	189.78	2.76e-18	3.46e-16
Cancer Detection\|\|TREATS\|\|cohort:8658716	10/138,393	19/26,262,527	99.88	2.86e-16	3.02e-14
nilutamide\|\|ISA\|\|Nonsteroidal antiandrogen:4683753	11/138,393	14/26,262,527	149.11	3.42e-19	4.56e-17
zoledronic acid\|\|TREATS\|\|Hormone-refractory prostate cancer:10433120	18/138,393	23/26,262,527	148.53	1.61e-30	3.77e-28
Prostate\|\|LOCATION_OF\|\|Malacoplakia:395539	14/138,393	73/26,262,527	36.40	4.47e-17	5.20e-15
Islet Cell Tumor\|\|ASSOCIATED_WITH\|\|Duodenum:123128	5/138,393	2/26,262,527	474.44	8.24e-11	5.13e-09
Prostate\|\|LOCATION_OF\|\|VEGF protein, human\|VEGFA:7529957	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Malignant neoplasm of prostate\|\|COEXISTS_WITH\|\|High-Risk Cancer:10008556	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
long-term care\|\|USES\|\|Finasteride:5352886	5/138,393	18/26,262,527	52.72	1.23e-07	4.49e-06
3 (or 17)-beta-hydroxysteroid dehydrogenase\|\|INTERACTS_WITH\|\|Androgens:7787578	5/138,393	15/26,262,527	63.26	5.75e-08	2.23e-06
Tumor cells, malignant\|\|PART_OF\|\|Malignant neoplasm of prostate:5635135	21/138,393	22/26,262,527	181.17	1.21e-36	3.64e-34
follow-up\|\|TREATS\|\|cohort:2179720	37/138,393	802/26,262,527	8.76	3.39e-22	5.53e-20
Transurethral Resection of Prostate\|\|ISA\|\|Operation on prostate:3083159	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Brachytherapy\|\|USES\|\|Needle device:3424785	7/138,393	14/26,262,527	94.89	1.19e-11	8.48e-10
Estrogen Receptor alpha\|\|PART_OF\|\|Stroma:8135299	6/138,393	42/26,262,527	27.11	2.11e-07	7.41e-06
Teleradiotherapy procedure\|\|PRECEDES\|\|Brachytherapy:6868278	9/138,393	23/26,262,527	74.26	7.52e-14	6.62e-12
Hypogonadism\|\|CAUSES\|\|Osteoporosis:4140038	7/138,393	22/26,262,527	60.38	1.53e-10	9.36e-09
vinorelbine\|\|TREATS\|\|Hormone-refractory prostate cancer:7712491	11/138,393	18/26,262,527	115.98	2.60e-18	3.34e-16
Immunotherapy\|\|TREATS\|\|Hormone-refractory prostate cancer:10665309	8/138,393	10/26,262,527	151.82	2.38e-14	2.15e-12
resveratrol\|\|TREATS\|\|Malignant neoplasm of prostate:10898265	14/138,393	15/26,262,527	177.13	8.52e-25	1.56e-22
Local\|\|ISA\|\|Extent:41239	46/138,393	310/26,262,527	28.17	5.10e-48	2.14e-45
Vaccines\|\|TREATS\|\|Prostate cancer metastatic:9775275	10/138,393	10/26,262,527	189.78	2.76e-18	3.46e-16
Positron-Emission Tomography\|\|DIAGNOSES\|\|Prostate cancer recurrent:9778107	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
Anandron\|\|TREATS\|\|Prostate cancer metastatic:4181611	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Prostate-Specific Antigen\|\|PART_OF\|\|[M]Unspecified tumor cell NOS:2639996	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Adenocarcinoma\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:6227934	5/138,393	4/26,262,527	237.22	4.90e-10	2.87e-08
Androgen Receptor\|AR\|\|PART_OF\|\|Malignant neoplasm of prostate:3765911	17/138,393	17/26,262,527	189.79	3.65e-30	8.38e-28
HNF1B\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:14001724	7/138,393	9/26,262,527	147.60	1.19e-12	9.12e-11
Secondary malignant neoplasm of bone\|\|PROCESS_OF\|\|Animal Model:4885407	6/138,393	18/26,262,527	63.26	2.58e-09	1.30e-07
genetic locus\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:10467929	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Androgen therapy\|\|USES\|\|Androgen Antagonists:5880743	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
PTEN gene\|PTEN\|\|ASSOCIATED_WITH\|\|Carcinogenesis:7786434	7/138,393	71/26,262,527	18.71	2.07e-07	7.31e-06
Neoplasm Metastasis\|\|COEXISTS_WITH\|\|Prostate cancer metastatic:9884554	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
loss; bone\|\|PROCESS_OF\|\|Cancer Patient:9421072	5/138,393	9/26,262,527	105.43	7.62e-09	3.62e-07
Pain relief\|\|TREATS\|\|Neoplasm Metastasis:1059200	5/138,393	13/26,262,527	72.99	3.20e-08	1.43e-06
Estrogens\|\|ASSOCIATED_WITH\|\|Prostate carcinoma:141971	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
leukemia\|\|PART_OF\|\|Breast:594778	8/138,393	35/26,262,527	43.38	7.02e-11	4.38e-09
Magnetic Resonance Imaging\|\|ADMINISTERED_TO\|\|radiologist:6724907	6/138,393	40/26,262,527	28.47	1.62e-07	5.75e-06
Neoplasm progression\|\|LOCATION_OF\|\|Stem cells:11209536	6/138,393	35/26,262,527	32.53	7.97e-08	3.08e-06
Therapeutic vaccine\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:12542953	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Human Cell Line\|\|LOCATION_OF\|\|Cell Proliferation:1813960	15/138,393	212/26,262,527	13.43	2.28e-12	1.71e-10
Radical prostatectomy\|\|compared_with\|\|Teleradiotherapy procedure:6557412	19/138,393	21/26,262,527	171.72	5.53e-33	1.43e-30
Androgen Receptor\|AR\|\|AUGMENTS\|\|Trans-Activation (Genetics):8741909	6/138,393	8/26,262,527	142.33	6.01e-11	3.76e-09
Androgen Receptor\|AR\|\|INHIBITS\|\|Androgens:4483183	11/138,393	15/26,262,527	139.17	5.90e-19	7.80e-17
Androgen Suppression\|\|TREATS\|\|Prostate cancer metastatic:6561840	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Pathological aspects\|\|ISA\|\|Diagnostic:190011	23/138,393	628/26,262,527	6.95	2.03e-12	1.52e-10
KLK3 gene\|KLK3\|\|INHIBITS\|\|Androgens:5888575	14/138,393	16/26,262,527	166.06	1.59e-24	2.88e-22
Androgen Antagonists\|\|PREVENTS\|\|Flare:14181168	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Paclitaxel\|\|TREATS\|\|Hormone-refractory prostate cancer:6474645	18/138,393	25/26,262,527	136.65	4.79e-30	1.10e-27
Prostascint\|\|ISA\|\|Monoclonal Antibodies:7870487	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Biopsy sample\|\|LOCATION_OF\|\|Prostate-Specific Antigen:3058073	13/138,393	16/26,262,527	154.20	1.42e-22	2.34e-20
Prostate\|\|LOCATION_OF\|\|Digital palpation:1078651	14/138,393	22/26,262,527	120.77	4.03e-23	6.92e-21
preference\|\|PROCESS_OF\|\|Urologist:8172142	5/138,393	14/26,262,527	67.78	4.33e-08	1.92e-06
Radical retropubic prostatectomy\|\|compared_with\|\|Brachytherapy:8193291	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
Anti-Inflammatory Agents, Non-Steroidal\|\|AFFECTS\|\|Malignant neoplasm of prostate:9197964	5/138,393	8/26,262,527	118.61	4.92e-09	2.37e-07
High fat diet NOS\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:11737732	8/138,393	11/26,262,527	138.02	4.09e-14	3.65e-12
Entire nerve\|\|LOCATION_OF\|\|Preservation, Biological:272089	50/138,393	292/26,262,527	32.51	7.94e-55	3.83e-52
Prostatic Tissue\|\|LOCATION_OF\|\|Androgens measurement:2214360	11/138,393	15/26,262,527	139.17	5.90e-19	7.80e-17
Mesenchyma\|\|PART_OF\|\|Urogenital sinus:1454759	35/138,393	187/26,262,527	35.53	4.41e-40	1.49e-37
Prostate\|\|LOCATION_OF\|\|Atypia:3114314	10/138,393	13/26,262,527	145.99	1.68e-17	1.99e-15
Biopsy sample\|\|LOCATION_OF\|\|Prostate carcinoma:1490359	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Flow Cytometry\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:4740331	8/138,393	10/26,262,527	151.82	2.38e-14	2.15e-12
Fluorescent Antibody Technique, Indirect\|\|DIAGNOSES\|\|Antimicrobial susceptibility:374548	4/138,393	2/26,262,527	379.55	1.12e-08	5.27e-07
ixabepilone\|\|TREATS\|\|Hormone-refractory prostate cancer:10889969	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Needle biopsy procedure\|\|METHOD_OF\|\|Cancer Diagnosis:10379898	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Insulin-Like Growth Factor I\|\|ASSOCIATED_WITH\|\|Benign prostatic hypertrophy:7202604	8/138,393	11/26,262,527	138.02	4.09e-14	3.65e-12
Prostate\|\|LOCATION_OF\|\|Induration:1583408	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Prostate\|\|LOCATION_OF\|\|Vitamin A:1448739	5/138,393	8/26,262,527	118.61	4.92e-09	2.37e-07
Malignant neoplasm of prostate\|\|PART_OF\|\|Bladder:1168785	11/138,393	11/26,262,527	189.78	5.49e-20	7.78e-18
Ultrasonography\|\|METHOD_OF\|\|Antigen assay:7192957	5/138,393	9/26,262,527	105.43	7.62e-09	3.62e-07
Serine Protease\|\|AUGMENTS\|\|Malignant neoplasm of prostate:10817661	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostatectomy\|\|PRECEDES\|\|Radical prostatectomy:8670099	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
MicroRNAs\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:14412001	28/138,393	34/26,262,527	156.31	4.11e-47	1.69e-44
Basal Cell\|\|PART_OF\|\|Prostatic epithelium:6247563	8/138,393	10/26,262,527	151.82	2.38e-14	2.15e-12
Secondary malignant neoplasm of bone\|\|MANIFESTATION_OF\|\|Malignant neoplasm of prostate:13513943	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Radical prostatectomy\|\|TREATS\|\|Locally Advanced Malignant Neoplasm:5550024	66/138,393	78/26,262,527	160.65	1.82e-109	2.05e-106
Prostatic Tissue\|\|LOCATION_OF\|\|Androstenedione:2424244	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Teleradiotherapy procedure\|\|TREATS\|\|Local disease:17052121	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Malignant neoplasm of prostate\|\|MANIFESTATION_OF\|\|Secondary malignant neoplasm of bone:7851535	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Endocrine therapy\|\|TREATS\|\|Secondary malignant neoplasm of bone:285475	6/138,393	22/26,262,527	51.76	7.08e-09	3.39e-07
Histiocytoma, Malignant Fibrous\|\|PART_OF\|\|Prostate:2861033	6/138,393	13/26,262,527	87.59	5.31e-10	3.10e-08
Androgens\|\|TREATS\|\|Tumorigenesis:8063500	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Androstenedione\|\|ISA\|\|Androgens:484186	11/138,393	215/26,262,527	9.71	4.50e-08	2.00e-06
Carcinogenesis\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:11568384	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Population-Based Registry\|\|ISA\|\|Cancer Registry:3420688	7/138,393	30/26,262,527	44.28	9.75e-10	5.17e-08
Scanning\|\|USES\|\|Prostascint:7452789	23/138,393	39/26,262,527	111.93	1.73e-36	5.20e-34
Androgen Suppression\|\|USES\|\|Goserelin:7141856	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Hospitals\|\|LOCATION_OF\|\|Needle biopsy procedure:785712	8/138,393	23/26,262,527	66.01	4.04e-12	2.98e-10
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Recipient, Transplant:7809966	22/138,393	27/26,262,527	154.65	2.92e-37	9.04e-35
Prednisone\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:11955139	10/138,393	11/26,262,527	172.53	5.24e-18	6.40e-16
Medical Castration\|\|TREATS\|\|Prostate cancer metastatic:6651327	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Prostate-Specific Antigen\|\|ISA\|\|Endopeptidases:6189572	12/138,393	16/26,262,527	142.34	1.21e-20	1.80e-18
Prostate\|\|LOCATION_OF\|\|Body Regions:5550062	8/138,393	16/26,262,527	94.89	3.89e-13	3.15e-11
Medical Imaging\|\|METHOD_OF\|\|Medical Imaging:562144	31/138,393	1,524/26,262,527	3.86	7.03e-10	4.08e-08
IMMUNOHISTOCHEMICAL\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:1775794	26/138,393	30/26,262,527	164.50	2.90e-44	1.12e-41
Cyproterone Acetate\|\|TREATS\|\|Prostate cancer metastatic:4145305	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
bortezomib\|\|TREATS\|\|Malignant neoplasm of prostate:10696044	7/138,393	6/26,262,527	221.41	1.82e-13	1.56e-11
MYC gene\|MYC\|\|PART_OF\|\|Prostate:3642702	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Chronic inflammation\|\|COEXISTS_WITH\|\|Carcinogenesis:9248625	8/138,393	28/26,262,527	54.22	1.51e-11	1.08e-09
IGF1 gene\|IGF1\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:11248070	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
PCNA gene\|PCNA\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9909766	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Prostate\|\|PART_OF\|\|Carcinoma:6137386	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Implantation procedure\|\|TREATS\|\|Malignant neoplasm of prostate:228760	73/138,393	79/26,262,527	175.45	7.13e-123	9.12e-120
Coagulation procedure\|\|TREATS\|\|Chronic radiation proctitis:12309456	5/138,393	11/26,262,527	86.26	1.65e-08	7.59e-07
Radiotherapy, Intensity-Modulated\|\|METHOD_OF\|\|Prostatic radiotherapies:14154162	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
peripheral blood\|\|LOCATION_OF\|\|Glutamate Carboxypeptidase II:8214437	9/138,393	12/26,262,527	142.33	8.30e-16	8.48e-14
Androgen Receptor\|AR\|\|COEXISTS_WITH\|\|Proprotein Convertase 1\|KRT6A\|PCSK1\|BTG2\|ACTR1B\|CBX8:12976417	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
African American\|\|USES\|\|Gleason grading system for prostatic cancer:13336904	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|gene polymorphism:8432892	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Carcinoma\|\|ASSOCIATED_WITH\|\|Prostate:34776	65/138,393	73/26,262,527	169.05	7.41e-109	8.24e-106
Malignant neoplasm of prostate\|\|COEXISTS_WITH\|\|Secondary malignant neoplasm of lymph node:6908938	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
sulindac sulfone\|\|TREATS\|\|Malignant neoplasm of prostate:9221859	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Stromal Cells\|\|LOCATION_OF\|\|TGFB1 protein, human\|TGFB1:5417968	6/138,393	36/26,262,527	31.63	9.26e-08	3.42e-06
Blood supply aspects\|\|PART_OF\|\|Solid tumor:1667931	8/138,393	53/26,262,527	28.65	1.31e-09	6.91e-08
Acetate\|\|TREATS\|\|Prostate cancer metastatic:14521794	75/138,393	85/26,262,527	167.53	3.90e-125	5.15e-122
Transgenes\|\|PART_OF\|\|Prostate:4340881	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Castration, Male\|\|ISA\|\|Castration:5914628	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
secretory protein\|\|PART_OF\|\|Prostate:1584256	7/138,393	26/26,262,527	51.09	4.12e-10	2.44e-08
Neonatal maladjustment syndrome\|\|PROCESS_OF\|\|Seeds:2418888	10/138,393	21/26,262,527	90.37	6.28e-16	6.50e-14
Clinic\|\|USES\|\|Urologic:1700699	6/138,393	31/26,262,527	36.73	4.20e-08	1.87e-06
Pelvic lymphadenectomy\|\|TREATS\|\|Localized Carcinoma:2120071	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostatic Tissue\|\|LOCATION_OF\|\|Androgen Receptor:1208448	5/138,393	12/26,262,527	79.07	2.32e-08	1.06e-06
Supernumerary mandibular left first primary molar\|\|LOCATION_OF\|\|tumor-associated antigen 72:17287468	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Androgen Receptor\|AR\|\|AFFECTS\|\|Cell Growth:9268846	8/138,393	12/26,262,527	126.52	6.79e-14	6.00e-12
Biopsy\|\|DIAGNOSES\|\|Adenocarcinoma:1047123	84/138,393	381/26,262,527	41.86	4.40e-99	4.48e-96
Human Cell Line\|\|LOCATION_OF\|\|Androgen Receptor\|AR:4923775	7/138,393	10/26,262,527	132.84	2.02e-12	1.52e-10
AR gene\|AR\|\|ASSOCIATED_WITH\|\|Neoplasm progression:10404989	26/138,393	33/26,262,527	149.54	1.70e-43	6.43e-41
Cancer Patient\|\|LOCATION_OF\|\|Prostate-Specific Antigen:4805386	10/138,393	11/26,262,527	172.53	5.24e-18	6.40e-16
CYP3A4 gene\|CYP3A4\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:7521368	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Androgen therapy\|\|USES\|\|agonists:8316346	19/138,393	21/26,262,527	171.72	5.53e-33	1.43e-30
Castration\|\|METHOD_OF\|\|Ablation:6097566	8/138,393	18/26,262,527	84.35	8.19e-13	6.38e-11
Androgen Receptor\|AR\|\|INTERACTS_WITH\|\|MicroRNAs:14306311	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Epidermal Growth Factor Receptor\|EGFR\|\|ASSOCIATED_WITH\|\|Prostate carcinoma:5061132	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Serum Proteins\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:699405	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Selenium\|\|DISRUPTS\|\|Malignant neoplasm of prostate:10504347	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
Breast\|\|ASSOCIATED_WITH\|\|melanoma:8189003	6/138,393	12/26,262,527	94.89	3.65e-10	2.16e-08
Orchiectomy\|\|ISA\|\|Endocrine therapy:1236579	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
CYP1A1 gene\|CYP1A1\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9042753	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Vitamin D Deficiency\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:5507677	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Palliative Care\|\|USES\|\|Radiopharmaceuticals:2740136	5/138,393	13/26,262,527	72.99	3.20e-08	1.43e-06
Estrogens\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:9094680	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Androgen Receptor\|AR\|\|INTERACTS_WITH\|\|Stanolone:1858434	7/138,393	25/26,262,527	53.14	3.26e-10	1.94e-08
Untranslated Regions\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:11998980	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Aromatase\|\|ASSOCIATED_WITH\|\|Prostate:3478933	5/138,393	12/26,262,527	79.07	2.32e-08	1.06e-06
Cell of bone\|\|PART_OF\|\|Malignant neoplasm of prostate:8219137	10/138,393	10/26,262,527	189.78	2.76e-18	3.46e-16
Pesticides\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:11335276	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Radical prostatectomy\|\|PRECEDES\|\|Salvage Therapy:6879871	39/138,393	37/26,262,527	200.08	6.35e-68	3.95e-65
Screening procedure\|\|METHOD_OF\|\|prostate cancer screening:5979729	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Bone neoplasms\|\|PART_OF\|\|Prostate:12318795	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostatic Tissue\|\|PART_OF\|\|Benign prostatic hypertrophy:2478435	10/138,393	14/26,262,527	135.56	2.87e-17	3.37e-15
Benign prostatic hypertrophy\|\|COEXISTS_WITH\|\|Benign prostatic hypertrophy:1372841	10/138,393	28/26,262,527	67.78	6.48e-15	6.37e-13
Radionuclide Imaging\|\|DIAGNOSES\|\|Prostate cancer metastatic:5299285	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Benign prostatic hypertrophy\|\|COEXISTS_WITH\|\|Adenocarcinoma:4599204	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Adenosquamous carcinoma\|\|PART_OF\|\|Prostate:2388369	18/138,393	35/26,262,527	97.61	4.84e-28	1.01e-25
Androgens\|\|ASSOCIATED_WITH\|\|Prostatic Neoplasms:1200543	6/138,393	5/26,262,527	227.73	9.37e-12	6.74e-10
Malignant neoplasm of urinary bladder\|\|PART_OF\|\|Prostate:3037037	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Entire lumbar disc\|\|LOCATION_OF\|\|Hernia:72058	1/138,393	5,299/26,262,527	0.04	5.23e-11	3.33e-09
Androgen Receptor\|AR\|\|AFFECTS\|\|Malignant neoplasm of prostate:9794377	9/138,393	8/26,262,527	213.50	6.99e-17	8.04e-15
Endocrine therapy\|\|AFFECTS\|\|loss; bone:6864369	5/138,393	12/26,262,527	79.07	2.32e-08	1.06e-06
High-Grade Prostatic Intraepithelial Neoplasia\|\|PART_OF\|\|Prostatic Tissue:6647706	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Hydrocortisone\|\|TREATS\|\|Hormone-refractory prostate cancer:8063049	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Dihydrotestosterone Assay\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:1473764	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Male gender\|\|PROCESS_OF\|\|Caucasoid Race:5617	60/138,393	2,078/26,262,527	5.48	1.06e-24	1.94e-22
Cyclooxygenase 2 Inhibitors\|\|TREATS\|\|Malignant neoplasm of prostate:8742137	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
Bladder\|\|PART_OF\|\|Prostate:103270	20/138,393	26/26,262,527	146.00	1.21e-33	3.23e-31
Adenocarcinoma\|\|PART_OF\|\|Organ:2063253	8/138,393	44/26,262,527	34.51	3.49e-10	2.08e-08
Osteoblasts\|\|LOCATION_OF\|\|Bone lesion:1379217	13/138,393	24/26,262,527	102.80	7.15e-21	1.07e-18
fosfestrol\|\|TREATS\|\|Prostate carcinoma:606930	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Tumor stage\|\|ASSOCIATED_WITH\|\|Prostate-Specific Antigen:12998214	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Racemases\|\|PART_OF\|\|Malignant neoplasm of prostate:9541669	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
Localized Malignant Neoplasm\|\|ASSOCIATED_WITH\|\|Prostate:3662509	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Prostate carcinoma\|\|PART_OF\|\|Prostate:1280696	17/138,393	22/26,262,527	146.66	7.79e-29	1.69e-26
Carcinoma, Endometrioid\|\|PART_OF\|\|Entire utricle:3272659	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Stereotactic radiotherapy\|\|TREATS\|\|AIDS related complex:14041852	6/138,393	18/26,262,527	63.26	2.58e-09	1.30e-07
Subcapsular orchidectomy\|\|TREATS\|\|Prostate cancer metastatic:3461017	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Transrectal Ultrasound\|\|METHOD_OF\|\|Early Diagnosis:3757330	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Insulin-Like Growth Factor I\|\|AFFECTS\|\|Malignant neoplasm of prostate:10216771	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
High weight\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:10690914	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Noninfiltrating Intraductal Carcinoma\|\|PART_OF\|\|Prostate:750486	37/138,393	62/26,262,527	113.28	6.53e-58	3.36e-55
melanoma\|\|PART_OF\|\|Prostate:103997	32/138,393	47/26,262,527	129.23	1.09e-51	4.95e-49
Carrier of disorder\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:8115300	22/138,393	24/26,262,527	173.98	4.71e-38	1.49e-35
Magnetic Resonance Imaging\|\|DIAGNOSES\|\|Secondary malignant neoplasm of lymph node:4856926	12/138,393	137/26,262,527	16.62	3.52e-11	2.25e-09
Prostate\|\|LOCATION_OF\|\|Stem cells:10220673	14/138,393	18/26,262,527	147.61	5.10e-24	9.12e-22
Androgens measurement\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:10205798	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Hematologic Neoplasms\|\|COEXISTS_WITH\|\|Solid tumor:4562543	6/138,393	27/26,262,527	42.17	2.03e-08	9.33e-07
Malignant neoplasm of prostate\|\|OCCURS_IN\|\|Workers:9152936	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Urethra\|\|LOCATION_OF\|\|polyps:343231	10/138,393	66/26,262,527	28.75	1.09e-11	7.83e-10
Estrogens\|\|TREATS\|\|Prostate carcinoma:103017	23/138,393	26/26,262,527	167.90	1.81e-39	5.98e-37
Observation parameter\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:6813103	21/138,393	22/26,262,527	181.17	1.21e-36	3.64e-34
AR gene\|AR\|\|AUGMENTS\|\|Transcription, Genetic:4597148	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
nilutamide\|\|TREATS\|\|Malignant neoplasm of prostate:4108651	15/138,393	16/26,262,527	177.93	1.72e-26	3.38e-24
Prostate\|\|LOCATION_OF\|\|Secondary malignant neoplasm of bone:4471962	21/138,393	23/26,262,527	173.29	2.30e-36	6.86e-34
bicalutamide\|\|TREATS\|\|Malignant neoplasm of prostate:6651311	69/138,393	81/26,262,527	161.73	1.64e-114	1.93e-111
Small cell carcinoma of lung\|\|ASSOCIATED_WITH\|\|Organ:3440950	6/138,393	10/26,262,527	113.87	1.59e-10	9.61e-09
Neck\|\|LOCATION_OF\|\|Bladder Neoplasm:619444	6/138,393	11/26,262,527	103.51	2.44e-10	1.46e-08
disorder control\|\|TREATS\|\|Malignant neoplasm of prostate:2810890	17/138,393	16/26,262,527	201.65	1.83e-30	4.28e-28
Molecular Fingerprint of Tumor\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:12364000	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Epithelial Cells\|\|PART_OF\|\|Intestines:63902	6/138,393	10,320/26,262,527	0.11	2.13e-16	2.33e-14
Prostate\|\|LOCATION_OF\|\|Carcinogenesis:8267104	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Estrogen Receptor beta\|\|PART_OF\|\|Prostate:7139641	5/138,393	11/26,262,527	86.26	1.65e-08	7.59e-07
Granulocytic Sarcoma\|\|PART_OF\|\|Prostate:3338398	5/138,393	9/26,262,527	105.43	7.62e-09	3.62e-07
imatinib\|\|TREATS\|\|Malignant neoplasm of prostate:9628939	7/138,393	9/26,262,527	147.60	1.19e-12	9.12e-11
Vitamin D3 Receptor\|\|ASSOCIATED_WITH\|\|Prostate:9229518	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Leuprolide Acetate\|\|INHIBITS\|\|Testosterone:3353635	6/138,393	9/26,262,527	126.52	9.97e-11	6.13e-09
Radical prostatectomy\|\|TREATS\|\|Sexual function:6237243	6/138,393	9/26,262,527	126.52	9.97e-11	6.13e-09
Prostate\|\|LOCATION_OF\|\|Functional assessment:8492055	18/138,393	19/26,262,527	179.80	1.43e-31	3.50e-29
Cell Proliferation\|\|PROCESS_OF\|\|Mice, Nude:938100	12/138,393	97/26,262,527	23.48	8.43e-13	6.56e-11
Prostate\|\|LOCATION_OF\|\|Phantoms, Imaging:6976008	58/138,393	94/26,262,527	117.14	1.68e-90	1.51e-87
Digital Rectal Examination\|\|ISA\|\|Diagnosis:1728673	16/138,393	25/26,262,527	121.47	2.96e-26	5.78e-24
Neoplasm progression\|\|PROCESS_OF\|\|cohort:6216544	6/138,393	16/26,262,527	71.17	1.44e-09	7.58e-08
Acid Phosphatase\|\|compared_with\|\|Prostate-Specific Antigen:3331878	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
Granulocyte-Macrophage Colony-Stimulating Factor\|LAMC2\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:6039938	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Angiogenesis\|\|PROCESS_OF\|\|Mice, Nude:5169637	8/138,393	108/26,262,527	14.06	2.19e-07	7.70e-06
Androgen Response Element\|\|INTERACTS_WITH\|\|Androgen Receptor\|AR:8013792	7/138,393	11/26,262,527	120.77	3.29e-12	2.43e-10
Malignant neoplasm of prostate\|\|COEXISTS_WITH\|\|Malignant neoplasm of urinary bladder:6030940	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Androgen Receptor\|AR\|\|ASSOCIATED_WITH\|\|Prostatic Neoplasms:2443342	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
FASN gene\|FASN\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:10492352	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostate\|\|LOCATION_OF\|\|Secretory Cell:1833555	8/138,393	19/26,262,527	79.91	1.16e-12	8.96e-11
Endocrine therapy\|\|PRECEDES\|\|Endocrine therapy:1994888	9/138,393	23/26,262,527	74.26	7.52e-14	6.62e-12
Androgen Antagonists\|\|STIMULATES\|\|Androgen Receptor\|AR:7617322	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Cultured Cells\|\|PART_OF\|\|Prostate:2202213	8/138,393	16/26,262,527	94.89	3.89e-13	3.15e-11
Urothelium\|\|PART_OF\|\|Prostatic Urethra:3412241	6/138,393	8/26,262,527	142.33	6.01e-11	3.76e-09
Hypogonadism\|\|CAUSES\|\|loss; bone:6053034	6/138,393	10/26,262,527	113.87	1.59e-10	9.61e-09
Radical prostatectomy\|\|TREATS\|\|organic disorders:8670989	20/138,393	22/26,262,527	172.54	1.13e-34	3.12e-32
Pelvis\|\|LOCATION_OF\|\|Positive Lymph Node:1280728	7/138,393	36/26,262,527	36.90	2.97e-09	1.49e-07
Urogenital sinus\|\|PART_OF\|\|Embryo:115796	5/138,393	17/26,262,527	55.82	9.68e-08	3.54e-06
AR gene\|AR\|\|PART_OF\|\|Malignant neoplasm of prostate:5114413	26/138,393	29/26,262,527	170.17	1.56e-44	6.10e-42
Vitamin D\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:6509101	24/138,393	29/26,262,527	157.08	1.25e-40	4.31e-38
Estrogens\|\|TREATS\|\|Malignant neoplasm of prostate:93544	85/138,393	90/26,262,527	179.33	2.36e-143	3.66e-140
Membrane Transport Proteins\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:13907739	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Breast\|\|PART_OF\|\|Prostate:8405669	8/138,393	13/26,262,527	116.79	1.09e-13	9.55e-12
8p21\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:6514129	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Proprotein Convertase 1\|KRT6A\|PCSK1\|BTG2\|ACTR1B\|CBX8\|\|PART_OF\|\|Human Cell Line:2681104	27/138,393	32/26,262,527	160.15	1.10e-45	4.36e-43
Ovaro-\|\|LOCATION_OF\|\|Flexible fiberoptic sigmoidoscopy:9721836	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostate-Specific Antigen\|\|PREDISPOSES\|\|Neoplasm Metastasis:6013475	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Testosterone\|\|COEXISTS_WITH\|\|Testosterone:497225	13/138,393	214/26,262,527	11.53	3.83e-10	2.27e-08
Pathologic stage\|\|ASSOCIATED_WITH\|\|Surgical margins:12862353	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Prostate\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:1794586	93/138,393	104/26,262,527	169.81	3.88e-155	6.37e-152
Tumor Cells, Cultured\|\|PART_OF\|\|Prostate:2434564	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
lycopene\|\|ISA\|\|Carotenoids:517390	37/138,393	334/26,262,527	21.03	9.98e-35	2.77e-32
AR gene\|AR\|\|compared_with\|\|AR gene\|AR:6441023	5/138,393	19/26,262,527	49.94	1.55e-07	5.48e-06
Carcinoembryonic Antigen\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:1528901	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Cryosurgery\|\|ISA\|\|Ablation:3765981	7/138,393	43/26,262,527	30.89	8.92e-09	4.21e-07
Capromab Pendetide\|\|TREATS\|\|Malignant neoplasm of prostate:7652836	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
Androgens\|\|TREATS\|\|Malignant neoplasm of prostate:713055	71/138,393	73/26,262,527	184.66	1.19e-120	1.49e-117
bicalutamide\|\|TREATS\|\|Prostate carcinoma:6508141	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Buserelin\|\|USES\|\|Buserelin:2101178	19/138,393	167/26,262,527	21.59	8.52e-19	1.12e-16
Residual Cancer\|\|PART_OF\|\|Prostate:3929358	34/138,393	42/26,262,527	153.66	1.06e-56	5.38e-54
Prostate carcinoma\|\|COEXISTS_WITH\|\|High-Grade Prostatic Intraepithelial Neoplasia:7151430	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
Anus\|\|LOCATION_OF\|\|Toxic effect:6638537	6/138,393	16/26,262,527	71.17	1.44e-09	7.58e-08
Acid Phosphatase\|\|ASSOCIATED_WITH\|\|Prostate carcinoma:269705	16/138,393	18/26,262,527	168.70	6.55e-28	1.35e-25
Mucins\|\|ASSOCIATED_WITH\|\|Prostate carcinoma:567851	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Prostate carcinoma\|\|ASSOCIATED_WITH\|\|Lobe:4379217	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
RNA, Messenger\|\|ASSOCIATED_WITH\|\|Prostatic Neoplasms:6439288	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Tumorigenesis\|\|ASSOCIATED_WITH\|\|Prostate:7188552	15/138,393	16/26,262,527	177.93	1.72e-26	3.38e-24
Malignant neoplasm of prostate\|\|AFFECTS\|\|Neoplasm progression:8961557	24/138,393	22/26,262,527	207.06	1.31e-42	4.84e-40
Malignant neoplasm of prostate\|\|NEG_COEXISTS_WITH\|\|Malignant neoplasm of prostate:7692348	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Cytosol\|\|LOCATION_OF\|\|KLK3 gene\|KLK3:6462460	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
treatment method\|\|TREATS\|\|Malignant neoplasm of prostate:220636	20/138,393	20/26,262,527	189.80	3.06e-35	8.64e-33
Transforming Growth Factor beta\|\|STIMULATES\|\|PMEPA1:10061108	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Teleradiotherapy procedure\|\|compared_with\|\|Brachytherapy:8716699	6/138,393	22/26,262,527	51.76	7.08e-09	3.39e-07
Interferon-beta\|\|TREATS\|\|Malignant neoplasm of prostate:4362703	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Genistein\|\|DISRUPTS\|\|Cell Growth:5706787	13/138,393	54/26,262,527	45.69	4.40e-17	5.12e-15
Brachytherapy\|\|AFFECTS\|\|Malignant neoplasm of prostate:9073007	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Malignant transformation\|\|ASSOCIATED_WITH\|\|Prostate:4194120	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Anaplasia\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:4546658	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
EZH2 gene\|EZH2\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:11257119	12/138,393	14/26,262,527	162.67	3.88e-21	5.87e-19
Bladder\|\|LOCATION_OF\|\|Neoplasm Metastasis:3444778	5/138,393	15/26,262,527	63.26	5.75e-08	2.23e-06
Bone Morphogenetic Proteins\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:6628962	11/138,393	16/26,262,527	130.48	9.91e-19	1.30e-16
PERINEURAL INVASION\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:10497251	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Urologist\|\|ISA\|\|Physicians:2720367	11/138,393	39/26,262,527	53.53	2.54e-15	2.55e-13
Peptide Hydrolases\|\|AFFECTS\|\|Tumor Cell Invasion:2574896	7/138,393	62/26,262,527	21.43	8.83e-08	3.41e-06
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|General Population:4352552	49/138,393	52/26,262,527	178.88	2.62e-83	2.09e-80
Secondary malignant neoplasm of bone\|\|COEXISTS_WITH\|\|Prostate carcinoma:463124	18/138,393	21/26,262,527	162.68	5.01e-31	1.19e-28
Primary Neoplasm\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:3876904	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
SPOP\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:15350212	10/138,393	11/26,262,527	172.53	5.24e-18	6.40e-16
Malignant Cystosarcoma Phyllodes\|\|PART_OF\|\|Prostate:2666943	10/138,393	20/26,262,527	94.89	4.28e-16	4.50e-14
Ablation\|\|TREATS\|\|Malignant neoplasm of kidney:8398735	5/138,393	13/26,262,527	72.99	3.20e-08	1.43e-06
Retinoids\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:6126056	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Antiandrogen therapy\|\|TREATS\|\|Prostate carcinoma:769553	10/138,393	10/26,262,527	189.78	2.76e-18	3.46e-16
Upper Extremity\|\|LOCATION_OF\|\|Antigen assay:7141858	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
taxane\|\|USES\|\|taxane:6361503	43/138,393	457/26,262,527	17.86	2.42e-37	7.53e-35
docetaxel\|\|USES\|\|docetaxel:6361506	347/138,393	1,177/26,262,527	56.08	0.00e+00	0.00e+00
loss; bone\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:9896345	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Relative Risk\|\|ISA\|\|Risk:1160881	22/138,393	747/26,262,527	5.59	3.25e-10	1.94e-08
Diethylstilbestrol\|\|TREATS\|\|Malignant neoplasm of prostate:49187	43/138,393	61/26,262,527	133.81	2.12e-69	1.36e-66
Androgens\|\|STIMULATES\|\|Glycoproteins:1911823	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Epothilones\|\|TREATS\|\|Malignant neoplasm of prostate:11332069	7/138,393	9/26,262,527	147.60	1.19e-12	9.12e-11
Adenocarcinoma of the prostate metastatic\|\|ISA\|\|Neoplasm Metastasis:4702846	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Tartrates\|\|INHIBITS\|\|Acid Phosphatase:64628	6/138,393	23/26,262,527	49.51	8.89e-09	4.20e-07
Plenaxis\|\|ISA\|\|abarelix:10594328	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Monoclonal Antibodies\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:3444797	13/138,393	13/26,262,527	189.79	2.20e-23	3.82e-21
Goserelin Acetate\|\|TREATS\|\|Malignant neoplasm of prostate:4909816	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Puncture biopsy\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:506481	11/138,393	12/26,262,527	173.97	1.05e-19	1.44e-17
Prostatic Tissue\|\|LOCATION_OF\|\|Selenium:3507225	7/138,393	10/26,262,527	132.84	2.02e-12	1.52e-10
Prostate\|\|LOCATION_OF\|\|Metastatic Lesion:6634345	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Prostatectomy\|\|TREATS\|\|Adenocarcinoma:4271179	16/138,393	20/26,262,527	151.83	2.15e-27	4.37e-25
Neoplasm Metastasis\|\|ASSOCIATED_WITH\|\|Epididymis:124464	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Testosterone\|\|AUGMENTS\|\|tumor growth:3983469	6/138,393	8/26,262,527	142.33	6.01e-11	3.76e-09
Radical retropubic prostatectomy\|\|TREATS\|\|Locally Advanced Malignant Neoplasm:6141008	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Prostate\|\|LOCATION_OF\|\|Estradiol:548362	7/138,393	23/26,262,527	57.76	1.99e-10	1.20e-08
Needle biopsy procedure\|\|ISA\|\|Procedures:867848	11/138,393	43/26,262,527	48.55	6.39e-15	6.29e-13
Oxidative Stress\|\|AFFECTS\|\|Malignant neoplasm of prostate:8120682	10/138,393	10/26,262,527	189.78	2.76e-18	3.46e-16
8q24\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:12301230	16/138,393	20/26,262,527	151.83	2.15e-27	4.37e-25
Estrogens\|\|TREATS\|\|Malignant neoplasm of prostate:9553405	7/138,393	2/26,262,527	664.22	3.88e-15	3.84e-13
Leuprolide Acetate\|\|STIMULATES\|\|Gonadorelin:3952894	7/138,393	13/26,262,527	102.19	7.94e-12	5.78e-10
Brachytherapy\|\|METHOD_OF\|\|Radical prostatectomy:9811706	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
bicalutamide\|\|STIMULATES\|\|Testosterone:6651304	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Cyclophosphamide\|\|TREATS\|\|Prostate carcinoma:1507537	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|network:14827252	10/138,393	12/26,262,527	158.15	9.56e-18	1.15e-15
Pelvis\|\|LOCATION_OF\|\|Prostate cancer metastatic:5653896	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Medulla Oblongata\|\|LOCATION_OF\|\|Spinal Muscular Atrophy:1831994	15/138,393	117/26,262,527	24.33	7.50e-16	7.75e-14
Stromal Neoplasm\|\|PART_OF\|\|Prostate:11214620	12/138,393	21/26,262,527	108.45	1.38e-19	1.88e-17
Glutamate Carboxypeptidase II\|\|INTERACTS_WITH\|\|Glutamate Carboxypeptidase II:10506167	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
penis\|\|LOCATION_OF\|\|Nodule:387277	9/138,393	59/26,262,527	28.95	1.11e-10	6.84e-09
Xenograft Model\|\|COEXISTS_WITH\|\|tumor growth:7147528	5/138,393	17/26,262,527	55.82	9.68e-08	3.54e-06
Castration\|\|AFFECTS\|\|Malignant neoplasm of prostate:12022568	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Prostate-Specific Antigen\|\|ASSOCIATED_WITH\|\|Gland structure:2567730	5/138,393	8/26,262,527	118.61	4.92e-09	2.37e-07
Secondary malignant neoplasm of bone\|\|COEXISTS_WITH\|\|Secondary malignant neoplasm of bone:1929376	6/138,393	32/26,262,527	35.58	4.96e-08	2.03e-06
Androgen Receptor\|AR\|\|PART_OF\|\|Recombinants:4545291	5/138,393	20/26,262,527	47.44	1.93e-07	6.79e-06
Prostate carcinoma\|\|PART_OF\|\|Homo sapiens:685737	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Bone Marrow\|\|LOCATION_OF\|\|Cell Line, Tumor:2797442	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Prostatic Neoplasms\|\|PRODUCES\|\|Prostate-Specific Antigen:5642811	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Endocrine therapy\|\|TREATS\|\|Prostate cancer stage C:6999725	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Androgen Suppression\|\|compared_with\|\|Androgen Suppression:6793961	13/138,393	14/26,262,527	176.23	4.22e-23	7.15e-21
Medulla Oblongata\|\|LOCATION_OF\|\|Muscular Atrophy:278066	14/138,393	320/26,262,527	8.30	4.63e-09	2.26e-07
Prostate\|\|LOCATION_OF\|\|Magnetic Resonance Spectroscopy:4143172	47/138,393	79/26,262,527	112.94	4.44e-73	3.07e-70
Disulfiram\|\|DISRUPTS\|\|Cancer Cell Growth:13697532	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Kininogenase\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:11094798	8/138,393	12/26,262,527	126.52	6.79e-14	6.00e-12
Papillary adenocarcinoma\|\|PART_OF\|\|Prostate:1087259	14/138,393	25/26,262,527	106.28	1.58e-22	2.60e-20
Prostate\|\|LOCATION_OF\|\|Transgenic Model:7590701	7/138,393	10/26,262,527	132.84	2.02e-12	1.52e-10
1p36\|\|LOCATION_OF\|\|Malignant neoplasm of prostate:8177920	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
alpha Tocopherol\|\|AFFECTS\|\|Malignant neoplasm of prostate:10219358	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Loss of Heterozygosity\|\|COEXISTS_WITH\|\|Prostate carcinoma:6690933	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Prostate-Specific Antigen\|\|ASSOCIATED_WITH\|\|Pelvic lymph node group:5461056	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Breast\|\|LOCATION_OF\|\|Neoplasm Metastasis:1511244	19/138,393	91/26,262,527	39.63	2.87e-23	4.95e-21
Prostate\|\|LOCATION_OF\|\|Carcinogens:956948	11/138,393	13/26,262,527	160.59	1.92e-19	2.59e-17
Xenograft Model\|\|PROCESS_OF\|\|Animalia:6511149	21/138,393	153/26,262,527	26.05	3.74e-22	6.09e-20
Transrectal Ultrasound\|\|ISA\|\|Diagnosis:5054355	12/138,393	19/26,262,527	119.86	5.54e-20	7.83e-18
Medical Castration\|\|USES\|\|Androgen Antagonists:4262110	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Prostatic Intraepithelial Neoplasias\|\|LOCATION_OF\|\|Epithelial Cells:5703270	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Androgen therapy\|\|TREATS\|\|Asymptomatic:10219129	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Single Nucleotide Polymorphism\|\|COEXISTS_WITH\|\|CYP17A1 gene\|CYP17A1:10720053	8/138,393	27/26,262,527	56.23	1.18e-11	8.48e-10
Digital Rectal Examination\|\|DIAGNOSES\|\|Hard prostate:9270073	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Small cell carcinoma of lung\|\|PART_OF\|\|Urinary tract:4586006	5/138,393	15/26,262,527	63.26	5.75e-08	2.23e-06
Prostate-Specific Antigen\|\|COEXISTS_WITH\|\|Androgen Receptor\|AR:6697322	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Acinar Cell\|\|PART_OF\|\|Prostate:877722	5/138,393	12/26,262,527	79.07	2.32e-08	1.06e-06
Null cell\|\|PART_OF\|\|Malignant neoplasm of prostate:8879262	10/138,393	13/26,262,527	145.99	1.68e-17	1.99e-15
Prostate-Specific Antigen\|\|CAUSES\|\|Antimicrobial susceptibility:5795162	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
docetaxel\|\|TREATS\|\|Prostate cancer metastatic:8190227	165/138,393	188/26,262,527	166.75	6.53e-273	2.14e-269
Cisplatin\|\|ASSOCIATED_WITH\|\|Hormone-refractory prostate cancer:8450015	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Radical prostatectomy\|\|compared_with\|\|Radical prostatectomy:6237242	109/138,393	171/26,262,527	121.06	9.80e-170	1.69e-166
Protein Expression\|\|ASSOCIATED_WITH\|\|Proprotein Convertase 1\|KRT6A\|PCSK1\|BTG2\|ACTR1B\|CBX8:10154057	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Radical prostatectomy\|\|TREATS\|\|Malignant neoplasm of prostate:505086	2,679/138,393	3,197/26,262,527	162.14	0.00e+00	0.00e+00
Xenograft procedure\|\|USES\|\|docetaxel:10169871	7/138,393	15/26,262,527	88.56	1.73e-11	1.23e-09
Radical prostatectomy\|\|TREATS\|\|Recurrent Carcinoma:6219377	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Malignant neoplasm of urinary bladder\|\|PART_OF\|\|Urothelium:1852090	24/138,393	427/26,262,527	10.67	9.34e-17	1.07e-14
Breast\|\|ASSOCIATED_WITH\|\|Osteoporosis:7545016	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Medical Castration\|\|USES\|\|Gonadotropin-Releasing Hormone Analog:3768586	8/138,393	11/26,262,527	138.02	4.09e-14	3.65e-12
gefitinib\|\|TREATS\|\|Hormone-refractory prostate cancer:11060755	6/138,393	9/26,262,527	126.52	9.97e-11	6.13e-09
Malignant neoplasm of prostate\|\|AFFECTS\|\|Aging:5997981	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Prostate\|\|LOCATION_OF\|\|Prostatic Intraepithelial Neoplasias:5972690	11/138,393	11/26,262,527	189.78	5.49e-20	7.78e-18
MicroRNAs\|\|ASSOCIATED_WITH\|\|Neoplasm progression:12588604	21/138,393	232/26,262,527	17.18	9.79e-19	1.29e-16
HIF1alpha protein\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:7927420	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
Radical prostatectomy\|\|PREDISPOSES\|\|Disease Progression:8055050	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Sirolimus (substance)\|\|TREATS\|\|Malignant neoplasm of prostate:13111198	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Malignant neoplasm of prostate\|\|AFFECTS\|\|Benign prostatic hypertrophy:11878986	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Paclitaxel\|\|USES\|\|Paclitaxel:5595757	43/138,393	1,657/26,262,527	4.93	1.40e-16	1.53e-14
Androgen Receptor\|AR\|\|STIMULATES\|\|Androgen Receptor\|AR:3134484	49/138,393	85/26,262,527	109.43	1.34e-75	9.70e-73
Toxic effect\|\|COEXISTS_WITH\|\|Toxic effect:981444	16/138,393	386/26,262,527	7.87	7.96e-10	4.60e-08
Glucocorticoid Receptor\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:12280269	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Gland structure\|\|PART_OF\|\|Carcinoma:1071871	6/138,393	12/26,262,527	94.89	3.65e-10	2.16e-08
immortalized cell\|\|PART_OF\|\|Malignant neoplasm of prostate:8143362	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Entire lumbar spine\|\|LOCATION_OF\|\|Neoplasm Metastasis:732357	6/138,393	32/26,262,527	35.58	4.96e-08	2.03e-06
Cancer-Predisposing Gene\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8508564	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Teleradiotherapy procedure\|\|TREATS\|\|advanced disease:7362328	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Flutamide\|\|compared_with\|\|Leuprolide:4108660	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Combination Drug Therapy\|\|TREATS\|\|Prostate cancer metastatic:2105248	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Cytotoxic Chemotherapy\|\|TREATS\|\|Prostate cancer metastatic:10967589	12/138,393	13/26,262,527	175.19	2.10e-21	3.22e-19
Prophylactic treatment\|\|TREATS\|\|Malignant neoplasm of prostate:1397380	42/138,393	44/26,262,527	181.20	8.51e-72	5.72e-69
Androgen Receptor\|AR\|\|CAUSES\|\|Malignant neoplasm of prostate:11961531	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Radical prostatectomy\|\|PRECEDES\|\|Drainage procedure:6095241	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Prostate\|\|LOCATION_OF\|\|Recurrent inflammation:10931980	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Epithelial Cells\|\|PART_OF\|\|Benign prostatic hypertrophy:2417954	18/138,393	25/26,262,527	136.65	4.79e-30	1.10e-27
Prostate cancer metastatic\|\|LOCATION_OF\|\|[M]Unspecified tumor cell NOS:11465685	13/138,393	14/26,262,527	176.23	4.22e-23	7.15e-21
vitamin E succinate\|\|ISA\|\|Vitamin E:3099020	6/138,393	21/26,262,527	54.22	5.59e-09	2.69e-07
Adenocarcinoma\|\|PART_OF\|\|Prostatic Tissue:5785716	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Orchiectomy\|\|ISA\|\|Castration:3586545	8/138,393	19/26,262,527	79.91	1.16e-12	8.96e-11
Biopsy\|\|USES\|\|Probes:366946	12/138,393	105/26,262,527	21.69	1.98e-12	1.51e-10
Orchiectomy\|\|TREATS\|\|Carcinoma:46263	13/138,393	18/26,262,527	137.07	4.26e-22	6.89e-20
docetaxel\|\|TREATS\|\|Hormone-refractory prostate cancer:8063031	121/138,393	159/26,262,527	144.54	3.34e-195	6.73e-192
Malignant neoplasm of prostate\|\|PART_OF\|\|Colon:4460598	6/138,393	5/26,262,527	227.73	9.37e-12	6.74e-10
Hospitals\|\|LOCATION_OF\|\|Core needle biopsy:3074875	6/138,393	17/26,262,527	66.98	1.94e-09	9.82e-08
leukemia\|\|PART_OF\|\|Colon:2018742	10/138,393	18/26,262,527	105.43	1.89e-16	2.06e-14
Prostate\|\|LOCATION_OF\|\|Neuroendocrine Cell:3586363	23/138,393	49/26,262,527	89.09	1.07e-34	2.98e-32
Preservation, Biological\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:8325641	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Ketoconazole\|\|INHIBITS\|\|Androgens:3223630	6/138,393	19/26,262,527	59.93	3.37e-09	1.66e-07
13q\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:6722131	11/138,393	12/26,262,527	173.97	1.05e-19	1.44e-17
docetaxel/estramustine\|\|TREATS\|\|Malignant neoplasm of prostate:9329988	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Proprotein Convertase 1\|KRT6A\|PCSK1\|BTG2\|ACTR1B\|CBX8\|\|PART_OF\|\|Prostate:9844297	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
sarcoma\|\|PART_OF\|\|Bladder:4926	15/138,393	81/26,262,527	35.15	5.44e-18	6.64e-16
Androgen Receptor\|AR\|\|INTERACTS_WITH\|\|TRANSCRIPTION FACTOR:13434842	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Apigenin\|\|USES\|\|Apigenin:7018890	11/138,393	124/26,262,527	16.84	2.02e-10	1.22e-08
TRANSCRIPTION FACTOR\|\|ASSOCIATED_WITH\|\|Carcinogenesis:5904920	7/138,393	56/26,262,527	23.72	4.65e-08	2.03e-06
Gelatinase B\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:7564920	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
Megavoltage radiation therapy\|\|TREATS\|\|Carcinoma:358967	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
GSTM1 gene\|GSTM1\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9042754	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
FAS\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:7743979	6/138,393	8/26,262,527	142.33	6.01e-11	3.76e-09
lymph nodes\|\|PART_OF\|\|Malignant neoplasm of prostate:10037112	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Paclitaxel\|\|TREATS\|\|Malignant neoplasm of prostate:7540581	36/138,393	36/26,262,527	189.82	2.92e-62	1.64e-59
Adrenalectomy\|\|TREATS\|\|Malignant neoplasm of prostate:130378	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Prostatic Neoplasms\|\|PROCESS_OF\|\|African American:13336903	6/138,393	8/26,262,527	142.33	6.01e-11	3.76e-09
Growth Inhibitors\|\|INTERACTS_WITH\|\|Transforming Growth Factor beta:3764211	8/138,393	96/26,262,527	15.81	9.39e-08	3.45e-06
Supplementation\|\|USES\|\|lycopene:7254818	21/138,393	185/26,262,527	21.54	1.35e-20	2.00e-18
Epithelial Cells\|\|LOCATION_OF\|\|Acid Phosphatase:883637	10/138,393	25/26,262,527	75.91	2.55e-15	2.56e-13
Chromosomes, Human, Pair 1\|\|LOCATION_OF\|\|Malignant neoplasm of prostate:6965020	9/138,393	11/26,262,527	155.27	4.76e-16	4.94e-14
Magnetic Resonance Imaging\|\|METHOD_OF\|\|Magnetic Resonance Imaging:2684345	30/138,393	652/26,262,527	8.73	2.85e-18	3.58e-16
Endothelial Cells\|\|PART_OF\|\|Aorta:405548	7/138,393	7,773/26,262,527	0.17	1.67e-10	1.01e-08
Bombesin\|\|ISA\|\|Neuropeptides:1860897	14/138,393	95/26,262,527	27.97	1.19e-15	1.21e-13
Supplementation\|\|USES\|\|Androgens:778771	27/138,393	140/26,262,527	36.61	1.34e-31	3.32e-29
Tomography, Emission-Computed\|\|DIAGNOSES\|\|Secondary malignant neoplasm of bone:12511227	8/138,393	35/26,262,527	43.38	7.02e-11	4.38e-09
PCNA gene\|PCNA\|\|PART_OF\|\|Malignant neoplasm of prostate:5952754	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Gene Expression Profiling\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:9923722	11/138,393	12/26,262,527	173.97	1.05e-19	1.44e-17
Prostate-Specific Antigen\|\|ASSOCIATED_WITH\|\|Prostate cancer metastatic:5196881	19/138,393	18/26,262,527	200.34	7.55e-34	2.03e-31
RNA, Messenger\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:6898597	17/138,393	17/26,262,527	189.79	3.65e-30	8.38e-28
ERG gene\|ERG\|\|ASSOCIATED_WITH\|\|Prostate carcinoma:15737177	5/138,393	4/26,262,527	237.22	4.90e-10	2.87e-08
Biopsy finding\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:7809968	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Endocrine therapy\|\|AFFECTS\|\|Malignant neoplasm of prostate:139144	14/138,393	14/26,262,527	189.79	4.43e-25	8.24e-23
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Angiogenesis:11127354	6/138,393	5/26,262,527	227.73	9.37e-12	6.74e-10
Invasive Carcinoma\|\|ASSOCIATED_WITH\|\|Prostate:5703269	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Orchiectomy\|\|compared_with\|\|Zoladex:3702547	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Ultrasonography\|\|DIAGNOSES\|\|Prostate carcinoma:2835972	21/138,393	22/26,262,527	181.17	1.21e-36	3.64e-34
lymph nodes\|\|PART_OF\|\|Prostate:1603835	9/138,393	11/26,262,527	155.27	4.76e-16	4.94e-14
Peptides\|\|INTERACTS_WITH\|\|Prostate-Specific Antigen:8790396	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Prostatic secretions\|\|LOCATION_OF\|\|Acid Phosphatase:46260	7/138,393	14/26,262,527	94.89	1.19e-11	8.48e-10
Urokinase\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:5920397	18/138,393	18/26,262,527	189.79	7.40e-32	1.83e-29
MicroRNAs\|\|ASSOCIATED_WITH\|\|Tumorigenesis:10352068	20/138,393	536/26,262,527	7.08	3.92e-11	2.51e-09
Radical prostatectomy\|\|TREATS\|\|PATHOLOGIC FINDINGS:7334738	11/138,393	12/26,262,527	173.97	1.05e-19	1.44e-17
Radical prostatectomy\|\|TREATS\|\|Participant:11433712	11/138,393	10/26,262,527	208.76	2.76e-20	4.03e-18
Upper Extremity\|\|LOCATION_OF\|\|Toxic effect:2375458	16/138,393	327/26,262,527	9.29	7.96e-11	4.96e-09
Angiogenesis\|\|PROCESS_OF\|\|Prostate:6785214	12/138,393	18/26,262,527	126.52	3.41e-20	4.96e-18
Malignant neoplasm of prostate\|\|ASSOCIATED_WITH\|\|Upper Extremity:3904835	32/138,393	43/26,262,527	141.25	1.32e-52	6.09e-50
Finasteride\|\|USES\|\|Finasteride:4457069	64/138,393	370/26,262,527	32.84	6.06e-70	3.93e-67
Upper arm\|\|LOCATION_OF\|\|Malignant neoplasm of prostate:8267118	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Renal Cell Carcinoma\|\|PART_OF\|\|Bladder:663554	8/138,393	37/26,262,527	41.03	1.03e-10	6.35e-09
Malignant neoplasm of prostate\|\|AFFECTS\|\|Pathogenesis:3748157	32/138,393	33/26,262,527	184.06	3.21e-55	1.56e-52
Papilloma, Inverted\|\|PART_OF\|\|Prostatic Urethra:2209080	8/138,393	12/26,262,527	126.52	6.79e-14	6.00e-12
Proto-Oncogene Proteins c-akt\|AKT1\|\|DISRUPTS\|\|tumor growth:9488078	9/138,393	39/26,262,527	43.80	4.17e-12	3.07e-10
alpha Tocopherol\|\|PREVENTS\|\|Malignant neoplasm of prostate:7427271	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Pelvis\|\|LOCATION_OF\|\|Malignant neoplasm of urinary bladder:11175230	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Proto-Oncogene Proteins c-akt\|AKT1\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9302614	48/138,393	49/26,262,527	185.96	3.37e-82	2.64e-79
OGX-011\|\|INHIBITS\|\|Clusterin\|CLU:11395606	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Treatment Protocols\|\|USES\|\|docetaxel:7337244	20/138,393	121/26,262,527	31.37	1.29e-22	2.14e-20
Diphosphonates\|\|TREATS\|\|Bone Diseases:792638	18/138,393	201/26,262,527	17.00	3.36e-16	3.54e-14
Malignant neoplasm of prostate\|\|ISA\|\|Malignant disease:3264032	28/138,393	28/26,262,527	189.81	9.26e-49	3.99e-46
KLK3 gene\|KLK3\|\|compared_with\|\|Prostate-Specific Antigen:7237958	7/138,393	10/26,262,527	132.84	2.02e-12	1.52e-10
Local Therapy\|\|TREATS\|\|Malignant neoplasm of prostate:5578310	58/138,393	61/26,262,527	180.51	1.81e-98	1.82e-95
Prolactin\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:3604349	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Brachytherapy\|\|PRECEDES\|\|Catheterization:9486465	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostate\|\|LOCATION_OF\|\|Radioisotope scan of lymphatic system:1607977	5/138,393	8/26,262,527	118.61	4.92e-09	2.37e-07
sulforafan\|\|TREATS\|\|Malignant neoplasm of prostate:15412689	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Leuprolide\|\|ISA\|\|Gonadorelin:2618515	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
GRP gene\|GRP\|\|PART_OF\|\|Colon:17235089	11/138,393	18/26,262,527	115.98	2.60e-18	3.34e-16
Castration\|\|TREATS\|\|Malignant neoplasm of prostate:49482	159/138,393	168/26,262,527	179.81	1.02e-266	3.23e-263
Androgen therapy\|\|TREATS\|\|Adenocarcinoma:6091166	9/138,393	11/26,262,527	155.27	4.76e-16	4.94e-14
KLK3 gene\|KLK3\|\|COEXISTS_WITH\|\|Prostate-Specific Antigen:11372544	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Radioactive destruction\|\|TREATS\|\|Adenocarcinoma:7149984	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Bone Marrow\|\|LOCATION_OF\|\|[M]Unspecified tumor cell NOS:254786	36/138,393	932/26,262,527	7.33	2.95e-19	3.96e-17
Gland structure\|\|PART_OF\|\|Prostatic Neoplasms:3673068	13/138,393	12/26,262,527	205.60	1.11e-23	1.96e-21
zoledronic acid\|\|TREATS\|\|Malignant neoplasm of lung:10947377	5/138,393	12/26,262,527	79.07	2.32e-08	1.06e-06
cohort\|\|LOCATION_OF\|\|KLK3 gene\|KLK3:10617179	11/138,393	17/26,262,527	122.80	1.62e-18	2.10e-16
EPHB2\|MAPK1\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:12145098	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
MMP14 protein, human\|MMP14\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8083068	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Epithelium\|\|PART_OF\|\|Adenocarcinoma:1414668	5/138,393	13/26,262,527	72.99	3.20e-08	1.43e-06
gefitinib\|\|ISA\|\|Epidermal growth factor receptor inhibitor:10142340	24/138,393	719/26,262,527	6.34	4.41e-12	3.25e-10
Endocrine therapy\|\|TREATS\|\|Adenocarcinoma of the prostate metastatic:4412176	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Frozen Sections\|\|PART_OF\|\|Benign prostatic hypertrophy:6378016	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Ultrasonic guidance procedure\|\|ISA\|\|Medical Imaging:6266594	11/138,393	45/26,262,527	46.39	9.84e-15	9.32e-13
Androgen therapy\|\|TREATS\|\|Physical function:8032001	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Malignant neoplasm of prostate\|\|AFFECTS\|\|gene polymorphism:8497854	22/138,393	22/26,262,527	189.80	1.27e-38	4.06e-36
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|American:4790753	14/138,393	13/26,262,527	204.39	2.22e-25	4.21e-23
Prostate-Specific Antigen\|\|ASSOCIATED_WITH\|\|Specimen from prostate:4363470	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
FGFR3 gene\|FGFR3\|\|ASSOCIATED_WITH\|\|Prostatic Neoplasms:10745855	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Prostate-Specific Antigen\|\|PART_OF\|\|Dendritic Cells:7898748	5/138,393	8/26,262,527	118.61	4.92e-09	2.37e-07
Carboplatin\|\|TREATS\|\|Malignant neoplasm of prostate:4465128	13/138,393	16/26,262,527	154.20	1.42e-22	2.34e-20
alpha-methylacyl-CoA racemase\|\|PART_OF\|\|Malignant neoplasm of prostate:10319843	12/138,393	14/26,262,527	162.67	3.88e-21	5.87e-19
Health care facility\|\|LOCATION_OF\|\|Clinical Trials, Phase II:2289158	8/138,393	72/26,262,527	21.09	1.18e-08	5.50e-07
glandular epithelium\|\|PART_OF\|\|Prostate:570177	27/138,393	61/26,262,527	84.01	6.56e-40	2.21e-37
tomography\|\|DIAGNOSES\|\|Prostatic Neoplasms:362957	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
IMMUNOHISTOCHEMICAL\|\|DIAGNOSES\|\|High-Grade Prostatic Intraepithelial Neoplasia:12636657	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Combined Modality Therapy\|\|USES\|\|agonists:1908586	20/138,393	195/26,262,527	19.47	6.80e-19	8.97e-17
Prostate\|\|LOCATION_OF\|\|Malignant disease:4634	43/138,393	48/26,262,527	170.05	1.21e-72	8.32e-70
Fruit\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:6515897	10/138,393	11/26,262,527	172.53	5.24e-18	6.40e-16
Androgen therapy\|\|TREATS\|\|Fracture:13495802	11/138,393	12/26,262,527	173.97	1.05e-19	1.44e-17
peripheral blood\|\|LOCATION_OF\|\|FOLH1 gene\|FOLH1:7189629	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
zoledronic acid\|\|compared_with\|\|amidronate:9007017	9/138,393	52/26,262,527	32.85	4.05e-11	2.59e-09
Prostate\|\|LOCATION_OF\|\|Bacteria:1002567	6/138,393	23/26,262,527	49.51	8.89e-09	4.20e-07
Diethylstilbestrol\|\|compared_with\|\|Cyproterone Acetate:1872490	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Digital Rectal Examination\|\|METHOD_OF\|\|Needle biopsy procedure:8146349	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Nerve Fibers\|\|AFFECTS\|\|Neuromuscular transmission:108786	4/138,393	2/26,262,527	379.55	1.12e-08	5.27e-07
tomography\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:2520598	17/138,393	17/26,262,527	189.79	3.65e-30	8.38e-28
Castration\|\|TREATS\|\|Xenograft Model:13094447	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
Human Glandular Kallikrein 2\|HK2\|\|ISA\|\|Kininogenase\|KLK4:6562471	6/138,393	18/26,262,527	63.26	2.58e-09	1.30e-07
sulforafan\|\|INHIBITS\|\|Histone Deacetylase:11679757	6/138,393	8/26,262,527	142.33	6.01e-11	3.76e-09
Neoplasm Metastasis\|\|COEXISTS_WITH\|\|Neoplasm Metastasis:949364	18/138,393	250/26,262,527	13.66	1.14e-14	1.08e-12
Radioimmunoassay\|\|DIAGNOSES\|\|Prostate carcinoma:1853881	4/138,393	2/26,262,527	379.55	1.12e-08	5.27e-07
Selenium\|\|ISA\|\|Trace Elements:240861	33/138,393	880/26,262,527	7.12	1.99e-17	2.36e-15
Candidate Disease Gene\|\|TREATS\|\|Prostate cancer metastatic:7697985	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Radical prostatectomy\|\|USES\|\|Phosphodiesterase 5 inhibitor:12826981	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Prostate\|\|PART_OF\|\|Ovaro-:950504	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Neoadjuvant Therapy\|\|TREATS\|\|Locally Advanced Malignant Neoplasm:2910499	22/138,393	96/26,262,527	43.50	1.75e-27	3.57e-25
Prognostic Factor\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:3781937	113/138,393	121/26,262,527	177.37	1.28e-189	2.42e-186
Proton therapy\|\|TREATS\|\|Cancer Patient:11354227	5/138,393	10/26,262,527	94.89	1.14e-08	5.31e-07
Secondary malignant neoplasm of bone\|\|ISA\|\|Solid tumor:9137962	10/138,393	16/26,262,527	118.61	7.71e-17	8.83e-15
[M]Papillary neoplasms\|\|ASSOCIATED_WITH\|\|Prostatic Urethra:2687020	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Cyst Fluid\|\|LOCATION_OF\|\|Prostate-Specific Antigen:6726404	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
Androgen Receptor\|AR\|\|STIMULATES\|\|Cell Proliferation:9068404	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Control Groups\|\|LOCATION_OF\|\|Prostate-Specific Antigen:6279182	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
Fatty Acids\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:9973195	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Somatostatin analog\|SST\|\|TREATS\|\|Malignant neoplasm of prostate:3673080	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Bone structure of tibia\|\|PART_OF\|\|SCID Mice:9950258	8/138,393	13/26,262,527	116.79	1.09e-13	9.55e-12
AR gene\|AR\|\|AUGMENTS\|\|Malignant neoplasm of prostate:5468517	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
Angiogenesis Inhibitors\|\|TREATS\|\|Malignant neoplasm of prostate:7379664	22/138,393	22/26,262,527	189.80	1.27e-38	4.06e-36
Prolactin\|\|ASSOCIATED_WITH\|\|Tumorigenesis:2151540	5/138,393	12/26,262,527	79.07	2.32e-08	1.06e-06
Neuroendocrine tissue\|\|PART_OF\|\|Pancreas:7923707	6/138,393	11/26,262,527	103.51	2.44e-10	1.46e-08
Ionizing radiation\|\|PROCESS_OF\|\|Malignant neoplasm of prostate:10787856	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
prostatitis\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:6002460	12/138,393	14/26,262,527	162.67	3.88e-21	5.87e-19
Malignant neoplasm of prostate\|\|AFFECTS\|\|Electromagnetic Energy:7586422	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Casodex\|\|INHIBITS\|\|Androgen Receptor\|AR:9096039	7/138,393	11/26,262,527	120.77	3.29e-12	2.43e-10
Prostate cancer metastatic\|\|ASSOCIATED_WITH\|\|lymph nodes:1775797	10/138,393	11/26,262,527	172.53	5.24e-18	6.40e-16
Methylation\|\|PROCESS_OF\|\|Malignant neoplasm of prostate:6769770	49/138,393	55/26,262,527	169.13	1.79e-82	1.42e-79
Stanolone\|\|PART_OF\|\|Prostate:1037072	9/138,393	32/26,262,527	53.38	9.00e-13	7.00e-11
Blood specimen\|\|LOCATION_OF\|\|Prostate-Specific Antigen:6277881	13/138,393	20/26,262,527	123.36	1.17e-21	1.83e-19
Neuroendocrine Cell\|\|PART_OF\|\|Prostate:3988644	31/138,393	75/26,262,527	78.45	7.71e-45	3.02e-42
Radical prostatectomy\|\|USES\|\|Mounts:6287664	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
tadalafil\|\|PREVENTS\|\|Erectile dysfunction:13017870	5/138,393	8/26,262,527	118.61	4.92e-09	2.37e-07
Zoladex\|\|USES\|\|Zoladex:3431670	11/138,393	24/26,262,527	86.98	3.05e-17	3.57e-15
Stanolone\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:5423947	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Radiotherapy, Conformal\|\|TREATS\|\|Localized Carcinoma:6047403	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Cancer Detection\|\|TREATS\|\|Suspected prostate cancer:8514676	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Proto-Oncogene Protein pp60 (c-src)\|SRC\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:12636018	7/138,393	6/26,262,527	221.41	1.82e-13	1.56e-11
Western Blot\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:9120251	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Single Nucleotide Polymorphism\|\|ASSOCIATED_WITH\|\|Aggressive behavior:13069995	8/138,393	14/26,262,527	108.44	1.71e-13	1.48e-11
Zometa\|\|ISA\|\|zoledronic acid:8907514	24/138,393	59/26,262,527	77.21	6.30e-35	1.76e-32
Radiotherapy, Conformal\|\|TREATS\|\|Prostate carcinoma:5709777	21/138,393	24/26,262,527	166.07	4.30e-36	1.26e-33
Stem cells\|\|PRODUCES\|\|Integrins:17266939	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Insulin-Like Growth Factor II\|\|ISA\|\|Somatomedins:944775	23/138,393	638/26,262,527	6.84	2.76e-12	2.06e-10
Specimen\|\|LOCATION_OF\|\|apoptogenic cytochrome c release channel activity:4405773	12/138,393	116/26,262,527	19.63	5.82e-12	4.26e-10
Malignant neoplasm of prostate\|\|COEXISTS_WITH\|\|Renal Cell Carcinoma:2289120	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Estramustine phosphate\|\|TREATS\|\|Hormone-refractory prostate cancer:5008022	29/138,393	39/26,262,527	141.14	8.25e-48	3.45e-45
BCL-2 Protein\|\|PART_OF\|\|Malignant neoplasm of prostate:6738914	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
KLK3 gene\|KLK3\|\|NEG_ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:10943963	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
PAK6 gene\|PAK6\|\|PART_OF\|\|Malignant neoplasm of prostate:12427388	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Glutamate Carboxypeptidase II\|\|PART_OF\|\|Human Cell Line:9935922	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Pads\|\|compared_with\|\|Pads:2175729	10/138,393	69/26,262,527	27.50	1.62e-11	1.16e-09
Neoplasms, Experimental\|\|PART_OF\|\|Prostate:397970	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Chromogranin A\|\|ASSOCIATED_WITH\|\|Prostate carcinoma:4190759	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Zinc\|\|PART_OF\|\|Prostate:230367	7/138,393	22/26,262,527	60.38	1.53e-10	9.36e-09
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|African American:4577837	156/138,393	177/26,262,527	167.44	2.51e-258	7.39e-255
Insulin-Like Growth Factor I\|\|ASSOCIATED_WITH\|\|Prostate:5781245	15/138,393	18/26,262,527	158.16	5.88e-26	1.13e-23
Prostate\|\|LOCATION_OF\|\|T-Lymphocyte:9749561	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Androgens\|\|AUGMENTS\|\|Neoplasm progression:10880165	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Radionuclide Imaging\|\|DIAGNOSES\|\|Neoplasm Metastasis:211005	35/138,393	230/26,262,527	28.88	2.81e-37	8.74e-35
Academic Medical Centers\|\|LOCATION_OF\|\|Biopsy:2375466	6/138,393	26/26,262,527	43.79	1.67e-08	7.69e-07
Androgens\|\|AFFECTS\|\|Cell Survival:3382004	5/138,393	11/26,262,527	86.26	1.65e-08	7.59e-07
prostate stem cell antigen\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:10537620	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Androgen therapy\|\|TREATS\|\|Prostate cancer metastatic:7366639	158/138,393	171/26,262,527	175.54	6.68e-264	2.09e-260
VEGF protein, human\|VEGFA\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:11260556	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Health Personnel:7903255	11/138,393	13/26,262,527	160.59	1.92e-19	2.59e-17
Prostate\|\|PART_OF\|\|Rodent:91758	15/138,393	43/26,262,527	66.21	1.49e-21	2.33e-19
Magnetic resonance imaging unit\|\|USES\|\|Robot:11861682	6/138,393	10/26,262,527	113.87	1.59e-10	9.61e-09
Administration, Oral\|\|TREATS\|\|Malignant neoplasm of prostate:4855557	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Malignant neoplasm of prostate\|\|COEXISTS_WITH\|\|Paraneoplastic Syndromes:13580724	5/138,393	4/26,262,527	237.22	4.90e-10	2.87e-08
Prostate\|\|LOCATION_OF\|\|PATHOLOGIC FINDINGS:4079939	11/138,393	14/26,262,527	149.11	3.42e-19	4.56e-17
Retinoids\|\|TREATS\|\|Malignant neoplasm of prostate:6330024	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Prostate-Specific Antigen\|\|compared_with\|\|Radical prostatectomy:7418092	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostate-Specific Antigen\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:3137096	281/138,393	313/26,262,527	170.71	0.00e+00	0.00e+00
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|son:6273666	9/138,393	15/26,262,527	113.87	3.64e-15	3.60e-13
Estrogen Receptor alpha\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8748106	13/138,393	15/26,262,527	164.48	7.85e-23	1.31e-20
Prostate\|\|LOCATION_OF\|\|[M]Adenocarcinoma, metastatic, NOS:2930441	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Dexamethasone\|\|TREATS\|\|Hormone-refractory prostate cancer:7242885	15/138,393	20/26,262,527	142.34	1.82e-25	3.46e-23
Salvage Therapy\|\|TREATS\|\|Malignant neoplasm of prostate:8505309	32/138,393	36/26,262,527	168.72	2.22e-54	1.06e-51
Glutamate Carboxypeptidase II\|\|ISA\|\|Peptide Hydrolases:10387315	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Manipulation procedure\|\|TREATS\|\|Malignant neoplasm of prostate:1781219	15/138,393	15/26,262,527	189.79	8.93e-27	1.77e-24
Nonsteroidal antiandrogen\|\|TREATS\|\|Malignant neoplasm of prostate:4992658	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Soy Proteins\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9413982	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Androgen Antagonists\|\|COEXISTS_WITH\|\|agonists:2465828	7/138,393	11/26,262,527	120.77	3.29e-12	2.43e-10
Prostate\|\|LOCATION_OF\|\|Carcinoma, Transitional Cell:7426506	4/138,393	3/26,262,527	253.03	2.61e-08	1.17e-06
Needle device\|\|USES\|\|Implants:2464195	6/138,393	21/26,262,527	54.22	5.59e-09	2.69e-07
Prostate\|\|LOCATION_OF\|\|Gene Expression Profiling:9862567	7/138,393	11/26,262,527	120.77	3.29e-12	2.43e-10
Selenium\|\|ISA\|\|Chemopreventive Agent:3339922	12/138,393	34/26,262,527	66.98	1.42e-17	1.71e-15
KLK3\|PLAG1\|PROS1\|NPEPPS\|PSAT1\|\|compared_with\|\|Prostate-Specific Antigen:5986972	8/138,393	10/26,262,527	151.82	2.38e-14	2.15e-12
Prostate\|\|LOCATION_OF\|\|Melanosis:688899	7/138,393	19/26,262,527	69.92	6.56e-11	4.09e-09
Prostate\|\|LOCATION_OF\|\|Stiffness:6404111	11/138,393	19/26,262,527	109.87	4.09e-18	5.11e-16
Pain management\|\|TREATS\|\|Prostate cancer metastatic:10416932	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Leuprolide\|\|PART_OF\|\|High-Risk Cancer:12188291	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostate specific antigen measurement\|\|USES\|\|Biopsy:6965951	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Prostate\|\|LOCATION_OF\|\|Hypertrophy:2704	45/138,393	192/26,262,527	44.49	6.19e-55	3.00e-52
MCAM gene\|MCAM\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:11173350	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Growth Factor\|\|AUGMENTS\|\|Malignant neoplasm of prostate:9311655	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Metformin\|\|TREATS\|\|Malignant neoplasm of prostate:14742191	23/138,393	28/26,262,527	155.91	6.03e-39	1.96e-36
Androgen Receptor\|AR\|\|DISRUPTS\|\|Cancer Cell Growth:9840813	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Radical prostatectomy\|\|PRECEDES\|\|Salvage procedure:10988050	7/138,393	9/26,262,527	147.60	1.19e-12	9.12e-11
Screening procedure\|\|TREATS\|\|Prostatic Diseases:5114418	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Radical perineal prostatectomy\|\|TREATS\|\|Adenocarcinoma:3065496	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Monoclonal Antibodies\|\|STIMULATES\|\|Acid Phosphatase:3526173	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
5-Alpha reductase inhibitor\|\|INHIBITS\|\|Androgens:4539594	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Prostatic Neoplasms\|\|LOCATION_OF\|\|Epithelial Cells:6962238	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
docetaxel\|\|INHIBITS\|\|Prostate-Specific Antigen:8942564	11/138,393	12/26,262,527	173.97	1.05e-19	1.44e-17
Androgen Receptor\|AR\|\|COEXISTS_WITH\|\|Androgen Receptor\|AR:3712440	16/138,393	32/26,262,527	94.89	6.25e-25	1.16e-22
Transurethral Resection\|\|TREATS\|\|Malignant neoplasm of prostate:1343443	40/138,393	43/26,262,527	176.58	3.85e-68	2.41e-65
Focused Ultrasound Therapy\|\|TREATS\|\|Malignant neoplasm of prostate:8919851	17/138,393	18/26,262,527	179.25	7.06e-30	1.59e-27
External Beam Radiation Therapy\|\|TREATS\|\|Prostate carcinoma:1837791	30/138,393	37/26,262,527	153.90	3.17e-50	1.41e-47
Flutamide\|\|ISA\|\|Androgen Antagonists:921199	162/138,393	646/26,262,527	47.64	2.72e-197	5.71e-194
Orchiectomy\|\|PRECEDES\|\|Estrogens:1930945	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
End Point\|\|USES\|\|Clinical Trials:1209926	39/138,393	757/26,262,527	9.78	6.18e-25	1.14e-22
Genistein\|\|CAUSES\|\|Cell Cycle Arrest:5927177	9/138,393	30/26,262,527	56.93	5.49e-13	4.43e-11
abiraterone\|\|INHIBITS\|\|Prostate-Specific Antigen:15941932	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Vitamin E\|\|DISRUPTS\|\|Malignant neoplasm of prostate:8317042	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
AMACR protein, human\|AMACR\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:9687613	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Prostate\|\|LOCATION_OF\|\|Organ Culture Techniques:186511	11/138,393	26/26,262,527	80.29	6.19e-17	7.15e-15
Neoplasm Metastasis\|\|PART_OF\|\|Organ:126578	19/138,393	340/26,262,527	10.61	1.53e-13	1.33e-11
Implantation procedure\|\|USES\|\|Stents:3612379	2/138,393	8,075/26,262,527	0.05	6.58e-16	6.80e-14
Second Primary Cancers\|\|ASSOCIATED_WITH\|\|Organ:1695355	6/138,393	22/26,262,527	51.76	7.08e-09	3.39e-07
Stanolone\|\|AUGMENTS\|\|Cell Growth:3765606	6/138,393	10/26,262,527	113.87	1.59e-10	9.61e-09
overdiagnosis\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:6415440	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Brachytherapy\|\|USES\|\|Implants:2051430	20/138,393	38/26,262,527	99.89	3.74e-31	8.98e-29
docetaxel\|\|TREATS\|\|Solid tumor:5625168	16/138,393	118/26,262,527	25.73	3.69e-17	4.30e-15
Medication Management\|\|TREATS\|\|Asymptomatic:14965071	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Epithelium\|\|PART_OF\|\|Prostatic Tissue:2824326	6/138,393	9/26,262,527	126.52	9.97e-11	6.13e-09
Aggressive behavior\|\|PROCESS_OF\|\|cohort:4424279	8/138,393	31/26,262,527	48.98	3.03e-11	2.01e-09
EGR1 gene\|EGR1\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:11091231	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Malignant neoplasm of prostate\|\|COEXISTS_WITH\|\|prostatitis:8400878	6/138,393	5/26,262,527	227.73	9.37e-12	6.74e-10
Prostatic Neoplasms\|\|PROCESS_OF\|\|Rodent:3444902	7/138,393	9/26,262,527	147.60	1.19e-12	9.12e-11
Prostate\|\|LOCATION_OF\|\|Hemorrhage:70617	12/138,393	33/26,262,527	69.01	1.05e-17	1.27e-15
Vitamin E\|\|NEG_PREVENTS\|\|Malignant neoplasm of prostate:13290242	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
High-Risk Cancer\|\|PART_OF\|\|Prostate:6283097	1,102/138,393	1,926/26,262,527	109.44	0.00e+00	0.00e+00
Tumor necrosis factor receptor 11b\|\|ASSOCIATED_WITH\|\|Secondary malignant neoplasm of bone:10268309	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
SPINK1 gene\|SPINK1\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:12977833	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Pelvis\|\|LOCATION_OF\|\|X-Ray Computed Tomography:1687071	54/138,393	527/26,262,527	19.45	2.93e-48	1.25e-45
Flutamide\|\|CAUSES\|\|Toxic effect:7246480	5/138,393	8/26,262,527	118.61	4.92e-09	2.37e-07
Face\|\|LOCATION_OF\|\|Malignant neoplasm of prostate:11692022	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Small cell carcinoma of lung\|\|PART_OF\|\|Bladder:1929335	22/138,393	524/26,262,527	7.97	4.66e-13	3.77e-11
Prostate\|\|LOCATION_OF\|\|Adenosis:2092044	6/138,393	9/26,262,527	126.52	9.97e-11	6.13e-09
density\|\|PROCESS_OF\|\|Malignant neoplasm of prostate:6281116	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Teleradiotherapy procedure\|\|TREATS\|\|Prostate carcinoma:537052	27/138,393	33/26,262,527	155.29	1.98e-45	7.85e-43
Gonadotropin releasing hormone antagonist\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8832739	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Metabolic syndrome\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:10877120	14/138,393	19/26,262,527	139.84	8.82e-24	1.57e-21
Diphosphonates\|\|AFFECTS\|\|Tumor cells, malignant:9575115	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Radical cystoprostatectomy\|\|TREATS\|\|Malignant neoplasm of prostate:8232328	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Suramin\|\|TREATS\|\|Hormone-refractory prostate cancer:5133046	17/138,393	20/26,262,527	161.32	2.45e-29	5.41e-27
Arachidonic Acid\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:6725176	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Insulin-Like Growth Factor Binding Protein 3\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8989860	14/138,393	17/26,262,527	156.30	2.88e-24	5.18e-22
Tetradecapeptide\|\|INTERACTS_WITH\|\|Bombesin Receptor:15541477	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Entire nerve\|\|ASSOCIATED_WITH\|\|organic disorders:12725418	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Prostatic Tissue\|\|PART_OF\|\|Stroma:1978350	11/138,393	21/26,262,527	99.41	9.57e-18	1.15e-15
Androgens\|\|TREATS\|\|Prostate cancer metastatic:3400808	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
lymph nodes\|\|LOCATION_OF\|\|Prostate-Specific Antigen:5477304	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Phytoestrogens\|\|AFFECTS\|\|Malignant neoplasm of prostate:7333208	5/138,393	8/26,262,527	118.61	4.92e-09	2.37e-07
invasive treatment\|\|TREATS\|\|Malignant neoplasm of prostate:6373582	37/138,393	38/26,262,527	184.82	1.18e-63	6.87e-61
Biopsy\|\|DIAGNOSES\|\|Local disease:1802723	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
docetaxel\|\|TREATS\|\|Prostate carcinoma:9721841	6/138,393	8/26,262,527	142.33	6.01e-11	3.76e-09
Isoenzymes\|\|ASSOCIATED_WITH\|\|Prostate:584992	7/138,393	16/26,262,527	83.03	2.48e-11	1.64e-09
Prostate\|\|LOCATION_OF\|\|Cancer Model:1791745	388/138,393	425/26,262,527	173.73	0.00e+00	0.00e+00
Positron-Emission Tomography\|\|DIAGNOSES\|\|Secondary malignant neoplasm of bone:7724898	10/138,393	53/26,262,527	35.81	1.55e-12	1.18e-10
Proto-Oncogene Proteins c-akt\|AKT1\|\|INHIBITS\|\|Proto-Oncogene Proteins c-akt\|AKT1:8348650	15/138,393	319/26,262,527	8.92	5.16e-10	3.02e-08
Polymorphism, Genetic\|\|ASSOCIATED_WITH\|\|PSCA gene\|PSCA:13641913	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Management procedure\|\|TREATS\|\|Rectal hemorrhage:1830509	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostate cancer metastatic\|\|PROCESS_OF\|\|cohort:9749404	12/138,393	12/26,262,527	189.78	1.10e-21	1.72e-19
Early Diagnosis\|\|DIAGNOSES\|\|Prostate carcinoma:728984	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Benign prostatic hypertrophy\|\|CAUSES\|\|Bladder outlet obstruction:1061058	14/138,393	165/26,262,527	16.10	1.24e-12	9.50e-11
Vaccines\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8570871	7/138,393	8/26,262,527	166.06	6.74e-13	5.29e-11
Fractionation\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:10977244	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostate carcinoma\|\|COEXISTS_WITH\|\|Carcinogenesis:7884769	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
AR gene\|AR\|\|AFFECTS\|\|Transcription, Genetic:6552011	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
Malignant neoplasm of lung\|\|ASSOCIATED_WITH\|\|Prostate:11054644	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Promoter (Genetics)\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:11231307	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Cholecalciferol\|\|TREATS\|\|Malignant neoplasm of prostate:11403344	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
KLK3 gene\|KLK3\|\|STIMULATES\|\|KLK3 gene\|KLK3:3729427	27/138,393	41/26,262,527	124.99	1.47e-43	5.58e-41
tomography\|\|DIAGNOSES\|\|Prostatic Diseases:2494960	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
DNA Methylation\|\|AFFECTS\|\|Malignant neoplasm of prostate:10845813	9/138,393	9/26,262,527	189.78	1.39e-16	1.52e-14
Radical prostatectomy\|\|PRECEDES\|\|Radical prostatectomy:3649199	85/138,393	102/26,262,527	158.24	4.36e-140	6.58e-137
Prostatectomy\|\|compared_with\|\|Patient observation:13305975	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Buserelin\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:2956805	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Magnetic Resonance\|\|PROCESS_OF\|\|Malignant neoplasm of prostate:11354239	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Endocrine therapy\|\|USES\|\|Gonadotropin-Releasing Hormone Analog:5134905	14/138,393	23/26,262,527	115.52	6.45e-23	1.09e-20
Epithelium\|\|LOCATION_OF\|\|Prostate-Specific Antigen:6718354	8/138,393	9/26,262,527	168.69	1.33e-14	1.22e-12
Malignant neoplasm of prostate\|\|LOCATION_OF\|\|Epithelial Cells:4164688	16/138,393	16/26,262,527	189.79	1.80e-28	3.82e-26
Racemases\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:9541668	9/138,393	11/26,262,527	155.27	4.76e-16	4.94e-14
Acetate\|\|DISRUPTS\|\|androgen biosynthesis:14703999	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Cell Cycle Arrest\|\|COEXISTS_WITH\|\|Cell division phases:5307099	19/138,393	244/26,262,527	14.78	5.58e-16	5.78e-14
Prostate-Specific Antigen\|\|PART_OF\|\|Voluntary Workers:5452686	6/138,393	8/26,262,527	142.33	6.01e-11	3.76e-09
Seed Implantation\|\|USES\|\|Gold:3700850	5/138,393	8/26,262,527	118.61	4.92e-09	2.37e-07
Choline\|\|ASSOCIATED_WITH\|\|Prostate:9778085	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Casodex\|\|ISA\|\|Androgen Antagonists:4173540	60/138,393	95/26,262,527	119.90	4.98e-94	4.69e-91
Malignant neoplasm of prostate\|\|OCCURS_IN\|\|African American:6229235	12/138,393	12/26,262,527	189.78	1.10e-21	1.72e-19
RNA, Small Interfering\|\|INTERACTS_WITH\|\|Androgen Receptor\|AR:12301426	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Testosterone\|\|TREATS\|\|Malignant neoplasm of prostate:13257289	13/138,393	11/26,262,527	224.29	5.34e-24	9.50e-22
Pelvis\|\|LOCATION_OF\|\|Prostate:1442171	11/138,393	12/26,262,527	173.97	1.05e-19	1.44e-17
External radiotherapy NOS\|\|TREATS\|\|Locally Advanced Malignant Neoplasm:8883293	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Nuclear Receptor Coactivator 4\|NCOA4\|\|INTERACTS_WITH\|\|Androgen Receptor\|AR:7347059	6/138,393	9/26,262,527	126.52	9.97e-11	6.13e-09
Androgen therapy\|\|TREATS\|\|Neoplasm progression:14563871	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostate-Specific Antigen\|\|PREDISPOSES\|\|Prostatic Diseases:7394057	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Health care facility\|\|LOCATION_OF\|\|Biopsy:1602504	74/138,393	271/26,262,527	51.85	1.71e-93	1.60e-90
Radical prostatectomy\|\|TREATS\|\|Ability:5304225	8/138,393	10/26,262,527	151.82	2.38e-14	2.15e-12
Urologist\|\|ISA\|\|Health Personnel:7394045	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Malignant neoplasm of prostate\|\|ISA\|\|Clinical finding:4641056	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Drug Delivery Systems\|\|TREATS\|\|Malignant neoplasm of prostate:9989476	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
alpha Tocopherol\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:12497338	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Prostate\|\|LOCATION_OF\|\|Biopsy of rectum:177384	17/138,393	25/26,262,527	129.06	3.83e-28	7.98e-26
Validation\|\|USES\|\|End Point:4454157	6/138,393	39/26,262,527	29.20	1.42e-07	5.16e-06
Malignant neoplasm of prostate\|\|AFFECTS\|\|Malignant neoplasm of prostate:244461	48/138,393	49/26,262,527	185.96	3.37e-82	2.64e-79
Breast\|\|LOCATION_OF\|\|Human Cell Line:3359977	5/138,393	18/26,262,527	52.72	1.23e-07	4.49e-06
Biopsy\|\|DIAGNOSES\|\|Prostate cancer metastatic:7385344	12/138,393	12/26,262,527	189.78	1.10e-21	1.72e-19
TGFB1 protein, human\|TGFB1\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:5027161	23/138,393	27/26,262,527	161.68	3.33e-39	1.09e-36
Annexin A2\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9248591	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Secondary malignant neoplasm of bone\|\|ASSOCIATED_WITH\|\|Breast:2916279	18/138,393	26/26,262,527	131.39	8.07e-30	1.81e-27
Urethra excision\|\|TREATS\|\|Malignant neoplasm of urinary bladder:815499	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Malignant neoplasm of prostate\|\|PRODUCES\|\|Testosterone:4107998	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Digital Rectal Examination\|\|NEG_DIAGNOSES\|\|Malignant neoplasm of prostate:4194121	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
VEGF protein, human\|VEGFA\|\|ASSOCIATED_WITH\|\|Prostatic Neoplasms:8619764	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Malignant neoplasm of prostate\|\|COEXISTS_WITH\|\|High-Grade Prostatic Intraepithelial Neoplasia:7860562	15/138,393	17/26,262,527	167.46	3.22e-26	6.27e-24
Prostate\|\|LOCATION_OF\|\|Androgens measurement:3458385	7/138,393	15/26,262,527	88.56	1.73e-11	1.23e-09
Carcinoma\|\|COEXISTS_WITH\|\|Benign prostatic hypertrophy:10063987	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
AR gene\|AR\|\|ASSOCIATED_WITH\|\|Tumorigenesis:9134451	7/138,393	10/26,262,527	132.84	2.02e-12	1.52e-10
Malignant neoplasm of prostate\|\|PART_OF\|\|Caucasoid Race:12906088	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Benign prostatic hypertrophy\|\|LOCATION_OF\|\|Epithelial Cells:2026997	22/138,393	31/26,262,527	134.70	2.66e-36	7.90e-34
Biopsy sampling\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:8747114	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Radical prostatectomy\|\|ADMINISTERED_TO\|\|Participant:7483807	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Clodronate\|\|TREATS\|\|Secondary malignant neoplasm of bone:3460647	9/138,393	32/26,262,527	53.38	9.00e-13	7.00e-11
Castration\|\|METHOD_OF\|\|Cancer Treatment:7933934	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
VEGFA\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:9491612	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Metastasis Suppressor Genes\|\|PART_OF\|\|Malignant neoplasm of prostate:8013347	12/138,393	12/26,262,527	189.78	1.10e-21	1.72e-19
Stroma\|\|ASSOCIATED_WITH\|\|Benign prostatic hypertrophy:3236326	5/138,393	21/26,262,527	45.18	2.37e-07	8.32e-06
Supplementation\|\|TREATS\|\|Malignant neoplasm of prostate:8907552	19/138,393	24/26,262,527	150.25	3.32e-32	8.35e-30
Malignant neoplasm of prostate\|\|COEXISTS_WITH\|\|Blood Coagulation Disorders:10459916	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Radical perineal prostatectomy\|\|TREATS\|\|Carcinoma:50072	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Breast\|\|LOCATION_OF\|\|docetaxel:5681216	5/138,393	14/26,262,527	67.78	4.33e-08	1.92e-06
Parenteral therapy\|\|USES\|\|Estrogens:3458389	8/138,393	11/26,262,527	138.02	4.09e-14	3.65e-12
Combination Drug Therapy\|\|USES\|\|Cisplatin:874925	21/138,393	856/26,262,527	4.66	1.75e-08	8.05e-07
zoledronic acid\|\|TREATS\|\|Solid tumor:10947378	14/138,393	32/26,262,527	83.03	2.42e-21	3.71e-19
ERG gene\|ERG\|\|PART_OF\|\|Malignant neoplasm of prostate:7698415	13/138,393	13/26,262,527	189.79	2.20e-23	3.82e-21
Angiogenesis Inhibitors\|\|TREATS\|\|Prostate cancer metastatic:9186651	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
KLK3 gene\|KLK3\|\|ASSOCIATED_WITH\|\|Prostate cancer metastatic:15207397	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Chronic inflammation\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:11209344	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Chondroblasts\|\|PRODUCES\|\|Glycoproteins:16361250	8/138,393	48/26,262,527	31.63	6.47e-10	3.76e-08
Undifferentiated carcinoma\|\|PART_OF\|\|Prostate:1208454	10/138,393	13/26,262,527	145.99	1.68e-17	1.99e-15
zoledronic acid\|\|INHIBITS\|\|Androgens:14130582	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
caveolin 1\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:10319599	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Neoplasm Metastasis\|\|COEXISTS_WITH\|\|Prostate carcinoma:736090	8/138,393	8/26,262,527	189.78	7.07e-15	6.71e-13
Prostate-Specific Antigen\|\|ADMINISTERED_TO\|\|Urologist:7288228	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostate\|\|LOCATION_OF\|\|Nodular hyperplasia:152579	11/138,393	23/26,262,527	90.77	2.10e-17	2.48e-15
Tumor cells, malignant\|\|LOCATION_OF\|\|Cell Cycle Arrest:8292188	17/138,393	172/26,262,527	18.76	4.87e-16	5.05e-14
Zoladex\|\|ISA\|\|Gonadorelin\|GNRH1:3026311	7/138,393	16/26,262,527	83.03	2.48e-11	1.64e-09
Prophylactic treatment\|\|TREATS\|\|Secondary malignant neoplasm of bone:10647032	17/138,393	43/26,262,527	75.03	5.32e-25	9.86e-23
Solid tumor\|\|ASSOCIATED_WITH\|\|Breast:1875799	5/138,393	13/26,262,527	72.99	3.20e-08	1.43e-06
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Rats, Wistar:1583782	23/138,393	25/26,262,527	174.62	9.63e-40	3.20e-37
lycopene\|\|INTERACTS_WITH\|\|Antioxidants:8056976	5/138,393	17/26,262,527	55.82	9.68e-08	3.54e-06
Cancer Patient\|\|LOCATION_OF\|\|KLK3 gene\|KLK3:5983937	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Candidate Disease Gene\|\|TREATS\|\|Hormone-refractory prostate cancer:12277834	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Prostate-Specific Antigen\|\|COEXISTS_WITH\|\|Finasteride:7280845	6/138,393	8/26,262,527	142.33	6.01e-11	3.76e-09
Medical pathologist\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:8425584	11/138,393	11/26,262,527	189.78	5.49e-20	7.78e-18
Prostatic Tissue\|\|LOCATION_OF\|\|Glycol:1910980	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
lycopene\|\|DISRUPTS\|\|Cell Growth:6846559	7/138,393	13/26,262,527	102.19	7.94e-12	5.78e-10
RNase L\|RNASEL\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:10002471	5/138,393	8/26,262,527	118.61	4.92e-09	2.37e-07
Pelvis\|\|LOCATION_OF\|\|Malignant neoplasm of kidney:1490467	9/138,393	135/26,262,527	12.65	8.99e-08	3.42e-06
glandular epithelium\|\|PART_OF\|\|Benign prostatic hypertrophy:3547202	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Radical prostatectomy\|\|TREATS\|\|Adenocarcinoma:957081	121/138,393	131/26,262,527	175.43	1.64e-202	3.66e-199
Oxidoreductase\|\|ASSOCIATED_WITH\|\|Prostate:347858	20/138,393	61/26,262,527	62.23	8.48e-28	1.75e-25
Estrogens\|\|CAUSES\|\|Malignant neoplasm of prostate:3286702	11/138,393	11/26,262,527	189.78	5.49e-20	7.78e-18
Benign prostatic hypertrophy\|\|PART_OF\|\|Prostate:481998	94/138,393	131/26,262,527	136.26	2.88e-150	4.61e-147
Chromosomes, Human, Pair 20\|\|LOCATION_OF\|\|Malignant neoplasm of prostate:8649183	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Malignant neoplasm of prostate\|\|PRODUCES\|\|AR gene\|AR:8699888	7/138,393	7/26,262,527	189.78	3.61e-13	2.93e-11
Immunotherapy\|\|METHOD_OF\|\|Cancer Treatment:1697525	8/138,393	69/26,262,527	22.00	8.70e-09	4.11e-07
lycopene\|\|PART_OF\|\|Prostate:9383092	5/138,393	11/26,262,527	86.26	1.65e-08	7.59e-07
Brachytherapy\|\|TREATS\|\|Adenocarcinoma:567122	46/138,393	63/26,262,527	138.61	1.19e-74	8.51e-72
Magnetic Resonance Imaging\|\|ISA\|\|Spectrum Analysis:3115190	19/138,393	336/26,262,527	10.73	1.26e-13	1.10e-11
Gossypol\|\|TREATS\|\|Malignant neoplasm of prostate:11875087	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Duct (organ) structure\|\|PART_OF\|\|Prostate:1473840	14/138,393	39/26,262,527	68.13	2.35e-20	3.46e-18
Epithelial Cells\|\|PART_OF\|\|Prostatic Neoplasms:3679995	25/138,393	29/26,262,527	163.62	1.41e-42	5.19e-40
tumor growth\|\|COEXISTS_WITH\|\|Tumor Angiogenesis:5910563	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Processed meat\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:12908507	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostatic Urethra\|\|LOCATION_OF\|\|Carcinoma, Transitional Cell:4525197	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Malignant neoplasm of prostate\|\|LOCATION_OF\|\|Fibroblasts:15383576	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Radiotherapy, Adjuvant\|\|TREATS\|\|Malignant neoplasm of prostate:7117721	32/138,393	33/26,262,527	184.06	3.21e-55	1.56e-52
Chamber\|\|LOCATION_OF\|\|Matrigel Invasion Assay:6936705	9/138,393	42/26,262,527	40.67	7.45e-12	5.43e-10
Androgen Antagonists\|\|compared_with\|\|Castration:2999676	15/138,393	15/26,262,527	189.79	8.93e-27	1.77e-24
radiotracer\|\|CAUSES\|\|Liver neoplasms:17287271	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Crosstalk\|\|COEXISTS_WITH\|\|Malignant neoplasm of prostate:11777751	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Cancer Diagnosis\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:8601206	10/138,393	9/26,262,527	210.87	1.39e-18	1.80e-16
Prostate carcinoma\|\|COEXISTS_WITH\|\|Hyperplasia:2762199	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Pelvis\|\|LOCATION_OF\|\|Cystic Neoplasm:3096689	5/138,393	10/26,262,527	94.89	1.14e-08	5.31e-07
Androgen Receptor\|AR\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:8073235	9/138,393	5/26,262,527	341.60	5.84e-18	7.12e-16
Kininogenase\|\|AFFECTS\|\|Carcinogenesis:8579804	4/138,393	6/26,262,527	126.52	1.55e-07	5.48e-06
Single Nucleotide Polymorphism\|\|LOCATION_OF\|\|Malignant neoplasm of prostate:13652702	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
The science and art of healing\|\|TREATS\|\|Anemia:110249	21/138,393	5/26,262,527	797.15	8.24e-44	3.16e-41
Plants\|\|LOCATION_OF\|\|Apigenin:2294633	7/138,393	47/26,262,527	28.26	1.55e-08	7.19e-07
Carcinoma in Situ\|\|PART_OF\|\|Prostate:879287	9/138,393	10/26,262,527	170.80	2.63e-16	2.79e-14
Biopsy\|\|DIAGNOSES\|\|Prostatic Intraepithelial Neoplasias:6925301	9/138,393	13/26,262,527	131.39	1.40e-15	1.41e-13
Radical prostatectomy\|\|TREATS\|\|Adenocarcinoma of prostate:1216758	32/138,393	32/26,262,527	189.81	1.64e-55	8.04e-53
Prostate-Specific Antigen\|\|higher_than\|\|Prostate-Specific Antigen:4176863	43/138,393	51/26,262,527	160.05	7.70e-72	5.19e-69
gene therapy\|\|TREATS\|\|Prostate cancer metastatic:8653086	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Androgen therapy\|\|USES\|\|bicalutamide:11454178	10/138,393	9/26,262,527	210.87	1.39e-18	1.80e-16
Secondary malignant neoplasm of bone\|\|COEXISTS_WITH\|\|Multiple Myeloma:8459499	5/138,393	4/26,262,527	237.22	4.90e-10	2.87e-08
FOLH1 gene\|FOLH1\|\|ASSOCIATED_WITH\|\|Prostate:6252578	6/138,393	7/26,262,527	162.67	3.45e-11	2.21e-09
Functional RNA\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:11162512	18/138,393	19/26,262,527	179.80	1.43e-31	3.50e-29
Androgens\|\|INTERACTS_WITH\|\|TMPRSS2 gene\|TMPRSS2:14808598	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Gonadorelin\|\|INHIBITS\|\|Testosterone:1342473	5/138,393	12/26,262,527	79.07	2.32e-08	1.06e-06
Tumorigenicity\|\|PROCESS_OF\|\|Mice, Nude:855176	60/138,393	1,555/26,262,527	7.32	5.85e-31	1.39e-28
Toxicology screen, general\|\|DIAGNOSES\|\|Malignant neoplasm of prostate:7665109	21/138,393	23/26,262,527	173.29	2.30e-36	6.86e-34
Pathologic stage\|\|ASSOCIATED_WITH\|\|Prostate-Specific Antigen:5467867	9/138,393	12/26,262,527	142.33	8.30e-16	8.48e-14
Photochemotherapy\|\|TREATS\|\|Prostate cancer recurrent:9783717	5/138,393	6/26,262,527	158.15	1.78e-09	9.03e-08
Estrogen Receptor beta\|EREG\|ESR1\|\|ASSOCIATED_WITH\|\|Malignant neoplasm of prostate:14633386	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Prostate\|\|LOCATION_OF\|\|Implants:148769	150/138,393	212/26,262,527	134.41	4.94e-238	1.34e-234
Transurethral Resection\|\|TREATS\|\|Benign prostatic hypertrophy:1332491	40/138,393	261/26,262,527	29.09	1.78e-42	6.54e-40
[M]Unspecified tumor cell NOS\|\|LOCATION_OF\|\|Prostate-Specific Antigen:2647136	13/138,393	13/26,262,527	189.79	2.20e-23	3.82e-21
Coffee\|\|PREDISPOSES\|\|Malignant neoplasm of prostate:5745824	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Prostate\|\|LOCATION_OF\|\|epigallocatechin gallate:10417535	4/138,393	4/26,262,527	189.77	5.20e-08	2.03e-06
Variation (Genetics)\|\|PROCESS_OF\|\|Malignant neoplasm of prostate:13273771	5/138,393	5/26,262,527	189.77	9.76e-10	5.17e-08
Prostate\|\|LOCATION_OF\|\|Histocytochemistry:172594	5/138,393	15/26,262,527	63.26	5.75e-08	2.23e-06
Radical prostatectomy\|\|PRECEDES\|\|adjuvant therapy:3789797	16/138,393	17/26,262,527	178.63	3.48e-28	7.27e-26
Osteoporosis\|\|ASSOCIATED_WITH\|\|Breast:11263858	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Flutamide\|\|compared_with\|\|Flutamide:4108662	6/138,393	11/26,262,527	103.51	2.44e-10	1.46e-08
Tumor cells, malignant\|\|PRODUCES\|\|Gonadotropin-Releasing Hormone Receptor:10292672	4/138,393	7/26,262,527	108.44	2.42e-07	8.38e-06
Malignant neoplasm of prostate\|\|PROCESS_OF\|\|Mice, Inbred C57BL:5435272	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
ERBB2\|NEU1\|NEURL1\|\|STIMULATES\|\|Androgen Receptor\|AR:8196713	6/138,393	6/26,262,527	189.78	1.87e-11	1.25e-09
Organoids\|\|PART_OF\|\|Prostate:7260163	6/138,393	14/26,262,527	81.33	7.55e-10	4.37e-08
Radiotherapy, Intensity-Modulated\|\|TREATS\|\|High-Risk Cancer:13734577	13/138,393	24/26,262,527	102.80	7.15e-21	1.07e-18
Risk Reduction\|\|USES\|\|Finasteride:11577672	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
External Beam Radiation Therapy\|\|PRECEDES\|\|External Beam Radiation Therapy:7149967	5/138,393	7/26,262,527	135.55	3.04e-09	1.50e-07
Combination Drug Therapy\|\|TREATS\|\|Hormone-refractory prostate cancer:6807440	4/138,393	5/26,262,527	151.82	9.32e-08	3.42e-06
Head\|\|LOCATION_OF\|\|Breast:2488810	5/138,393	15/26,262,527	63.26	5.75e-08	2.23e-06
Androgens\|\|STIMULATES\|\|Gonadorelin\|GNRH1:2273609	7/138,393	14/26,262,527	94.89	1.19e-11	8.48e-10